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Thesis summary
Previous studies have shown that dietary supplementation of curcumin or omega-3 
polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid can reduce behavioural 
deficits and β-amyloid (Aβ) pathology in several models of Alzheimer’s disease (AD), 
including Tg2576 mice. However, no study to date had examined the effect of omega-3
PUFA and curcumin co-supplementation on behaviour or β-amyloid pathology in mouse 
models of AD. Further to this, no study to date had examined the effect of longitudinal 
omega-3 PUFA or curcumin supplementation provided from an early age before significant 
pathological development in the Tg2576 model. This was deemed important since human 
studies have suggested that lifelong dietary choices before disease development are an 
important factor in disease risk. Finally, although a plethora of studies has examined the 
effect of omega-3 PUFA supplementation, none has accurately examined its effect against an 
appropriate control diet. For example, some control diets contained differential levels of fatty 
acids such as excess total fat and omega-6 PUFAs. Such differences in the control diet may 
have contributed to the observed beneficial effects of dietary omega-3 PUFA 
supplementation, particularly since these dietary factors can exacerbate pathological 
processes related to AD. 
Using this experimental design, chapter 3 found longitudinal dietary supplementation of 
omega-3 PUFA docosahexaenoic acid (DHA) from an early age in Tg2576 mice provided 
some protection from cognitive decline that was limited to later but not early stages of 
pathology. In contrast to previous reports however, Aβ pathology was unaltered by DHA 
supplementation. Providing DHA supplementation from an even earlier age, chapter 4
showed that DHA reduced behavioural deficits at an early age (prior to Aβ pathology), 
although interestingly, these effects were less robust at the later age. Chapter 5 examined 
longitudinal supplementation of curcumin, fish oil containing omega-3 PUFAs (DHA and 
eicosapentaenoic acid, EPA) and their co-supplementation from an early age in Tg2576 mice. 
The results consistently revealed no beneficial effects of dietary supplementation on 
behaviour or Aβ pathological measures. The findings from this thesis indicate that dietary 
supplementation of DHA relative to a suitable control diet can provide only limited 
protection against behavioural deficits in Tg2576 mice. In contrast, fish oil supplementation 
containing omega-3 PUFAs DHA and EPA provided no protection, indicating that DHA 
monotherapy may be a more advisable treatment. The null effects of curcumin 
supplementation at earlier stages relative to previous studies suggest that curcumin may only 
be effective during advanced stages of pathology, although further investigation is needed. 
Finally, the null effects of curcumin and fish oil/omega-3 PUFA co-supplementation suggest 
that this is not an optimal intervention strategy in reducing Aβ-induced changes.
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1Chapter 1
General Introduction
1.0 Overview of the general introduction
The general introduction will first describe the characteristics of Alzheimer’s disease (AD)   
and outline the rationale for studying the disease and developing therapies. The current 
literature surrounding its aetiology, pathology and potential therapeutic targets will then be 
described. An introduction into the importance of dietary factors in disease risk and 
progression will then be presented, with a particular focus on omega-3 polyunsaturated fatty 
acids (PUFAs) and curcumin compounds. The effect of these dietary compounds on AD 
pathology and related dysfunction is evaluated, in the context of in vitro, human and animal 
studies. The main aim of this thesis is to evaluate the effects of dietary intervention on brain 
pathology and cognition in a mouse model of amyloid pathology. The introduction therefore 
also includes an overview of animal models of AD and their relative strengths and 
weaknesses.
1.1 Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative disorder, first described by Alois Alzheimer in 
1906 (Berchtold & Cotman, 1998). This incurable and terminal disease is the most common 
form of dementia. Its prevalence in 2006 was estimated at 26.6 million people worldwide and 
is predicted to quadruple by 2050, affecting 1 in 85 people (Ferri et al., 2005; Brookmeyer et 
al., 2007). Alzheimer’s disease has a huge socioeconomic impact, with 43% of cases 
estimated to need a high level of care which puts a great financial burden on society 
(Brookmeyer et al., 2007). As a result it is one of the most costly diseases in developed 
countries, estimated to cost $160 billion per year worldwide (Wimo, Jonsson & Winblad, 
2006). Brookmeyer et al. (2007) estimated that if an intervention were to delay disease onset 
and progression by even one year, this would decrease the predicted 2050 prevalence by over 
9 million, with the majority being high-level care cases.
2Alzheimer’s disease can be categorised in several ways, depending upon risk factors involved 
and the time of onset. These include familial and sporadic AD, or late-onset (senile) and 
early-onset (presenile) AD. Despite the different types of AD, pathology and clinical features 
appear the same (Selkoe, 2001). The stage at which pathology is present however is different, 
with pathology developing later and over a longer period in sporadic and late-onset AD
compared with familial or early-onset AD (Anekonda & Reddy, 2005). As a result, early-
onset AD (EOAD) is the term used for AD cases diagnosed before the age of 65 years, 
whereas late-onset AD (LOAD) is diagnosed after the age of 65 years (Brookmeyer, Gray & 
Kawas, 1998). The four main pathological traits of AD include: 1) the overproduction and 
accumulation of the beta-amyloid (Aβ) peptide which is neurotoxic and aggregates to form 
extracellular Aβ plaques, 2) the aggregation and hyperphosphorylation of tau proteins 
forming intracellular neurofibrillary tangles (NFTs), 3) neuronal cell loss, and 4) 
neuroinflammation and oxidative stress (Mattson, 2004).
Familial AD (FAD) is an autosomal dominant disease associated with genetic mutations of 
the amyloid precursor protein (APP), presenilin-1 (PS1) and presenilin-2 (PS2) genes 
(Mattson, 2004; Waring & Rosenberg, 2008). Numerous other genes are likely to be 
responsible but remain to be discovered (Jones, Harold & Williams, 2010). These APP and 
presenilin mutations alter APP processing to increase Aβ production (Scheuner et al., 1996; 
Citron et al., 1997; Wolfe et al., 1999). The APP gene has several mutations around the Aβ-
dependant cleavage sites including APP K670N, M671L and V717I, which represent 
mutations at codons 670 and 671 in exon 16, and 717 in exon 17 of the APP gene (Mullan et 
al., 1992). FAD accounts for approximately 4 to 5% of all AD cases, and less than 10% of 
EOAD are due to autosomal dominant mutations (Waring & Rosenberg, 2008). Despite 
genetic mutations representing only 0.1% of all AD cases (Blennow, de Leon & Zetterberg, 
2006), their role is central to FAD and has been key to furthering our understanding of the 
disease, particularly through the use of animal models. 
Sporadic AD (SAD) accounts for the majority of cases and often develops in people after the 
age of 65 (therefore often referred to as LOAD), with increasing incidence in later years 
(Brookmeyer, Gray & Kawas, 1998). Although there is no known cause, there are several risk 
factors involved including a genetic component. It is well documented that the apolipoprotein 
E (ApoE) gene is implicated in SAD/LOAD. More specifically, the ApoE ε4 isoform 
accounts for up to 50% of late-onset cases (Saunders, 1993; Raber, Huang & Ashford, 2004). 
3Its precise role in pathogenesis remains inconclusive, although it is thought to alter APP 
metabolism or Aβ aggregation (Holtzman et al., 1999; Ma et al., 1999). It may also increase 
neuroinflammation and oxidative stress (e.g. Jofre-Monseny, Minihane & Rimbach, 2008). 
As almost half of LOAD sufferers do not carry the ApoE4 ε4 allele, other genetic or 
environmental factors must be involved. Indeed, research has claimed over 500 putative risk 
genes, with strong support for linkage on chromosomes 9, 10 and 12 (Pericak-Vance, 1997; 
Myers et al., 2000; Bertram, 2007). More recent genome-wide association studies have 
identified variants in four novel susceptibility genes (CLU, PICALM, CR1 and BIN1)
providing compelling evidence for their association with AD risk (as reviewed in 
Hollingworth et al., 2011). Further support comes from their involvement in processes related 
to disease pathogenesis such as inflammation, amyloid clearance, lipid transport and 
metabolism, as well as endocytosis and intracellular trafficking (e.g. Jones, Harold & 
Williams, 2010; Hollingworth et al., 2011). In conclusion, genetic inheritance makes a 
significant contribution to the risk of AD, although it is clear that environmental factors must 
also may a substantial role in sporadic AD.
1.2 Clinical features of Alzheimer’s disease
Alzheimer’s disease is characterised by atrophy in multiple brain regions including the 
temporal lobe, parietal lobe, frontal cortex and cingulate gyrus (Wenk, 2003). The most 
commonly observed symptom of AD is cognitive dysfunction, including the inability to 
acquire new memories, a reduction in short-term and long-term memory, and loss of 
communicative abilities (Waldemar et al., 2007). Other behavioural symptoms such as 
confusion and emotional disturbances are observed, and these symptoms worsen in a time-
dependant manner as the disease progresses. The precise behavioural phenotype of AD is 
detailed in conjunction with modelling the disease in animals, whereby similarities and 
dissimilarities are drawn (section 1.7).
The progression of AD is categorised into four stages; pre-dementia, early, moderate and 
advanced. Pre-dementia often goes undetected as symptoms are mistaken for normal age-
related decline (Waldemar et al., 2007). Detailed diagnosis often reveals (amnesic) mild 
cognitive impairment (MCI), which frequently leads to the diagnosis of AD up to 8 years 
later (Arnáiz & Almkvist, 2003). A decline in short-term memory is the most common 
symptom of pre-dementia, in addition to subtle problems with executive functions (such as 
4attention, planning, and cognitive flexibility), semantic memory and sometimes apathy 
(Landes et al., 2001; Arnáiz & Almkvist, 2003; Bäckman et al., 2004). Early AD is diagnosed 
with increased learning and memory impairments, although individual cases do not follow 
the same progression of symptoms. For example, some sufferers exhibit agnosia, apraxia and 
communicative problems more than memory impairments (Förstl & Kurz, 1999). Short-term 
memory is most clearly affected at this stage, with loss of episodic, semantic and implicit 
memory to a lesser degree (Carlesimo & Oscar-Berman, 1992; Jelicic, Bonebakker & Bonke,
1995). At this early stage in the disease, AD sufferers can continue to perform tasks 
independently but may require assistance with difficult cognitive tasks (Förstl & Kurz, 1999). 
Moderate AD is primarily associated with long-term memory impairment, such the inability 
to recognise close relatives (Förstl & Kurz, 1999). Loss of communication is also obvious, 
with patients showing difficulty with speech and fine motor skills such as writing (Frank,
1994; Taler & Phillips, 2008). Gross motor skills are also affected which commonly leads to 
falls. Other changes in behaviour are observed such as wandering, confusion, emotional
problems (such as irritability, aggression, emotional lability, anxiety) and delusions 
(Waldermar et al., 2007). At this stage, sufferers find it difficult to maintain independence 
and often require caregivers to help perform daily activities (Förstl & Kurz, 1999). Advanced 
AD is the final terminal stage, whereby communication is severely affected and patients 
suffer from extreme apathy and fatigue, resulting in complete dependence upon caregivers
(NIA, 2008). Eventually, bodily functions are lost and the disease results in death typically 
from secondary illness such as pneumonia (NIA, 2008).
Alzheimer’s disease can often go undiagnosed for many years before symptoms develop 
enough to become apparent. This is likely to account for the limited effectiveness of 
treatments which begin after the patient becomes symptomatic. The need for earlier diagnosis 
and thus treatment is therefore imperative. The next section will overview the core features 
that characterise the pathogenesis of AD.
1.3 Alzheimer’s disease: Pathogenesis
The theoretical characterisation of AD pathogenesis has evolved from early theories of 
cholinergic system disruption, to the now more generally accepted amyloid and tau 
hypotheses (Hardy & Allsop, 1991; Tiraboschi et al., 2004).  The amyloid cascade hypothesis 
5proposes that the production and/or accumulation of β-amyloid is critical to the onset of 
changes that culminate in plaque formation, tau pathology and eventually, neuronal loss. 
Other pathological mechanisms include neuroinflammation and oxidative stress (Tuppo &
Arias, 2005). Evidence suggests that these mechanisms are secondary to amyloid and tau 
pathology, but can further promote these pathological processes (Akiyama et al. 2000; Cai & 
Yan, 2007). The following sections will discuss how these factors lead to neurodegenerative 
loss and dysfunction in AD. 
1.3.1 Amyloid and APP
The current literature has focused on the hypothesis that beta-amyloid (Aβ) is the major 
causative factor in AD pathogenesis - a view that has received support from genetic and
histological evidence, along with animal studies (Hardy & Allsop, 1991). Masters et al. 
(1985) first recognised Aβ as the primary component of senile neuritic plaques, a major
pathological hallmark of AD. Soon after, the first genetic mutations associated with AD were
discovered on the APP gene localised on chromosome 21, which were found to promote the 
production of Aβ (Goate et al., 1991; Mullan et al., 1992). Further support for this 
proposition came from the observation that Down’s syndrome ‘Trisomy 21’ sufferers, also 
associated with a genetic abnormality on chromosome 21, develop AD and Aβ plaques
(Hardy & Allsop, 1991; Hardy & Selkoe, 2002). 
Aβ is formed from proteolysis of the amyloid precursor protein (APP). APP is an integral 
transmembrane glycoprotein found in many tissues, particularly neuronal synapses. Its 
primary function is undetermined, although has been implicated in neural plasticity, synapse 
formation and repair (Turner et al., 2003; Priller et al., 2006). APP can be cleaved by three 
types of enzymes: α-, β- and γ-secretase. Importantly, only sequential cleavage by β- and γ-
secretase produces Aβ in a process termed the “amyloidogenic pathway” (Boudrault et al.,
2009). As illustrated in Figure 1.1, APP is firstly cleaved by β-secretase (e.g. BACE1) at its 
NH2-terminus, to form the N-terminus of the peptide and two cleavage fragments. These two 
fragments include soluble βAPP (βAPPs, the secreted ectodomain) and the β-carboxyl 
terminal fragment C99 (β-CTF, a membrane bound fragment). This cleavage by β-secretase
is a prerequisite for Aβ formation. The C99 fragment is then further cleaved by γ-secretase (a 
complex of presenilin, nicastin, Aph1 and Pen2) to release AICD (γ-CTF) and the C-terminus 
6of Aβ from the membrane (Marlow et al., 2003). AICD interacts with transcription factors at 
the nucleus while Aβ is secreted into the extracellular space (Boudrault et al., 2009). 
Figure 1.1 Amyloidogenic and non-amyloidogenic pathways of APP processing. The amyloidogenic 
pathway involves the sequential proteolysis of APP by β- and γ-secretase to produce the Aβ peptide. 
The non-amyloidogenic pathway involves APP cleavage by α- and γ-secretase which does not result 
in Aβ production.
Alternatively, APP can be first processed by α-secretase in the “non-amyloidogenic pathway”
which prevents Aβ production (Figure 1.1). Here, α-secretase (e.g. TACE, ADAM9 and 
ADAM10 candidates) cleaves APP to form the αAPP soluble fragment (αAPPs, the secreted 
ectodomain) and the α-CTF, C83 (Lammich et al., 1999; Kojro & Fahrenholz, 2005). The 
C83 fragment can be further cleaved by γ-secretase to form P3 (a 3 kDa fragment) and AICD 
(Brunkan & Goate, 2005). 
It is important to note that APP is metabolised in all cells and Aβ is produced at ‘healthy’
levels in non-demented individuals, although this can increase as a consequence of age likely 
due to an imbalance in oxidation status (Shoji et al., 1992; Meydani, 2001). However, Aβ 
production is significantly increased in patients with AD relative to aged individuals (Hardy 
& Allsop, 1991). One possible reason for this is that APP mutations in FAD generally cluster 
at or near β- and γ-secretase protease cleavage sites, thereby promoting Aβ production 
(Citron et al., 1992; Cai, Golde & Younkin, 1993). In sporadic AD, a combination of genetic 
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(e.g. type II diabetes) can cause accelerated formation of Aβ. Such examples are outlined in 
section 1.5. For example, hypercholesterolemia resulting from excess low-density lipoprotein 
(LDL) ‘bad’ cholesterol in the diet is a known risk factor that can increase amyloidosis 
(Refolo et al., 2000; Puglielli, Tanzi & Kovacs, 2003). Elevated cholesterol may 
accommodate Aβ production since cholesterol is an integral component of lipid rafts where 
amyloidogenic pathways of APP processing occur (Wahrle et al., 2002; Ehehalt et al., 2003; 
Vetrivel et al., 2004). 
The overproduction of Aβ is central to the sequence of pathological events leading to AD 
development and progression (Näslund et al., 2000; Selkoe, 2000, 2001). Firstly, soluble 
monomeric Aβ aggregate to form oligomeric forms which are particularly neurotoxic and 
associated with cognitive decline in AD (Lue et al., 1999; Hardy & Selkoe, 2002). Secondly, 
Aβ folds incorrectly, accumulates and aggregates to form insoluble fibrils and deposits in the 
form of senile neuritic plaques which disrupt neuronal function (Hardy & Allsop, 1991).
Finally, Aβ production can have downstream effects such as initiating the onset of tau 
pathology, neuroinflammation and oxidative stress, which together leads to further neuronal 
damage and Aβ production (Akiyama et al., 2000; Lewis et al., 2001; Hardy & Selkoe, 2002). 
1.3.2 Tau and neurofibrillary tangles
Tau proteins are known as microtubule-associated proteins where their primary function is to 
regulate the assembly and stability of axonal microtubules in neurons by interacting with 
tubulin, the structural component of microtubules (Weingarten et al., 1975; Cleveland, Hwo 
& Kirschner, 1977). One of the characteristic hallmarks of AD is the abnormal aggregation of 
tau proteins leading to the formation of neurofibrillary tangles (NFTs) (Schneider & 
Mandelkow, 2008). Although the molecular mechanisms are not well understood, the tau 
hypothesis proposes that tau becomes saturated with phosphates in a process termed 
‘hyperphosphorylation’, which prevents microtubule binding and results in its detachment 
from microtubules (Schneider & Mandelkow, 2008). This leads to microtubule instability and 
disintegration, and leads to disruption of axonal transport and synaptic degeneration 
(Mandelkow & Mandelkow, 1998; Hernández & Avila, 2007). Furthermore, the detached tau 
aggregate into self-assembled paired helical filaments (PHFs) which bundle together to form 
intracellular NFTs (see Figure 1.2; Hernández & Avila, 2007). Ultimately this obstructs 
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to further neurodegeneration (Mandelkow et al., 2003). Oxidative damage can also be 
induced which exacerbates neurodegeneration (Stamer et al., 2002).
The number of NFTs strongly correlates with the degree of cognitive decline and 
neurodegeneration in AD patients (Arriagada et al., 1992; Thal et al., 2000). The majority of 
NFTs are distributed in Aβ-affected brain regions, including the entorhinal region, 
hippocampus and frontal cortex (Arriagada et al., 1992). Although genetic tau mutations are 
not associated with AD, the identification of tau mutations in other neurodegenerative 
diseases, such as frontotemporal dementia, has highlighted its causative role in 
neurodegeneration (Poorkaj et al., 1998; Spillantini et al., 1998).
Figure 1.2 Section from an AD human brain showing pyramidal cells with tau neurofibrillary tangles 
within the hippocampal CA1 region (sourced from Schneider & Mandelkow, 2008).
1.3.3 Neuroinflammation
Neuroinflammation in the brain is a common feature of AD and is detected early before 
clinical onset (Engelhart et al., 2004). Most inflammatory pathways have been implicated in 
AD, as comprehensively reviewed in Akiyama et al. (2000) and Tuppo and Arias (2005). For 
example, upregulation of complement molecules, chemokines, cyclooxygenase, eicosanoids 
and cytokines such as IL-1β, IL-6 and TNF-α are detected in the AD brain (e.g. Kitamura et 
al., 1999; Xia & Hyman, 1999; Swardfager et al., 2010). Activation of inflammatory cells, 
microglia and astrocytes, are elevated and are often clustered at sites of Aβ deposition (e.g. 
Mrak, Sheng & Griffin, 1996; Ishizuka et al., 1997; Frautschy et al., 1998). Similarly, COX 
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distribution suggests that these pathological hallmarks are involved in inflammatory
development. Indeed, tau, Aβ and even APP have been shown to upregulate inflammation 
(e.g. Chong, 1997; Rogers et al., 1998; Suo et al., 1998). The development of these 
pathological hallmarks from early preclinical to advanced stages of AD therefore leads to a 
chronic state of neuroinflammation (Akiyama et al., 2000).
Chronic neuroinflammation has been shown to cause significant neuronal damage and
behavioural dysfunction, highlighting its role in AD (e.g. Giulian et al., 1995; Heyser et al., 
1997; Parachikova et al., 2007). Furthermore, inflammatory mediators can significantly 
increase pathological processes including amyloid pathology, tau phosphorylation, oxidative 
stress and can further perpetuate inflammation (e.g. Mackenzie, Hao & Muoz, 1995; 
McDonald et al., 1997, 1998; Griffin et al., 1998; Guo et al., 2002; Qin et al., 2003). This 
reciprocal relationship whereby inflammatory mechanisms both induce and are induced by 
AD pathology can therefore lead to a positive feedback cycle of greater neuroinflammation 
and amyloid/tau pathogenesis.
1.3.4 Oxidative stress
Oxidative stress is a disturbed redox state whereby antioxidant processes are unable to 
detoxify overproduced reactive oxygen species (ROS) such as free radicals and peroxides 
(Tuppo & Arias, 2005; Cai & Yan, 2007). These highly reactive molecules are free to interact 
with cells, driven by molecular instability, causing considerable damage to cells and results in 
a greater state of oxidative stress (Chauhan & Chauhan, 2006). Oxidative stress is a key 
feature of AD. Increased manifestations of oxidative stress are consistently shown in AD 
including lipid peroxidation, protein and DNA oxidation (Markesbery, 1997; Butterfield et 
al., 2001; Cai & Yan, 2007). These are detected from an early stage in AD and in multiple 
brain regions including the frontal, temporal, parietal and occipital cortices (Williams et al., 
2006; Zafrilla et al., 2006). Manifestations are particularly marked in histopathologically-
affected areas (Palmer & Burns, 1994).
It is generally accepted that oxidative stress significantly contributes to AD pathogenesis 
including the development of Aβ, NFTs and chronic neuroinflammation (e.g. Gamblin et al., 
2000; Chauhan & Chauhan, 2006; Cai & Yan, 2007; Smith, Cappai & Barnham, 2007). For 
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example, it has been proposed that oxidative damage to DNA may result in altered protein 
synthesis, leading to abnormal tau and amyloid production in AD (Gabbita, Lovell & 
Markesbery, 1998; Markesbery & Lovell, 2006). The ‘mitochondrial cascade hypothesis’ 
also proposes that oxidative damage to mitochondria leads to amplification of ROS 
production which causes increased Aβ, tau pathology and apoptotic neuronal cell loss 
(Swerdlow & Khan, 2004; supported by Cardoso et al., 2004; Mancuso et al., 2007; Reddy, 
2009). Conversely, Aβ, tau and neuroinflammation processes have also been shown to 
increase oxidative stress (e.g. Butterfield & Lauderback, 2002; Behl, 2005; Chauhan & 
Chauhan, 2006; Cai & Yan, 2007). Oxidative stress is therefore a potential target for AD 
therapeutic intervention. Current treatments under investigation include antioxidant 
compounds such as vitamin C, vitamin E and curcumin (Butterfield et al., 2002). 
1.4 Therapeutic interventions for Alzheimer’s disease
1.4.1 Aβ-based therapeutic strategies
A number of strategies are being investigated which target Aβ pathology. For example, active 
and passive anti-Aβ immunisation has shown some success in clearing Aβ and alleviating 
Aβ-induced cognitive deficits in mouse models of AD (e.g. Bard et al., 2000; DeMattos et al.,
2001; Jensen et al., 2005), although clinical trials in AD patients have been halted due to 
complications (as reviewed in Hawkes & McLaurin, 2007 and Dodel et al., 2010). Other 
studies have reported inhibition of Aβ oligomerisation and aggregation by compounds such 
as apomorphine and metal chelators such as clioquinol (e.g. Lashuel et al., 2002; Walsh et al., 
2005; Allana et al., 2009). Approaches that reduce Aβ production by modulating APP 
processing have been proposed, such as β- and γ-secretase inhibitors (Yin et al., 2007). For
example, Semagacestat is a γ-secretase inhibitor and Tarenflurbil modulates γ-secretase to 
selectively lower Aβ42 for shorter less toxic Aβ peptides (Citron, 2004). Aβ production may 
also be reduced by altering dietary intake of cholesterol or saturated fatty acids. The latter are
major components of lipid raft membranes where amyloidogenic APP processing occurs 
(Ehehalt et al., 2003). Further support for the role of lipid rafts in AD pathogenesis comes 
from Aβ-reducing effects of cholesterol-lowering drugs such as statins (Jick et al., 2000; 
Fassbender et al., 2001). Other strategies being investigated are anti-inflammatory and 
antioxidant compounds (Citron, 2004), which are examined in this thesis.
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1.4.2 Tau-based therapeutic strategies
A number of approaches that could target tau pathology are being examined, such as the 
inhibition of kinases and phosphatases involved in tau phosphorylation (Kosik et al., 2002; 
Pei et al., 2003; Noble et al., 2005) and microtubule-stabilising agents to counteract the 
effects of hyperphosphorylated tau, such as Taxol (Parness & Horwitz, 1981; Boutté et al. 
2005; Michealis et al., 2005). Tau aggregates could also be cleared using anti-tau 
immunotherapy (e.g. Asuni et al., 2007; Chai et al., 2011) or compounds which activate tau 
degradation pathways (e.g. Ravikumar, Duden & Rubinsztein, 2002). Tau aggregation could 
also be inhibited using anti-aggregation substances (e.g. Doody et al., 2008; Harrington et al.,
2008; Bulic et al., 2010). Furthermore, due to the relationship between tau and Aβ 
development, tau has also been shown to be reduced by targeting Aβ production (e.g. Oddo et 
al., 2004). Although such therapies remain in their infancy of development, they are receiving 
greater attention and are on the verge of providing new AD treatment strategies within a few 
years (Medina, 2011).
1.4.3 Anti-inflammatory drug studies
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, aspirin and
indomethacin have been shown to reduce neuroinflammation, slow Aβ pathology and provide 
cognitive protection in AD models (e.g. Rogers et al., 1993; Lim et al., 2000; as reviewed in 
Cole & Frautschy, 2010). Epidemiological studies have also shown NSAIDs to lower the risk 
of AD and slow disease progression (in t’ Veld et al., 2001; Zandi et al., 2002; McGeer & 
McGeer, 2007). Unfortunately however, these drugs have shown limited therapeutic effect in 
human clinical trials, perhaps due to the primary action of COX inhibition which is 
predominately expressed during preclinical not late stages of AD (McGeer & McGeer, 2007; 
Yermakova & O’Banion, 2001; Hoozemans & O’Banion, 2005). Furthermore, NSAID drugs 
that inhibit COX-1 activity are not suitable for chronic use due to side-effects such as 
gastrointestinal problems (Soll et al., 1991). Steroidal anti-inflammatory drugs, such as 
synthetic glucocorticoids, have had positive effects in reducing neuroinflammation in AD 
patients (Aisen et al., 1996); although this has not been supported in other clinical trials and 
epidemiological studies (e.g. Aisen et al., 2000; as reviewed in Akiyama et al., 2000). Their 
use is therefore not recommended, particularly since glucocorticoid administration has been 
shown to increase Aβ and tau pathology (Green et al., 2006; Wang et al., 2010). This 
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therefore warrants further investigation into other anti-inflammatory treatments. One such 
strategy is the dietary supplementation of natural compounds possessing anti-inflammatory 
properties. This is discussed further in section 1.6.
1.5 Alzheimer’s disease risk factors
AD is a complex disorder with a number of risk factors, primarily including genetics (cf. 
section 1.1), age in LOAD (Hebert et al., 2003; Bermejo-Pareja et al., 2008) and health-
related conditions such as cardiovascular disease (Stampfer, 2006; Rosendorff, Beeri & 
Silverman, 2007) and Type II diabetes or insulin malfunction (Farris et al., 2003; Luchsinger
et al., 2004; Biessels et al., 2006). In addition to this, AD risk is influenced by environmental 
factors such as physical exercise (Larson et al., 2006; Scarmeas et al., 2009), mental 
stimulation and social engagement (Wilson et al., 2002; Bennett et al., 2006). Another 
important factor is diet, which will be considered in section 1.6.
1.6 Effect of diet in protecting against Alzheimer’s disease
This section aims to overview the current literature surrounding the influence of diet in AD 
and its potential for therapeutic intervention. A general introduction to the forms of dietary 
intervention currently investigated will first be described, followed by a more detailed 
analysis of human and animal studies regarding the affect of omega-3 fatty acids and the 
polyphenolic compound curcumin on cognitive decline and AD pathology. 
It is well documented that eating a healthy balanced diet can reduce the incidence of many 
chronic diseases, such as heart disease, and there is rising evidence that the same is applicable 
to AD (Scarmeas et al., 2009). Epidemiological evidence suggests that certain nutritional 
factors can increase or decrease the risk of AD, and clinical studies in patients and mouse 
models highlight the important contribution of diet to AD pathogenesis (Morris, 2004). For 
example, eating a Mediterranean diet is associated with reduced incidence of AD and 
dementia (Scarmeas et al., 2006, 2007, 2009). A number of dietary compounds have been 
found to have a beneficial effect in reducing the risk, symptoms and pathology of AD, 
including vitamin C and E, curcumin, garlic extract, Ginkgo biloba extract, green tea and red 
wine (Morris et al., 2004; Frank & Gupta, 2005). A common feature of these compounds is 
their antioxidant and anti-inflammatory actions (Akiyama et al., 2000). Moreover, these 
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compounds also have beneficial effects on Aβ-induced toxicity and restoring abnormal 
neurotransmitter release (e.g. Kim et al., 2004). These putatively therapeutic dietary
supplements can be generally categorised into polyphenols, vitamins and fatty acids.
1.6.1 Polyphenols
Polyphenols are molecules containing multiple phenolic hydroxyl groups that are commonly 
sourced from fruit, plants and their extracts (Butterfield et al., 2002). They have potent 
antioxidant properties denoted by the number of hydroxyl groups on the aromatic phenyl 
rings (van Acker et al., 1996). The grape-derived polyphenol resveratrol and red wine have 
been shown to reduce oxidative stress, neuronal damage, AD risk and even Aβ and tau 
development (e.g. Orgogozo et al., 1997; Bastianetto, Zheng & Quirion, 2000; Wang et al.,
2008, 2010). Similarly, green tea leaves and their extracts are highly abundant in polyphenols 
and have shown to be neuroprotective against Aβ toxicity, reduce oxidative stress and 
improve cognitive function (e.g. Serafini, Ghiselli & Fero-Luzzi Ghiselli, 1996; Choi et al.,
2001; Kim et al., 2004; Weinreb et al., 2004). However, Foster et al. (1995) reported no 
significant benefits in AD patients. Polyphenolic Ginkgo biloba leaves and its EGb 761 
extract are also neuroprotective against oxidative stress and Aβ toxicity, can improve 
cognitive function in AD patients and animal models, and increases non-amyloidogenic APP 
processing (e.g. Le Bars et al., 1997, 2002, 2003; Schindowski et al., 2001; Yao, Drieu & 
Papadopoulos, 2001; Stackman et al., 2003; Colciaghi et al., 2004). As a result, EGb 761 is 
currently approved for dementia treatment in Germany (Butterfield et al., 2002). Similar 
effects have been described for the polyphenolic compound curcumin, which is discussed in 
section 1.6.4.
1.6.2 Vitamins
Vitamin intake is thought to influence AD. Firstly, AD patients have low or deficient levels 
of vitamins B12, C and E, which was correlated with cognitive decline (Levitt & Karlinsky,
1992; McCaddon & Kelly, 1994; Riviere et al., 1998; Perkins et al., 1999). The potent 
antioxidant vitamin E was found to alter processes involved in AD including reduced Aβ-
induced oxidative stress, neuronal damage and behavioural deficits (Butterfield et al., 1999; 
Yamada et al., 1999; Yatin et al., 2000). Furthermore, vitamin E and high levels of combined 
vitamin C and E was related to reduced AD risk and incidence (Morris et al., 2002; 
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Engelhart, Geerling & Ruitenberg, 2002; Morris et al., 1998, 2005; Zandi et al., 2004). Sano 
et al. (1997) also reported positive effects of vitamin E supplementation in a clinical trial of 
AD patients. Similarly, supplementation of vitamin B1 and B12 showed clinical improvements 
in AD and dementia patients (Meador et al., 1993; Mimori, Katsuoka & Nakamura, 1996; 
Nilsson et al., 2000). Although many studies have demonstrated potential use of these 
vitamins for AD treatment, clinical trials have produced mixed results. For example, vitamin 
B1 treatment was shown to have no beneficial effect in AD (e.g. Nolan et al. 1991). Similar 
reports have been found with vitamin E (e.g. Petersen et al. 2005).
1.6.3 Omega-3 polyunsaturated fatty acids (PUFAs)
Omega-3 (ω-3) PUFAs are carbon chains with three or more double bonds, characterised by 
the first double bond in the n-3 position which is between the third and fourth carbons from 
the terminal methyl end (Boudrault et al., 2009). The three major omega-3 PUFAs are α-
linolenic acid (ALA, 18:3ω-3), docosahexanoic acid (DHA, 22:6ω-3) and eicosapentaenoic 
acid (EPA, 20:5ω-3). The nomenclature of DHA for example, 22:6, indicates a 22-carbon 
chain with 6 double bonds. Omega-3 PUFAs are known as essential fatty acids as they are 
crucial for normal biological processes within the body, particularly brain health. Omega-3 
PUFAs must be obtained through the diet as they cannot be synthesised de novo within the 
body; although long-chain omega-3 PUFA, such as DHA and EPA, can be formed from the 
short-chain ALA, and DHA can be derived from the shorter-chain EPA (DeMar et al., 2008; 
Gao et al., 2009). However it is important that high levels are consumed in the diet as 
conversion from ALA is inefficient (ranging from <0.2% to 8%; Gerster, 1998; Pawlosky et 
al., 2001; Brenna, 2002; Burdge & Caulder, 2005). Furthermore, brain uptake of preformed 
DHA is 7 times greater than DHA derived from ALA (Su et al., 1999).
DHA and EPA are predominantly sourced from fish oils and cold-water oily fish including 
salmon, mackerel and herring (Whelan & Rust, 2006). Fish do not synthesize omega-3 PUFA 
but obtain them from the algae or plankton in their diet (Falk-Petersen et al., 1998). 
Microalgae, such as Crypthecodinium cohnii and Schizochytrium, are therefore commonly 
grown to commercially produce DHA and EPA which are readily added to foodstuffs or 
capsuled for supplementation (e.g. Martek, 2007). Omega-3 PUFA can also be sourced at 
lower levels from vegetables, vegetable oils, fruits, grains and seeds such as flaxseeds 
(Whelan & Rust, 2006).
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i) The importance of omega-3 PUFAs for brain health and cognitive status
Omega-3 PUFAs are crucial for normal brain health and cognitive status. DHA is the most 
abundant PUFA in the brain, where it is an integral component of neural membrane 
phospholipids and is particularly concentrated in synaptic membranes, myelin sheaths, 
synaptic vesicles and growth cones (Horrocks & Farooqui, 2004). It has great neuronal 
demand in the brain due to its high turnover in maintaining neural membranes (Farooqui & 
Horrocks, 2001). Specifically, DHA accounts for 10-20% of total brain fatty acid 
composition in humans and rodents (McNamara & Carlson, 2006), 8% of the brain dry 
weight (Muskiet et al., 2006) and 50% of the neuronal plasma membrane weight (Singh,
2005). In contrast, other omega-3 PUFAs including EPA and ALA comprise less than <1% 
of total brain fatty acids (McNamara & Carlson, 2006). Omega-3 PUFAs play a major role in
neuronal growth and repair, neurotransmission, gene expression, membrane-bound enzyme 
and ion channel activities, intracellular and intercellular signalling, and synaptic plasticity (as 
reviewed in Horrocks & Farooqui, 2004; McNamara & Carlson, 2006). 
                                                                                                     
Consistent with the importance of DHA in the brain structure and function, reduced brain 
DHA in healthy aged individuals has been associated with impaired neuronal and cognitive 
function (Horrocks & Yeo, 1999). Interestingly, animal studies have shown age-related 
dysfunction can be ameliorated with DHA supplementation (Favrelière et al., 2003).
Epidemiological studies have also shown that consumption of omega-3 PUFAs and fish 
(containing omega-3 PUFA) is associated with a reduced risk of cognitive dysfunction in a 
middle-aged population (Kalmijn et al., 2004) and cognitive decline in an elderly population 
(van Gelder et al., 2007). Although inconsistent results have been reported (Kalmijn et al.,
1997b; Morris et al., 2005), van Gelder et al. (2007) argued that this may be attributable to a 
shorter follow-up and less accurate information regarding omega-3 sources. Heude, 
Ducimetiere and Berr (2003) also reported a reduced risk of cognitive decline with higher 
plasma levels of omega-3 PUFAs. Similarly, reduced omega-3 PUFA intake or DHA 
deficiency in tissue sample measures was reported in neurological disorders including forms 
of depression, attention deficit hyperactivity disorders and schizophrenia (e.g. Mahadik et al.,
1996; Burgess et al., 2000; Su et al., 2003). Interesting, omega-3 PUFA supplementation 
exerted clinical improvements in these disorders (e.g. Yoshida, Sato & Okuyama, 1998; Su et 
al., 2003; Richardson, 2006; Bélanger et al., 2009).
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Similar to epidemiological studies, a randomized double-blind placebo-controlled multi-
centre clinical trial reported DHA supplementation reduced age-related cognitive dysfunction 
in healthy aged individuals (Yurko-Mauro et al., 2009). However, this was not supported in 
similar clinical trials of DHA and omega-3 PUFA (EPA+DHA) supplementation using a 
number of doses matching or exceeding equivalent intake in epidemiological studies 
(Johnson et al., 2008; van de Rest et al., 2005, 2008; Dangour et al., 2010). However, it is 
important to note that clinical trials are much shorter than epidemiological studies, which 
may limit the detection of effects (Dangour et al., 2010; Quinn et al., 2010). For example, 
significant cognitive decline is not observed in healthy elderly individuals over short periods 
of time, and dietary interventions are relatively short in clinical trials compared to long-term 
dietary choices in epidemiological studies.
ii) The association between omega-3 PUFAs and Alzheimer’s disease
There is strong evidence of a link between AD and omega-3 PUFA, particularly DHA. 
Firstly, DHA levels are markedly reduced in the brain (Söderberg et al., 1991; Prasad et al.,
1998; Lukiw et al., 2005) and serum (Kyle et al., 1999; Conquer et al., 2000; Tully et al.,
2003; Beydoun et al., 2007) of AD patients compared to age-matched controls. This is 
particularly the case in affected brain regions such as the frontal cortex and hippocampus 
(Söderberg et al., 1991). Although these reports are not always consistent (Skinner et al.,
1993; Corrigan et al., 1998; Prasad et al., 1998), it is evident that DHA levels are altered in 
most cases in at least one area of the brain (Cunnane et al., 2007). Supporting this, Schaefer 
et al. (2006) reported high DHA plasma levels were associated with low AD risk. It is 
proposed that the DHA deficiency in AD may be attributable to low dietary intake, metabolic 
alterations or oxidative damage. For example, the stimulation of plasmalogen-selective 
phospholipase A2 enzymes in AD may suggest increased release and metabolism of DHA, 
resulting in low levels (Farooqui, Rapoport & Horrocks, 1997; Farooqui, Ong & Horrocks,
2003). However, this has been considered unlikely as Lukiw et al. (2005) reported a 
reduction in DHA metabolites including neuroprotectin D1. In contrast, a reduction of brain 
DHA by oxidative processes has received strong support from evidence of increased lipid 
peroxidation products in AD, including DHA (Subbarao, Richardson & Ang, 1990; Praticò et 
al., 1998; Nourooz-Zadeh et al., 1999; Reich et al., 2001; Yao et al., 2003; Montine et al.,
2004). Furthermore, these markers have been highly correlated with disease severity 
(Montine et al., 2002).
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Epidemiological studies have shown high omega-3 PUFA or DHA intake to be associated 
with reduced incidence of AD (Friedland, 2003; Morris et al., 2003) and dementia 
(Barberger-Gateau et al., 2007). Further support for this has emerged from regular fish 
consumption, which is high in omega-3 PUFAs (Kalmijn et al., 1997a; Barberger-Gateau et 
al., 2002, 2007; Friedland, 2003; Morris et al., 2003; Albanese et al., 2009). Indeed, Huang et 
al. (2005) reported this association was applicable to fatty but not lean fish, which are 
particularly high in omega-3 PUFAs. However, it should be noted that these epidemiological 
findings on omega-3 PUFA and fish intake have not been consistently supported (Engelhart,
Geerling & Ruitenberg, 2002; Devore et al., 2009). Studies in animal models of AD showing 
a therapeutic effect of omega-3 PUFA supplementation (reviewed in section 1.6.3 v) however 
provides support for the former results. Overall, these epidemiological results may explain 
why AD incidence is particularly high in Western societies, where the diet is omega-3 PUFA 
deficient. For example, the daily DHA intake in America is predicted to be ~80mg, which is 
less than half the intake reported in low-dementia groups (200mg/day) of epidemiological 
studies (Cole, Ma & Frautschy, 2009). Similarly, the high incidence of AD in Western 
societies may be related to the high intake of saturated fat, omega-6 PUFA and cholesterol,
which appears to increase the risk of AD (Kalmijn et al., 1997a; Barberger-Gateau et al.,
2007; Beydoun et al., 2007). Further supporting this, epidemiological studies show that a 
Mediterranean diet high in omega-3 PUFA is associated with lowered incidence of AD and 
MCI (Scarmeas et al., 2007, 2009).
iii) Potential mechanisms of omega-3 PUFAs in Alzheimer’s disease
The following subsections will discuss the potential mechanisms by which omega-3 PUFAs 
could reduce the risk, incidence, pathology or symptoms of AD. This evidence has come 
from a mixture of in vivo and in vitro studies. Overall, this section demonstrates that omega-3 
PUFAs have the potential to affect AD pathogenesis in a number of ways, including a 
reduction of disease processes and improvements in neuronal and memory function.
A. Affects on amyloid pathology
There is substantial empirical evidence that omega-3 PUFAs can reduce amyloid pathology 
both in vivo and in vitro (e.g. Lim et al., 2005; Lukiw et al., 2005; Oksman et al., 2006; 
Boudrault et al., 2009). Although in vivo studies cannot dismiss Aβ reduction through 
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indirect mechanisms, such as effects on neuroinflammation, several in vitro studies have 
shown omega-3 PUFA to reduce Aβ directly, as discussed below.
Sorting, transport and clearance of APP and Aβ
Omega-3 PUFAs increase levels of the Aβ/APP transport proteins transthyretin (TTR) and 
SORLA1 (LR11) both in vivo and in vitro (Puskás et al., 2003; Barceló-Coblijn et al., 2003; 
Ma et al., 2007). This may in turn reduce Aβ pathology as TTR can cleave Aβ, and inhibit Aβ 
aggregation and fibril formation through its sequestering and binding action (Stein & 
Johnson, 2002; Costa et al., 2008). In contrast, LR11 regulates intracellular transport of APP 
to reduce its processing into Aβ (Andersen et al., 2005; Cam & Bu, 2006; Spoelgen et al.,
2006). Supporting this, LOAD sufferers have reduced LR11 which accelerate APP trafficking 
into endocytic Aβ-generating compartments thus increasing Aβ production (Dodson et al.,
2006; Offe et al., 2006). Both genetic (inherited LR11 gene polymorphisms) and 
environmental factors (regulated by lipid intake) contribute to this reduction in LOAD (Ma et 
al., 2007; Rogaeva et al., 2007). Although a reduction in TTR by omega-3 PUFAs have not
been consistently reported (Ma et al., 2007; Lim et al., 2005; Green et al., 2007), this 
highlights the potential involvement of other Aβ-reducing mechanisms.
Aβ degrading enzymes
Omega-3 PUFAs may reduce Aβ pathology by increasing the insulin-degrading enzyme IDE 
that degrades Aβ (Farris et al., 2003, 2004). Alterations to the IDE gene are associated with 
AD risk and IDE is reduced in patients with AD (Ertekin-Taner et al., 2004; Cook et al.,
2003; Caccamo et al., 2005). Although no evidence has directly supported that increased 
dietary DHA can increase IDE (Green et al., 2007; Ma et al., 2007), Zhao et al. (2004) 
reported a low-DHA diet reduced IDE resulting in increased Aβ monomers. Under certain 
conditions, this suggests that a high DHA diet could increase IDE and therefore reduce Aβ. 
For example, IDE expression is regulated by PI3-K/Akt pathway, which is altered by DHA
intake (Calon et al., 2004; Akbar et al., 2005). 
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APP processing and subsequent Aβ production
DHA supplementation reduced the γ-secretase PS1 component in vivo and in vitro and 
reduced Aβ levels (Green et al., 2007). Cole and Frautschy (2006) also found omega-3 PUFA 
limited γ-secretase activity by suppressing glycogen synthase kinase alpha (GSKα) via 
increasing PI3-K/Akt activity. DHA has also been shown to inhibit Aβ formation in vitro by 
inhibiting both α- and β-secretase activity (de Wilde et al., 2003). Supporting this, Lim et al. 
(2005) found a DHA-depleted diet to increase APP proteolysis by α- and β-secretase and
increased Aβ levels in vivo. This was then reduced with DHA supplementation. In contrast 
however, α- and β-secretase has been reportedly unaffected by DHA supplementation in vivo
(Green et al., 2007; Ma et al., 2007). DHA is also thought to reduce Aβ production by 
regulating the lipid microdomains where APP is processed (Lim et al., 2005; Boudrault et al.,
2009). Non-amyloidogenic APP processing is believed to occur in caveolae, whereas 
amyloidogenic APP processing is believed to occur in lipid rafts (Ikezu et al., 1998; Ehehalt 
et al., 2003; Kawarabayashi et al., 2004). DHA is thought to encourage non-amyloidogenic 
pathways competitively over amyloidogenic pathways by affecting the relative proportion of 
these lipid microdomains, as well as their composition and functional properties (Shaikh et 
al., 2003; Ma et al., 2004; Hashimoto et al., 2005a; Eckert et al., 2011). 
Aβ formation
Omega-3 PUFA can reduce the formation of oligomeric Aβ and subsequent mature fibrils in 
vitro (Hashimoto et al., 2009b). Although mechanisms remain elusive, DHA is thought to 
inhibit β-sheet transformation from α-helix monomers. Hashimoto et al. (2009b) reported 
DHA to prevent fibril formation by altering the morphology of Aβ fibres to highly 
unstructured and amorphous granular aggregates rather than normal ribbon-like structured 
forms. Similarly, Johansson et al. (2007) reported DHA to hinder Aβ fibrillisation by directly 
interacting with the Aβ peptide to stabilise oligomer species, thereby preventing Aβ-induced 
neurotoxicity.
B. Affects on tau pathology
DHA supplementation can reduce somatodendritic tau in an AD model expressing tau, APP 
and PS1 mutations (Green et al., 2007). The proposed mechanism was linked to a decrease in 
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Aβ levels (c.f., Oddo et al., 2004), and a reduction of tau phosphorylation as indicated by a 
reduction in early (but not late) phospho-tau epitopes and the tau kinase phospho-JNK (Green 
et al., 2007). Phospho-JNK, which is involved in tau phosphorylation, has also been reduced 
by DHA and EPA supplementation (Moon & Pestka, 2003; Xue et al., 2006). Since phospho-
JNK is a member of the stress-activated MAP kinase family, its reduction may be related to a 
decline in inflammation by DHA (see Davis, 1999; Kyriakis & Avruch, 2001). Interestingly, 
diets low in omega-3 PUFA can increase tau pathology without affecting Aβ (Julien et al.,
2010). In light of these studies, it is evident that tau pathology can therefore be modulated by 
omega-3 PUFA with mechanisms related to Aβ and neuroinflammation, and also independent 
of Aβ. Furthermore, omega-3 PUFAs may reduce tau pathology through its suppression of 
GSKα, which is involved in tau phosphorylation (Cole & Frautschy, 2006).
C. Modulation of inflammatory processes
Initial evidence that omega-3 PUFAs possess anti-inflammatory properties comes from 
clinical improvements in rheumatoid arthritis, psoriasis and ulcerated colitis following 
omega-3 PUFA treatment (as reviewed in Blok, Katan & van der Meer, 1996). The first 
mechanism whereby omega-3 PUFAs can reduce inflammation is by producing metabolites 
which exert potent anti-inflammatory effects, including resolvins, docosatrienes and 
protectins (Hong et al., 2003; Bazan, 2007; Dyall, 2010). For example, omega-3 PUFA 
metabolites can inhibit production and activity of cytokines, leukocytes, NfκB and COX (e.g. 
Marcheselli et al., 2003; Farooqui, Horrocks & Farooqui, 2007; Bazan, 2009). They can also 
agonise PPAR which is involved in the inhibition of inflammatory response genes 
(Chambrier et al., 2002; Yamamoto et al., 2005; Itoh et al., 2006). It is also important to note 
that these anti-inflammatory effects may reduce Aβ pathology as cytokines have been shown 
to increase β-secretase BACE1 expression, and PPARγ can increase Aβ uptake and clearance 
(Camacho et al., 2004; Sastre et al., 2003, 2006). 
A second mechanism by which omega-3 PUFAs can reduce inflammation is by lowering the 
level of omega-6 (ω-6) PUFAs in the brain that can stimulate pro-inflammatory eicosanoid 
metabolites including prostaglandins, leukotrienes and thromboxanes (Wu & Meydani, 1998; 
Calder & Grimble, 2002; Horrocks & Farooqui, 2004; Farooqui, Horrocks & Farooqui,
2007). These fatty acids interact competitively for relative incorporation into brain 
phospholipids, availability for metabolism (release by phospholipases) and metabolism by 
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COX enzymes (Russo, 2009). The relative intake of these fatty acids therefore determines the 
relative production of anti-inflammatory omega-3 PUFA metabolites or pro-inflammatory 
omega-6 PUFA metabolites. High levels of omega-3 PUFA intake, specifically relative to 
omega-6 PUFA, would therefore have anti-inflammatory effects. The relative shift in the ω-
6/ω-3 PUFA ratio by increasing omega-3 PUFA levels may explain the health benefits 
associated with high omega-3 PUFA intake and fish oils, which contain around seven times 
more omega-3 than omega-6 PUFA. A healthy ω-6/ω-3 ratio of 1:1 to 4:1 is recommended, 
although typical western diets currently provide skewed ratios of 10:1 to 30:1 (Simopoulos,
2002, 2003; Hibbeln et al., 2006) which may explain the increasing prevalence of AD in 
Western societies, since omega-6 PUFAs pro-inflammatory effects may acerbate AD 
pathology. This ratio should therefore be an important consideration during omega-3 PUFA 
intervention studies for AD.
D. Antioxidant effects
As outlined in section 1.3.4, oxidative stress is elevated in AD and promotes AD-related 
pathology and reduces brain DHA. Antioxidant protection may therefore restore brain DHA 
and reduce pathology. A number of studies have demonstrated the antioxidant properties of 
omega-3 PUFAs (as reviewed in Yavin, Brand & Green, 2002; Dyall, 2010). For example, 
omega-3 PUFA supplementation can reduce markers of oxidative stress such as protein 
carbonyls in humans (Mori et al., 2000) and animal models of AD with Aβ pathology 
(Hashimoto et al., 2002, 2005b; Calon et al., 2004). Furthermore, DHA supplementation 
increased antioxidant substances such as glutathione and antioxidant defence enzymes 
including catalase, glutathione peroxidise and glutathione reductase in hypercholesterolemic 
and Aβ-infused rats (e.g. Hossain et al., 1999; Hashimoto et al., 2002).
E. Affects on neural membrane structure and function
Synapses and dendritic spines are reduced in AD (Selkoe, 2002; Knobloch & Mansuy, 2008). 
This synaptic loss and resulting dysfunction is hypothesised to be the primary cause of AD 
cognitive changes, such as memory loss and is correlated better with synapse loss than Aβ 
plaques or NFTs (Montine et al., 2004). DHA plays a central role in neuronal structure and 
synaptogenesis, and its supplementation has been found to increase the number of synaptic 
proteins and dendritic spines (as reviewed in Wurtman et al., 2010). DHA supplementation                                                                                                                              
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also reversed synaptic deficits following DHA depletion in an AD mouse model (Cole & 
Frautschy, 2006). Consistent with these beneficial effects on the brain, DHA supplementation 
can improve cognitive function in rodents and mild-to-moderate AD patients (Holguin et al.,
2008a,b; Scheltens et al., 2008). Reduced brain DHA alters neural membrane activity by 
influencing neuronal conduction and transmission, neurotransmitters, enzymatic activities, 
receptors, ion channels and gene expression (as reviewed in Horrocks & Farooqui, 2004). 
Omega-3 supplementation however can correct these changes (as reviewed in Yehuda et al.,
2002; Horrocks & Farooqui, 2004). For example, fish oil containing omega-3 PUFAs can 
normalise synaptosomal Na+ and K+-ATPase activity (e.g. Gerbi et al., 1994) and gene 
expression controlling signal transduction, ion channel formation, regulatory proteins and 
synaptic plasticity (e.g. Kitajka et al., 2002; Barcelo-Coblijn et al., 2003). Furthermore, DHA 
supplementation can improve neural membrane conduction and transmission by reducing the 
impact of excess omega-6 PUFAs and membrane-bound cholesterol, which can cause 
membrane rigidity (Yehuda et al., 2002).
F. Modulation of memory processes
Omega-3 PUFAs may directly influence cellular mechanisms of learning and memory 
processes by modulating putative synaptic mechanisms of memory, i.e., the induction of 
long-term potentiation (LTP) and long-term depression (LTD) (Chen & Tonegawa, 1997). 
These terms describe activity-dependent long-term increases (LTP) and decreases (LTD) in 
synaptic strength that may model synaptic processes mediating learning and memory (Bliss & 
Collingridge, 1993; Linden & Conner, 1995). Since memory is encoded by synaptic strength, 
LTP is considered the major cellular mechanism underling enhanced learning and memory 
(Bliss & Collingridge, 1993). Studies have found endogenously released DHA to block LTD 
and trigger or restore LTP in a concentration-dependant manner (e.g. Young et al., 1998; 
McGahon et al., 1999; Fujita et al., 2001). Evidence has shown DHA to influence LTP and 
LTD processes by directly altering the cellular mechanisms involved including potassium 
channels, the NMDA receptor and phospholipase A2 (e.g. Nishikawa, Kimura & Akaik,
1994; Poling et al., 1995; Fujita et al., 2001; Calon et al., 2005). DHA may also influence 
synaptic plasticity by modulating the PI3-K pathway (e.g. Akbar et al., 2005), which is 
implicated in LTP induction (Sanna et al., 2002; Opazo et al., 2003). Since the level of 
endogenously released DHA is determined by phospholipid content and thereby dietary 
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intake, it is hypothesised that increasing dietary DHA could promote learning and memory 
processes.
G. Neuroprotection
The neuroprotective effect of DHA is well documented. Firstly, it can provide 
neuroprotection by reducing the toxic effects of Aβ, tau, inflammation and oxidative stress 
(as outlined previously; e.g. Wang, Chen & Su, 2010). Secondly, DHA has multiple 
neuroprotective effects by producing neuroprotectins such as NPD1, which is dramatically 
reduced in AD (Lukiw et al., 2005). NPD1 can downregulate pro-inflammatory genes, 
upregulate anti-apoptotic genes such as Bcl-2, Bcl-xl and Bfl-1, and protect against oxidative 
stress and Aβ-induced apoptosis (e.g. Lukiw et al., 2005; Bazan, 2005; Dyall et al., 2010). 
Consistent with this, DHA is reported to reduce markers of cell death, lower apoptosis and 
increase cell viability in neuronal and retinal cells (e.g. Kim et al., 2000; Rotstein et al., 2003; 
Florent et al., 2006). DHA can prevent neuronal apoptosis by increasing PI3-K/Akt 
signalling, inhibiting caspase-3 activity, reducing pro-apoptotic protein BAD and increasing 
phosphatides (e.g. Kim et al., 2000; Calon et al., 2004; Serhan et al., 2004; Akbar et al.,
2005). Finally, DHA can have neuroprotective activity by potentiating activation of 
neurotrophic factors such as brain derived neurotrophic factor (Wu, Ying & Gómez-Pinilla,
2004).
iv) Omega-3 PUFA clinical trials in Alzheimer’s disease and MCI patients 
Although a number of epidemiological studies may suggest that omega-3 may provide some 
clinical benefit for AD and dementia, randomised double-blind placebo-controlled clinical 
trials were required to investigate these claims under more controlled conditions. Yehuda et 
al. (1996) first reported that a daily ‘SR-3’ supplement containing relatively high levels of 
omega-3 PUFA (ω-3/ω-6 ratio of 1:4) for 4 weeks relative to a typical western diet high in 
omega-6 PUFAs had multiple symptomatic improvements in AD patients including improved 
short-term memory, navigation, mood, cooperation, appetite and sleep. Otsuka (2000) then 
reported that a prescription of 900mg/day EPA for 3 to 6 months improved cognitive function 
in AD patients, but effects ceased after 6 months suggesting only short-term therapeutic 
efficiency. In another clinical trial, Chiu et al. (2008) found 1800mg/day DHA and EPA for 6 
months to improve clinical condition (on a CIBIC-plus measure) in mild-to-moderate AD and 
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MCI patients compared to an olive oil placebo. The omega-3 PUFA supplement also 
improved cognition in MCI patients only, but no effects on cognitive decline could be 
attained as there was no cognitive change during the 6 month period. 
In contrast to these promising findings, many clinical trials have failed to support beneficial 
effects of omega-3 in AD patients, although no adverse effects have been reported. Boston et 
al. (2004) reported no cognitive or clinical benefit from 500mg/day ethyl-EPA administration 
for 3 months in AD patients. Freund-Levi et al. (2006) found omega-3 PUFA 
supplementation (1700mg DHA and 600mg EPA) for 6 months did not delay cognitive 
decline in mild-to-moderate AD patients, although positive cognitive effects were observed in 
a subgroup of very mild AD patients. Similarly, Kotani et al. (2006) reported that 3 month 
supplementation of 240mg/day DHA (plus 240mg/day ARA) improved cognitive dysfunction 
in MCI and brain lesion patients, but not AD patients. In order to examine whether DHA 
treatment was only effective during early stages of pathological development in AD, Quinn et 
al. (2010) designed a study to include subjects with probable AD diagnosis. This large 
clinical trial found 200mg/day algal DHA supplementation for 18 months did not slow the 
rate of cognitive and functional decline in mild-to-moderate AD patients compared to soy or 
corn oil placebo. 
Following this review of the current omega-3 PUFA literature, it is worth highlighting a 
number of common factors reported in these studies which may contribute to the observed 
effects. Firstly, higher doses of omega-3 PUFA supplementation were generally found to 
produce positive results in AD patients (Otsuka, 2000; Freund-Levi et al., 2006; Chiu et al.,
2008), in contrast to relatively low doses showing no effect in AD patients (Kotani et al.,
2006; Boston et al., 2004; Quinn et al., 2010). For example, the positive effect reported by 
Otsuka (2000) using 3-month EPA supplementation was almost double the EPA dose 
reported in the 3-month Boston et al. (2004) study. Interestingly, Freund-Levi et al. (2006) 
reported limited benefits in only very mild AD patients despite using the highest dose 
reported in clinical trials. This may suggest that extremely high doses may not be the optimal 
strategy. It is interesting that the relatively low dose supplemented in Quinn et al (2010) study 
was not beneficial, yet this was similar to levels reported as ‘protective’ in epidemiological 
studies and was higher than the average US dietary intake of omega-3 PUFA at 70mg/day. 
This therefore highlights that epidemiological findings are likely a result of an interaction of 
factors. 
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It remains unclear whether longitudinal supplementation is more effective than short-term, 
due to inconsistent results and a limited intervention period. The only study to report 
supplementation longer than 6 months was Quinn et al. (2010), reporting no benefits 
following 18-month treatment. However, the low dose and relatively short intervention 
period (compared to the period of high omega-3 PUFA intake in epidemiological studies) 
prevents the conclusion that longitudinal supplementation was ineffective. It is possible that 
positive effects may take longer to manifest or that omega-3 PUFAs may target AD at 
different stages of pathological development. In order to address this, longitudinal 
supplementation using a larger dose (perhaps similar to that used by Chiu et al., 2008) is 
recommended. Overall, EPA monotherapy is not recommended since the only study to report 
positive results found effects ceased over time. It is therefore possible that EPA and DHA co-
supplementation is necessary for positive results, although this remains unclear due to 
inconsistent reports. Further examination of DHA monotherapy is therefore recommended (at 
larger doses than reported by Quinn et al., 2010) since DHA may be the most bioactive 
omega-3 PUFA, suggested by its importance in the brain and its positive effects in 
epidemiological studies. Furthermore, DHA appeared to account for the majority of positive 
effects in reducing pathological mechanisms of AD, as outlined in section 1.6.3 iii.
Although clinical trial results on omega-3 PUFA treatment were not overall convincing, it 
should be outlined that clinical trials have several limitations. For example, treatments are 
applied over only a short period of time which may limit the detection of later-stage or long-
term effects. This may also prevent detection of effects as the level of clinical decline in 
which to observe effects is limited. Furthermore, treatments are applied once symptoms are 
present which does not assess the effect of early-stage treatment. Interestingly, some clinical 
trials reported beneficial effects of omega-3 PUFAs in very mild AD patients and MCI 
patients only (e.g. Freund-Levi et al., 2006; Kotani et al., 2006; Chui et al., 2008). This may 
suggest that omega-3 PUFAs are particularly effective when consumed during the very early 
stages of disease onset and may therefore influence early pathological processes. Clinical 
trials should aim to address these early stages (Cole & Frautschy, 2010), although the stage of 
diagnosis limits this. Studies using animal models of AD could therefore be used to shed 
some light on this.
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v) Omega-3 PUFA studies in animal models of Alzheimer’s disease
This section focuses on research carried out in rodents, although other studies have been 
carried out in higher species (e.g. Connor, Neuringer & Lin, 1990). This section provides an 
overview of studies investigating the effect of dietary omega-3 PUFAs in rodent models of 
AD. The main aim is to outline the experimental approach and results of these studies in 
order to examine the differences or similarities between their findings, and thus outline the 
theoretical justifications for the experimental designs used in this thesis. The following 
subsection will first outline the advantages of using animal studies to investigate dietary 
omega-3 PUFAs compared to human studies. 
A. Human vs. animal studies
Animal studies offer a valuable opportunity to examine disease intervention in a tightly 
controlled manner, in contrast to human studies which have many confounding factors. For 
example, the use of prospective questionnaires for epidemiological results may be imprecise 
regarding omega-3 PUFA intake (Boudrault et al., 2009). Furthermore, the putative effect of 
omega-3 PUFA intake may result from simultaneous intake of other dietary components 
(Devore et al., 2009). For example, the reduced risk of AD with high fish consumption could 
be related to healthier lifestyle choices adopted by fish-eaters, not omega-3 PUFAs or fish 
intake per se (Arendash et al., 2007). Discrepancies in epidemiological results may also be 
related to food preparation, which is not taken into account. For example, fish may be 
beneficial but not if fried in saturated or transfats (Devore et al., 2009). Clinical trials are also 
problematic (despite increased control) as external factors such as diet cannot be controlled. 
Another limitation is the accuracy of measuring omega-3 PUFAs in serum as a marker of 
brain status or dietary intake, which has mixed views (Ma et al., 1995; Beydoun et al., 2007; 
Kuratko & Salem, 2009). In contrast, animal studies allow direct measure of omega-3 PUFAs 
in the brain, serum and even precise measures and control of dietary intake (including omega-
3 PUFAs and complete nutritional content). Animal studies also allow longitudinal 
investigations which are impractical in human studies. This is particularly important when 
examining disease which develops over many years, since earlier exposures may 
fundamentally influence disease risk later in life (Launer, 2005). Animal studies have 
limitations however when applied to human disease due to their limited capacity to model 
disease states. Further details regarding animal models of AD are discussed in section 1.7.
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B. Affect of omega-3 PUFA administration in rat and transgenic mouse models of 
Alzheimer’s disease
A number of studies have examined the effect of omega-3 PUFA supplementation in rodent 
models of AD. Rat models are typically produced by the infusion of human Aβ40 into the 
cerebral ventricle, which causes accumulation of Aβ, oxidative stress, neuronal apoptosis, 
synaptic and cognitive deficits (Hashimoto et al., 2002, 2005a, 2005b, 2006). Interestingly, 
several studies have reported pre-administration of DHA or EPA before Aβ-infusion to 
protect against these Aβ-induced deficits (Hashimoto et al., 2002, 2006, 2009a). Hashimoto 
et al. (2005a,b) also reported amelioration of deficits with DHA administration following 
three generations of omega-3 PUFA deficiency. Overall these studies demonstrate the 
potential of EPA as well as DHA in reducing a number of Aβ40-induced deficits. Transgenic 
mice are also used to model aspects of pathology in AD by expressing genetic mutations that 
reproduce specific features of AD pathology such as increased Aβ and tau deposition (Hsiao 
et al., 1996; Oddo et al., 2003). An overview of these transgenic models is provided in 
section 1.7 and should be referred to for clarification of the models and their mutations
referred to below. In particular, these genetically modified models are useful in examining 
the effect of intervention strategies on AD-like pathology.
Several studies have also examined omega-3 PUFA treatment in the triple transgenic mouse 
model, which possesses APPswe, presenilin-1 (PS1) and tau mutations resulting in 
accelerated Aβ and tau pathology (Table 1.1). All published studies have reported some 
positive effects including reductions in tau accumulation, tau phosphorylation, Aβ levels and 
JNK activation, as well as improved memory and neuronal function. Interestingly, a 
reduction in Aβ levels has not been consistently reported. Nevertheless, these studies have 
demonstrated the potential of omega-3 PUFA supplementation in ameliorating tau and Aβ, as 
well as their associated deficits. One of the major criticisms that can be levied against these 
studies is that the choice of experimental control limits the conclusion that omega-3 PUFA 
supplementation per se can result in beneficial effects. For example, Green et al. (2007) 
reported positive effects of DHA supplementation relative to a diet depleted in omega-3 
PUFAs and containing almost double the amount of omega-6 PUFA. Similarly, Ma et al. 
(2009) reported positive effects of fish oil supplementation relative to a diet depleted in 
omega-3 PUFAs with high levels of saturated fat. Likewise, Arsenault et al. (2011) reported 
positive effects of fish oil supplementation relative to a diet high in omega-6 PUFA. 
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These differences in control diet may contribute to the apparent positive effects observed 
since diets with depleted omega-3 PUFA and high saturated, total or omega-6 fat can 
acerbate inflammation, oxidative stress, tau and Aβ pathology in transgenic models (e.g. 
Calon et al., 2004, 2005; Hooijmans et al., 2007; Ma et al., 2009; Julien et al., 2010). 
Furthermore, these factors can cause cognitive and neuronal dysfunction in healthy rodents 
(e.g. Gamoh et al., 1999; Greiner et al., 1999; Carrie et al., 2000; Moriguchi, Greiner & 
Salem, 2000; Ikemoto et al., 2001). To illustrate this point further, Green et al. (2007) 
reported the efficiency of DHA supplementation in reducing Aβ and tau pathology 
diminished after 6 months when co-supplemented with omega-6 PUFAs DPA or ARA, 
highlighting the detrimental effect of omega-6 PUFAs on pathology. In conclusion therefore, 
these studies show that omega-3 PUFA supplementation can be beneficial compared to 
conditions which may acerbate pathology or deficits. This may be particular relevant to AD 
patients in Western societies which have comparable diets. However, further examination 
into the effect of omega-3 PUFA supplementation compared to ‘neutral’ conditions is 
required to establish whether supplementation in a population consuming a healthy diet may 
ameliorate AD pathogenesis.
Several studies have also examined omega-3 PUFA treatment in double transgenic 
APPswe/PS1(dE9) mice expressing accelerated amyloid pathology (Table 1.2). All but one 
study demonstrated some positive effects including reductions in Aβ levels, deposits and 
plaque load, behavioural deficits, inflammatory markers and improved blood circulation. 
Although inconsistencies were found in amyloid load and the reduction of behavioural 
deficits, these studies demonstrate the potential of omega-3 PUFA supplementation 
ameliorating Aβ-induced deficits. Similar to studies in the triple transgenic model however, 
these effects may be attributable to differences in the control diet. For example, Oksman et al. 
(2006) found positive effects of fish oil relative to diets containing excess omega-6 PUFAs, 
and positive effects of omega-3 PUFAs relative to a diet containing excess omega-6 PUFAs
and two diets almost depleted in omega-3 PUFAs. Similarly, Hooijmans et al. (2007) 
compared omega-3 PUFA supplementation to control diets containing higher levels of 
omega-6 PUFAs or excess saturated fat. Hooijmans et al. (2009) compared omega-3 PUFA 
supplementation to control diets containing relatively depleted omega-3 PUFAs and excess 
saturated fat. Consequently, it can be concluded that omega-3 PUFA supplementation can be 
beneficial compared to conditions which may acerbate pathology or deficits. Again, further 
examination is required under ‘neutral’ control conditions. 
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In contrast to these studies, Arendash et al. (2007) reported no positive effects of 13% 
omega-3 PUFA supplementation in APPswe/PS1(dE9) mice. It is argued however that this be 
related to the high levels of omega-6 and saturated fatty acids in the omega-3 PUFA diet 
relative to control (despite the high ω-3/ω-6 ratio), which may have masked the positive 
effects of omega-3 PUFA supplementation. Furthermore, the null effect may be related to the 
lack of omega-3 PUFA incorporation into the brain of transgenic mice, as indicated by 
unaltered levels omega-3 and omega-6 PUFAs in the cortex. This study cannot therefore rule 
out the possibility that beneficial effects may be observed when omega-3 PUFA penetrates 
the brain, as shown in other studies (e.g. Calon et al., 2004; Oksman et al., 2006; Arsenault et 
al., 2011).
A number of studies have also examined DHA supplementation in the Tg2576 mouse model,
which expresses the APPswe mutation, amyloid pathology and Aβ-induced synaptic and 
behavioural deficits (Table 1.3). These studies are particularly relevant to this thesis as 
omega-3 PUFA supplementation was assessed in the Tg2576 model. These studies by 
Gregory Cole’s research group demonstrated positive effects of DHA administration 
including reductions in Aβ pathology, synaptic deficits and oxidative stress, and 
improvements in processes underlying learning and memory including changes to CaMKII, 
drebrin and caspase activation. One study also reported reduced spatial memory deficits. The 
potential mechanisms for reduced Aβ were also reported including reduced APP processing 
and increased LR11. Importantly however, the majority of positive effects were relative to a 
DHA-depleted diet containing almost double the amount of omega-6 PUFA linoleic acid, and 
as argued above, this may have contributed to the apparent beneficial effects. In contrast, few 
effects were observed with DHA supplementation relative to the standard diet containing a 
similar level of omega-6 PUFA and low level of total omega-3 PUFA (~0.3%) and 
cholesterol. The only significant effect of DHA supplementation relative to the standard diet
was a reduction in Aβ40. These results therefore suggest that DHA or omega-3 PUFA 
supplementation may not be beneficial in an AD model when relative to a normal baseline 
diet, and the most striking effects are observed against a poor-diet control group. In 
conclusion, further research is required to accurately examine whether omega-3 PUFA
supplementation is beneficial relative to a baseline diet that controls for factors which may 
alter pathology and its associated deficits.
Table 1.1 Omega-3 PUFA intervention studies in triple transgenic (APPswe, tau + PS1) model mice
Study Omega-3 PUFA diet Control diet Design Reported effects
Green DHA TWD Age: From 3 months ↓ Tau accumulation
et al. (2007) ω-3/ω-6 ratio = 1:1 ω-3/ω-6 ratio = 1:10 Length: 6 months ↓ Aβ40 + Aβ42 (Soluble and intraneuronal)
1.3% total ω-3 (DHA) 0.2% total ω-3 (ALA) No effect on insoluble Aβ
1.3% total ω-6 (ARA) 2.3% total ω-6 (ARA)
Ma HFBD + Fish oil (2.4%) HFBD Age: From 4 months Improved spatial memory in Y-maze
et al. (2009) ~0.6% DHA 0% total ω-3 Length: 5 months ↓ JNK activation (inflammatory mediator)
1.5% Cholesterol 1.5% Cholesterol ↓ Tau phosphorylation (trend only)
Safflower oil (high ω-6) Safflower oil (high ω-6) Improved insulin signalling (trend only)
No coconut oil = lower SAT Coconut oil (high SAT)
Arsenault Omega-3 PUFA fish oil High omega-6 PUFA diet Age: From 4 months ↓ Phosphorylated tau (soluble, not insoluble)
et al. (2011) ω-3/ω-6 ratio = 1:2.8 ω-3/ω-6 ratio = 1:10.4 Length: 8-10 months Improved N.O.R. memory in Tg + Non-Tg mice
9.5μM/g DHA 0μM/g DHA + EPA Improved entorhinal cortex neuronal function
~2μM/g EPA, 0.5μm/g ALA 7μM/g ALA No effect on Aβ40/42 (soluble + insoluble)
34μM/g ω-6 LA 67μM/g ω-6 LA No effect on pre-synaptic marker synaptophysin
No effect on post-synaptic marker PSD-95
HFBD = High fat bad diet, ω-3 = omega-3 PUFA, ω-6 = omega-6 PUFA, ↓ = Reduced, N.O.R. = Novel object recognition, μM = μmole, SAT = 
Saturated fat, TWD = Typical Western Diet, LA = linoleic acid (major omega-6 PUFA), ALA = α-linolenic acid (omega-3 PUFA).
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Table 1.2 Omega-3 PUFA intervention studies in double transgenic APPswe/PS1(dE9) model mice.
Study Omega-3 PUFA diet Control diet Design Reported effects
Oksman Fish oil Corn oil diet Age: From 6 months ↓ Aβ42 levels and microglial activation
et al. (2006) 2.2% fish oil supplement ω-3/ω-6 ratio = 1:70 Length: 3-4 months No effect on Aβ plaque load
ω-3/ω-6 ratio = 1:1.4 1% ω-3, 54% ω-6
22% ω-3, 30% ω-6 Soy oil diet Age: From 6 months ↓ Aβ42 levels and microglial activation
ω-3/ω-6 ratio = 1:8 Length: 3-4 months No effect on Aβ plaque load
7% ω-3, 52% ω-6
Oksman Omega-3 PUFA 1) Soy oil diet (as above) Age: From 6 months ↓ Aβ40 + Aβ42 (cf. diet 3 only)
et al. (2006) 14% ω-3, 40% ω-6 2) Lipid neutral diet Length: 3-4 months ↓ Exploratory deficits (cf. diets 1-3)
0.5% DHA 1% ω-3, 31% ω-6 No effect on spatial memory deficits in MWM
3) TWD (1% cholesterol) No effect on Aβ plaque load
1% ω-3, 31% ω-6
Hooijmans Omega-3 PUFA 1) Standard chow Age: From 6 months ↓ Aβ deposits
et al. (2007) 14% ω-3, 40% ω-6 7% ω-3, 52% ω-6, 15% SAT Length: 12 months Improved blood circulation
19% SAT 2) TWD (1% cholesterol)
1% ω-3, 31% ω-6, 44% SAT
Hooijmans Omega-3 PUFA 1) Standard chow Age: From 2 months ↓ Aβ deposits (after 13 not 6 months treatment)
et al. (2009) 7% ω-3, 18% ω-6, 20% SAT 2.2% ALA, 16% ω-6, 38% S. Length: 6-13 months ↓ MWM deficits (after 13 months cf. diet 2)
(3% DHA, 0.8% EPA) ω-3/ω-6 ratio = 1:7.5, Improved blood circulation (after 6m cf. diet 2)
ω-3/ω-6 ratio = 1:2.5 2) TWD (1% cholesterol) Improved blood circulation (after 13m cf. diet 2)
0.5% ALA, 11% ω-6, 53% S. No effect on open field, reverse MWM or circular
ω-3/ω-6 ratio = 1:22.5      hole board behaviour
Arendash Omega-3 PUFA TWD Age: From 2 months No effect on memory: MWM, RAWM, Y-maze,
et al. (2007) 13% total ω-3 3% total ω-3 Length: 7 months       circular platform, platform recognition
ω-3/ω-6 ratio = 1:3.8 ω-3/ω-6 ratio = 1:11.4 No effect in balance beam or string activity
20% SAT, 51% ω-6 10% SAT, 31% ω-6 No effect on Aβ40/42 (soluble or insoluble)
TWD = Typical Western Diet, ω-3 = omega-3 PUFA, ω-6 = omega-6 PUFA, ↓ = Reduced, MWM = Morris water maze, RAWM = Radial arm water maze, 
cf. = compared to, SAT (or S.) = Saturated fat.
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The Tg2576 studies outlined in Table 1.3 also provided evidence for the negative effects 
associated with diets depleted in omega-3 PUFA with high levels of omega-6 PUFA. The 
low-DHA diet relative to the standard diet resulted in spatial memory deficits, synaptic losses 
(PSD-95), and alterations to processes involved in learning and memory including reduced 
PI3-K signalling, increased caspase activation and reduced drebrin (Calon et al., 2004). Calon 
et al. (2005) similarly reported caspase activation, reduced NMDA receptor subunits, reduced 
CaMKII and increased pro-apoptotic BAD protein. Cole and Frautschy (2006) also reported 
increased protein carbonyls, and reduced drebrin, CaMKII and the PSD-95 synaptic marker. 
Furthermore, Lim et al. (2005) reported increased Aβ40 and APP proteolytic activity, and Ma 
et al (2007) reported reduced LR11. These results therefore support the potential contribution 
of depleted omega-3 and high omega-6 PUFA levels have to the effects observed when DHA
supplementation is compared to such a diet.
Finally, another issue that requires further examination is the effect of omega-3 PUFA
supplementation from an early age prior to pathological development. All transgenic studies 
outlined in this section provided treatment after pathology had developed, often during 
advanced stages (particularly in the Tg2576 model). The earlier the intervention is initiated 
then arguably the greater impact it may have on the initial and later stages of amyloid-
induced pathology. This thesis therefore aims to examine the effect of omega-3 PUFA 
supplementation from an early age in Tg2576 mice, relative to a baseline control diet 
designed to control for other fatty acids which may have otherwise contributed to an apparent 
beneficial effect.
Table 1.3 Omega-3 PUFA intervention studies in APPswe Tg2576 model mice
Study Omega-3 PUFA diet Control diet Design Reported effects
Calon et High DHA (0.6%) 1) Low-DHA (<0.01%) Age: From 17 months ↓ MWM acquisition deficits, partially restored PI3-K pathway
al. (2004) ω-3/ω-6 ratio 1:5 ω-3/ω-6 ratio 1:85, 4.9% LA Length: 4-5 months ↓ Post-synaptic marker drebrin and PSD-95 losses
6.1% total fat 6.1% total fat, 750ppm Chol. ↓ pro-apoptotic BAD activity, caspase activation, fractin/actin ratio
750ppm Chol. No effect on SNAP-25, synaptophysin, synaptotagmin,
2.5% ω-6 LA      + synaptobrevin
2) Standard (0.09% DHA) Age: From 17 months No effects on any of above
ω-3/ω-6 ratio 1:7, 2.5% LA Length: 4-5 months MWM not examined
11% total fat, 290ppm Chol.
Calon et High DHA (0.6%) 1) Low-DHA (<0.01%) Age: From 17 months ↓ NMDA receptor subunits (NR2A, NR2AB, NR1) losses
al. (2005) ω-3/ω-6 ratio 1:4 ω-3/ω-6 ratio 1:82, 4.9% LA Length: 5.5 months ↓ Fodrin (caspase cleavage product) losses
6.1% total fat 6.1% total fat, 750ppm Chol. No effects on CaMKII, synaptophysin or SNAP-25 (in hipp.)
750ppm Chol. 2) Standard (0.09% DHA) Age: From 17 months No effect on any of above
2.8% ω-6 LA ω-3/ω-6 ratio 1:9, 2.5% LA Length: 5.5 months
11% total fat, 290ppm Chol.
Lim et High DHA (0.6%) 1) Low-DHA (<0.01%) Age: From 17-19months ↓ total insoluble Aβ, Aβ42, Aβ40 + plaque burden
al. (2005) Same as Calon Same as Calon et al. (2004) Length: 3-5 months ↓ C83 + C99 APP processing products
et al. (2004) No effect on BACE mRNA, ApoE, TTR expression, soluble Aβ
2) Standard (0.09% DHA) Age: From 17-19months No effects on any of above except ↓ Aβ40
Same as Calon et al. (2004) Length: 3-5 months Plaque burden not examined
Cole & High DHA (0.6%) 1) Low-DHA (<0.01%) Age: From 17 months ↓ Aβ42 and Aβ40, carbonyls, fractin
Frautschy Same as Calon Same as Calon et al. (2004) Length: 5 months ↑ drebrin, PSD-95, CaMKII
(2006) et al. (2004) No effects on or GFAP or synaptophysin (although trend of ↑)
2) Standard (0.09% DHA) Age: From 17 months ↓ Aβ42 + PSD-95, CaMKII (statistical significance unknown)
Same as Calon et al. (2004) Length: 5 months ↑ Aβ40 + carbonyls + fractin, synaptophysin (S.S.U.)
No effect on drebrin or GFAP (S.S.U)
Ma et High DHA (0.6%) 1) Low-DHA (<0.01%) Age: From 17 months ↑ LR11 losses
al. (2007) Same as Calon Same as Calon et al. (2004) Length: 3.5 months
et al. (2004) 2) Standard (0.09% DHA) Age: From 17 months No effect on LR11
Same as Calon et al. (2004) Length: 3.5 months
ω-3 = omega-3 PUFA, ω-6 = omega-6 PUFA, ↓ = reduced, MWM = Morris water maze, Chol. = Cholesterol, S.S.U = Statistical significance unknown, LA = 
linoleic acid, hipp. = hippocampus
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1.6.4 Curcumin
Curcumin (diferuloylmethane) [1,7-bis(4- hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione] is a naturally-occurring polyphenolic compound extracted from turmeric, the powered 
rhizome of the plant Curcuma longa. Curcumin comprises 3 to 5% of turmeric and is its 
pharmacologically active component (Salvioli et al., 2007). It is a biphenolic compound 
composed of two aromatic rings (polyphenols) with hydroxyl groups which are connected by 
a β-diketone bridge (Figure 1.3). The β-diketone bridge features two α, β-unsaturated 
carbonyl groups (composed of double bonds or dienone) which can undergo Michael addition 
and is critical for some of the effects of curcumin (Weber et al., 2006). Curcumin is a spice 
commonly used as a yellow pigment for food colouring and a flavouring additive typically in 
Indian Cuisine. Curcumin has also been used for centuries in traditional Indian “Ayurvedic” 
medicine for its various indications (Chainani-Wu, 2003).
Figure 1.3 Structure of curcumin, highlighting the phenol groups (indicated by red circles) and the 
connecting β-diketone bridge (indicated by grey circles). Diagram adapted from Begum et al., 2008.
Several in vitro, animal and human studies have demonstrated potent antioxidant and anti-
inflammatory properties of curcuminoids, as well as anti-viral, anti-fungal, anti-amyloid and 
anti-carcinogenic activities (e.g. Yang et al., 2005; as reviewed in Chainani-Wu, 2003). The 
ability for curcumin to reduce amyloid, inflammation and oxidative stress highlights it 
potential for AD treatment. Due to its extensive screening for cancer chemoprevention, 
curcumin has undergone thorough toxicological testing and preclinical investigation in 
several species including mice, rats, dogs, monkeys and humans, and is considered safe 
(Kelloff et al., 1996; Chainani-Wu, 2003; Cheng et al., 2001; Sharma et al., 2004; but see 
Lopez-Lazaro, 2008 for a cautionary use of curcumin).  However, it has been suggested that 
very high doses of curcumin may lead to a switch from antioxidant to pro-oxidant effects 
which may have important therapeutic applications (Sandur et al., 2007a,b; Lopez-Lazaro,
2008). Despite this, a number of studies using mice and rats have shown no toxic effects of 
large doses around 5000ppm or 3500mg/kg body weight (Srimal & Dhawan, 1972; Kelloff et 
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al., 1996; Lim et al., 2001). This therefore shows potential for chronic use in AD, unlike 
NSAID intervention which is unsuitable long-term consumption due to safety issues (Rao & 
Knaus, 2008). 
One potential issue with curcumin treatment however, is that it has poor bioavailability which 
may limit its pharmacological effect (Anand et al., 2007). This is attributed to poor 
absorption, rapid metabolism and rapid systematic elimination through the faeces (e.g. Pan, 
Huang & Lin, 1999; see Aggarwal & Harikumar, 2009). For example, curcumin is poorly 
absorbed into the bloodstream after oral consumption (Wahlstrom & Blennow, 1978; Kelloff 
et al., 1996; Cheng et al., 2001; Lao et al., 2006; Sharma et al., 2004). Even when 
administered via other administration routes such as i.p. injection, curcumin is rapidly 
metabolised and eliminated from the body (e.g. Pan, Huang & Lin, 1999), although tissue 
levels remain higher than oral dosing (e.g. Yang et al., 2005). Curcumin also has difficulty 
crossing the blood brain barrier (e.g. Pan, Huang & Lin, 1999). This could pose a potential 
problem for therapeutic use in AD where localisation to brain pathology is essential. Despite 
these issues, studies have proven curcumin to be biologically effective, particularly when 
provided in larger doses (Kelloff et al., 1996; Frautschy et al., 2001). Other attempts to 
increase bioavailability include provision of adjuvants such as piperine which block curcumin 
metabolism (Shoba et al., 1998) and special formulations such as lipid complexes or 
nanoparticles (Bisht et al., 2007; Maiti et al., 2007).
i) Potential mechanisms of curcumin in Alzheimer’s disease
Although curcumin is not an essential nutrient required for general health, it has shown 
clinical benefit in health and disease states such as inflammatory conditions through its 
various biological activities (Sikora, Scapagnini & Barbagallo, 2010). With its favourable 
toxicity profile, curcumin is therefore being investigated as a treatment for various 
conditions, including AD. It has shown positive actions in reducing AD pathology, as 
detailed below.
A. Affects on amyloid pathology
A large number of studies have shown curcumin reduced amyloid accumulation both in vivo 
and in vitro (e.g. Frautschy et al., 2001; Lim et al., 2001; Ono et al., 2004; Yang et al., 2005; 
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Begum et al., 2008). In vitro studies have shown curcumin to inhibit Aβ40/42 fibril formation 
and aggregation, as well as inhibit Aβ extension and disaggregate pre-aggregated Aβ (Ono et 
al., 2004; Yang et al., 2005). Evidence suggests that curcumin may reduce Aβ indirectly 
through its antioxidant and anti-inflammatory properties (Begum et al., 2008), or by affecting 
ApoE, cholesterol and α1ACT which regulate α- and β-secretases to be pro-amyloidogenic (as 
reviewed by Lim et al., 2001). Evidence has largely supported the role of curcumin in 
amyloid degradation and clearance, principally by activating resident brain macrophages such 
as microglia within and surrounding Aβ deposits (e.g. Frautschy et al., 2001; Lim et al.,
2001) which are dysfunctional in AD (Fiala et al., 2007). This proposed amyloid-
phagocytosing clearing effect was supported by Zhang et al. (2006) who found curcumin 
treatment to enhance Aβ uptake by macrophages of AD patients in vitro. 
Evidence also suggests that curcumin can block Aβ aggregation through metal chelation 
(Baum & Ng, 2004; see Cherny et al., 2001, Ritchie et al., 2003 and Atwood et al., 2004 for 
effect of metals and chelators on Aβ). Curcumin may also reduce amyloid by its binding to 
aggregated Aβ, similarly to other Aβ-binding compounds such as Congo Red, Chrysamine G 
and RS-0406 (as reviewed in Yang et al., 2005; Garcia-Alloza et al., 2007). The binding of 
these compounds to Aβ prevents its polymerisation into oligomers and fibrils, thereby 
stabilising Aβ monomers and preventing Aβ aggregation (Podlisny et al., 1998; Nakagami et 
al., 2002). Since curcumin also labels Aβ and has similar structural properties to these 
compounds, it is thought that curcumin reduces Aβ pathology through the same processes. 
The curcumin metabolite tetrahydrocurcumin can also attenuate aggregated Aβ, although is 
less effective due to the loss of the dienone structure (Begum et al., 2008).
B. Affects on tau pathology
While curcumin can influence Aβ, the influence of this compound on tau pathology remains 
less clear. Garcia-Alloza et al. (2007) failed to report any effects of curcumin on tau 
pathology in a triple transgenic AD model. However, other evidence suggests potential for 
curcumin to alter tau pathology as curcumin altered tau-associated kinases such as CDK and 
ERK (as reviewed in Lin, 2004; Giri et al., 2004; Kim et al., 2008). Furthermore, the 
inhibition of Aβ fibril formation by several polyphenolic compounds was shown to also
inhibit tau aggregation (Taniguchi et al., 2005). Although curcumin was not investigated in 
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this study, the latter shows that polyphenols have the potential for reducing tau pathology. 
Further investigation is therefore required.
C. Modulation of inflammatory processes
Curcumin is well known for its anti-inflammatory properties and may thus be effective in
reducing the chronic state of neuroinflammation present in AD. Curcumin regulates several 
inflammatory mediators linked to AD including transcription factors (e.g. NFκB), cytokines 
(e.g. TNF-α, IL-1, IL-6 and IL-8), protein kinases (e.g. p38 MAP, IkBα, Akt), enzymes (e.g. 
LOX, COX, iNOS) and adhesion molecules (e.g. leukotrienes) both in vivo and in vitro (as 
reviewed in Chainani-Wu, 2003; Aggarwal & Harikumar, 2009). Furthermore, indices of 
inflammation such as GFAP, microglial activation and IL-1β are reduced by curcumin in 
animal models of AD (Frautschy et al., 2001; Lim et al., 2001; Begum et al., 2008) and other 
inflammatory disorders such as inflammatory bowel disease, arthritis and cardiovascular 
disease (Aggarwal & Harikumar, 2009). Interestingly, Yang et al. (2005) reported curcumin 
to be more effective at reducing amyloid pathology through its anti-inflammatory effects than 
high doses of NSAIDs.
Evidence suggests that the anti-inflammatory effects of curcumin can be concentration-
dependant (e.g. Abe, Hashimoto & Horie, 1999; Grandjean-Laquerriere, et al. 2002; Chun et 
al., 2003) and some studies suggest its effectiveness is dependent upon large doses (e.g. 
Huang et al., 1991; Sharma et al., 2004). Furthermore, evidence suggests that anti-
inflammatory effects are dependent upon curcumin supplementation prior to inflammatory 
development (e.g. Chun et al., 2003; Funk et al., 2006). This may suggest that in order for 
curcumin to reduce inflammation in AD, it may need to be taken in large doses prior to 
inflammatory changes. This was a major factor in considering the experimental design 
described in this thesis. 
D. Antioxidant effects
Curcumin has potent antioxidant activities by targeting multiple sources of oxidative stress, 
even at small doses (Chan et al., 1998). Curcumin is a potent free radical scavenger of ROS 
including superoxide, peroxyl and hydroxyl radicals (Fujisawa et al., 2004). Curcumin also 
acts as a scavenger of NO-based free radicals such as nitric oxide and peroxynitrite, in 
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addition to iNOS (inducible nitric oxide synthase) which catalyses NO production (Sreejayan 
& Rao, 1997; Chan et al., 1998; as reviewed in Butterfield et al., 2002). Curcumin can also 
increase levels of the antioxidant glutathione (Jaruga et al., 1998; Piwocka et al., 2001) and 
activate the antioxidant response element (ARE) by affecting transcription factors such as 
Nrf2, HIF-1 and NFκB (Balogun et al., 2003; Calabrese et al., 2008). Furthermore, curcumin 
can inhibit enzymes involved in lipid oxidation including lipoxygenase and phospholipase D 
(Yamamoto et al., 1997; Began, Sudharshan & Rao, 1998; Skrzypczak-Jankun et al., 2000). 
As a result, curcumin can inhibit lipid peroxidation, protein oxidation and oxidative DNA 
damage (as reviewed in Butterfield et al., 2002). Such antioxidant effects have been 
demonstrated in vivo in animal models of AD (e.g. Frautschy et al., 2001; Lim et al., 2001; 
Begum et al., 2008). The reduction of lipid peroxidation in AD is particularly important as it 
otherwise exaggerates neurodegeneration by oxidising phospholipids (Asai, Nakagawa & 
Miyazawa, 1999; Butterfield & Lauderback, 2002). 
Conversely, curcumin possesses pro-oxidant properties (Ahsan et al., 1999; Sandur et al., 
2007a,b). This is well-documented in cancer studies whereby curcumin exerts pro-oxidant 
effects by generating ROS which arrests cancer cell proliferation and induces apoptosis (e.g. 
Javvadi et al., 2008; Kim & Lee, 2010; Lee et al., 2011). Although the mechanism mediating 
these opposing activities of curcumin is not fully understood, some evidence suggests that the 
switch between anti- and pro-oxidant activities may be concentration dependant (Aggarwal & 
Harikumar, 2009). However, other mechanisms must be involved as curcumin can induce 
opposing activity within the same dose study. Further research is therefore required to 
understand the oxidative properties of curcumin. This is particularly important if used to treat 
AD as pro-oxidant effects could exacerbate AD pathology.
E. Neurological effects and modulation of memory processes
There is accumulating evidence that curcumin is neurogenerative, neuroprotective and can 
influence memory processes. Firstly, curcumin administration can promote neurogenesis and 
development in the dentate gyrus of adult mice, as well as neurogenesis and synaptogenesis 
in vitro at low concentrations in neural progenitor and brain-derived adult neural stem cells 
(Kang, Cha & Jeon, 2006; Kim et al., 2008). This neurogenic effect may be particularly 
valuable in disorders such as AD whereby extensive neurodegeneration occurs. Interestingly 
however, Kim et al. (2008) found high concentrations of curcumin exerted cytotoxic effects 
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in vitro but not in vivo, highlighting the need for further investigation. Evidence supports a 
neuroprotective role of curcumin against age-related brain changes, traumatic injury and 
neurotoxic-induced effects, including administration of Aβ, kainic acid, lead and ethanol 
(Rajakrishnan et al., 1999; Kim, Park & Kim, 2001; Shukla et al., 2003; Yang et al., 2005; 
Bala, Tripathy & Sharma, 2006; Sumanont et al., 2006; Cole, Teter & Frautschy, 2007). 
These effects were closely linked with the antioxidant and anti-inflammatory properties of 
curcumin. The curcumin metabolite tetrahydrocurcumin was also neuroprotective against Aβ-
induced toxicity (Begum et al., 2008; Mishra et al., 2011). Curcumin can also normalise 
memory and synaptic plasticity after injury (Wu, Ying & Gomez-Pinilla, 2006) and curcumin 
can inhibit JNK activation which may prevent LTP deficits (Chen & Tan, 1998; Begum et al.,
2008).
ii) Curcumin studies in humans: epidemiological evidence
Epidemiological studies show urban and rural Indian populations have some of the lowest 
prevalence and incidence rates of AD and dementia worldwide (Chandra et al., 1998, 2001; 
Vas et al., 2001). Interestingly, Chandra et al. (2001) reported that a Northern Indian rural 
population in Ballabgarh had a 1 in 3.7 less risk of AD than an American population in the 
Monongahela Valley of Pennsylvania. Similarly, Ganguli et al. (2000) reported a 4.4-fold 
lower prevalence of AD in 70 to 79 year olds in Ballabgarh compared with the Monongahela 
valley population. They also calculated the probable frequency of AD in the Indian and 
American populations to be 0.7% and 3.1% in those aged 70 to 79 years, and 4.0% and 
15.7% in those aged over 80 years, respectively. These studies therefore suggest that the 
American and Indian population had important differences in dementia risk factors. 
Consistent with this, Ganguli et al. (2000) reported a lower frequency of ApoE ε4 status in 
Ballabgarh (0.07) compared to the Monongahela Valley (0.11). This lower genetic risk 
(associated with AD) may be one factor that accounted for the reduced prevalence of AD in 
Indian populations. 
However, another proposed factor is that of diet. Ng et al. (2006) reported that increased 
curry consumption was associated with better cognitive performance in a non-demented 
Asian population aged between 60 and 93 years (n=1010). Since the spice turmeric is used 
and consumed in large amounts in curries, this spice may be responsible for the observed 
effect. Although numerous alternative explanations could explain the results, these studies 
40
have provided grounds for the initiation of controlled experimental studies into turmeric 
treatment for AD using its pharmacologically active substance, curcumin. 
iii) Curcumin studies in humans: clinical trials
Two human clinical trials investigating curcumin supplementation in AD have been 
conducted. The first clinical trial was completed by the NIA in 2007 (ClinicalTrials.gov 
identifier: NCT00099710). This phase II, double-blind, placebo-controlled study used two 
doses of curcumin C3 complex® (2000 or 4000mg/day) in 33 mild-to-moderate AD patients 
over 24 weeks, followed by an extension study for another 24 weeks using one of the two 
curcumin doses (Ringman et al., 2005). Unfortunately however, no results have been 
published and the NIA assert that the study may be ongoing, extended or result submission 
has been delayed. No conclusions can therefore be obtained from this study. 
In contrast, Baum et al. (2008) published results from a randomised, double-blind, placebo-
controlled pilot clinical trial investigating 6-month curcumin supplementation (1g/day or 
4g/day) in 27 AD patients. No cognitive protective effect was reported, likely due to the lack 
of cognitive decline detected during the short study period. However, Aβ40 serum levels 
were increased, perhaps suggesting that curcumin disaggregated Aβ deposits in the brain 
which were released into circulation. The interpretation of these results is limited and longer 
and larger trials are required to determine the efficiency of curcumin in AD. Another 
limitation of this study is that 120 mg/day standardized ginkgo leaf extract was supplemented 
in combination with curcumin and the placebo. Although the design has controlled for this in 
both the curcumin and placebo group, it is not possible to ascertain whether the outcome is 
related to curcumin alone or an interaction between the curcumin and ginkgo leaf extract. In 
conclusion, no human clinical trial provides strong evidence for a beneficial effect of 
curcumin on cognitive function or pathology in AD.
iv) Curcumin studies in rat and transgenic mouse models of Alzheimer’s disease
Dietary curcumin treatment has been examined in two rat models of AD pathology. In Aβ-
infused rats, Frautschy et al. (2001) found 1 month pre-treatment of 2000ppm curcumin 
reduced plaque pathology and protected against Aβ-induced lipid peroxidation, 
synaptophysin loss and microglia activation. Conversely, microglial labelling within and 
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around Aβ deposits was increased, suggesting phagocytic plaque clearance. They also 
reported that 2 month pre-treatment of 500ppm curcumin protected against Aβ-induced 
spatial memory deficits in the Morris Water Maze and PSD-95 loss. Interestingly, the 
500ppm dose was found more effective at reducing plaque pathology than 2000ppm 
treatment. Ishrat et al. (2009) examined curcumin treatment in a sporadic AD rat model 
which expresses oxidative neuronal damage, neuronal dysfunction (such as cholinergic 
deficiency) and cognitive deficits caused by a cerebroventricular injection of streptozotocin
(e.g. Prickaerts, Fahrig & Blokland, 1999; Sharma & Gupta, 2001). Ishrat et al. (2009) found 
3 week oral post-treatment of curcumin (80mg/kg body weight) ameliorated cognitive 
deficits in the passive avoidance and water maze task, attenuated markers of oxidative stress, 
and increased glutathione levels.
Garcia-Alloza et al. (2007) examined curcumin treatment in 7.5 to 8.5 month old double 
transgenic APPswe/PS1(dE9) mice, when amyloid pathology is well developed. Daily i.v. 
injection of curcumin (7.5mg/kg/day) for 7 days labelled senile plaques and cerebrovascular 
amyloid angiopathy, illustrating that curcumin can cross the blood-brain barrier and bind to 
amyloid deposits. Longitudinal in vivo imaging showed 7-day treatment reduced the size and 
number of plaques. In contrast, treatment failed to reduce soluble and insoluble Aβ40-42 and 
interestingly increased the soluble Aβ42:Aβ40 ratio. Although the latter is associated with 
neurotoxic effects (Walker et al., 2005), the authors suggest this may have simply been the 
immediate effects of curcumin. Curcumin treatment also reduced the size of dystrophic
neurites immediately surrounding senile plaques and reversed dendritic morphological 
abnormalities (dendritic curvature) near and far from plaques, suggesting reduced toxicity 
caused by both aggregated and soluble Aβ. In summary, low dose short-term curcumin 
treatment reduces plaque pathology and the neurotoxic effects of Aβ on dendrites. Ma et al. 
(2009) investigated the effect of 4-month 500ppm dietary curcumin supplementation in 5-
month old triple transgenic mice relative to a high-fat poor diet (high in saturated fat and
omega-6 PUFA). Curcumin suppressed poor diet-induced tau phosphorylation, abnormal 
insulin signalling and pJNK (latter was non-significant). Furthermore, curcumin improved 
cognitive performance in the Y-maze following 2 months of dietary supplementation, but not 
after 1 month. No measures related to amyloid pathology (e.g. APP, PS1 or Aβ) were 
reported.
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Lim et al. (2001) examined the effect of 6-month 160ppm low-dose and 5000ppm high-dose 
curcumin in Tg2576 mice from 10 months of age. Both doses significantly reduced 
inflammation (IL-1β) and oxidative stress (protein carbonyls), although low-dose curcumin 
also significantly reduced GFAP and microglia activation. Consistent with Frautschy et al. 
(2001) however, microgliosis was increased immediately outside and within plaques, 
suggesting amyloid phagocytosis. Indeed, low but not high-dose curcumin significantly 
reduced soluble and insoluble Aβ, and plaque burden. Consistent with unpublished findings 
by Chu, Lim and Cole (reported in Lim et al., 2001), high-dose curcumin suppressed amyloid 
clearance by glia in organotypic hippocampal slice cultures. This study reported no changes 
to APP production, suggesting that curcumin alters post-Aβ production mechanisms. In 
another study, Yang et al. (2005) examined the effects of a 5-month medium-dose (500ppm) 
curcumin supplementation in Tg2576 mice aged 17 months, relative to a control safflower 
oil-based diet. Curcumin supplementation significantly reduced insoluble Aβ by 85% and 
plaque burden by 33%. In vitro studies supported this, showing curcumin reduced amyloid 
aggregates and Aβ toxicity, even at micromolar concentrations. A 200μl i.v. injection of 
50μM curcumin was also found to label plaques to a greater extent than dietary 
administration, suggesting curcumin can cross the blood-brain barrier but is less bioavailable 
following oral administration.
Begum et al. (2008) examined the effects of 4-month curcumin supplementation in 14.5 
month old Tg2576 mice compared to control chow. Supplementation of tetrahydrocurcumin 
(TC), a curcumin metabolite, was also examined. Chronic feeding of 500ppm curcumin or 
TC resulted in a similar reduction of inflammatory markers IL-1β and GFAP. Curcumin was 
also found to reduce protein carbonyl levels, insoluble Aβ, soluble Aβ, plaque size and 
number. In contrast, TC failed to significantly reduce protein carbonyl levels, plaque 
pathology and insoluble Aβ, but was more effective at reducing soluble Aβ. This greater 
reduction by TC was correlated to a greater reduction in pJNK, a stress-activated kinase 
which is thought to influence Aβ (Borsello & Forloni, 2007). Curcumin also reduced pJNK, 
suggesting a potential mechanism for soluble Aβ reduction. Supporting the reduction of 
inflammatory markers by curcumin and TC, Begum et al. (2008) also reported that acute 
administration of these compounds by gavage, i.p. or i.m. reduced markers of inflammation 
and oxidative stress in lipopolysaccharide-injected C57BL6/J mice (a model of induced 
inflammation) compared to vehicle. These markers included IL-1β, iNOS, F2-isoprostanes 
and protein carbonyls. Curcumin was reported more effective than TC, and both studies 
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reported curcumin to reach the brain at higher levels. Since curcumin is naturally metabolised 
into TC, this highlights the use of curcumin for AD treatment.
In conclusion to these studies, it is evident that curcumin can effectively reduce multiple 
aspects of AD-like pathology. Although further investigation is required to examine the 
optimal treatment dose, it appears that 500ppm curcumin dosage was effective, as were lower 
160ppm doses. The inefficiency of higher doses (5000ppm) to reduce amyloid pathology 
questions the mechanistic actions of curcumin and warrants further examination. 
Furthermore, all transgenic mouse studies have examined the effect of curcumin treatment 
during advanced stages of pathological development only, highlighting the need for 
examination at early stages which may unlock its full clinical potential in preventing or 
delaying the onset of pathology. Supporting this, several studies showed curcumin was more 
potent or only effective at reducing pathological measures such as inflammation when 
administered prior to its development (e.g. Chun et al., 2003; Funk et al., 2006). This could 
explain the limited results in clinical trials. This thesis therefore examined the effects of early 
administration of curcumin on A pathology and cognitive deficits in Tg2576 mice.
1.7 Modelling Alzheimer’s disease 
The previous sections have outlined the rationale for exploring the putative beneficial effects 
of diet on AD pathogenesis. Clearly in evaluating these compounds on AD-like pathology a 
suitable animal model is required. This section will outline the use of animal models for 
Alzheimer’s disease. Firstly, it will discuss the advantages and disadvantages of studying 
human disease in an animal model, followed by a summary of the different types of animal 
model used to study AD. Finally, a more detailed discussion of the Tg2576 model will be 
delivered in order to give an outline of the model utilised in the experimental chapters.
1.7.1 Why use animal models? The advantages and disadvantages
Studying human disease using animal models and human subjects both have their advantages 
and flaws. Neither alone can provide a comprehensive account, and so we depend on 
translational research which encompasses a bidirectional flow of information between animal 
and human research (Trojanowski et al., 2008). The study of human disease using human 
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subjects is ideal but limited due to the large number of extraneous factors such as 
environmental and genetic differences. Another constraint of human research is the limited
time period which can practically be examined, which is a particular problem when 
investigating chronic diseases which develop over long periods of time. Another drawback is 
the detail or accuracy of data that can be obtained. 
Animal models have therefore been developed which offer a valuable opportunity to 
investigate disease and intervention in a tightly controlled manner. For example, the 
development of transgenic models allows a large degree of genetic homogeneity in the 
sample population which may otherwise interfere with the research question. Environmental 
factors can also be significantly controlled and maintained for all subjects, such as dietary 
intake. Furthermore, the relatively short lifespan of animals allows rapid and comprehensive 
collection of longitudinal data, which is impractical in human studies. Moreover, animal 
studies allow more comprehensive collection of data, from biological samples to behavioural 
analysis, and increased control of when these data are collected. In contrast, the major 
disadvantage of using animal models to study human disease is their limited capacity to 
model the disease state and important physiological species-differences. Although models 
can encapsulate some of the main characteristics and symptomatic features of the disease, 
none can simulate the disease exactly in humans which limit the application of findings. 
Despite this, the ability to model specific aspects of AD pathology in animals is advantageous 
in allowing further understanding of pathological processes and potential intervention effects 
on specific pathologies.
1.7.2 Animal models of Alzheimer’s disease
Animal models can be used to study AD by reproducing some behavioural and pathological 
changes observed in AD patients. A basic type of model uses non-transgenic rodents injected 
with pathological or pathological-inducing substances, such as Aβ, lipopolysaccharide or 
streptozotocin, into the cerebroventricular area of the brain. These substances induce features 
of AD such as amyloid pathology, neuroinflammation, oxidative damage, cognitive deficits 
and neuronal dysfunction (as outlined previously; reviewed in Yamada & Nabeshima, 2000). 
Tau pathology can also be induced by inhibiting phosphatase activity (e.g. by i.c.v infusion of 
okadaic acid) or through potentiating kinase activity in order to produce hyperphosphorylated 
tau and NFTs (Arendt et al., 1994, 1995). Although these non-transgenic models are useful 
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for investigating therapeutic effects on pathology, these models have limited face and 
construct validity.
The identification of genes associated with familial and sporadic forms of AD have made 
possible the development of transgenic mouse models, which arguably have greater face and 
construct validity. This approach inserts or deletes known human genetic mutations into the 
mouse genome. Deleted-gene ‘knockout’ models are used to explore gene function and role 
in AD pathogenesis (Spires & Hyman, 2005). More commonly, genes are inserted in order to 
induce pathological development and associated behavioural deficits. The three mutations 
commonly inserted include APP, tau and PS1 genes. Many types of AD model have been 
developed based on these mutations, including triple (possessing all three mutations), double 
and single transgenic mice. Importantly, these models develop pathology over time and so 
can be used to understand pathological processes, as well as examine potential therapeutic 
measures. A summary of the most common mouse models used to study AD are provided in 
Table 1.4 and will be described briefly in the following subsections. Other less commonly 
used models will also be discussed, although a more systematic review of AD models can be 
found in Spires and Hyman (2005).
i) Triple transgenic models
One of the most successful replications of AD neuropathy is the triple transgenic mouse 
model (3xTg-AD) which harbours PS1M164V, APPswe and TauP301L mutations (Oddo et al.,
2003). It was the first model to develop both accelerated amyloid and tau pathology, allowing 
examination of their interaction which was particularly relevant to AD. This model displays 
an age-related progression of pathology which shows a regional distribution pattern similar to 
human AD brains, as well as Aβ deposits preceding tau pathology (Oddo et al., 2003). Likely 
to be initiated by intracellular Aβ deposition at 3 months, behavioural deficits and synaptic 
dysfunction develop around 4 to 6 months, with NFT development at a later age (Table 1.4; 
Oddo et al., 2003; Billings et al., 2005). 
ii) Double transgenic models
A number of double transgenic mice carrying mutant PS1 and APP transgenes have been 
developed (Table 1.4). These mice display amyloid pathology and behavioural deficits, as 
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well as cerebral amyloid angiopathy, oxidative stress and dystrophic neurites (Holcomb et al.,
1998, 1999; Arendash et al., 2001b; Garcia-Alloza et al., 2006a,b; Jankowsky et al., 2004a). 
Importantly, amyloid pathology and cognitive dysfunction develop at a greater rate and 
earlier age than single APP mutant mice, due to the PS1 mutation which alters APP 
processing to preferentially deposit high levels of Aβ42 (Borchelt et al., 1997; Holcomb et 
al., 1998; Westerman et al., 2002). Although this allows study of pathological development 
within a shorter time period, this may be problematic if examining behavioural changes in 
large cohorts or if aiming to target therapeutic intervention before pathological development. 
Double transgenic mice harbouring Tau and APP mutations are used model both tau and 
amyloid pathology, such as the JNPL3/Tg2576 cross (Lewis et al., 2001). Interestingly, 
amyloid pathology develops at the same age as Tg2576 mice yet tau pathology is enhanced 
compared to JNPL3 mice, thereby supporting literature suggesting that Aβ exacerbates tau 
pathology. Furthermore, models lacking amyloid pathology such as PS1M146V/TauP301L mice 
fail to produce LTP deficits despite expressing tau similarly to 3xTg-AD mice, which 
highlights the importance of APP mutations and Aβ pathology (Oddo et al., 2003).
Table 1.4 Summary of current mouse models used to study Alzheimer’s disease. Table adapted and extended from Reddy & McWeeney 2006.
Mouse model Pathological changes Behavioural changes References
APP mutations:
Tg2576 (APPswe/K670M/N671L) Aβ deposits from 8–9 months From 6 months (Hsiao et al., 1996)
TgCRND8 (APPswe+V717I) Aβ deposits from 3 months, From 3 months (Chishti et al., 2001)
amyloid plaques from 5 months (e.g. MWM reference memory)
PDAPP(V717F) Aβ deposits from 6-9 months From 6-9 months (Games et al., 1995; Chen et al., 2000)
APP23 (APPswe) Aβ deposits from 3-6 months dependant From 3 months (Sturchler-Pierrat et al., 1997; Kelly et
on expression levels (e.g. MWM, hyperactivity, open-field, PA) al., 2003; Van Dam et al., 2003)
C3-3 (APPswe) Aβ deposits, ↑ Aβ40-42, plaques at 18 mon. Not reported (Borchelt et al., 1997)
PS1 mutations:
PS1 ↑ Aβ42 Not reported (Duff et al., 1996) 
PS1P264L/P264L  ↑ Aβ42 Not reported (Flood et al., 2002)
Tau mutations:
JNPL3(P301L) NFTs from 4.5-6.5 months Motor and behavioural deficits from 4.5 months (Lewis et al., 2000)
H Tau40 Axonal degeneration, no NFTs Sensorimotor dysfunction (Spittaels et al., 1999)
H Tau ↑ hyperphosphorylated tau at 6 months, Cognitive dysfunction from 12 months (Andorfer et al., 2003; Polydoro et 
tau redistribution (3 mon.), NFTs (9mon.) (e.g. Object recognition, MWM) al., 2009)
Double mutations:
PS1(dE9) x Tg2576 Aβ deposits from 4-6 months, Cognitive dysfunction (from 3m, before Aβ) (Holcomb et al., 1998, 1999; Arendash
high Aβ42/Aβ40 ratio (e.g. Y-maze, water maze, RAWM) et al. 2001b;Garcia-Alloza et al. 2006b)
PS1 x TgCRND8 Aβ deposits from 1 month Not reported (Chishti et al., 2001)
PS1P264L/P264L x Tg2576 Aβ deposits from 6 months, ↑ Aβ42 Not reported (Flood et al., 2002)
PS2N141I x APPswe Aβ deposits from 5 months From 8 months (Richards et al., 2003)
JNPL3 x Tg2576 Aβ deposits from 8-9 months, Not reported (Lewis et al., 2000)
accelerated tau pathology
Triple mutations:
3xTg PS1/APP/Tau Aβ deposits from 3-6 months, From 4 months (Oddo et al., 2003; Billings et al. 2005)
NFTs from 12 months (e.g. MWM, Contextual fear conditioning)
RAWM = Radial arm water maze, MWM = Morris water maze, PA = passive avoidance, mon. = months.
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iii) Single transgenic models: Tau, presenilin and ApoE mutations
Single transgenic models have been used to study pathological features of AD in isolation, 
which is advantageous in further understanding their role in AD. PS1 models are useful for 
examining the role of PS1 and the preferentially expressed Aβ42, although the lack of plaque 
development limits their application in modelling amyloid pathology (Flood et al., 2002). 
Models expressing human tau mutations have also been developed since APP models show 
limited tau hyperphosphorylation and fail to exhibit NFTs or significant neuronal loss 
(Takeuchi et al., 2000; Kurt et al., 2003). Although no tau mutations have been identified in 
AD patients, tau mutations associated with frontotemporal dementia were found to cause 
aggregation of hyperphosphorylated tau and NFT development similar to that observed in 
AD, and so were used to model tauopathy in AD (Götz, 2001; Andorfer et al., 2003; Lewis et 
al., 2000). Such tau-expressing models (Table 1.4) show age-dependant tau 
hyperphosphorylation, tau redistribution and accumulation, NFT formation and extensive 
atrophy (Andorfer et al., 2003). Tau models have also been developed using mutations of 
phosphatases and kinases involved in tau hyperphosphorylation (reviewed in Götz, 2001). 
ApoE models were developed to further understand the role of ApoE in AD since ApoE ε4 is 
a major genetic risk factor (Saunders, 1993; Strittmatter et al., 1993). Models include ApoE 
or ApoE allele overexpression or deficient (knock out) mice (reviewed in Spires & Hyman,
2005). Such models provide evidence for the importance of ApoE in neuronal and cognitive 
function, and Aβ development (Masliah et al., 1995, 1997; Tibolla et al., 2006).
iv) Single transgenic APP mutant models
The discovery of APP mutations on chromosome 21 in familial AD cases and its involvement 
in overproducing the principal pathological hallmark β-amyloid led to the development of the 
first transgenic AD models which reproduced aspects of amyloid pathology similar to that 
observed in AD (Chapman et al., 2001; Spires & Hyman, 2005). Table 1.4 presents a variety 
of single, double and triple transgenic models harbouring APP mutations. A review of each 
model is beyond the scope of this chapter, and so a more comprehensive review can be found 
in Reddy and McWeeney (2006) or Eriksen and Janus (2007). This section will briefly outline 
the development of APP models and their main characteristics. Due to its use in the 
experimental chapters, the Tg2576 mouse model will be detailed in the next subsection.
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The pathological and behavioural phenotype of APP transgenic mice is dependent upon the 
APP missense mutation (Figure 1.4), background strain, APP primary structure (ranging from 
563 to 770 amino acids in length) and the level of APP expression controlled under different 
gene promoters (Hsiao et al., 1996; Lamb et al., 1997). The most common APP mutations 
used to generate AD models include the APPV717 and the Swedish double APP (APPswe 
K670M/N671L) mutations. Specifically, the human APPV717 gene mutation harbours the amino 
acids phenylalanine (F), glycine (G) or isoleucine (I) in substitution of valine (V) at codon 
717 in exon 17 of the APP gene (Lamb et al., 1997; Figure 1.4). These mutations are referred 
to as the APPV717F, APPV717G, and APPV717I mutation, respectively. The APPswe gene 
mutation is detailed in the Tg2576 model section (section 1.7.3). As illustrated in Figure 1.4, 
the majority of APP mutations occur close to or at the cleavage sites of APP, resulting in 
altered APP processing and Aβ production (Mullan et al., 1992). For example, mutations 
located around the β-secretase cleavage site are associated with a reduction in sAPPα
products and increased Aβ (Lamb et al., 1997). 
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Figure 1.4 Amyloid precursor protein (APP) with the β-amyloid (Aβ) segment enlarged to show α-, β-
and γ-secretase cleavage sites, the amino acid sequence (letters) and substitution sites (in red) of the 
APP gene associated with FAD mutations. The two most commonly used APP mutations, 
APPsweK670M/N671L and APPV717, have been labelled. Information sourced from Van Dam & De Deyn 
(2006). 
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As shown in Table 1.4, the APPV717F mutation was used to create the PDAPP model. This 
mutation is driven by the PDGF-β (platelet-derived growth factor-β) promoter in a Swiss 
Webster-B6D2F1 mouse strain (Games et al., 1995). APP is overexpressed and the mutation 
located around the transmembrane domain of APP (cleaved by γ-secretase) leads to a greater 
production of longer Aβ peptides terminating at amino acid 42(43), resulting in an elevated 
Aβ42:Aβ40 ratio (Suzuki et al., 1994; Lamb et al., 1997). This results in early and extensive 
AD-like neuropathy including plaque formation, synaptic density loss, phosphorylated tau, 
memory impairment, and plaque-associated neuroinflammation (Games et al., 1995; Chen et 
al., 2000; Lanz, Carter & Merchant, 2003). This model therefore shows amyloid pathology 
and neuronal dysfunction similar to AD (Masliah et al., 1996; Irizarry et al., 1997). 
The Swedish double APPK670M/N671L mutation was used to create the Tg2576, APP23, C3-3 
and TgCRND8 model (Table 1.4). APP23 mice express this mutation under the control of the 
murine Thy1.2 promoter on the C57BL6/DBA2 strain (Sturchler-Pierrat et al., 1997). The 
C3-3 model expresses this mutation on the C57BL6/C3H background strain, driven by the 
mouse prion promoter (Borchelt et al., 1997). This model develops plaques at a much later 
stage than the other models which have much earlier onset of amyloid pathology. The 
CRND8 model expresses both the APPswe and APPV717I (London) mutation, driven by the 
Syrian hamster prion (PrP) promoter on the C57BL6/CH3 background strain (Chishti et al.,
2001). This causes early amyloid development and cognitive impairment, but can cause 
premature death dependent upon background strain, thereby highlighting the importance of 
genetic background on the effects of APP overexpression.
These APP mutations therefore generate AD models that exhibit amyloid pathology and Aβ-
associated neuropathy including senile plaques, synaptic changes, cholinergic degeneration, 
mitochrondrial abnormalities, neuroinflammation and hyperphosphorylated tau in an age- and 
distribution-dependant manner similar to that found in AD patients (Reddy & McWeeney,
2006). Plaque pathology is particularly characteristic of that observed in human patients, 
including fibrillar Aβ cores surrounded by dystrophic neurites, activated microglia and 
astrocytes (Sturchler-Pierrat, 1997; Calhoun et al., 1998). These APP mutations typically lead 
to cognitive dysfunction similarly observed in AD patients including memory deficits, 
executive dysfunction and behavioural changes to exploration and anxiety (e.g. Lalonde et 
al., 2002; Kelly et al., 2003; Van Dam et al., 2003). In contrast to AD patients however, these 
APP models fail to exhibit NFT development and neuronal loss (as reviewed in Reddy & 
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McWeeney, 2006). An exception to this is the APP23 model which shows some limited 
neuronal death in CA1 pyramidal neurons (Calhoun et al., 1998).
1.7.3 The Tg2576 mouse model
The Tg2576 mouse model is the focus of the animal models section as it is the AD model of 
choice used in the experimental chapters. The following subsections will detail the APP 
mutation, its resulting pathology and phenotypic characteristics, as well as justify the use of 
the model in the experimental chapters. Particular reference will be made to how accurately 
the Tg2576 model mimics AD in human patients. 
i) The Swedish double APP mutation
The Tg2576 model expresses the human Swedish double APPK670N/M671L mutation which was 
discovered in a Swedish family with early-onset familial AD (Hsiao et al., 1996). As 
illustrated in Figure 1.4, this mutation harbours the amino acid asparagine (N) in substitution 
of lysine (K) at codon 670 (referred to as K670N), and leucine (L) in substitution of 
methionine (M) at codon 671 (referred to as M671L) in exon 16 of the APP gene (Mullan et 
al., 1992; Lamb et al., 1997). This 695-amino acid mutation in the Tg2576 model is 
controlled under the hamster prion protein promoter in a hybrid background strain of 
C57BL6/SJL (Hsiao et al., 1996). The resulting mutation leads to the overexpression of 
transgenic APP in the brain which is ~5.5 fold higher than endogenous mouse APP (Hsiao et 
al., 1996). The mutation occurs close to the β-secretase amyloidogenic processing site of 
APP, leading to increased cleavage by β-secretase and Aβ production (Figure 1.4; Mullan et 
al., 1992). 
ii) Pathology
The Tg2576 model shows several features of amyloid neuropathy similar to AD patients. 
Firstly, they show an age-related increase in Aβ in multiple brain regions including the cortex 
(frontal, temporal and entorhinal cortex), hippocampus, presubiculum and subiculum, but 
limited in the cerebellum (Hsiao et al., 1996; Irizarry et al., 1997; Irizarry, Locascio & 
Hyman, 2001; Praticò et al., 2001; Bizon, Prescott & Nicolle, 2007). Soluble Aβ levels start 
to increase in the Tg2576 model from 4 to 5 months of age, which becomes significant by 6 
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to 7 months (Hsiao et al., 1996; Kawarabayashi et al., 2001; Westerman et al., 2002; 
Jacobsen et al., 2006; Bizon, Prescott & Nicolle, 2007). Between 6 to 10 months of age, 
insoluble forms of Aβ increase exponentially, mirrored by a slight reduction in soluble forms 
suggesting their conversion to insoluble forms (Kawarabayashi et al., 2001). Significant 
levels of insoluble Aβ are present in 70% of mice at 6 months and 100% at 10 months 
(Westerman et al., 2002). Accordingly, diffuse deposits and senile plaques start to develop 
between 9 to 12 months of age (Hsiao et al., 1996; Kawarabayashi et al., 2001; Bizon, 
Prescott & Nicolle, 2007). However, these insoluble forms of Aβ do not produce significant 
numbers of diffuse plaques until 12 months, and between 12 to 23 months these diffuse 
plaques increase and neuritic plaques with amyloid cores develop (Kawarabayashi et al.,
2001). Consistently, Jacobsen et al. (2006) reported a detectable but modest scattered plaque 
load at 12 months which becomes significant by 18 months.
An amyloid burden similar to AD patients of 4 to 8% in affected regions was reported at 16 
months by Irizarry, Locascio and Hyman (2001), although Kawarabayashi et al. (2001) 
reported comparable levels at 21 months. Between 2 and 8 months, Tg2576 mice have a 5-
fold increase in Aβ40 and 14-fold increase in Aβ42 concentration (Scheuner et al., 1996). 
Consistently, Hsiao et al. (1996) reported that 11 to 13 month old mice had a greater 
Aβ40:Aβ42 ratio. This significant deposition of Aβ40 is similar to that found in ~33% of AD 
patients, although ~67% patients show very little Aβ40 deposition (Gravina et al., 1995). 
Also similar to ~33% of AD cases, Tg2576 mice show marked angiopathy (Gravina et al.,
1995). Other parallels to the AD brain include Aβ deposits with fibres radiating from a 
central mass and some small deposits possessing an amyloid core with a ‘Maltese cross’ 
structural pattern (Hsiao et al., 1996). This model also shows multiple aspects of amyloid-
associated pathology similar to aged AD brains including amyloid plaques surrounded by 
dystrophic neurites at 15 to 16 months, reactive astrocytes at 18 months and activated 
microglia from 10 months (Irizarry et al., 1997; Frautschy et al., 1998; Sasaki et al., 2002; 
Jacobsen et al., 2006). Importantly, this plaque-associated microgliosis is evidence of 
increased neuroinflammation, similar to AD patients. Consistent with this inflammatory 
response, other markers of inflammation have been reported in Tg2576 mice including IL-1β, 
TNF-α, COX-2, complement protein C1q and chemoattractant protein-1 (Lim et al., 2000, 
2001; Sastre et al., 2006). 
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As well as neuroinflammation, the Tg2576 model shows a widespread pattern of oxidative 
stress similar but not identical to that observed in AD brains. Oxidative damage is one of the 
earliest events in the human AD brain (Nunomura et al., 2001). Mirroring this, lipid 
peroxidation was significantly elevated from 8 months of age in Tg2576 mice before plaque 
deposition (Praticò et al., 2001). Other oxidative markers increased globally in an age-
dependant manner between 13 and 25 months (Pappolla et al., 1998; Smith et al., 1998; Lim 
et al., 2001). Some markers correlated with localisation or burden of plaque deposition, 
although others did not, suggesting some role of plaques in oxidative stress. The lack of 
oxidative markers at 4 months of age prior to the onset of Aβ development suggests the 
involvement of Aβ accumulation (Pappolla et al., 1998). 
Tg2576 mice show an age-related disruption of neuronal processes emerging from an early 
age. Transgene-dependant reductions in CA1 and DG hippocampal dendritic spine density 
were observed from approximately 4 months of age in Tg2576 mice, with further reductions 
reported at 11-12 and 18-20 months (Figure 1.5; Lanz, Carter & Merchant, 2003; Jacobsen et 
al., 2006). Similar losses were observed in AD patients within this region (Scheff, Sparks & 
Price, 1996). These significant dendritic spine deficits were not observed at 2 months of age, 
suggesting a modulatory role of soluble Aβ (Lanz, Carter & Merchant, 2003; Jacobsen et al.,
2006). Jacobsen et al. (2006) also reported impaired LTP and a basal synaptic transmission 
deficit at 4 to 5 months in the DG of hippocampal slices. Consistent with early changes, 
Klingner et al. (2003) reported cholinergic and noradrenaline neurotransmitter receptor 
alterations at 5 and 17 months of age. The early emergence of synaptic deficits in Tg2576 
mice was central to the rationale for using this model in evaluating early dietary interventions 
presented in the experimental chapters. 
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Figure 1.5 Loss of dendritic spine density in the DG region of the hippocampus in Tg2576 mice (B, 
D, F and H) relative to wildtype mice (A, C, E and G) at 2, 4, 12 and 18 months, respectively. Figure 
sourced from Jacobsen et al., 2006.
In contrast to reports of early synaptic deficits, Chapman et al. (1999) failed to find LTP 
impairments in Tg2576 mice aged 2 to 8 months, although confirmed CA1 and DG 
impairments at 15 to 17 months. Consistent with a later synaptic deficit, Stern et al. (2004) 
reported severe synaptic response impairment of cortical neurons at ≥14 months, which 
correlated with substantial plaque accumulation, but not at 8 to 9 months of age. Alpar et al. 
(2006) also reported reduced spine density in apical dendrites of pyramidal cells in the 
primary somatosensory cortex at 11 months. Furthermore, Spires et al. (2005) reported a 
~50% spine density reduction, disrupted neurite trajectories and loss of presynaptic and 
postsynaptic markers (synaptophysin and PSD-95, respectively) in the vicinity of plaques in 
the cortex at 21 to 24 months. A 25% reduction of spine density was also observed not 
associated with plaques, suggesting widespread loss. Loss of presynaptic and postsynaptic 
structural elements was however not reported at the earlier age of 15 to 17 months in the 
hippocampus (Chapman et al., 1999). Pre- and post-synaptic alterations, such as reduced 
PDS-95 and GluR1, in Tg2576 neurons are supported in vitro (Almeida et al., 2005). The 
disrupted synaptic morphology and function reported in Tg2576 mice has been proposed as 
the main agent underlying at least some of the observed behavioural deficits outlined in 
section 6c iii (Ashe, 2001).
While outlining similarities between AD neuropathy in humans and the Tg2576 model, it is 
also important to highlight their dissimilarities. Unlike the human AD brain, Tg2576 mice do 
not show profound neuronal loss and tau pathology, such as extensive tau
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hyperphosphorylation, PHF and NFT formation (Irizarry et al., 1997; Frautschy et al., 1998; 
Sasaki et al., 2002). Furthermore, Sasaki et al. (2002) reported that aged 18 to 29 month old 
Tg2575 mice had 10-fold more relatively large-size plaques than AD patients, and had giant 
plaques which are almost never observed in the human AD brain. Despite these differences,
AD and potential therapeutic strategies as it shows multiple temporally-associated
neuropathological changes (such as amyloid pathology, inflammation, oxidative stress, 
dystrophic neurites and synaptic dysfunction) and obvious behavioural deficits (reviewed in 
the next section) which are both progressive and characteristic of the disease. Moreover, 
Tg2576 mice show a limited extent of tau pathology by exhibiting tau hyperphosphorylation
in neurites surrounding Aβ deposits (Puig et al., 2004). Furthermore, Tg2576 mice make for a 
suitable model to study pathological processes that characterise the early (or even pre-
symptomatic; Ashe 2001) brain changes in AD and thus the potential benefit that may be 
gleaned from early intervention therapies.
iii) Behavioural phenotype
Human AD patients have impaired declarative memory (including semantic and episodic 
memory), recognition memory, visuospatial abilities and executive function, consistent with 
pathological disruptions to the medial temporal lobe, hippocampus, amygdala, 
parahippocampus (entorhinal and perirhinal cortices) and the cortex (as reviewed in Nestor, 
Scheltens & Hodges, 2004). Similarly, the Tg2576 model shows an age-related increase in 
Aβ-associated pathology in these brain regions which appear to correlate with a rather 
specific cognitive deficit controlled by these structures (Frautschy et al., 1998; Chapman et 
al., 1999; Arendash et al., 2001b; Lehman et al., 2003; Wilcock et al., 2004; Hale & Good, 
2005). For example, the Tg2576 model is primarily characterised by impairments dependent 
upon hippocampal and medial temporal lobe function such as spatial, recognition and 
configural memory, as well as emotional disturbances (e.g. Hsiao et al., 1996; Corcoran et al.,
2002; King & Arendash, 2002; Hale & Good, 2005; Lelos et al., 2011). 
These deficits mimic symptoms observed in AD patients. For example, Tg2576 mice have 
impaired recognition memory concerning social information and object-location information 
(e.g. Hale & Good, 2005; Ognibene et al., 2005; Good & Hale, 2007; Good, Hale & Staal,
2007; Deacon et al., 2009). This is also reported in AD patients (Swainson et al., 2001; 
Willems, Adam & Van der Linden, 2002; Lee et al., 2003). Similarly, Tg2576 mice show
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frontal lobe-dependant executive dysfunction in tasks, which is correlated to amyloid 
pathology in this region (e.g. Zhuo et al., 2007, 2008). Impaired executive function and 
attentional control has also been shown in AD patients (as reviewed in Collette, Van der 
Linden & Salmon, 1999; Foldi, Lobosco & Schaefer, 2002; Nagahama et al., 2003), which is 
related to pathology and significant neuronal loss in the frontal lobes (Arriagada et al., 1992; 
Salat, Kaye & Janowsky, 2001; Mintun et al., 2006). Despite the established pathology and 
cognitive deficits observed in AD patients and Tg2576 mice in the frontal lobe, this region 
has not been extensively studied in Tg2576 mice, unlike the medial temporal lobe and 
hippocampal memory domain. This is particularly interesting since frontal-lobe dysfunction 
has been reported before hippocampal-dependant deficits and pathology in Tg2576 mice 
(Zhuo et al., 2007). Further examination is therefore required.
Also similar to AD patients, Tg2576 mice show low susceptibility of certain structures, such 
as the striatum and cerebellum, to extensive Aβ pathology in the cortex and hippocampus 
(Middei et al., 2004; Zhuo et al., 2008). This results in a relative sparing of certain 
behaviours. For example, sensorimotor performance and certain forms of implicit memory, 
such as procedural memory/discrimination learning are unaffected, at least until late stages of 
pathology (e.g. Damasio et al., 1990; Hartman & Pirnot, 1995; Middei et al., 2004; 
Fleischman et al., 2005). Further detail of deficits in Tg2576 mice, particularly frontal and 
medial temporal lobe dysfunction, is detailed throughout chapters 3, 4 and 5.
The onset of behavioural and cognitive deficits in the Tg2576 model is variable. Generally 
however, behavioural deficits emerge from 6 to 9 months of age, coinciding with the 
appearance of amyloid pathology (e.g. Ognibene et al., 2005; Zhuo et al., 2008). Behavioural 
deficits in a number of cognitive domains are obvious from 9 months of age onwards when 
there is a marked increase in Aβ, particularly when Aβ is deposited to form plaques in the 
neocortex and hippocampus (Hsiao et al., 1996). Despite the majority of deficits occurring 
after 6 to 9 months of age, behavioural changes have been documented at an earlier age when 
the brain is free of amyloid plaques and deposits (King et al., 1999; Deacon et al., 2008). For 
example, studies have documented selective memory (passive avoidance, water maze and 
circular platform), sensorimotor (balance beam) and spontaneous behaviour impairments 
(hyperactivity, burrowing and nesting) at 3 months of age (King et al., 1999; King & 
Arendash, 2002; Deacon et al., 2008). Furthermore, a spatial memory deficit (Y-maze 
spontaneous alternation) was reported at 3 to 4 months (Hsiao et al., 1996; King et al., 1999),
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and impaired contextual fear conditioning at 5 months (Dineley et al., 2002; Comery et al.,
2005; Jacobsen et al., 2006). The appearance of such early deficits is supported by the 
presence of morphological and functional synaptic changes in the Tg2576 brain from 4 
months of age, as detailed previously.
The discovery of behavioural and synaptic deficits at an early age is indicative of early-stage 
pathological events or mechanisms which precede substantial Aβ deposition, such as 
increased soluble Aβ or oxidative stress and inflammation. Indeed, Westerman et al. (2002) 
reported the presence of soluble Aβ from 4 to 5 months. An increase in soluble Aβ may 
therefore trigger early-onset morphological and functional synaptic deficits that lead to 
behavioural dysfunction (Jacobsen et al., 2006). The discovery of both behavioural and 
pathological changes during early stages of the disease provides justification for evaluating
early intervention strategies using this model.
Although early changes are apparent which highlights the pathological role of soluble Aβ 
accumulation, it is also important to note that several measures of cognitive impairment are 
not demonstrated at an early age. For example, King et al. (1999) shows no impairment in Y-
maze alternation, water maze acquisition, passive avoidance and active avoidance tests at 3 
and 9 months. Similarly, Chapman et al. (1999) reported hippocampal LTP deficits at 17 to 
19 months but not at 6 to 8 months, which correlated with impaired spatial working memory 
at the later age. This later onset of cognitive impairment has led to various conclusions 
regarding the form of Aβ that is responsible. For example, the onset of deficits from ~9 
months implicates insoluble Aβ and amyloid plaques (e.g. Hsiao et al., 1996). In support of 
this, Westerman et al. (2002) reported that spatial memory deficits in the Morris water maze 
at 6 months correlated with an elevation of detergent insoluble Aβ aggregates. Furthermore, 
they reported that the presence of soluble Aβ in the absence of insoluble Aβ at 4 to 5 months 
was insufficient to cause spatial memory deficits before 6 months, therefore supporting the 
role of insoluble Aβ. 
Interestingly, Westerman et al. (2002) also reported that the association of memory loss and 
insoluble Aβ levels was lost when correlated in older mice, suggesting that cognitive  
dysfunction in AD is related not necessarily to amyloid load but the conversion of soluble to 
insoluble Aβ. Similarly, Wang et al. (1999) reported the pathogenic importance of a 
progressive shift from soluble to insoluble pools of Aβ.  Such theories are supported by the 
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neurotoxic properties of small intermediate Aβ assemblies such as oligomers and photofibrils 
(Lambert et al., 1998; Hartley, 1999). Similarly, Walsh et al. (2002) demonstrated the 
neurotoxic effect of Aβ oligomers in the absence of Aβ monomers and fibrils, which 
disrupted hippocampal LTP in rats in vivo. Furthermore, Lesné, Kotilinek and Ashe (2008) 
identified Tg2576 mice with plaques but markedly reduced levels of Aβ oligomers to have 
normal memory function. These studies suggest that preclinical and early clinical progression 
of AD is driven by accumulation of soluble Aβ and intermediate Aβ assemblies. Importantly, 
this may suggest that late-stage therapeutic intervention may not be the optimal strategy to 
ameliorate behavioural dysfunction. Overall, the precise roles of the diverse amyloid 
assembly states in AD-associated cognitive dysfunction remain unclear, with both amyloid 
plaques and soluble Aβ oligomers associated with impaired neuronal and cognitive function.
iv) Justification for use of the Tg2576 model
The Tg2576 mouse model was selected to investigate dietary intervention for AD in this 
thesis for various reasons including suitability and availability. Firstly, this model expresses 
multiple features of AD pathology and behavioural deficits which mimic that observed in 
AD. It is therefore thought to be a credible model of amyloid-induced pathology presented in 
AD. Secondly, the behavioural and pathological phenotype of this model has been 
extensively characterised which has uncovered robust behavioural deficits suitable for 
examining putatively therapeutic interventions. Thirdly, the onset and development of 
pathology and behavioural deficits in this model are compatible with multiple aims of this 
thesis, primarily including: 1) assessing both early (before pathological development) and 
longitudinal therapeutic intervention, and 2) further characterising the behavioural phenotype 
of the model, including the onset and variation of deficits historically associated with
different neural structures. One potential disadvantage of the model is the lack of NFT 
development and neuron loss. However, this model provides an excellent opportunity to 
assess the impact of interventions on pathology and behavioural changes associated with a 
theoretically leading cause of AD pathogenesis.
1.8 Thesis aims
This introduction has highlighted a number of areas surrounding dietary supplementation and 
the Tg2576 model which require further research, and so the present study has multiple aims. 
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Despite considerable research into the effect of dietary omega-3 PUFAs on pathology and 
behaviour in animal models of AD, very few studies have attempted to examine the impact of 
this supplement in comparison to a suitable control diet which controls for the level of 
various other fatty acids, particularly the content of omega-6 PUFA. It is argued that such 
control is vital in order to understand the effect of omega-3 PUFAs, rather than its effect 
relative to a control diet with an unequal level of fatty acids or a high level of omega-6 
PUFAs which may contribute to the observed effects. This would arguably provide a more 
valid assessment of its potential benefits in the context of a human population that maintains 
a relatively healthy diet. The first aim of the present study therefore was to investigate the 
impact of dietary omega-3 PUFAs and fish oil containing omega-3 PUFAs in comparison to a 
control diet which had an equal level of fatty acids and a ‘neutral’ blend of fatty acids in 
replacement of the additional omega-3 PUFAs/fish oil in the experimental diet. In particular, 
the level of omega-6 PUFA was controlled.
The second aim of the present study was to investigate the effect of dietary curcumin 
supplementation on behaviour and pathology in the Tg2576 mouse model. In particular, the 
present study examined the effect of curcumin when supplemented from an early age prior to 
the onset of pathology. This was particularly important as the current literature surrounding 
curcumin supplementation in AD models has examined intervention during late stages of 
pathology development only. Although these studies have shown positive effects, even earlier 
intervention was hypothesised to prove a more successful at reducing pathological changes 
that disrupt memory function. For similar reasons, supplementation of omega-3 PUFAs/fish 
oil was also examined from an early age. This was particularly important as no studies had 
examined early omega-3 PUFA treatment in the Tg2576 model, and no study had examined 
the effect of fish oil supplementation in the Tg2576 model at any time-point. Furthermore, 
the examination of behaviour was an important aspect of this research as only one study had 
reported the effects of dietary omega-3 PUFA supplementation on behaviour in the Tg2576 
model.
A third aim of the present study was to investigate the effect of a combination of omega-3 
PUFA (sourced from fish oil) and curcumin supplements. No published in vivo study to date 
has reported examination of these supplements in an AD mouse model. It was hypothesised 
that a combination of these supplements would have more potent effects than individual 
supplementation as previous research has outlined the potential synergistic effects of 
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combining treatments. More specifically, evidence shows that the efficiency of omega-3 
PUFAs may be improved through its combination with curcumin as it provides antioxidant 
protection. Similarly, curcumin efficiency may be improved through its combination with 
omega-3 PUFAs as it may increase its bioavailability.
In particular, the present study aimed to investigate chronic treatment of these dietary 
supplements. Further investigation was required into the effects of longitudinal treatment as 
curcumin supplementation had been limited to 6 months in animal model studies. Although 
omega-3 PUFA supplementation has been more extensive in its time course, this has been 
limited to intervention at a later stage in transgenic models; highlighting the need for 
examination of chronic treatment from an early age. The potential importance of early 
intervention may be interpreted through human studies of dietary intervention, whereby 
short-term clinical trials of omega-3 PUFA have reported few positive effects in contrast to 
long-term epidemiological studies. The positive results from epidemiological studies may 
reflect long-term lifestyle choices of diet, perhaps suggesting that longitudinal dietary 
intervention may offer more positive effects. Furthermore, as AD is a long-term condition 
that develops over time, it is likely that longitudinal intervention would be required to 
provide therapeutic effects throughout the time course of the disease. Longitudinal treatment 
was therefore hypothesised to delay disease onset and reduce disease progression.
The overarching hypothesis under test in this thesis is that the pleiotropic actions of omega-3 
PUFAs and curcumin on Aβ, inflammation and oxidative stress, will reduce behavioural and 
pathological indices of AD-like pathology in Tg2576 mice.
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Chapter 2
Preparation of mouse colonies and dietary intervention
2.1 Introduction
Prior to presenting the results of the studies examining dietary supplementation in Tg2576 
mice in chapters 3, 4 and 5, this chapter summarises the methods employed for generating 
and maintaining the mouse cohorts used, including genotypic analysis to identify transgenic 
mice harbouring the APPswe mutation. This chapter also outlines the experimental diets used 
in chapters 3, 4 and 5, including the methodology and results of the lipid analysis performed 
on the diets to ensure dietary content was accurate after production. Furthermore, this chapter 
outlines the statistical analysis design commonly employed throughout chapters 3, 4 and 5.
2.2 Preparation of mouse colony
2.2.1 Generation and maintenance of the Tg2576 colony
The Tg2576 model, possessing the human double APPswe mutation on a hybrid background 
strain of C57Bl/6 x SJL, was developed by Karen Hsiao and colleagues in 1996 (Hsiao et al.,
1996). The transgene was generated by inserting human APP open reading frame into a 
hamster prion protein (PrP) cosmid vector and mutating the insert. The Tg2576 line was 
originally established by crossing a C57Bl/6j x SJL F3 founder twice into C57Bl/6j 
(Chapman et al., 1999). Overexpression of the transgene was maintained in subsequent 
generations by crossing heterozygous Tg2576 to a C57Bl/6j x SJL F1 line (Chapman et al., 
1999). Each generation possessed differences in the relative percentage of each of these 
background strains, with an estimated 59% to 88% contribution of C57Bl/6j and 12% to 41% 
of SJL (Chapman et al., 1999). The separate mouse cohorts used in chapters 3, 4 and 5 were
generated by pairing male heterozygous Tg2576 mice with female C57Bl/6j x SJL F1 mice. 
The resulting offspring were either heterozygous Tg2576 transgenic (Tg) mice, possessing 
the mutation, or homozygous Tg2576 wildtype (WT) mice, at a ratio of 50:50. The 
62
possession of the transgene was detected through genotyping, as detailed in section 2.2.2. 
Genotype status (Tg or WT) was re-confirmed upon termination at the end of the study.
Following successful breeding, litters were weaned into same-sex mixed-genotype littermate 
groups consisting of 2 to 4 individuals at approximately 6 weeks of age. Only male mice 
were used in the experiments in order to reduce variability induced by gender differences, as 
reported in several tasks (e.g. King et al., 1999; Deacon et al., 2008, 2009). Mice were 
immediately ear marked for identification, and ear- or tail-biopsied for genotyping to 
determine genotype status. Tail biopsies (<0.05cm) were removed using ethyl chloride local 
anaesthetic and a silver nitrate pen to seal the incision. Tissue samples were stored at -20°C 
until further use. Mice were individually housed at 8 weeks of age following genotype 
results. 
Mice were fed standard laboratory mouse chow (RM1 Rodent, SDS, England) until replaced 
with experimental diets (detailed in section 2.3) at either 2 months of age (in chapters 4 and 
5) or 4 months of age (in chapter 3). Diets were allocated pseudo-randomly, controlling for 
genotype and littermate groups as far as possible. Mice were housed in a colony room 
maintained at a temperature of 21 ± 2°C and a humidity of 55% ± 10%. Colony rooms 
operated on a 12-hour light-dark cycle (lights on at 7:00 to 19:00) and behavioural 
experimentation took place during the light phase of the cycle as far as possible. The running 
order of mice during behavioural experimentation was counterbalanced for genotype and diet, 
and run blindly to the experimenter. All mice were experimented and maintained in full 
compliance with Home Office (United Kingdom) guidelines on the use of animals in 
scientific procedures.
2.2.2 Genotyping of the Tg2576 colony
2.2.2.1 Introduction
Tissue biopsies from mice were genotyped using the polymerase chain reaction (PCR) 
molecular biology technique to determine whether they harboured the human double APPswe 
mutation. PCR selectively amplifies specific deoxyribonucleic acid (DNA) regions 
exponentially for measurement using gel electrophoresis. In our protocol, specific 
oligonucleotide primers were used to selectively amplify the nucleic acid sequence coding the 
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APPswe transgene. Selective DNA amplification in PCR occurs through enzymatic 
replication by utilising repeated thermal cycling of a DNA sample containing multiple 
reagents including DNA polymerase, oligonucleotide primers and deoxynucleoside 
triphosphates (dNTPs).
2.2.2.2 Methods
Digestion and extraction of DNA
In preparation for the PCR, DNA was digested and extracted from the tissue sample. 
Defrosted tissue samples were digested by incubating in 600 µl of TES cell lysis buffer (1M 
Tris HCl Buffer pH 8.0, 0.5M EDTA pH 8.0, 10% SDS, dH20) at 55°C for 20 minutes. 
Following this, 1.5µl of 25mg/ml Proteinase K (Sigma, Cat.# P2308) was applied to each 
sample, vortexed and incubated overnight at 55°C. Following digestion, DNA was extracted 
by adding 200µl of 5M ammonium acetate, vortexed and centrifuged for 10 minutes at 
14,000 rpm to pellet the proteins. 650µl of supernatant was removed carefully not to dislodge 
the pellet, and transferred into 600µl of molecular biology grade isopropanol. This solution 
was mixed using inversion and centrifuged for 2 minutes at 14,000 rpm. The supernatant was 
discarded and 150µl of ice cold 70% molecular biology grade ethanol was applied to the 
DNA-containing pellet, and then centrifuged for 2 minutes at 14,000 rpm. Following a repeat 
of the latter process, the supernatant was removed and the samples were dried at 37 ºC until 
the ethanol was evaporated. DNA was resuspended in 60µl of TE buffer (1M Tris HCl pH 
8.0, 0.5M EDTA pH 8.0, dH20) and incubated overnight at 55°C. PCR was then carried out 
on the DNA samples within 24 hours or stored at-20°C until use.
PCR analysis and electrophoresis of DNA
1 µl of DNA sample was added to 24µl of master mix to make a 25µl solution. The samples 
and master mix were maintained on ice during this process. Master mix was prepared using 
2.5µl 10x reaction buffer, 1.25µl 50mM MgCl2, 1.25µl 10mM dNTPs, 0.25µl Primer 1501 
(50 pmol), 0.25µl Primer 1502 (10 pmol), 0.25µl Primer 1503b (10 pmol), 1.5µl BIOTAQ 
Red DNA Polymerase (1µg/µl) and 16.75µl nuclease-free MilliQTM water (Millipore, USA).
The DNA polymerase, 10x reaction buffer and MgCl2 were supplied in BIOTAQ Red DNA 
Polymerase kit (Bioline, Cat.# BIO-21041). The oligonucleotide primers 1502 (5’-
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GTGGATAACCCCTCCCCCAGCCTAGACCA-3’, 600bp) and 1503b (5’-
CTGACCACTCGACCAGGTTCTGGGT-3’, 450bp) were used to amplify the APPswe 
transgene, while primer 1501 (5’-AAGCGGCCAAAGCCTGGAGGGTGGAACA-3’, 
600bp) amplified the endogenous murine prion protein (PrP) with primer 1502.
The 25µl solution for each sample was vortexed and centrifuged for 6 seconds at 4000rpm. 
Each sample was placed into the PCR cycle machine, alongside one positive Tg control (1µl 
of confirmed Tg DNA plus 24µl master mix), one negative WT control (1µl of confirmed 
WT DNA plus 24µl master mix), and one blank control (1µl nuclease-free water plus 24 µl 
master mix). The blank control was run as a means of detecting potential contamination. The 
PRC cycler was programmed to carry out APPswe transgene amplification through 
initialisation at 72°C for 2 minutes followed by 36 cycles of: 1) denature at 94ºC for 1 
minute, 2) anneal and amplify at 62ºC for 1 minute, and 3) incubate at 72ºC for 2 minutes for 
elongation, with 2 seconds added to the elongation step per cycle. Samples were then 
maintained at 4ºC in the PRC cycler until collected for electrophoresis.
Gel electrophoresis was then used to separate the amplification products. A 17-tooth-combed 
1.5% agarose gel was made using 3g NuSieve® molecular grade agarose (Fisher scientific, 
Cat.# BMA50091) in 200ml of TAE buffer (40 mM Tris base, 1 mM EDTA pH 8.0, 0.01% 
v/v glacial acetic acid, dH2O) with 20µl of SYBR
® Safe DNA gel stain (Invitrogen, Cat.# 
S33102). Once set, the gel was placed into a RunOne system® gel tank with TAE buffer, then 
10µl of DNA marker, 8µl of each sample and 8µl of each control was applied into separate 
tooth-comb slots. The DNA marker was made from 10µl DNA marker (Promega, Cat.# 
G3161) with 2µl Orange G (0.25% Orange G, 15% Ficoll in MilliQTM water), which was
vortexed and centrifuged for 10 seconds at 4000rpm. Following this, the gel tank was run at 
100V for approximately 20 minutes to drive the electrophoresis. Results were obtained by 
observing the gel under UV light.
Figure 2.1 presents an example of a photographed gel under UV light that has undergone 
electrophoresis. The figure depicts the 100 bp DNA ladder (DNA marker) run alongside 13 
samples, followed by the blank (nuclease-free water), positive (Tg) and negative (WT) 
controls. A single band at ~600 bp corresponds to amplification of the endogenous murine 
prion protein gene by oligonucleotide primers 1501 and 1502, which should be present in all 
tissue samples from Tg2576 transgenic and WT mice. The presence of the second band 
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corresponds to amplification of the APPswe transgene by oligonucleotide primers 1502 and 
1503b, which confirms the tissue sample was collected from a Tg mouse. According to the 
bands in Figure 2.1, the samples corresponding to lanes 5, 6, 9, 10 and 13 were Tg mice and 
the samples corresponding to lanes 2, 3, 4, 7, 8, 11, 12 and 14 were WT mice.
Figure 2.1 Representative photograph of gel electrophoresis showing PCR amplification of DNA from 
Tg2576 and WT mice. Lane 1 = 100bp DNA ladder; Lanes 2, 3, 4, 7, 8, 11, 12 and 14 = single band 
corresponding to amplification of endogenous murine prion protein, therefore representing WT mice; 
Lanes 5, 6, 9, 10 and 13 = double band corresponding to amplification of endogenous murine prion 
protein and APPswe transgene, therefore representing Tg mice; Lane 15 = Blank (water) control, 
Lane 16 = Positive control (known Tg sample), Lane 17 = Negative control (known WT sample).
2.3 The experimental and control diets
2.3.1 Introduction
Chapters 3 and 4 examined the effect of a diet supplemented with the omega-3 PUFA 
docosahexaenoic acid (DHA), whereas chapter 5 examined the effect of diets supplemented 
with fish oil (rich in omega-3 PUFAs DHA and EPA), curcumin or a combination of fish oil 
and curcumin. 
In order to accurately examine the effect of dietary fish oil or DHA supplementation, the 
design of the experimental and control diets was an important consideration of the study. It is 
thought that the interpretation of omega-3 PUFA/fish oil/DHA supplementation findings have 
been confounded by the control diet in previous reports. For example, several studies in AD 
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mouse models have used a control diet which had an unequal level of total fatty acids relative 
to the experimental diet (e.g. Arendash et al., 2007; Green et al., 2007). The consequence of 
supplementing fish oil/DHA in the experimental diet without substituting the fatty acid 
content in the control diet prevents the conclusion that any effects are a result of fish oil/DHA
specifically rather than merely increased quantities of fatty acids. In order to ascertain the 
effects of fish oil/DHA specifically, a suitable control diet should therefore contain an equal 
level of fatty acids as the experimental diet. This was controlled for in the fish oil/DHA 
dietary interventions assessed in the chapters 3, 4 and 5.
Several studies have however controlled for this matter, although omega-3 PUFA/fish 
oil/DHA supplementation has been primarily replaced by omega-6 PUFAs in the control diet, 
often resulting in a excessive ω-6/ω-3 ratio (e.g. Calon et al., 2004, 2005; Lim et al., 2005; 
Cole & Frautschy, 2006; Ma et al., 2007, 2009; Green et al., 2007; Arsenault et al., 2011). 
Since the metabolic effects of omega-6 PUFAs can be pro-inflammatory, the excess omega-6 
PUFA content in the control diet may accelerate pathological development (as outlined in 
chapter 1). This approach is therefore comparing an omega-3 PUFA/fish oil/DHA diet with 
potential anti-inflammatory effects to a control diet with potential pro-inflammatory effects. 
Consequently, this design does not examine the effect of omega-3 PUFA/fish oil/DHA 
supplementation per se, but rather relative to a particularly poor diet which likely contribute 
to the beneficial effects. The supplementary fatty acids added to the control diet in chapters 3, 
4 and 5 were therefore composed of an oil blend low in omega-6 PUFAs (and equal to that in 
the fish oil/DHA diet), in order to prevent an excessive ω-6/ω-3 ratio. The supplemented oil 
blend in the control diet was composed of fatty acids typically found in an average U.K. diet, 
primarily composed of ‘neutral’ saturated and monounsaturated fatty acids which were not 
expected to induce pro- or anti-inflammatory effects.
The majority of previous studies have shown ~0.6% DHA supplementation effective at 
reducing behavioural deficits and pathology in AD models (e.g. Calon et al., 2004, 2005, Lim 
et al., 2005; Hooijmans et al., 2007, 2009; Ma et al., 2009). Similarly, Green et al. (2007) 
found 1.3% DHA effective in a 3xTg model. In contrast, Arendash et al. (2007) reported 13% 
omega-3 PUFA supplementation (containing 5.71% DHA) to be ineffective in the 
APPswe/PS1 model, although this may have been attributed to a lack of incorporation into 
the brain or the high levels of fat. High levels of fat have been shown to increase pathology 
and so the 13% oil supplement may have been detrimental and overshadowed any positive 
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effects of DHA. Supporting this, Julien et al. (2010) reported that a 35% fat diet increased Aβ 
pathology in Tg2576 mice compared to a 5% fat diet. Based on these results, a high level of 
DHA or oil supplementation (e.g. 13%) was deemed inappropriate. Similarly, it was proposed 
that low levels of DHA supplementation (e.g. 0.06%) may not be suitable, as although it 
showed positive effects in previous studies, this was relative to a poor control diet with a high 
ω-6/ω-3 ratio. It could therefore be argued that higher levels of DHA supplementation may 
be required to be effective relative to a control diet with a relatively low ω-6/ω-3 ratio, as 
used in chapters 3, 4 and 5. It was therefore decided that the DHA supplemented diet used in 
chapters 3 and 4 would contain a 5% DHA-rich oil (containing 45% DHA, equating to 2.25% 
DHA of the diet dry weight), compared to a control diet containing a 5% ‘neutral’ oil blend. 
Results from Julien et al. (2010) lead us to conclude that this level of supplementation should 
not be detrimental. Furthermore, this level of DHA supplementation would provide levels 
compatible to human supplementation.
Previous studies examining fish oil supplementation in AD-model mice have reported 
positive effects of fish oil at a dose of 2.2% to 2.4% of total diet weight (Oksman et al., 2006; 
Ma et al., 2009). Ma et al. (2009) examined the effect of 2.4% fish oil in the 3xTg AD model 
relative to a particularly poor-diet high in saturated and omega-6 PUFA. The positive effects 
of fish oil reported in this study were therefore limited to fish oil supplementation relative to 
a poor-diet. Similarly, Oksman et al. (2006) examined the effect of a 2.2% fish oil 
supplemented diet (plus 2.4% soy oil) with an ω-6/ω-3 ratio of 1.4:1 compared to 5% soy-oil 
supplemented standard chow (ω-6/ω-3 ratio of 8:1) and 5% corn-oil supplemented standard 
chow (ω-6/ω-3 ratio of 70:1). Although the soy-oil diet allowed a more accurate examination 
of fish oil than the corn-oil diet, both control diets had excessive levels of omega-6 PUFAs 
which prevented the accurate examination of fish oil supplementation per se. Chapter 5 
therefore aimed to examine the effect of a 2.5% fish oil supplemented diet relative to a 2.5% 
‘neutral’ oil blend supplemented diet, containing similar levels of omega-6 PUFA. 
In order to examine the effect of curcumin supplementation in chapter 5 it was important to 
select a dose that was previously reported as effective in reducing pathology and behavioural 
deficits. In addition to this, the dose must be safe and bioavailable in vivo. Frautschy et al. 
(2001) first showed positive effects of 500ppm and 2000ppm curcumin doses in the Aβ-
infused AD rat model. Supporting this, studies in the 3xTg AD model (Ma et al. 2009) and 
Tg2576 model (Yang et al., 2005; Begum et al., 2008) showed a 500ppm curcumin dose to be 
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effective. Interestingly, Lim et al. (2001) reported that 160ppm curcumin was more effective 
than 5000ppm curcumin at reducing oxidative stress and inflammation in the Tg2576 model, 
and that only the 160ppm dose reduced amyloid pathology. Although further investigation is 
therefore required to discover the optimal treatment dose, it is advisable to provide dosages 
lower than 5000ppm and closer to 500ppm. Chapter 5 therefore examined a 500ppm
curcumin dose since this dose appears effective at reducing pathological processes in a 
number of AD models including Tg2576 mice. Furthermore, 500ppm curcumin was the only 
reported dose to reduce spatial memory deficits (Frautschy et al., 2001). In order to 
accurately assess co-supplementation of curcumin (500ppm) and fish oil (2.5%) in chapter 5, 
a 2.5% neutral oil blend supplement was added to the curcumin diet to ensure that any 
observed differences in the combination diet was attributable to the fish oil and curcumin 
rather than curcumin with additional fatty acids. Although a curcumin alone supplemented 
diet would have been ideally been examined, the size of the mouse cohorts in chapter 5
limited the addition of this group. Also due to this issue, fish oil and curcumin co-
supplementation was only examined in Tg2576 not WT mice as this condition was of 
theoretical interest. In all other conditions, both Tg2576 and WT control mice were used.
2.3.2 Overview of the experimental diets used in chapters 3 and 4
The experimental mouse diets used in chapters 3 and 4 were composed of a standard mouse 
chow (RM1 Rodent, Special Diet Services, SDS, Essex, UK) containing sufficient amounts 
of nutrients, including essential fatty acids. These diets were supplemented with either a 5% 
DHA-rich oil containing ~45% DHA (produced by DHASCO, Martek Biosciences 
Corporation, Columbia, MD, USA) or a 5% oil blend composed of lard, palm oil, olive oil 
and coconut oil (3:3:3:1 by weight, respectively). Diets were supplied in 5kg bags and stored 
in a refrigerated room at 4ºC or a -20ºC freezer throughout the course of the study, except 
when in use when one 5kg bag of each diet was stored in the mouse colony room in sealed 
containers at room temperature in an effort to limit lipid peroxidation. Limiting the oxidation 
of lipids, especially long-chain PUFAs such as DHA which are particularly vulnerable to 
oxidation, is essential when formulating or storing diets in order to maintain the level of fatty 
acids in the diet and prevent intake of oxidised fatty acids which may induce an oxidative 
state (e.g. Calon et al., 2004; Calon & Cole, 2007).
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The composition of these food pellets were approximately equal with 12.8% crude protein, 
7.2% crude oil, 3.9% crude fibre and 5.6% ash, with a calorific value of 3407-3409 kcal/kg, 
according to the manufacturer (SDS) specification. The fatty acid profile of each diet 
provided by SDS is presented in Table 2.1. The table shows that the DHA supplemented diet 
contained 2.25% DHA, with small levels of other omega-3 PUFAs. In contrast, the oil blend 
supplemented diet contained 0% DHA, with small levels of omega-3 PUFAs. The diets 
contained similar levels of omega-6 fatty acids. Importantly, SDS also reported that the diets 
contained no cholesterol. A lipid analysis was performed by a research associate (Dr. Cécile 
Bascoul-Colombo) on three diet samples taken from 3 diet bags to confirm the fatty acid 
profiles of these diets (excluding cholesterol levels). This was carried out 3 weeks after the 
date of arrival, whilst being stored in a refrigerated room at 4ºC. The methodology of this 
analysis is detailed in section 2.3.4. Results from the analysis of diet samples for chapter 3 
are shown section 2.3.5, and results of diet samples for chapter 4 are shown in section 2.3.6.
Table 2.1 Fatty acid compositions of the DHA and oil blend diets, expressed as percentage of fresh 
diet weight. Information provided by the manufacturer (SDS, Essex, UK.)
Fatty acids         Rodent chow + 5% DHA rich oil        Rodent chow + 5% oil blend
Dodecanoic (Lauric) acid 12:0 0.10% 0.26%
Tetradecanoic (Myristic) acid 14:0 0.64% 0.24%
Myristoleic acid 14:1 0.01% 0.00%
Hexadecanoic (Palmitic) acid 16:0 0.87% 1.34%
Sapienic (Palmitoleic) acid 16:1ω-7 0.08% 0.08%
Octadecanoic acid (Stearic) 18:0 0.09% 0.31%
Oleic acid 18:1ω-9 2.04% 2.79%
Linoleic acid 18:2ω-6 0.95% 1.13%
α-Linolenic acid 18:3ω-3 0.08% 0.08%
Arachidonic acid 20:4ω-6 0.12% 0.11%
Docosapentaenoic acid 22:5ω-3 0.01% 0.00%
Docosahexaenoic acid 22:6ω-3 2.25% 0.00%
Total saturated fatty acids * 1.70% 2.15%
Total monounsaturated fatty acids * 2.13% 2.87%
Total polyunsaturated fatty acids * 3.41% 1.32%
Total omega-3 (ω-3) PUFA* 2.34% 0.08%
Total omega-6 (ω-6) PUFA* 1.07% 1.24%
Omega-3/omega-6 (ω-3/ω-6) ratio * 2.19:1 0.06:1
Omega-6/omega-3 (ω-6/ω-3) ratio 0.46:1 15.5:1
*Calculated from the manufacturer’s specification.
According to manufacturer specifications, the DHA and oil blend diets contained equal levels 
of vitamins including 8150 iu/kg Vitamin A, 72 iu/kg Vitamin E, 7.66 mg/kg Vitamin B1 
(Thiamine), 3.36mg/kg Vitamin B2 (Riboflavin), 4.3 mg/kg Vitamin B6 (Pyridoxine), 5.78 
70
μg/kg Vitamin B12 (Cyanocobalamine), 3.47 mg/kg Vitamin C (Ascorbic acid), 9.71 mg/kg 
Vitamin K (Menadione), 0.57 mg/kg Folic acid (Vitamin B9), 54.75 mg/kg Nicotinic acid 
(Vitamin PP), 18.66 mg/kg Pantothenic acid (Vitamin B3/5), 1015.36 mg/kg Choline 
(Vitamin B4/7), 2115.75 mg/kg Inositol, 247.44 mg/kg Biotin (Vitamin H). The DHA and oil 
blend diets also contained equal levels of macrominerals (reported as a percentage of fresh 
diet) including 0.8% Calcium, 0.46% Phosphorus, 0.25% Phylate phosphorus, 0.22% sodium, 
0.34% Chloride, 0.58% Potassium, 0.21% Magnesium; and equal levels of microminerals 
including 162.35 mg/kg Iron, 11.19 mg/kg Copper, 64.68 mg/kg Manganese, 14.57 mg/kg 
Zinc, 591.6 μg/kg Cobalt, 1067.36 μg/kg Iodine, 266.96 μg/kg Selenium and 9.36 mg/kg 
Fluorine. It is important to note that SDS reported that the diets contained no synthetic 
antioxidant such as butylated hydroxytoluene (BHT), but vitamins such as Vitamin E can 
provide antioxidant protection.
2.3.3 Overview of the experimental diets used in chapter 5
The experimental mouse diets used in chapter 5 were composed of a standard mouse chow 
(RM1 Rodent, Special Diet Services, SDS, Essex, UK) containing sufficient amounts of 
nutrients. According to the manufacturer (SDS) specification, the composition of the food 
pellets prior to supplementation were approximately 12.6% crude protein, 2.2% crude oil, 
3.9% crude fibre, 5.6% ash and 0% cholesterol, with a calorific value of 2875 kcal/kg. In 
order to produce the experimental mouse diets, standard chow was supplemented with 7.5% 
of freeze-dried powder (produced by Cultech Ltd, Port Talbot, UK) containing the 
supplements. One third of the powder contained oil and so all experimental diets contained 
2.5% oil. The control ‘neutral’ oil blend diet (OB) contained 2.5% of an oil blend composed 
of lard, palm oil, olive oil and coconut oil (3:3:3:1 by weight, respectively). The composition 
of this oil blend matched the control diet used in chapters 3 and 4. The fish oil diet (FO) 
contained 2.5% of fish oil comprised of 21% EPA and 15% DHA, equating to 0.53% EPA 
and 0.38% DHA in the fish oil diet. In contrast, the oil blend diet did not contain detectable 
levels of EPA or DHA. The freeze-dried powders produced for the curcumin diets contained 
500ppm of curcumin with 2.5% oil blend (OB+C) or 2.5% fish oil (FO+C).
To ensure fatty acids in the diet were not affected by lipid peroxidation, additional efforts 
were taken to prevent oxidation. This included maintaining 2.5kg of diet in vacuum-packed 
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bags which were stored at 4ºC. Once a diet bag was opened for use, bags were sealed and 
maintained at 4ºC. In an extra effort to limit lipid peroxidation during supply, each mouse 
received fresh pellets every week in their homecage and pellets were examined 
approximately every 2 to 3 days to check for noticeable decomposition. Degraded pellets 
were replenished with fresh pellets. This method was in contrast to the approach taken in 
chapters 3 and 4 whereby mice received pellets in their food hopper which were topped up 
when food levels became low. Furthermore, the diets used in chapters 3 and 4 were stored in 
5kg non vacuum-packed bags, maintained at 4ºC or frozen at -80°C until use when stored in 
the mouse colony room at room temperature in sealed containers. This was an important 
consideration of the study as it is well documented that long-chain PUFAs are particularly 
vulnerable to oxidation, which would reduce the amount of fatty acids in the diet and perhaps 
lead to an accumulation of oxidation products which could increase the state of oxidative 
stress in vivo (Calon et al., 2004; Calon & Cole, 2007).
The fatty acid profile for the diets provided by the manufacturer were presented as an average 
of all experimental diets and thereby lacked accuracy. Lipid analysis of diets (excluding 
cholesterol content) was therefore performed by a research associate (Dr. Cécile Bascoul-
Colombo) on three samples taken from 3 bags of each diet, 3 weeks after arrival. The results 
are presented in section 2.3.7. Further to this, fatty acid composition of the diets was 
monitored over the course of the 12-month study to test for degradation of EPA and DHA. 
Samples were taken from each 2.5kg diet bag upon opening and finishing the bag, and stored 
immediately at -80ºC until analysis. Lipid analysis results revealed that over the course of 12 
months, the reduction of EPA and DHA in the fish oil diets was below 5%.
According to manufacturer specifications, the diets contained equal levels of vitamins 
including 8142 iu/kg Vitamin A, 72 iu/kg Vitamin E, 7.51 mg/kg Vitamin B1 (Thiamine), 
3.34mg/kg Vitamin B2 (Riboflavin), 4.2 mg/kg Vitamin B6 (Pyridoxine), 5.78 μg/kg Vitamin 
B12 (Cyanocobalamine), 3.47 mg/kg Vitamin C (Ascorbic acid), 9.7 mg/kg Vitamin K 
(Menadione), 0.55 mg/kg Folic acid (Vitamin B9), 53.5 mg/kg Nicotinic acid (Vitamin PP), 
18.29 mg/kg Pantothenic acid (Vitamin B3/5), 1012.86 mg/kg Choline (Vitamin B4/7), 
2040.75 mg/kg Inositol, 242.44 mg/kg Biotin (Vitamin H). The diets also contained equal 
levels of macrominerals (reported as a percentage of fresh diet) including 0.8% Calcium, 
0.45% Phosphorus, 0.24% Phylate phosphorus, 0.22% sodium, 0.34% Chloride, 0.57% 
Potassium, 0.21% Magnesium; and equal level of microminerals including 160.96 mg/kg 
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Iron, 11.07 mg/kg Copper, 63.68 mg/kg Manganese, 14.2 mg/kg Zinc, 640.72 μg/kg Cobalt, 
1066.36 μg/kg Iodine, 264.96 μg/kg Selenium and 9.24 mg/kg Fluorine. Therefore, the diets 
used in chapter 5 contained approximately the same levels of vitamins and minerals as the 
DHA and oil blend diets in chapters 3 and 4, with slightly higher levels of the micromineral 
Cobalt. It is also important to note that the diets contained no synthetic antioxidant such as 
butylated hydroxytoluene (BHT).
2.3.4 Lipid analysis of diets: Methods
2.3.4.1 Materials
Chemicals and solvents were purchased from Fisher Scientific (Loughborough, UK) and
Sigma (Poole, UK). The internal standard fatty acid, pentadecanoic acid (15:0), was obtained 
from Nu-Check Prep Inc. (Elysian, MN, USA). Gas liquid chromatography was carried out 
on samples using a Clarus 500 gas chromatograph fitted with a Perkin Elmer 8500 flame 
isonisation detector and a 30m x 0.25mm internal diameter Elite 225 polar capillary column, 
all sourced from Perkin Elmer (Norwalk, Connecticut, USA). 
2.3.4.2 Procedure
Lipid analysis to confirm the fatty acid profile of the diets was carried out on 3 samples of 
each diet, and the replicates were averaged for presentation. Lipids were extracted based on 
the protocol described by Garbus et al. (1963). Before lipid profiles could be analysed by gas 
liquid chromatography (GLC), lipid extracts had to be converted into fatty acid methyl esters 
(FAME) by acid-catalysed transmethylation. GLC analysis was then carried out on the 
samples. These steps are detailed below.
Lipid extraction
Diet pellets were crushed using a pestle and mortar, and 0.5g was added to 0.5ml MilliQTM
water to achieve a 1g/ml aqueous phase. This was sonicated in 3.75ml chloroform-methanol 
(1:2, by volume) for 20 minutes at room temperature for homogenisation. 1.25ml of 
chloroform and 1.25ml of Garbus solution (2M potassium chloride in 0.5M potassium 
phosphate buffer, pH 7.4) was added, vortexed and centrifuged at 1500 rpm for 5 minutes. 
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The upper phase of the solution was discarded and the remaining lipid-containing lower 
phase was washed by applying 4.45ml of fresh upper phase solution (the upper phase of 
‘mixture solution’: dH2O-chloroform-methanol-Garbus, 4:10:10:5, by volume). Following 
vortex and centrifugation at 1500 rpm for 5 minutes, the upper phase was discarded and the 
lower phase transferred to a clean tube, comprising the first extract. The remaining lipids 
were extracted from the remaining sample by applying 3ml of mixture solution (mixed
immediately before application). Following vortex and centrifugation at 1500 rpm for 5
minutes, the upper phase was again discarded and the lower phase (the second extract) was 
transferred to the first extract. This combined lower phase was then dried down under 
nitrogen at room temperature and resuspended in 250µl of chloroform-methanol, vortexed 
and transferred to a glass vial. This latter process was repeated and stored at -20°C until 
further use.
Methyl-esterification of lipids
Before fatty acids could be analysed by gas liquid chromatography (GLC), lipid extracts had 
to be converted into fatty acid methyl esters (FAME) by acid-catalysed transmethylation. 
Lipid extract samples were defrosted and vortexed, then dried down under nitrogen. To 
equalise volumes, 1ml of chloroform-methanol was added to dried samples and vortexed. 
30µl was transferred to a tube containing 50µl of the internal standard fatty acid, 
pentadecanoic acid (C15:0) in toluene (1mg/1ml). The standard was used to calculate the 
amount of fatty acids in the samples during GLC. Following this, 3ml of methylation solution 
(2.5% [v/v] sulphuric acid in methanol-toluene, 2:1 by volume) was applied to each sample 
and incubated for 2 hours at 70C. FAME were extracted by adding 2ml of 5% (w/v) sodium 
chloride in MilliQTM water and 3ml of HPLC grade hexane. After vortexing, the top layer 
containing FAME was transferred to a clean tube. This latter step was repeated for a second 
extraction. Following this, 3ml of 2% (w/v) potassium carbonate in MilliQTM water was 
applied to neutralise any remaining acidity and the top layer was transferred to a clean tube.
Samples were then dried down under nitrogen and resuspended in 50µl of HPLC grade 
hexane, vortexed and transferred to GLC injection vials (Chromacol Ltd, UK). Samples were 
stored at -20C until ready for GLC analysis.
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Fatty acid analysis by gas liquid chromatography (GLC) and data analysis
GLC analysis was carried out by a research assistant (Dr. Irina Guschina). 10µl of FAME 
samples were analysed by GLC using a gas chromatograph, injected at a flow rate of 
20ml/minute-1 with a split ratio of 20:1, using nitrogen as the carrier gas. The GLC followed a 
temperature programme whereby samples were initially heated to 170°C for 3 minutes, 
followed by heating to 220°C at a rate of 4°C per min-1 and maintained for 30 minutes. The 
chromatograms obtained showed peaks corresponding to different fatty acids which were 
identified by comparing retention times with those obtained from the standard fatty acids. 
Using the areas under the peaks, the percentage of each fatty acid was expressed as a 
percentage of total fatty acids. Using the data, the percentage of fatty acids as a percentage of 
fresh diet weight was also calculated using the milligrams of fatty acids per gram of diet 
(mg/g).
2.3.5 Results: Lipid analysis of diets used in chapter 3
Tables 2.2 and 2.3 shows the lipid analysis results of the diet samples used in chapter 3. The 
lipid analysis showed a similar pattern to the fatty acid composition provided by SDS. These 
data reveal that the main saturated fatty acids (SAT) in the diets were 16:0, followed by 14:0, 
with small amounts of 18:0, 12:0, 20:0, 22:0 and 24:0. The main monounsaturated fatty acids 
(MUFA) were 18:1ω-9, with small amounts of 16:1ω-7 and 20:1ω-9. Greater levels of 
polyunsaturated fatty acids (PUFA) was present than MUFA and SAT. The main omega-3 
PUFAs of the DHA diet were of course 22:6ω-3 (DHA), representing 1.86% of fresh diet 
weight, followed by small amounts of 22:5ω-3 and 18:3ω-3. The only omega-3 PUFA in the 
oil blend diet was 18:3ω-3 (α-linolenic acid), which was also detected in the DHA diet at 
similar levels. Omega-3 PUFAs 22:6ω-3 and 22:5ω-3 were at undetectable levels in the oil 
blend diet. The main omega-6 PUFA was 18:2ω-6, representing 1.6% of the DHA diet and 
~2.1% of the oil blend diet. As a result of the high level of DHA in the DHA diet and the 
similar levels of omega-6 in both diets, the DHA diet showed a greater omega-3/omega-6 
ratio relative to the oil blend diet.
75
Table 2.2 Fatty acid compositions of the DHA and oil blend diets used in chapter 3, expressed as 
mean percentage of fresh diet weight ± S.E.M (Standard error of the mean). Mean value of 3 
replicates. Information sourced from the lipid analysis carried out at Cardiff University.
Fatty acids          Rodent chow + 5% DHA rich oil     Rodent chow + 5% oil blend
Dodecanoic acid 12:0 0.04 ± 0.01% 0.05 ± 0.01%
Tetradecanoic acid 14:0 0.38 ± tr. % 0.08 ± tr. %
Hexadecanoic acid 16:0 0.86 ± tr. % 1.65 ± 0.07%
Hexadecenoic acid 16:1ω-7 0.08 ± tr. % 0.03 ± tr. %
Octadecanoic acid 18:0 0.07 ± tr. % 0.37 ± 0.01%
Oleic acid 18:1ω-9 1.66 ± 0.01% 2.87 ± 0.13%
Linoleic acid 18:2ω-6 1.60 ± 0.02% 2.06 ± 0.09%
α-Linolenic acid 18:3ω-3 0.17 ± 0.01% 0.20 ± 0.01%
Eicosanoic acid 20:0 0.01 ± tr. % 0.01 ± tr. %
Eicosenoic acid 20:1ω-9 0.01 ± tr. % 0.02 ± tr. %
Eicosadienoic acid 20:2ω-6 N.D. 0.01 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. N.D.
Arachidonic acid 20:4ω-6 N.D. N.D.
Eicosapentaenoic acid 20:5ω-3 N.D. N.D.
Docosanoic acid 22:0 0.01 ± tr. % 0.01 ± tr. %
Docosapentaenoic acid 22:5ω-3 0.01 ± tr. % N.D.
Docosahexaenoic acid 22:6ω-3 1.86 ± 0.04% N.D.
Tetracosanoic acid 24:0 N.D. N.D.
Total saturated fatty acids 1.37 ± 0.01% 2.17 ± 0.09%
Total monounsaturated fatty acids 1.75 ± 0.01% 2.92 ± 0.13%
Total polyunsaturated fatty acids 3.64 ± 0.07% 2.27 ± 0.10%
Total omega-3 (ω-3) PUFA 2.04 ± 0.05% 0.20 ± 0.01%
Total omega-6 (ω-6) PUFA 1.60 ± 0.02% 2.07 ± 0.09%
Omega-3/omega-6 (ω-3/ω-6) ratio 1.28:1 0.10:1
Omega-6/omega-3 (ω-6/ω-3) ratio 0.78:1 10.35:1
N.D. = not detected, tr. = trace (less than 0.05%).
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Table 2.3 Fatty acid compositions of the DHA and oil blend diets used in chapter 3, expressed as 
mean percentage of total fatty acid (by weight) ± S.E.M. Mean value of 3 replicates. Information 
sourced from the lipid analysis carried out at Cardiff University.
Fatty acids          Rodent chow + 5% DHA rich oil     Rodent chow + 5% oil blend
Dodecanoic acid 12:0 0.7 ± 0.1% 0.7 ± 0.1%
Tetradecanoic acid 14:0 5.6 ± 0.1 % 1.1 ± tr. %
Hexadecanoic acid 16:0 12.7 ± 0.1 % 22.4 ± tr. %
Hexadecenoic acid 16:1ω-7 1.1 ± tr. % 0.5 ± tr. %
Octadecanoic acid 18:0 1.0 ± tr. % 5.1 ± tr. %
Oleic acid 18:1ω-9 24.6 ± tr. % 39.0 ± 0.1 %
Linoleic acid 18:2ω-6 23.6 ± 0.1% 28.0 ± tr. %
α-Linolenic acid 18:3ω-3 2.5 ± 0.1% 2.7 ± tr. %
Eicosanoic acid 20:0 0.1 ± tr. % 0.2 ± tr. %
Eicosenoic acid 20:1ω-9 0.2 ± tr. % 0.3 ± tr. %
Eicosadienoic acid 20:2ω-6 N.D. 0.1 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. N.D.
Arachidonic acid 20:4ω-6 N.D. N.D.
Eicosapentaenoic acid 20:5ω-3 N.D. N.D.
Docosanoic acid 22:0 0.2 ± tr. % 0.01 ± tr. %
Docosapentaenoic acid 22:5ω-3 0.1 ± tr. % N.D.
Docosahexaenoic acid 22:6ω-3 27.5 ± 0.3% N.D.
Tetracosanoic acid 24:0 N.D. N.D.
Total saturated fatty acids 20.3 ± 0.3% 29.4 ± 0.1%
Total monounsaturated fatty acids 25.9 ± 0.1% 39.7 ± 0.1%
Total polyunsaturated fatty acids 53.9 ± 0.3% 30.8 ± tr. %
Total omega-3 (ω-3) PUFA 30.1 ± 0.3% 2.7 ± tr. %
Total omega-6 (ω-6) PUFA 23.6 ± 0.1% 28.1 ± tr. %
Omega-3/omega-6 (ω-3/ω-6) ratio 1.28:1 0.10:1
Omega-6/omega-3 (ω-6/ω-3) ratio 0.78:1 10.35:1
N.D. = not detected, tr. = trace (less than 0.05%).
In summary therefore, the lipid analysis importantly confirmed the main difference between 
the two diets were the high level of omega-3 PUFA DHA in the DHA diet, and that both diets 
had similar levels of omega-6 PUFA. Although there was a slight difference in omega-6 
PUFA levels between diets (0.47% diet weight), this was minimal compared with previous 
studies investigating omega-3 PUFA supplementation whereby the control diet contained
high levels of omega-6 PUFA (e.g. Calon et al., 2004; Green et al., 2007). Furthermore, the 
analysis confirmed that the absence of DHA in the oil blend diet was compensated by 
“neutral” monounsaturated fatty acids and saturated fatty acids. Interestingly, the lipid 
analysis revealed that the difference between ω-3/ω-6 ratios of the two diets were not as wide 
as predicted by SDS, with the DHA diet containing a ratio of 1.28:1 (in contrast to their 
reported 2.19:1) and the oil blend diet a ratio of 0.10:1 (in contrast to their reported 0.06:1).
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2.3.6 Results: Lipid analysis of diets used in chapter 4
Tables 2.4 and 2.5 shows the lipid analysis results of the diet samples used in chapter 4. This 
data reveals that the fatty acids in the diets were primarily composed from PUFAs, followed 
by MUFAs and SATs. The main SATs in the diets were 16:0, followed by 14:0, with small 
amounts of 18:0, 12:0, 20:0 and 22:0. The main MUFA was 18:1ω-9, with small amounts of 
16:1ω-7, 20:1ω-9 (only shown in the lipid analysis) and 14:1 (only shown in SDS profile).
According to our results, the main omega-3 PUFA of the DHA diet was of course 22:6ω-3
(DHA), representing 1.86% of fresh diet weight and 27.5% of total fatty acids, followed by 
18:3ω-3 and small amounts of 22:5ω-3. The only omega-3 PUFA in the oil blend diet was 
18:3ω-3 (α-linolenic acid), representing 0.20% of the fresh diet weight, which was
importantly detected in the DHA diet at similar levels. Omega-3 PUFAs 22:6ω-3 and 22:5ω-
3 were at undetectable levels in the oil blend diet. Similar to the DHA diet, 20:3ω-3 and
20:5ω-3 was also undetectable in the oil blend diet. The main omega-6 PUFA was 18:2ω-6, 
representing 1.6% of the DHA diet (by weight) and approximately 2.1% of the oil blend diet. 
As a result of the high level of DHA in the DHA diet and the similar levels of omega-6 
PUFA in both diets, the DHA diet showed a greater ω-3/ω-6 ratio relative to the oil blend 
diet. Importantly, this ratio difference was caused almost entirely by the DHA content. The 
difference between the ω-3/ω-6 ratios of the two diets were not as wide as predicted by SDS, 
with the DHA diet containing a ratio of 1.28:1 (in contrast to their reported 2.19:1) and the oil 
blend diet a ratio of 0.11:1 (in contrast to their reported 0.06:1). Although there was a slight 
difference in omega-6 PUFA levels between diets (0.47% diet weight), this was minimal 
compared with previous studies investigating omega-3 PUFA supplementation whereby the 
control diet contained excess levels of omega-6 PUFA (e.g. Calon et al., 2005; Green et al.,
2007). In summary, the lipid analysis confirmed the main difference between the two diets 
was the high level of omega-3 PUFA DHA in the DHA diet, and the absence of DHA in the 
oil blend diet which was compensated by “neutral” monounsaturated fatty acids and saturated 
fatty acids, including 16:0, 18:0 and 18:1ω-9. Importantly, analysis also confirmed that both 
diets had similar levels of omega-6 PUFAs. Furthermore, the lipid analysis results of the 
DHA and oil blend diets were almost identical to the diets used in chapter 3, thereby allowing 
direct comparison of dietary design.
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Table 2.4 Fatty acid compositions of the DHA and oil blend diets used in chapter 4, expressed as 
mean percentage of fresh diet weight ± S.E.M. Mean value of 3 replicates. Information sourced from 
the lipid analysis carried out at Cardiff University.
Fatty acids          Rodent chow + 5% DHA rich oil     Rodent chow + 5% oil blend
Dodecanoic acid 12:0 0.04 ± 0.01% 0.05 ± 0.01%
Tetradecanoic acid 14:0 0.38 ± tr. % 0.08 ± tr. %
Hexadecanoic acid 16:0 0.86 ± tr. % 1.65 ± 0.07%
Hexadecenoic acid 16:1ω-7 0.08 ± tr. % 0.03 ± tr. %
Octadecanoic acid 18:0 0.07 ± tr. % 0.37 ± 0.01%
Oleic acid 18:1ω-9 1.66 ± 0.01% 2.87 ± 0.13%
Linoleic acid 18:2ω-6 1.60 ± 0.02% 2.06 ± 0.09%
α-Linolenic acid 18:3ω-3 0.17 ± 0.01% 0.20 ± 0.01%
Eicosanoic acid 20:0 0.01 ± tr. % 0.01 ± tr. %
Eicosenoic acid 20:1ω-9 0.01 ± tr. % 0.02 ± tr. %
Eicosadienoic acid 20:2ω-6 N.D. 0.01 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. N.D.
Arachidonic acid 20:4ω-6 N.D. N.D.
Eicosapentaenoic acid 20:5ω-3 N.D. N.D.
Docosanoic acid 22:0 0.01 ± tr. % 0.01 ± tr. %
Docosapentaenoic acid 22:5ω-3 0.01 ± tr. % N.D.
Docosahexaenoic acid 22:6ω-3 1.86 ± 0.04% N.D.
Tetracosanoic acid 24:0 N.D. N.D.
Total saturated fatty acids 1.37 ± 0.01% 2.17 ± 0.09%
Total monounsaturated fatty acids 1.75 ± 0.01% 2.92 ± 0.13%
Total polyunsaturated fatty acids 3.64 ± 0.07% 2.27 ± 0.10%
Total omega-3 (ω-3) PUFA 2.04 ± 0.05% 0.20 ± 0.01%
Total omega-6 (ω-6) PUFA 1.60 ± 0.02% 2.07 ± 0.09%
Omega-3/omega-6 (ω-3/ω-6) ratio 1.28:1 0.10:1
Omega-6/omega-3 (ω-6/ω-3) ratio 0.78:1 10.35:1
N.D. = not detected, tr. = trace (less than 0.05%).
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Table 2.5 Fatty acid compositions of the DHA and oil blend diets used in chapter 4, expressed as 
mean percentage of total fatty acid (by weight) ± S.E.M. Mean value of 3 replicates. Information 
sourced from the lipid analysis carried out at Cardiff University.
Fatty acids          Rodent chow + 5% DHA rich oil     Rodent chow + 5% oil blend
Dodecanoic acid 12:0 0.6 ± 0.10% 0.7 ± 0.10%
Tetradecanoic acid 14:0 5.6 ± tr. % 1.1 ± tr. %
Hexadecanoic acid 16:0 12.7 ± tr. % 22.4 ± 0.07 %
Hexadecenoic acid 16:1ω-7 1.2 ± tr. % 0.4 ± tr. %
Octadecanoic acid 18:0 1.0 ± tr. % 5.0 ± 0.01 %
Oleic acid 18:1ω-9 24.6 ± 0.01 % 39.0 ± 0.13 %
Linoleic acid 18:2ω-6 23.7 ± 0.02% 28.0 ± 0.09 %
α-Linolenic acid 18:3ω-3 2.5 ± 0.1% 2.7 ± 0.01 %
Eicosanoic acid 20:0 0.1 ± tr. % 0.1 ± tr. %
Eicosenoic acid 20:1ω-9 0.1 ± tr. % 0.3 ± tr. %
Eicosadienoic acid 20:2ω-6 N.D. 0.1 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. N.D.
Arachidonic acid 20:4ω-6 N.D. N.D.
Eicosapentaenoic acid 20:5ω-3 N.D. N.D.
Docosanoic acid 22:0 0.1 ± tr. % 0.1 ± tr. %
Docosapentaenoic acid 22:5ω-3 0.1 ± tr. % N.D.
Docosahexaenoic acid 22:6ω-3 27.5 ± 0.04% N.D.
Tetracosanoic acid 24:0 N.D. N.D.
Total saturated fatty acids 20.3 ± 0.01% 29.5 ± 0.09%
Total monounsaturated fatty acids 25.9 ± 0.01% 39.7 ± 0.13%
Total polyunsaturated fatty acids 53.8 ± 0.07% 30.8 ± 0.10%
Total omega-3 (ω-3) PUFA 30.2 ± 0.05% 2.7 ± 0.01%
Total omega-6 (ω-6) PUFA 23.7 ± 0.02% 28.1 ± 0.09%
Omega-3/omega-6 (ω-3/ω-6) ratio 1.28:1 0.10:1
Omega-6/omega-3 (ω-6/ω-3) ratio 0.78:1 10.35:1
N.D. = not detected, tr. = trace (less than 0.05%).
2.3.7 Results: Lipid analysis of diets used in chapter 5
Tables 2.6 and 2.7 present the results from the lipid analysis of diet samples from chapter 5.
Abbreviations are used as follows: control oil blend diet (OB), fish oil diet (FO), curcumin 
diet (OB+C), and fish oil and curcumin diet (FO+C). This data reveals that the fatty acid
composition of the diets was primarily composed from PUFAs, followed by MUFAs and 
SATs. The main SAT in the diets were 16:0, followed by 18:0, with small amounts of 12:0
(trace levels in FO and FO+C diets), 14:0, 20:0 and 22:0, and trace levels of 24:0. The main 
MUFA was 18:1ω-9, with small amounts of 16:1ω-7 and 20:1ω-9. The main omega-6 PUFA 
of all diets was 18:2ω-6 (linoleic acid), representing between 1.32% to 1.64% of fresh weight 
diet and 33.62% to 34.35% of total fatty acids, whereby the oil blend diets (OB and OB+C) 
contained the higher amounts relative to the fish oil diets (FO and FO+C). Relatively small 
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amounts of other omega-6 PUFAs (20:2ω-6 and 20:4ω-6) were contained in the diets at 
similar levels. 
The main omega-3 PUFA of the fish oil diets (FO and FO+C) were 20:5ω-3 (EPA) and 
22:6ω-3 (DHA), representing 0.53% and 0.34% of fresh diet weight respectively and ~13.6% 
and 8.62% of total fatty acids respectively. In contrast, the oil blend diets (OB and OB+C) 
contained EPA and DHA at trace or non-detectable levels. Relatively small amounts of 
18:3ω-3 (ALA) was contained in the diets at similar levels, whereas 22:5ω-3 (DPA) was 
detected at small levels only in the fish oil diets. Importantly, fatty acid composition was 
almost identical between the oil blend containing diets, OB and OB+C, and almost identical 
between the fish oil containing diets, FO and FO+C.
As a result of similar levels of omega-6 PUFA in all diets and a high level of omega-3 
PUFAs EPA and DHA in the fish oil diets (FO and FO+C), the fish oil diets showed a greater 
ω-3/ω-6 ratio relative to the oil blend diets (OB and OB+C). The ω-3/ω-6 ratio was 1.21:1 
and 1.19:1 for the FO and FO+C diets, respectively, and 0.10:1 for both the OB and OB+C 
diets. Although there was a slight difference in total omega-6 PUFA levels between the oil 
blend and fish oil containing diets, this was minimal compared with previous studies 
investigating fish oil supplementation whereby the control diet contains high levels of omega-
6 PUFA (e.g. Oksman et al., 2006; Ma et al., 2009). In summary, lipid analysis confirmed the 
main difference between the oil blend and fish oil containing diets was the high level of 
omega-3 PUFAs EPA and DHA in the fish oil diets, and their absence in the oil blend diets
which was compensated by “neutral” fatty acids including predominately 18:1ω-9 MUFA, 
and smaller amounts of 12:0, 16:0 and 18:0 SAT, as well as 18:2ω-6 PUFA. Importantly, 
lipid analysis confirmed that both diets had similar levels of omega-6 PUFA, comprising 
~34% of total fatty acids in all diets. 
The ω-3/ω-6 ratio of the oil blend and fish oil diets were extremely similar to the ratios 
reported in chapters 3 and 4 of the oil blend and DHA supplemented diets. In contrast, they 
contained differential amounts of certain fatty acids such as EPA. Together, this may allow 
some comparison of results in the general discussion related to the effects of the ω-3/ω-6 
ratio, the levels of supplementation and the presence of certain fatty acids in the diet.
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Table 2.6 Fatty acid composition of the oil blend (OB), oil blend and curcumin (OB+C), fish oil (FO), 
and fish oil and curcumin (FO+C) diets used in chapter 5, expressed as mean percentage of fresh diet 
weight ± S.E.M. Mean value of 3 replicates. Information sourced from the lipid analysis carried out at 
Cardiff University.
Fatty acids OB    OB+C FO FO+C
Dodecanoic acid 12:0 0.06 ± 0.01% 0.06 ± 0.01% tr. ± tr. % tr. ± tr. %
Tetradecanoic acid 14:0 0.05 ± tr. % 0.05 ± tr. % 0.10 ± tr. % 0.10 ± tr. %
Hexadecanoic acid 16:0 1.04 ± 0.03% 0.95 ± 0.02% 0.62 ± tr. % 0.61 ± 0.01%
Hexadecenoic acid 16:1ω-7 0.02 ± tr. % 0.02 ± tr. % 0.08 ± tr. % 0.08 ± tr. %
Octadecanoic acid 18:0 0.23 ± 0.01% 0.21 ± tr. % 0.10 ± tr. % 0.10 ± tr. %
Oleic acid 18:1ω-9 1.53 ± 0.04% 1.39 ± 0.03% 0.49 ± 0.01% 0.49 ± 0.01%
Linoleic acid 18:2ω-6 1.64 ± 0.06% 1.51 ± 0.01% 1.32 ± 0.01% 1.33 ± 0.02%
α-Linolenic acid 18:3ω-3 0.16 ± 0.01% 0.15 ± tr. % 0.16 ± 0.01% 0.15 ± tr. %
Eicosanoic acid 20:0 0.01 ± tr. % 0.01 ± tr. % 0.01 ± tr. % 0.01 ± tr. %
Eicosenoic acid 20:1ω-9 0.02 ± tr. % 0.02 ± tr. % 0.05 ± tr. % 0.05 ± tr. %
Eicosadienoic acid 20:2ω-6 0.01 ± tr. % tr. ± tr. % 0.01 ± tr. % 0.01 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. tr. ± tr. % tr. ± tr. % tr. ± tr. %
Arachidonic acid 20:4ω-6 tr. ± tr. % tr. ± tr. % 0.03 ± tr. % 0.03 ± tr. %
Eicosapentaenoic acid 20:5ω-3 tr.± tr. % N.D. 0.53 ± 0.01% 0.53 ± 0.02%
Docosanoic acid 22:0 0.01 ± tr. % 0.01 ± tr. % 0.01 ± tr. % 0.01 ± tr. %
Docosapentaenoic acid 22:5ω-3 N.D. N.D. 0.07 ± tr. % 0.07 ± tr. %
Docosahexaenoic acid 22:6ω-3 N.D. N.D. 0.34 ± tr. % 0.34 ± 0.01%
Tetracosanoic acid 24:0 tr.± tr. % tr.± tr. % tr.± tr. % tr.± tr. %
Total saturated fatty acids 1.41 ± 0.04% 1.29 ± 0.03% 0.84 ± 0.01% 0.84 ± 0.02%
Total monounsaturated fatty acids 1.58 ± 0.04% 1.43 ± 0.03% 0.62 ± 0.01% 0.62 ± 0.01%
Total polyunsaturated fatty acids 1.81 ± 0.06% 1.66 ± 0.02% 2.46 ± 0.03% 2.45 ± 0.06%
Total omega-3 (ω-3) PUFA 0.17 ± 0.01% 0.15 ± tr. % 1.64 ± 0.02% 1.62 ± 0.05%
Total omega-6 (ω-6) PUFA 1.65 ± 0.06% 1.51 ± 0.01% 1.36 ± 0.01% 1.36 ± 0.03%
Omega-3/omega-6 (ω-3/ω-6) ratio 0.10:1 0.10:1 1.21:1 1.19:1
Omega-6/omega-3 (ω-6/ω-3) ratio 9.71:1 10.10:1 0.83:1 0.84:1
N.D. = not detected, tr. = trace (less than 0.01%).
82
Table 2.7 Fatty acid composition of the oil blend (OB), oil blend and curcumin (OB+C), fish oil (FO), 
and fish oil and curcumin (FO+C) diets used in chapter 5, expressed as mean percentage of total fatty 
acid (by weight) ± S.E.M. Mean value of 3 replicates. Information sourced from the lipid analysis 
carried out at Cardiff University. 
Fatty acids OB    OB+C FO FO+C
Dodecanoic acid 12:0 1.32 ± 0.04% 1.37 ± 0.08% 0.03 ± tr. % 0.03 ± tr. %
Tetradecanoic acid 14:0 1.10 ± 0.01% 1.09 ± 0.01% 2.56 ± 0.01% 2.44 ± 0.03%
Hexadecanoic acid 16:0 21.63 ± 0.20% 21.60 ± 0.22% 15.71 ± 0.09% 15.69±0.12%
Hexadecenoic acid 16:1ω-7 0.49 ± tr. % 0.49 ± 0.01% 2.15 ± 0.01% 2.07 ± 0.01%
Octadecanoic acid 18:0 4.85 ± 0.04% 4.81 ± 0.06% 2.63 ± 0.02% 2.65 ± 0.02%
Oleic acid 18:1ω-9 31.87 ± 0.27% 31.68 ± 0.39% 12.42 ± 0.11% 12.55±0.11%
Linoleic acid 18:2ω-6 34.17 ± 0.39% 34.35 ± 0.19% 33.62 ± 0.32% 33.95±0.28%
α-Linolenic acid 18:3ω-3 3.34 ± 0.03% 3.35 ± 0.01% 4.02 ± 0.14% 3.84 ± 0.03%
Eicosanoic acid 20:0 0.29 ± tr. % 0.29 ± tr. % 0.26 ± tr. % 0.26 ± tr. %
Eicosenoic acid 20:1ω-9 0.51 ± tr. % 0.51 ± 0.01% 1.24 ± tr. % 1.23 ± 0.01%
Eicosadienoic acid 20:2ω-6 0.11 ± tr. % 0.11 ± tr. % 0.13 ± tr. % 0.14 ± tr. %
Eicosatrienoic acid 20:3ω-3 N.D. 0.03 ± 0.01% 0.04 ± 0.01% 0.04 ± tr. %
Arachidonic acid 20:4ω-6 0.03 ± tr. % 0.03 ± tr. % 0.81 ± 0.01% 0.80 ± 0.01%
Eicosapentaenoic acid 20:5ω-3 0.02 ± tr. % N.D. 13.62 ± 0.15% 13.60±0.20%
Docosanoic acid 22:0 0.21 ± tr. % 0.21 ± tr. % 0.23 ± tr. % 0.24 ± tr. %
Docosapentaenoic acid 22:5ω-3 N.D. N.D. 1.82 ± 0.01% 1.78 ± 0.03%
Docosahexaenoic acid 22:6ω-3 N.D. N.D. 8.62 ± 0.10% 8.62 ± 1.13%
Tetracosanoic acid 24:0 0.07 ± tr. % 0.08 ± tr. % 0.09 ± 0.01% 0.09 ± tr. %
Total saturated fatty acids 29.47 ± 0.30% 29.44 ± 0.38% 21.51 ± 0.14% 21.40±0.18%
Total monounsaturated fatty acids 32.87 ± 0.28% 33.84 ± 0.41% 17.15 ± 0.13% 17.20±0.13%
Total polyunsaturated fatty acids 37.66 ± 0.42% 37.87± 0.21% 62.68 ± 0.73% 62.75±0.69%
Total omega-3 (ω-3) PUFA 3.48 ± 0.04% 4.54 ± 0.02% 41.08 ± 0.41% 42.81±0.40%
Total omega-6 (ω-6) PUFA 34.30 ± 0.39% 34.48 ± 0.19% 34.56 ± 0.33% 34.88±0.29%
Omega-3/omega-6 (ω-3/ω-6) ratio 0.10:1 0.10:1 1.21:1 1.19:1
Omega-6/omega-3 (ω-6/ω-3) ratio 9.71:1 10.10:1 0.83:1 0.84:1
N.D. = not detected, tr. = trace (less than 0.01%).
2.4 Statistical analysis
All statistical analysis reported throughout this thesis were carried out using SPSS 16 
software, and results were considered significant when p<0.05. Parametric statistical analyses 
were carried out primarily using an analysis of variance (ANOVA) since differences between 
groups were examined under more than 2 conditions, which warranted the use of an 
ANOVA. Furthermore, parametric tests have greater statistical power than non-parametric 
tests. In order to use this statistical approach, the assumptions of a between-subjects ANOVA 
were met or tested, which included independence of observations, normal distribution 
(normality) and homogeneity of variance. The assumptions of a within-subjects ANOVA 
were also tested, which included normality, homogeneity of variance and sphericity. 
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Normality was tested in SPSS using the Shapiro-Wilk test of normality, and if this 
assumption was violated (p<0.05) then the kurtosis value was checked since an ANOVA is 
robust against violations of normality and can therefore be reported, except when 
platykurtosis is present (Kinnear & Gray, 2009). Since platykurtosis (a flat distribution; 
kurtosis value of 3) was not present under circumstances when the normality assumption was 
violated, the ANOVA result was reported without the need for transforming the data or using 
non-parametric statistical tests. The assumption of homogeneity of variance was tested in 
SPSS using the Levene’s test of equality of error variances, and when the assumption was 
violated non-parametric tests were used (Mann Whitney-U test selected if a between-subjects 
design, or Wilcoxon signed-rank test or Kruskal Wallis test selected if a within-subjects 
design). Since the results of the non-parametric tests were the same pattern of significance as 
reported by the parametric tests on these occasions, the ANOVA result could be used since 
our confidence that the ANOVA result was accurate, despite violation, had been tested 
(Kinnear & Gray, 2009). Finally, the assumption of sphericity was tested in SPSS by using 
the Mauchly’s test of sphericity, and if this assumption was violated (p<0.05) then an epsilon 
correction was made by reporting the Greenhouse-geisser result in the SPSS output table.
Statistical analyses were primarily carried out using an ANOVA with genotype (Tg, WT) and 
diet (DHA, OB; or OB, OB+C, FO, FO+C) as between-subject factors. Experiments 
requiring analysis of data with inclusion of within-subject factor(s) (e.g. day, block, Aβ 
isoform, response type) were carried out using a mixed factorial ANOVA design with 
between-subject factors of genotype (Tg, WT) and diet (DHA, OB; or OB, OB+C, FO, 
FO+C), and the within-subject factor(s). Significant between-subjects interactions were 
followed up with tests of simple main effects using MANOVA syntax, as described in 
Kinnear and Gray (2009), p.295. Significant within-subject interactions were followed up 
with tests of simple main effects and interactions using MANOVA syntax, as described in 
Kinnear and Gray (2009), p.350. Finally, significant interactions between mixed (between-
and within-subject) factors were followed up with tests of simple main effects and 
interactions using MANOVA syntax, as described in Kinnear and Gray (2009), p.375. When 
testing whether performance was above chance level, an unpaired (independent) samples t-
test was selected as this statistical choice was appropriate for the number of conditions 
compared, the type of sample and type of data.
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2.5 Chapter Discussion
One aim of this chapter was to summarise the procedures used for breeding and identifying 
Tg2576 mice possessing the APPswe transgene, for use in experimental testing. A second 
aim of this chapter was to outline the experimental and control diet design employed in 
chapters 3, 4 and 5. Lipid analysis results confirmed that the diets contained very similar 
levels of fatty acids after production compared to the details provided by SDS. The DHA-rich 
diet and oil blend diets examined in chapters 3 and 4 contained 1.86% DHA and 0% DHA, 
respectively. The oil blend diet was indeed supplemented with a blend of ‘neutral’ oils 
including primarily MUFAs and some SAT. The levels of omega-6 PUFAs were very 
similar, as were levels of other fatty acids. This design therefore allowed more accurate 
examination of the effect of dietary DHA supplementation compared with previous studies 
(e.g. Calon et al., 2004; Green et al., 2007). 
Similarly, the fish oil-containing diets and oil blend-containing diets examined in chapter 5 
were primarily differentiated by the level of omega-3 PUFAs EPA and DHA. The fish oil 
diets contained 0.53% EPA and 0.34% DHA, which were absent from the oil blend diets. In 
compensation, the lipid analysis confirmed that the oil blend diets contained supplementary 
levels of MUFAs (primarily), with small levels of SAT and PUFA. Similar to the diets 
examined in chapters 3 and 4, the fish oil and oil blend diet contained very similar levels of 
omega-6 PUFAs. Importantly, combination of curcumin with the oil blend or fish oils had 
minimal effect on the fatty acid composition of the diets. Again, this design therefore 
allowed more accurate examination of the effect of dietary fish oil and curcumin 
supplementation compared to previous studies (e.g. Oksman et al., 2006; Ma et al., 2009). 
Importantly, SDS reported that the standard diet (RM1) before supplementation contained nil 
levels of cholesterol. The supplementary oil blend, DHA-rich oil and curcumin also contained 
no cholesterol, although the fish oil supplement was likely to contain small levels of 
cholesterol (although this was not measured). This difference in cholesterol levels should 
therefore be considered when interpreting the results in later chapters. The aim of the 
following chapters was to examine the effect of these diets on the behavioural phenotype and 
pathology of Tg2576 mice.
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Chapter 3
The longitudinal effect of dietary omega-3 PUFA docosahexaenoic acid 
(DHA) supplementation on spatial learning and Aβ pathology in Tg2576 
mice
3.1 Introduction
The aim of the experiments in this chapter was to test the hypothesis that longitudinal 
exposure to a diet supplemented with omega-3 PUFA DHA from an early age will protect 
Tg2576 mice from the development of cognitive abnormalities and associated Aβ pathology. 
Although it is well documented that DHA supplementation can reduce behavioural deficits 
and pathology in animal models of AD, these studies do not evaluate the effect of DHA 
supplementation per se due to the experimental design of the control diet. All studies 
investigating DHA supplementation in animal models of AD to date used a control condition 
with different levels of total fat, depleted levels of omega-3 PUFA or excess levels of omega-
6 PUFA (resulting in a particularly high ω-6/ω-3 ratio) compared to the DHA diet.
For example, the five studies investigating DHA supplementation in Tg2576 mice carried out 
by Greg Cole’s lab compared a DHA diet to a safflower oil-based diet depleted in DHA with 
a considerably high ω-6/ω-3 ratio (Calon et al., 2004, 2005; Lim et al., 2005; Cole & 
Frautschy, 2006; Ma et al., 2007). The ‘high-DHA’ diet contained 0.6% DHA, ~2.8% linoleic 
acid (18:2ω-6) and a low ω-6/ω-3 ratio of 4:1-5:1, whereas the ‘low-DHA’ diet contained 0% 
DHA, ~4.9% linoleic acid and a very high ω-6/ω-3 ratio of 82:1-85:1. Diets were matched in 
total fat (6.1%) and cholesterol (750ppm). The reported beneficial effects of DHA 
supplementation (e.g. improved cognition, increased post-synaptic markers, reduced Aβ 
pathology and increased LR11 levels; as outlined in section 1.6.3 v) were relative to the 
DHA-depleted diet, and so effects could therefore be attributable to the large difference in ω-
3/ω-6 ratio or linoleic acid content, rather than DHA content.
These studies also compared the high-DHA and DHA-depleted diets to a standard control 
chow containing 0.09% DHA, ~2.8% linoleic acid and a low ω-6/ω-3 ratio of 7:1. The 
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similarities between the standard control and high-DHA diet would have made the standard 
diet a relatively suitable baseline diet to compare the effects of DHA supplementation. 
However, the control diet contained higher levels of total fat (11%) and lower cholesterol 
(290ppm) than both high-DHA and depleted-DHA diets, which may contribute to the 
reported effects. Interestingly, when compared to the control diet, beneficial effects of DHA 
supplementation on pathology and synaptic markers was limited to a reduction in total Aβ42 
only, thereby suggesting that DHA supplementation, total fat and/or cholesterol had little 
effect in reducing pathology or deficits in Tg2576 mice. In contrast, major differences in 
pathology and synaptic markers were reported when comparing the control diet with the 
DHA-depleted diet, which would suggest that the differences observed were likely 
attributable to the high ω-6/ω-3 ratio or high levels of omega-6 PUFA linoleic acid in the 
DHA-depleted diet. 
Similar issues were found in studies investigating the effect of DHA supplementation in other 
transgenic AD models. For example, Green et al. (2007) reported DHA supplementation to 
reduce Aβ and tau pathology in the 3xTg AD model by comparing a DHA diet containing 
1.3% DHA (accounting for all omega-3 PUFA content), 1.3% total omega-6 PUFA and a ω-
6/ω-3 ratio of 1:1, relative to a control chow depleted in DHA and omega-3 PUFAs (0% 
DHA, 0.2% total omega-3 PUFA), and containing higher levels of total omega-6 PUFA 
(2.3%) and ω-6/ω-3 ratio (10:1). Rather than a beneficial effect of DHA supplementation, the 
effects may have been attributable to the higher ω-6/ω-3 ratio in the control diet resulting 
from low levels of total omega-3 PUFAs and the high levels of total omega-6 PUFAs. In 
support of the potent effects of a high ω-6/ω-3 ratio, Oksman et al. (2006) reported that a diet 
deficient in DHA with a high ω-6/ω-3 ratio of 70:1 increased Aβ pathology in the 
APPswe/PS1 model, compared to mice fed a control diet also deficient in DHA but with 
increased levels of omega-3 PUFAs and a lower ω-6/ω-3 ratio of 8:1.
It is therefore clear that further research is required to accurately examine the effect of DHA 
supplementation relative to a suitable baseline diet. The following experiments therefore used 
a suitable baseline control diet whereby the primary difference between the DHA and control 
diet was the DHA content. Details surrounding the design of the experimental diets are 
described in chapter 2 and briefly outlined in section 3.2. Further investigation into the effect 
of DHA supplementation is also required as only one study has reported beneficial effects of 
DHA supplementation on reducing pathology (Lim et al., 2005) and behavioural deficits 
87
(Calon et al., 2004) in the Tg2576 model, and this was relative to diets which do not 
accurately assess the effect of DHA supplementation.
Furthermore, this chapter aims to examine the effect of longitudinal DHA supplementation 
from an early age of 4 months in Tg2576 mice. This dietary intervention therefore aimed to 
target underlying pathology during its initial stages of development, as the presence of 
soluble Aβ levels have been reported from 4 to 5 months in the Tg2576 model (Westerman et 
al., 2002). In contrast, all studies investigating the effects of DHA supplementation in the 
Tg2576 model have been initiated during advanced stages of amyloid pathology from 17 
months of age (Calon et al., 2004, 2005; Lim et al., 2005; Cole & Frautschy, 2006; Ma et al., 
2007). Similarly, the investigation of omega-3 PUFA or DHA supplementation in double and 
triple transgenic mouse models of AD has primarily been limited to periods of established 
pathology (Oksman et al., 2006; Hooijmans et al., 2007, 2009; Ma et al., 2009). Although 
these late-stage interventions are particularly applicable to the potential treatment in AD 
patients whereby the disease is often not detected until more advanced stages, they do not 
examine the effectiveness of DHA as an early-stage preventative measure. Supporting this, 
Arendash et al. (2007) argued that because cognitive impairment is already well-established, 
the published studies failed to examine whether DHA is ‘cognitively protective’. 
To date, the potential effectiveness of early-stage intervention of DHA has been investigated 
by only three studies in transgenic models of AD. Green et al. (2007) and Arsenault et al. 
(2011) showed positive effects of DHA supplementation from 3 to 4 months of age on 
cognition, tau and Aβ measures in the triple transgenic mouse model, where pathology 
develops from 3 to 6 months (Oddo et al., 2003; Billings et al., 2005). Arendash et al. (2007) 
also examined the effect of omega-3 supplementation from 2 months of age in the double 
transgenic APP/PS1 model, where Aβ pathology is detected as early as 6-12 weeks (Holcomb 
et al., 1998). Although no positive effects of omega-3 PUFAs on behavioural deficits or Aβ 
pathology were reported in the latter study, this may be attributable to the lack of omega-3 
PUFA incorporation into the brain of Tg mice. Overall, these early intervention studies show 
potential for slowing pathological progression and associated deficits. The potential 
effectiveness or necessity of early-stage intervention is further indicated by results from 
clinical trials which generally showed no beneficial effect of omega-3 PUFA treatment in 
patients with developed AD (Freund-Levi et al., 2006; Quinn et al., 2010). In contrast, the 
positive results from epidemiological studies suggest longitudinal dietary intake of omega-3 
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PUFA before the onset of disease may be necessary for effective results in AD and dementia 
(e.g. Kalmijn et al., 1997a; Morris et al., 2003; Huang et al., 2005; Barberger-Gateau et al.,
2007).
Using a suitable baseline diet, it was hypothesised that longitudinal dietary DHA 
supplementation from an early age would slow the onset and reduce the progression of 
behavioural deficits and Aβ pathology in Tg2576 mice. In order to test this hypothesis, 
Experiment 1 assessed longitudinal spatial learning performance of non-transgenic (wildtype) 
and Tg2576 mice at 8, 12 and 16 months of age using a test sensitive to the APPswe 
mutation, the T-maze forced choice alternation task. Following this, Experiment 2 examined 
the effect of DHA on Aβ pathology in Tg2576 mice using an enzyme-linked immunosorbent 
assay (ELISA) detection method to measure levels of Aβ in the brain of mice sacrificed at 16 
months of age. Finally, Experiment 3 examined the fatty acid profile of the mouse brain to 
confirm whether dietary DHA supplementation altered fatty acid levels, and importantly, to 
confirm whether dietary omega-3 PUFAs were incorporated into brain fractions.
3.2 Overview of the mouse cohort and dietary intervention design used
The experiments in this chapter used one cohort of male Tg2576 transgenic (Tg) and non-
transgenic (wildtype, WT) mice. The cohort of Tg2576 and WT mice used in this chapter was 
generated and maintained as outlined in chapter 2, section 2.2. At 4 months of age, mice were 
taken off standard laboratory mouse chow and were fed experimental diets composed of 
standard mouse chow containing either a 5% DHA-rich oil (DHA; containing 1.86% DHA, 
2.05% total omega-3 PUFA, 1.60% total omega-6 PUFA, and an ω-3/ω-6 ratio of 1.28:1) or 
the 5% oil blend enriched control diet (OB; containing 0% DHA, 0.22% total omega-3
PUFA, 2.07% total omega-6 PUFA, and an ω-3/ω-6 ratio of 0.10:1). Importantly, the 
difference in ω-3/ω-6 ratio was caused almost entirely by the DHA content, and the 
difference in omega-6 PUFA content between the two diets was minimal compared with 
previous studies investigating DHA supplementation (e.g. Calon et al., 2005; Green et al., 
2007). Furthermore, the absence of DHA in the control oil blend diet was compensated by 
‘neutral’ monounsaturated fatty acids and saturated fatty acids. Further details concerning 
these diets are outlined in chapter 2, section 2.3. It was thought that the different diets would 
not alter body weight in the mice, since this was not found between the fish oil diet 
(containing DHA) and oil blend diet in chapte
experimental schedule employed for c
Figure 3.1 Experimental schedule employed in 
3.3 Experiment 1: Longitudinal T
3.3.1 Introduction
This experiment aimed to test the hypothesis that longitudinal exposure to a diet 
supplemented with DHA from 4 months of age will improve memory function in Tg2576 and 
WT mice. These mice were assessed at 8, 12 and 16 months of age in order to examine 
whether early intervention delayed the onset or progression of memory impairment. These 
ages where selected as Aβ pathology is reportedly developed by 8 months of age, with 
diffuse deposits and plaques developing at 12 months of age, which are extensive by 16 
months (e.g. Hsiao et al., 1996; Kawarabayashi et al.
et al., 2006; Bizon, Prescott & Nicolle
ages may therefore indicate which stages of pathological developmen
DHA supplementation. Previous studies have already demonstrated the potential for DHA 
supplementation to reduce cognitive deficits during late stages of pathological development 
in the Tg2576 model (Calon et al., 2004), the APPswe/PS1 
and the 3xTg model (Ma et al., 2009; Arsenault et al., 2011). 
The assessment of spatial memory was selected because it is particularly affected in 
transgenic models of AD and is dependent on hippocampal function, which is p
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compromised early in AD models and patients (see Ashe, 2001; Corcoran et al., 2002). 
Tg2576 mice show a rather specific learning and memory impairment in spatial memory 
tests, such as the T-maze, water maze, radial arm maze, radial arm water maze, Y-maze and 
circular platform, as well as versions of these tasks (Table 3.1). Importantly, these tasks 
measure different forms of spatial memory including ‘reference’ and ‘working’ memory, 
which can be differentially affected by pathology at different time points. Spatial ‘reference’ 
memory is where animals need to encode and recall a specific spatial location over the course 
of the test, which is trial-independent and probes long-term memory (Olton et al., 1979; 
Olton, 1986). Such tasks include the water maze or radial arm maze whereby an escape 
platform or reward can be found in a fixed location, and successful memory of this can be 
used to navigate to this ‘goal’ location to complete the task. Spatial ‘working’ memory is 
where animals use short-term memory of spatial information to solve the task, which is trial-
dependent. Such tasks include the T-maze or Y-maze whereby a reward can be found in a 
previously unvisited location and so requires memory of the previously visited location. This 
is similarly required in tasks measuring species-typical behaviour such as spontaneous 
alternation, which measures the typical response for rodents to explore new environments and 
therefore switch between two maze arms on successive trials (Lalonde, 2002). 
As shown in Table 3.1, these spatial memory deficits predominately emerge after 6 months of 
age in Tg2576 mice and are progressive, resulting in a relatively robust deficit at later stages. 
However, there is some evidence of early deficits at 3 months of age, and some later reports 
are inconsistent, thereby highlighting the need for further examination into the onset and 
progression of spatial memory deficits (which is further examined in chapter 4). For example, 
King and Arendash (2002) reported normal performance of transgenic mice in the circular 
platform and water maze at 3, 9, 14 and 19 months of age. In contrast, transgenic mice 
showed a stable deficit in the Morris water maze from 6 to 10 months of age onwards (Hsiao 
et al., 1996; Westerman et al., 2002; Adriani et al., 2006). Similarly, spontaneous alteration in 
the Y-maze and T-maze was reported normal at 3 to 4, 9, 12 and 14 months, whereas others 
report an impairment at 3, 7 to 12, 10, 12, 15, 17 and 19 months (Table 3.1). Such 
discrepancies could be due to methodological differences within tasks, differences in the 
sensitivity of various tests in detecting spatial memory deficits, or poor performance from 
controls. 
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The T-maze forced choice alternation (FCA) task was selected to assess the effect of DHA 
supplementation in this experiment as it is a robust test widely used to assay spatial working 
memory in rodents, and is sensitive to the APPswe mutation in an age-dependant manner and 
hippocampal dysfunction (e.g. Barnes, Hale & Good, 2004; Deacon & Rawlins, 2005). A 
transgene-related impairment in the T-maze had been reported from 8 months of age in 
Tg2576 mice, during the first point of assessment (Barnes, Hale & Good, 2004). A deficit has 
also been reported after 8 months of age, at 12 and 16 month assessment points (Chapman et 
al., 1999; Corcoran et al., 2002; Barnes, Hale & Good, 2004). It was therefore hypothesised 
that Tg2576 mice would show a deficit on this procedure at all ages. Based on previous 
evidence showing DHA supplementation to reduce cognitive deficits in rodent models of AD, 
it was hypothesised that DHA supplementation would reduce spatial memory deficits in 
Tg2576 mice. Furthermore, it was hypothesised that dietary DHA would improve T-maze 
performance in WT mice. Previous research has shown that omega-3 PUFA and DHA 
supplementation induced superior spatial learning and memory performance in healthy 
rodents (e.g. Jensen, Skarsfeldt & Høy, 1996; Suzuki et al., 1998; Lim & Suzuki, 2000a,b; 
Arsenault et al., 2011).
Table 3.1 Summary of hippocampal-dependant spatial memory measures in the Tg2576 mouse model. 
Hippocampal-dependant spatial memory tasks
Behavioural task Age (months)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Morris water maze 
acquisition
N1 N6 Y1 Y1 Y1,2 Y1 Y6
Y6 Y6
Morris water maze 
retention (probe)
N1 N1 Y1 Y1 Y1
Water maze 
acquisition
N3 N18 N3 Y2 N16 N16
N16 N16 N18
Water maze retention 
(probe)
Y3♀ N18 N3 N16 N16
N16 N16 N18
T-maze forced-choice 
rewarded alternation
N7 N18 Y12 N4 Y7 N4 Y10 N15 Y7
N9 Y12 Y12, N18 Y9
T-maze spontaneous 
alternation
N4 Y28
Y-maze spontaneous 
alternation
Y1,3 N3,16 Y1 Y4 N16 Y19 Y16
N5 Y14
Appetitive Y-maze Y4 Y4
8-arm Radial arm 
maze
Y17
6-arm Radial arm 
water maze
Y11 Y13 Y13
Paddling Y-maze N4 Y4 Y4 N4
Circular platform task Y3♀ N3 N16 N16
N16 N16
Adapted circular 
platform acquisition
N8
Redundancy cued 
water maze
N15
Closed field 
symmetrical maze
Y17
Y= Transgene-dependant spatial memory deficit in Tg mice compared to age-matched WT controls, N = No transgene-dependant deficit, ♀ = gender-
dependant deficit (females only). References (Y/N#) listed in Footnote 1.
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Footnote 1. References (Y/N#) for Table 3.1: 1 Hsiao et al., 1996, 2 Adriani et al., 2006, 3 King et al., 
1999, 4 Deacon et al., 2008, 5 Holcomb et al., 1998, 6 Westerman et al., 2002, 7 Chapman et al., 1999, 8
Pompl et al., 1999, 9 Corcoran et al., 2002, 10 Hale & Good, 2005, 11 Wilcock et al., 2006, 12 Barnes, 
Hale & Good, 2004, 13 Wilcock et al., 2004, 14 Ognibene et al., 2005, 15 Bizon, Prescott & Nicolle, 
2007, 16 King & Arendash, 2002, 17 Asuni et al., 2006, 18 Zhuo et al., 2007, 19 Middei et al., 2004.
3.3.2 Methods
3.3.2.1 Design
One cohort of male Tg2576 transgenic (Tg) and non-transgenic (wildtype, WT) mice were
evaluated in the T-maze forced-choice alteration (FCA) task at three ages. Experimentally 
naïve mice were first tested at 8 months of age, a period where behavioural abnormalities 
have been previously reported (e.g. Barnes, Hale & Good, 2004). This cohort was tested 
again at 12 months of age, when plaque development is typically at an early stage in this 
transgenic line, and once again at 16 months of age when plaque pathology is well 
established. This design therefore investigated transgene- and diet-dependant changes at these 
ages, in addition to whether these changes were age-dependant. 
3.3.2.2 Subjects
The cohort of mice used in this experiment consisted of 25 Tg2576 (Tg) mice and 24 
wildtype (WT) control mice. When tested at 8 months of age, 12 Tg mice received DHA diet 
(Tg DHA), 13 Tg mice received the oil blend diet (Tg OB), 13 WT mice received the DHA 
diet (WT DHA) and 11 WT mice received the oil blend diet (WT OB). By the second stage 
of experimentation at 12 months of age, the loss of 10 mice resulted in group numbers of 10
Tg DHA, 10 Tg OB, 10 WT DHA and 9 WT OB. By the third stage of experimentation at 16 
months of age, the further attrition of 3 mice resulted in group numbers of 7 Tg DHA, 10 Tg 
OB, 10 WT DHA and 9 WT OB. The running order of mice was counterbalanced so that 
approximate equal numbers of each experimental group of mice were run in each batch 
(n=8), with several batches of mice being tested once per day over 14 consecutive days. 
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3.3.2.3 Apparatus
The T-maze was constructed from three arms each 9cm wide and 13cm tall in the formation 
of a ‘T’, and composed from clear Perspex (Figure 3.2). The long start arm was 52cm long 
and the two goal arms were each 26cm long, with the maze elevated 92cm from the floor. 
The maze was situated in a quiet, illuminated room surrounded by numerous distinct visual 
cues such as posters and shelving on the walls, benching and air conditioning ducts. Entrance 
to and exit from selected goal arms during the task were controlled using removable doors 
made from opaque Perspex. Approximately 50µl of a 10% sucrose solution in distilled water 
was used as a liquid reward during the task and placed in black-coloured recessed wells at the 
end of each goal arm.
Figure 3.2 T-maze apparatus, showing maze construction and recessed wells.
3.3.2.4 Procedure
Behavioural experiments were carried out by the author and a research assistant (Vicky 
Staal), with all data analysis carried out by the author. Mice were water deprived throughout 
this experiment in order to motivate them to consume the 10% sucrose reward. Water 
deprivation consisted of unrestricted access to water in their home cage for 2 hours each day, 
which was provided after completing the last training or test session of the day. Each mouse 
was checked daily for general health and weighed to ensure their body weight was 
maintained at over 85 to 90% of their ad lib weight. The experimenter remained in the room 
throughout all sessions and maintained a consistent position in the room throughout training. 
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The T-maze FCA experiment consisted of 4-day habituation to the testing room and 
apparatus, and a 10-day training (testing) period. Mice received one habituation session per 
day, which involved 5-minute free access within the T-maze in order to explore the maze. 
Each goal arm was baited with a 10% sucrose reward located in a recessed food well, and for 
the first 2 days of habituation, reward was also placed on the lip of the well. If the reward was 
not consumed within 5 minutes, the mice received a further 5 minutes in the T-maze. The 
maze was cleaned using a 1:20 dilution of Mr Muscle® glass cleaner with water, and dried 
with paper towelling, prior to placing each mouse in the apparatus. Mice were transported to 
the test room in individual home cages and acclimatised to the room for 10 minutes prior to 
each habituation and testing session.
Each mouse received a total of 10 days of training. After 5 consecutive days of training, the 
mice received a two-day break during which the mice received 48-hour ad lib water access. 
Each testing day was comprised of six trials whereby mice received a sample (forced-choice) 
trial and test (free-choice) trial, which were separated by a ~30 second interval. Each trial was 
separated by an inter-trial interval of approximately 10 minutes, during which the mouse was 
placed in their home cage. Before the start of each sample trial, the maze was cleaned and 
both goal arms were baited with ~50µl of 10% sucrose reward. Each mouse was placed at the 
end of the start arm and given access to one goal arm (left or right). The location of this 
‘sample arm’ was selected pseudo-randomly by the experimenter, such that each mouse were 
exposed to three left and three right sample arms within each training session, with the 
restriction that each mouse received no more than two consecutive trials to the same sample 
location. Access to the remaining arm was blocked using an opaque Perspex door located at 
the start of the goal arm. Once the mouse had entered the sample arm, it was given 30 
seconds to consume the reward and was then removed. The maze (including both goal and 
non-goal arms) was then cleaned to obscure any potential intra-maze odour cues. 
Approximately 30 seconds after the sample trial, the mouse received the test trial whereby the 
Perspex door was removed providing access to both left and right goal arms, and the mouse 
was again placed at the base of the start arm. The mouse was presented with a choice of 
access to either the left or right arm, and once the choice had been made the mouse was 
confined to the arm using the Perspex door. Entry to the novel (non-sample) arm resulted in 
access to liquid reward and was recorded as a correct choice. An entry was defined as when 
the rear of the body, excluding the tail, passed the entrance to the arm. In contrast, entry to 
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the previously visited sample arm resulted in no reward and the mouse was restricted to this 
arm for 15 seconds. This was recorded as an incorrect choice. The mouse was then placed 
into their home cage until the next session.
3.3.2.5 Scoring and data analysis
T-maze performance was calculated as a percentage of correct trials (successful alternations) 
of the six trials conducted per day. Statistical analyses were carried out using an ANOVA 
with genotype (Tg or WT) and diet (DHA or oil blend) as between-subject factors, and day 
(1-10) as a within-subject factor. Following significant interactions, tests of simple main 
effects and simple interactions were carried out. A separate ANOVA analysed the data at 8, 
12 and 16 months independently. In addition to this, a comparison of all three ages was 
carried out using a repeated-measures ANOVA. This analysis used the percentage of correct 
trials on the last day of acquisition (day 10) only to assess whether optimal learning 
performance varied with age in the Tg and WT groups across diet conditions. As attrition in 
the number of mice occurred over the period of testing, the latter analysis only included mice 
that were assessed at all three ages (Tg DHA n=7, Tg OB n=10, WT DHA n=10 and WT OB
n=9).
3.3.3 Results: T-maze task
Figure 3.3 shows the percentage of correct trials for both Tg and WT mice fed the DHA or oil 
blend diet during acquisition of the T-maze FCA task at 8 months of age. An ANOVA with 
genotype, diet and day as factors revealed no significant effect of genotype (F(1,45)=1.660, 
p>0.05), diet (F(1,45)=0.103, p>0.05) or interaction between these factors (F(1,45)=1.025, 
p>0.05). As illustrated in Figure 3.3, these results indicate that Tg and WT mice performed 
equally well with no significant effect of 4-month dietary DHA supplementation. Statistical 
analysis also showed a significant effect of day (F(9,405)=11.447, p<0.001), a significant 
interaction of day by genotype (F(9,405)=3.255, p<0.01), no significant interaction of day by 
diet (F(9,405)=1.823, p>0.05) and no significant three-way interaction of day by genotype by 
diet (F(9,405)=1.009, p>0.05). Tests of simple main effects for the significant day by 
genotype interaction revealed that WT mice performed significantly better than Tg mice on 
day 9 (F(1,47)=16.25, p<0.001).
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Figure 3.3 T-maze performance at 8 months of age. Mean percentage of correct trials over 10 days 
acquisition in Tg and WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M 
(standard error of the mean).
Figure 3.4 shows the percentage of correct trials for both Tg and WT mice fed the DHA or oil 
blend diet during T-maze acquisition at 12 months of age. An ANOVA with day, genotype 
and diet as factors revealed a significant effect of genotype (F(1,35)=16.918, p<0.001), but 
no significant effect of diet (F(1, 35)=2.806, p>0.05) and no interaction of genotype by diet 
(F(1,35)=0.556, p>0.05). As illustrated in Figure 3.4, WT mice performed significantly better 
than Tg mice. However, there was no significant effect of 8-month dietary DHA 
supplementation on performance. Statistical analysis also showed a significant effect of day 
(F(9,315)=10.950, p<0.001), a significant interaction of day by genotype (F(9,315)=1.920, 
p<0.05), and no significant interaction of day by diet (F(9,315)=0.707, p>0.05) or day by 
genotype by diet (F(9,315)=0.264, p>0.05). A follow-up test of simple main effects for the 
significant day by genotype interaction revealed that WT mice performed significantly better 
than Tg mice on day 2 (F(1,37)=5.12, p<0.05), day 5 (F(1,37)=5.79, p<0.05), day 7 
(F(1,37)=21.57, p<0.001), day 8 (F(1,37)=11.19, p<0.01), day 9 (F(1,37)=30.80, p<0.001) 
and day 10 (F(1,37)=45.74, p<0.001). This genotype effect was particularly evident on day 9 
of training, which was likely due to the more rapid learning by WT mice on the last two 
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acquisition days compared with Tg mice which demonstrated slower acquisition and erratic 
performance (together with a better performance on day 10 than day 9). 
Figure 3.4 T-maze performance at 12 months of age. Mean percentage of correct trials over 10 days 
acquisition in Tg and WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
Figure 3.5 shows the percentage of correct trials for both Tg and WT mice fed the DHA or oil 
blend diet during T-maze acquisition at 16 months of age. An ANOVA with day, genotype 
and diet as factors revealed a significant effect of genotype (F(1,32)=21.409, p<0.001), no 
significant effect of diet (F(1, 32)=2.292, p>0.05) and no interaction between these factors 
(F(1,32)=1.363, p>0.05). As illustrated in Figure 3.5, this analysis indicates that WT mice 
performed significantly better than Tg mice, and there was no significant effect of 12-month 
DHA supplementation on performance. Statistical analysis also showed a significant effect of 
day (F(9,288)=6.106, p<0.001) and significant interaction of day by genotype 
(F(9,288)=3.349, p<0.001), but no significant interaction of day by diet (F(9,288)=0.924, 
p>0.05). Follow-up tests of simple main effects for the significant day by genotype 
interaction revealed that WT mice performed significantly better than Tg mice on day 4 
(F(1,32)=22.22, p<0.001), day 5 (F(1,32)=8.94, p<0.01), day 6 (F(1,32)=7.17, p<0.05), day 7 
(F(1,32)=21.63, p<0.001), day 9 (F(1,32)=13.06, p<0.001) and day 10 (F(1,32)=21.61, 
p<0.001). Statistical analysis also revealed a significant three-way interaction of day by 
genotype by diet (F(9,288)=2.541, p<0.01). A follow-up test of simple interactions revealed a 
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significant genotype by diet interaction on day 3 (F(3,32)=5.57, p<0.05). Tests of simple 
main effects revealed a significant difference between Tg OB and WT OB mice 
(F(1,32)=9.15, p<0.01) and a significant difference between Tg DHA and Tg OB on day 3 
(F(1,32)=10.71, p<0.01).
Figure 3.5 T-maze performance at 16 months of age. Mean percentage of correct trials over 10 days 
acquisition in Tg and WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
Figure 3.6 shows the percentage of correct trials for both Tg and WT mice on DHA or oil 
blend diet on the last day of acquisition (day 10) of the T-maze task at 8, 12 and 16 months of 
age. This examined the effect of age, as well as genotype and diet, on learning. Due to 
mortalities throughout the course of experimentation several mice were excluded from this 
analysis including 3 Tg OB, 5 Tg DHA, 2 WT OB and 3 WT DHA. The last day of 
acquisition was used as it was thought to correspond to asymptotic performance, as shown in 
Figures 3.3 to 3.5. An ANOVA with age, genotype and diet as factors revealed a significant 
effect of genotype (F(1,32)=36.920, p<0.001), a significant effect of diet (F(1,32)=4.478, 
p<0.05) and a significant interaction of genotype by diet (F(1,32)=4.926, p<0.05). Following-
up this interaction, tests of simple main effects revealed that Tg OB mice performed 
significantly worse than all groups including Tg DHA (p<0.05), WT DHA (p<0.001) and WT 
OB (p<0.001). There was no significant effect of age (F(2,64)=2.905, p>0.05), a significant 
interaction of age by genotype (F(2,64)=3.469, p<0.05), no significant interaction of age by 
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diet (F(2,64)=1.164, p>0.05) and no significant three-way interaction of age by genotype and 
diet (F(2,64)=0.340, p>0.05). Follow-up tests of simple main effects for the age by genotype 
interaction revealed Tg mice to perform significantly worse than WT mice at 12 
(F(1,34)=42.51, p<0.001) and 16 months (F(1,34)=22.39, p<0.001), but not 8 months 
(F(1,34)=3.92, p>0.05), supporting the analysis at separate ages. These results suggest that T-
maze performance was sensitive to age-related changes in Tg but not WT mice, suggesting 
that a decline in Tg performance was caused by Aβ-associated pathology. In contrast, the T-
maze task was not sensitive to age-related cognitive decline in WT mice at these ages.
Figure 3.6 T-maze performance at 8, 12 and 16 months of age. Mean percentage of correct trials on 
the last day (day 10) of trial acquisition in Tg and WT mice fed the DHA or oil blend diet. Values are 
mean scores ± S.E.M.
In summary, the analysis of the T-maze FCA task showed that Tg2576 mice were impaired at 
12 and 16 months, but not 8 months of age. Although DHA supplementation generally failed 
to enhance performance in Tg and WT mice, follow-up tests of a significant three-way 
interaction of day by genotype by diet at 16 months revealed Tg mice fed the oil blend diet to 
perform significantly worse than all groups on day 3. The transitory nature of these effects 
may suggest that it is attributable to sampling error or random fluctuations in performance.
However, an analysis of the terminal levels of performance achieved by the end of training 
across all age groups in mice that completed the full set of tests also revealed a positive effect 
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of DHA diet on the performance of Tg mice. This was particularly illustrated in mice aged 16 
months whereby Tg DHA mice achieved 76% correct compared to 57% correct reported in
Tg OB mice. Tg OB performance was just above chance level (whereby a mouse can achieve 
50% correct trials through chance alone), thereby suggesting limited learning or memory by 
Tg OB at 16 months, unlike the Tg DHA group. An unpaired samples t-test confirmed this by 
comparing the performance of Tg groups aged 16 months to chance levels (50%), revealing a 
non-significant difference for the Tg OB group (t(18)=0.885, p>0.05) but a significant 
difference for the Tg DHA group (t(12)=4.260, p<0.001).
3.3.4 Discussion
The T-maze FCA task revealed Tg2576 mice to be significantly impaired relative to WT 
control mice at 12 and 16 months of age, which supports previous findings of an age-
dependant deficit (e.g. Chapman et al., 1999; Corcoran et al., 2002; Hale & Good, 2005;
Barnes, Hale & Good, 2004; Zhuo et al., 2007). Although the lack of transgene-induced 
deficit at 8 months of age was in contrast to previous reports in the T-maze (Barnes, Hale & 
Good, 2004), our data revealed an impairment on day 9 of the task which perhaps suggested
the onset of a modest deficit at this age.
Figure 3.6 showed Tg performance (particularly the Tg OB group) appeared significantly 
lower as a consequence of age. Using day 10 data it was calculated that Tg OB performance 
reduced by 15% from 8 to 16 months of age down to 56.6% correct trials, Tg DHA 
performance reduced by 9.5% down to 76.2%, WT OB performance increased by 3.7% up to 
90.7%, and WT DHA performance increased by 3.3% up to 91.67%. These results therefore 
suggest that the APPswe mutation leads to an age-related decline in spatial learning likely 
resulting from increasing Aβ pathology with age. In contrast, the lack of mutation in WT 
mice and practice effects may have led to the increased performance observed. This general 
pattern suggests that DHA may provide subtle protection against age-related cognitive 
decline of spatial working memory in Tg2576 mice.
Supplementation of DHA provided limited protection against a decline in spatial working 
memory, albeit subtle, in Tg2576 mice at 16 months. This is supported by Calon et al. (2004) 
who reported that DHA supplementation reduced spatial learning deficits in 21-22 month old 
Tg2576 mice. In contrast, the present study found DHA supplementation did not benefit Tg 
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performance at 8 or 12 months of age. This may suggest that DHA may only be effective in 
the presence of advanced Aβ pathology. It is therefore possible that DHA targets plaque 
development, which is extensive at 16 months of age (Hsiao et al., 1996; Kawarabayashi et 
al., 2001; Bizon, Prescott & Nicolle, 2007). This may explain the lack of dietary effect at 12 
months of age when plaque load has been reported scattered and modest (Jacobsen et al.,
2006).
Although the results indicate modest positive effects of dietary supplementation during late 
but not early stages of pathology, it could be argued that the T-maze test was not sufficiently 
sensitive to detect more subtle dietary-induced behavioural changes at early stages. For 
example, despite the T-maze being a robust test widely used to assess spatial working 
memory, its 50% chance level results in a small window to detect subtle differences in 
learning and memory, and changes as a function of treatment. For example, transgene-
dependant deficits in spatial memory are not detected in Tg2576 mice in the T-maze until 8 
months, yet spatial deficits have been reported from 3 months in the Y-maze, circular 
platform and water maze task (King et al., 1999). It is therefore argued that performance 
should be further assessed using a wider range of cognitive tasks, particular more difficult 
tasks, in order to probe potential subtle effects. This was therefore examined in chapter 4.
This issue may also explain the lack of diet effect in WT mice in this study, which was 
unexpected as several studies have reported positive effects of omega-3 PUFA and DHA 
supplementation in normal healthy rodents. Supporting this argument, such studies have 
detected positive effects of dietary supplementation using more complex tasks including the 
Morris water maze and a multiple-alley maze (Jensen, Skarsfeldt & Høy, 1996; Suzuki et al., 
1998; Lim & Suzuki, 2000a,b). In contrast to the latter tasks which provide multiple 
opportunities for error (e.g. several arm choices), the T-maze provides less opportunity for 
error with only 2 arm choices. Furthermore, it may be important to assess different forms of 
spatial memory, as highlighted in Gamoh et al. (1999) study which reported cognitive 
benefits of omega-3 PUFA supplementation in rodents which were limited to reference not 
working memory in the 8-arm radial maze. As the T-maze assesses working memory, it may 
therefore be important to assess dietary intervention using tests of spatial reference memory.
On another note, it is possible that performance in the T-maze or other spatial memory tasks 
could be confounded by visual ability as several AD mouse models harbouring the APPswe 
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mutation suffer from retinal degeneration related to Aβ pathology (see Garcia et al., 2004; 
Ning et al., 2008; Liu et al., 2009). Importantly however, Garcia et al. (2004) argue that 
APPswe mice show impaired spatial memory irrespective of retinal degeneration status. 
Moreover, intact novel item recognition in Tg2576 mice suggests at least some visual 
integrity (e.g. Good & Hale, 2007). Tests measuring visual ability have produced mixed 
results, with some deficits reported in a water maze task at 9, 14 and 19 months (King et al.,
1999; King & Arendash, 2002), but not at 3, 6 and 14 months (King et al., 1999; King & 
Arendash, 2002; Zhuo et al., 2007). Moreover, no visual deficit was reported in the Morris 
water maze at 9-10 months (Hsiao et al., 1996) or radial arm water maze at 24 months 
(Wilcock et al., 2006). In order to rule out the possibility of retinal degeneration accounting 
for impaired performance otherwise attributed to memory dysfunction, future studies should 
assess the degree of visual integrity or screen for retinal degeneration gene status.
3.4 Experiment 2: Pathological assessment
3.4.1 Introduction
This experiment aimed to investigate the effect of longitudinal dietary DHA supplementation 
from an early age on later-stage Aβ pathology in Tg2576 mice. A vast body of literature has 
shown DHA to reduce Aβ pathology both in vivo and in vitro (e.g. Lim et al., 2005; Oksman 
et al., 2006; Green et al., 2007; Boudrault et al., 2009). As important as it was to assess the 
behavioural effects of DHA supplementation relative to a suitable baseline diet, it was 
equally important to assess the pathological effects to determine any changes to the 
underlying pathology of the disease. Although these measures normally correlate, one does 
not consistently predict the other, as demonstrated by Oksman et al. (2006) who reported 
DHA supplementation to reduce Aβ levels but did not improve spatial learning in the water 
maze. Conversely, Calon et al. (2004) reported the opposite. Based on previous literature and 
the longitudinal design of our dietary supplementation during early onset to later stages of 
pathology, it was hypothesised that DHA supplementation would reduce Aβ accumulation in 
Tg2576 mice. Furthermore, the T-maze results in experiment 1 may suggest that DHA could 
reduce plaque pathology to some extent, as suggested by some spatial learning improvements 
at 16 months of age.
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In order to test this hypothesis, pathological analysis was carried out following behavioural 
testing in the T-maze task at 16 months of age when Aβ accumulation should be significant. 
Amyloid pathology can be assessed using immunohistochemistry and an enzyme-linked 
immunosorbent assay (ELISA) detection method. These techniques use specific human Aβ1-
40 and Aβ1-42 detection antibodies to indicate the presence of these proteins in tissue 
samples. Immunohistochemistry is frequently used to assess the pattern of Aβ accumulation 
throughout the brain and can be used to quantify Aβ aggregates, although this is less precise 
than an ELISA (Kawarabayashi et al., 2001). In contrast, an ELISA is specifically used to 
quantify both soluble and insoluble Aβ levels in biological tissue samples, for example, from 
a whole brain or brain regions such as the cortex and hippocampus. Soluble Aβ exists in non-
aggregated fashion in a non-fibrous form, whereas insoluble Aβ exists as diffuse and senile 
neuritic plaques of aggregated Aβ (Hardy & Allsop, 1991). 
The ability to measure soluble forms of Aβ in addition to insoluble forms is particularly 
important as soluble, but not insoluble forms, are strongly correlated with markers of AD 
severity such as cognitive and synaptic impairment (Lue et al., 1999; McLean et al., 1999; 
Wang et al., 1999; Näslund et al., 2000). Furthermore, post-mortem studies have revealed the 
presence of cortical Aβ deposits in humans without AD symptoms (Arrigada et al., 1992; 
Crystal et al., 1998), and Holmes et al. (2008) reported maintained AD progression when 
plaques were removed with Aβ immunisation. This therefore suggests a key role of soluble 
Aβ in AD pathogenesis.
For the purpose of this experiment, an ELISA detection method was therefore selected in 
order to measure both soluble and insoluble Aβ. Supporting this selection, Oksman et al. 
(2006) reported DHA to reduce total Aβ levels measured in an ELISA, but had no effect on 
plaque load measured by immunohistochemistry. Measuring both soluble and insoluble 
extracts may also shed light on the potential action of DHA. For example, selective reduction 
of insoluble but not soluble Aβ by DHA may suggest inhibition of Aβ aggregation. The 
specific measurement of Aβ40 and Aβ42 isoforms were also selected as these proteins are 
commonly assessed in Tg2576 intervention studies, and are the most common and pathogenic 
forms of Aβ in the Tg2576 model (Hsiao et al., 1996) and in AD patients (Kawarabayashi & 
Shoji, 2008). Using this highly sensitive ELISA measure, this experiment assessed Aβ 
accumulation in the cortex as this is one of the most pathologically affected brain regions 
(e.g. Hsiao et al., 1996). Although Aβ could have been measured in plasma samples, this may 
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not be representative of levels in the brain as Kawarabayashi et al. (2001) reported that the 
human APPswe transgene in Tg2576 mice is expressed at substantial levels in other organs 
and so plasma Aβ is likely derived from both the brain and peripheral organs.
3.4.2 Methods
3.4.2.1 Design and subjects
Soluble and insoluble human Aβ1-40 and Aβ1-42, expressed from the APPswe transgene, 
were quantified by ELISA in cortex samples of Tg2576 mice aged 16 months by a research 
associate (Dr. Cécile Bascoul-Colombo). This experiment analysed 3 Tg mice from each diet 
group (DHA and OB), following the T-maze FCA task at 16 months of age. WT mice were 
not systematically assessed as they do not express human Aβ. Analysis of one WT mouse 
from each diet group confirmed the absence of human Aβ.
3.4.2.2 Procedure
Tissue preparation
Mice were culled by cervical dislocation. The brain was immediately removed and 
maintained on ice while dissecting the cortex, hippocampus and cerebellum. The dissected 
tissue samples were immediately weighed and snap-frozen in liquid nitrogen. These samples 
were then stored at -80ºC until ready to be analysed.
Protein extraction
In order to extract soluble and insoluble proteins from the tissue, tissue samples were 
maintained on ice and homogenised using an autoclaved micropestle in freshly-made 
extraction buffer 1, added at a rate of 1ml per 150mg wet tissue weight. Extraction buffer 1 
contained 2% (w/v) sodium dodecyl sulphate (SDS, Sigma) in MilliQTM water with 1% (v/v) 
protease inhibitor cocktail (Calbiochem, Cat.# 539134), pH 7.4. Samples were rotated on a 
rotating plate overnight at 4ºC (approximately 16 hours). Homogenates were then vortexed 
and centrifuged (Boeco U-32 R) at 21,000g RCF for 1 hour at 4ºC. Careful not to extract the 
protein pellet containing insoluble Aβ, the supernatant containing soluble Aβ protein (SDS 
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extracts) was removed and stored at -80ºC. In order to extract the insoluble Aβ, freshly-made 
ice-cold extraction buffer 2 was added to the protein pellet at the same rate as SDS, then 
homogenised and rotated overnight at 4ºC. Extraction buffer 2 contained 5M guanidine 
hydrochloride (Sigma, Cat.# 64505) in PBS containing 1% (v/v) protease inhibitor cocktail, 
pH 7.4. Homogenates were then vortexed and centrifuged at 16,000g RCF for 20 minutes at 
4ºC. The supernatant containing the insoluble Aβ protein (guanidine extracts) was removed 
from under the lipid layer and stored at -80ºC.
Protein assay
A protein assay was carried out in order to measure the total volume of protein in each 
sample, which was necessary to express the amount of Aβ protein per total protein following 
ELISA measurements. Total protein concentration was measured using the bicinchoninic acid
(BCA) method, with the Pierce® BCA Protein assay kit (Thermo Scientific, Cat.# 23227). 
This method combines the Biuret reaction (the reduction of Ca+2 and Cu+1 by proteins in an 
alkaline medium) with the colorimetric detection of Cu+ using a BCA-containing reagent.
The resulting purple-coloured reaction is dependent on protein concentration, which exhibits 
a strong absorbance at 562 nm that is nearly linear with increasing protein concentrations 
over a working range of 20 to 2,000 µg/ml. The absorbance readings of samples containing 
an unknown concentration of protein can be used to calculate quantitative measurements with 
reference to a standard curve based on known dilutions of a standard protein (bovine serum 
albumin, BSA) which is assayed alongside the samples (the soluble and insoluble Aβ protein 
extracts).
The assay was carried out as detailed in the kit instruction manual. In brief, protein samples 
maintained on ice were diluted with dH20 to fall within the working range and to ensure no 
interference of substances including SDS and guanidine. Serial dilutions of the BSA protein 
with dH20 were then prepared to create the standards (2000, 1500, 1000, 750, 500, 250, 125, 
25 and 0 µg/ml concentrations) for the standard curve. Using the microplate procedure, 25µl 
of each sample and standard were added to the 96-well Greiner 96 F-Bottom microplate, in 
duplicate. 200µl of BCA working reagent (50 parts BCA Reagent A with 1 part BCA 
Reagent B) were then applied to each sample and standard, and mixed thoroughly for 30 
seconds. The plate was then covered and incubated for 30 minutes at 37ºC. Following a 
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cooling period at room temperature for 5 minutes, the absorbance was read at 570 nm using a 
microplate reader (FLUOStar Optima, BMG Labtech).
In order to calculate accurate protein concentrations of the samples, the duplicate absorbance 
values were averaged and the average blank replicate value was subtracted from all standards 
and samples. The standard curve was then obtained by plotting the standard absorbance 
readings versus its concentration in µg/ml. The protein concentration of each sample was 
then calculated using the program Microsoft Excel using the standard curve. Finally, the mg 
of total protein per mg of tissue was calculated by correcting for sample dilutions, converting 
µg/ml value to mg/ml, and using the tissue sample weight (mg). The total protein referred to 
the total soluble protein, since levels of total insoluble protein were negligible, as expected.
Enzyme-linked immunosorbent assay (ELISA)
Human Aβ levels, expressed by the APPswe mutation in Tg2576 mice, were quantitatively 
measured in samples (the soluble and insoluble Aβ protein extracts) by ELISA using 
commercial colorimetric immunoassay kits for human Aβ1-40 (Invitrogen, Cat.# KHB3482) 
and human Aβ1-42 (Invitrogen, Cat.# KHB3442). This sandwich ELISA uses microtiter 
strips with wells coated with monoclonal antibody specific for the NH2-terminus of human 
Aβ. Similar to the BCA assay, diluted standards of known concentration were assayed 
alongside the samples in order to create a standard curve to accurately measure sample 
concentrations of the desired proteins, Aβ1-40 and Aβ1-42. The intensity of the coloured end 
reaction is read by a plate-reader and is directly proportional to the concentration of human
Aβ40 or Aβ42 present in the sample.
In preparation of the ELISA, the human Aβ40 and Aβ42 standards were reconstituted from 
powder with standard reconstitution buffer (55 mM sodium bicarbonate, pH 9.0), as indicated 
by the manufacturer, and diluted 1:20 in BSAT-DPBS (0.2 g/l KCl, 0.2g/l KH2PO4, 8.0 g/l 
NaCl, 1.150 g/l Na2HPO4, 5% BSA, 0.03% Tween-20 in MilliQ
TM water, pH 7.4). The 
samples, maintained on ice, were also diluted 1:20 in BSAT-DPBS containing 1:100 protease 
inhibitor cocktail (Calbiochem, Cat.# 539134). Serial dilutions of the standards in standard 
diluent buffer (provided in kits) were then made for the standard curve, from 500 to 7.81 
pg/ml for Aβ40 standard and 1000 to 15.63 pg/ml for Aβ42 standard. Samples were then 
diluted further with standard dilution buffer to make two sample dilutions for the ELISA to 
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ensure detection within the standard curve range. The dilution required was previously 
piloted as it varies with Aβ type (soluble and insoluble), isoform (Aβ1-40 and Aβ1-42) and 
with age (as Aβ increases with age). For example, a whole hippocampus at 12 months of age 
for soluble Aβ needs to be diluted 1:400 and 1:800 to be detected within the standard curve 
range.
Once prepared, 50µl of each diluted standard and sample were applied to the antibody-coated 
microtiter strip wells, in duplicate, with 50µl of rabbit anti-human Aβ1-40 or Aβ1-42 
detection antibody. Following a 3 hour incubation period on a shaking plate at room 
temperature, liquid was discarded from each well and washed four times with working wash 
buffer (25x concentrate wash buffer 1:24 in deionised water). 100µl of the secondary 
antibody (1:100 anti-rabbit Ig’s-HRP 100x concentrate in HRP diluent) was applied to each 
well using a multi-channel pipette and incubated for 30 minutes on a shaking plate at room 
temperature. Following washes (as described), 100µl of stabilised chromogen was applied to 
each well and incubated for approximately 20 minutes at room temperature in the dark. This 
blue-coloured reaction was then stopped by applying 100µl of stop solution into each well
and the absorbance was measured at 450 nm using a colorimeter plate reader (FLUOStar 
Optima, BMG Labtech). Optima 2.0 software directly calculated Aβ concentrations of each 
sample based on the absorbance values relative to the absorbance values of the standard curve 
(based on known concentrations of standard serial dilutions). Only values within the standard 
range were used. Aβ protein concentrations were calculated by taking the mean value of 
duplicates, and expressed as pg of Aβ per µg of protein, using the protein concentrations 
obtained in the BCA assay.
3.4.3 Results
Figure 3.7 presents the levels of soluble and insoluble Aβ1-40 and Aβ1-42 measured by 
ELISA in the cortex of Tg2576 mice fed the oil blend and DHA diet at 16 months of age. 
Individual values are shown in addition to the mean value (indicated by the black bar). The 
graphs show that the Tg OB and Tg DHA groups appear to have similar levels of soluble 
Aβ1-40 and soluble Aβ1-42, but levels of insoluble Aβ1-40 and Aβ1-40 were slightly lower 
in the Tg DHA group relative to Tg OB group. In order to test whether diet altered Aβ levels 
in the cortex of Tg2576 mice, an ANOVA with diet (OB, DHA) as a between-subject factor, 
and brain extract (soluble, insoluble) and Aβ isoform (Aβ1-40, Aβ1-42) as within-subject 
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factors was carried out. Statistical analysis revealed no significant effect of diet 
(F(1,4)=0.301, p>0.05), no significant interaction of isoform by diet (F(1,4)=0.332, p>0.05), 
no significant interaction of extract by diet (F(1,4)=0.668, p>0.05) and no three-way 
interaction of isoform by extract by diet (F(1,4)=0.671, p>0.05). These results therefore 
demonstrate that DHA supplementation failed to reduce Aβ pathology. 
Figure 3.7 Levels of Aβ in the cortex of 16 month old male Tg2576 mice fed the oil blend (Tg OB) 
and DHA (Tg DHA) diet. Four species of Aβ were analysed by ELISA: A. Soluble Aβ1-40, B. 
Insoluble Aβ1-40, C. Soluble Aβ1-42, and D. Soluble Aβ1-42. Individual values are presented, in 
addition to the mean value (black bar).
Statistical analysis also revealed a significant effect of isoform (F(1,4)=9.117, p<0.05) caused 
by higher levels of Aβ1-40 than Aβ1-42, a significant effect of extract (F(1,4)=11.386, 
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p<0.05) caused by higher levels of insoluble Aβ than soluble Aβ, and a significant interaction 
of isoform by extract (F(1,4)=10.386, p<0.05). A test of simple main effects revealed this 
interaction to be caused by higher levels of insoluble than soluble Aβ for both the Aβ1-40 
isoform (F(1,5)=10.99, p<0.05) and Aβ1-42 isoform (F(1,5)=19.34, p<0.01), and higher 
levels of Aβ1-40 than Aβ1-42 for both soluble extracts (F(1,5)=7.27, p<0.05) and insoluble 
extracts (F(1,5)=11.88, p<0.05).
3.4.4 Discussion
ELISA analysis of Aβ pathology confirmed the presence of soluble and insoluble Aβ1-40 and 
Aβ1-42 in brains of Tg2576 mice aged 16 months, consistent with previous reports (Hsiao et 
al., 1996; Kawarabayashi et al., 2001; Westerman et al., 2002). This analysis also 
corroborated evidence by Kawarabayashi et al. (2001) reporting higher levels of insoluble 
Aβ1-40 and Aβ1-42 relative to their soluble forms from 10 months of age. Greater levels of 
Aβ1-40 than Aβ1-42 levels were also found at 16 months of age, consistent with reports from 
Hsiao et al. (1996) in Tg2576 mice aged 11 to 13 months.
Inconsistent with the experimental hypothesis, the experiment revealed no significant effect 
of diet or significant interactions of isoform or extract with diet on Aβ levels. These results 
are in contrast to previous reports of beneficial effects of DHA supplementation effects on 
amyloid pathology. For example, DHA supplementation reduced total, soluble and insoluble 
Aβ1-40 and Aβ1-42, as well as Aβ deposition in the 3xTg (APP/PS1/Tau) model, the 
APPswe/PS1 model and the Tg2576 model (Lim et al., 2005; Oksman et al., 2006; Green et 
al., 2007; Hooijmans et al., 2007, 2009). It is important to note however that several factors 
may account for these discrepancies, such as differences in animal model and their 
underlying pathology, as well as the experimental design surrounding the diets and time of 
intervention. For instance, Lim et al. (2005) reported 0.6% DHA supplementation with an ω-
6/ω-3 ratio of 4:1 reduced total (Aβ1-40 and Aβ1-42) insoluble Aβ levels in cortex samples 
of Tg2576 mice aged 22.5 months relative to a DHA-depleted diet with a ω-6/ω-3 ratio of 
85:1, but not compared to a control chow containing 0.09% DHA with a ω-6/ω-3 ratio of 7:1. 
This may therefore suggest that a DHA-rich diet is only effective at reducing Aβ pathology 
when compared to a diet with excessive levels of omega-6 PUFA. Such issues will be further 
reviewed in the chapter discussion.
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Although this experiment revealed no statistically significant effect on Aβ pathology as a 
function of diet, it is important to note that levels of insoluble Aβ1-40 and Aβ1-42 appeared 
reduced by DHA supplementation, suggesting that DHA may reduce insoluble Aβ 
accumulation when compared with a suitable baseline control diet. Before disregarding this 
non-significant effect, it is important to consider that the small number of mice examined in 
each group and the high variability of Aβ levels between individual mice may have limited 
the detection of a statistically significant effect of DHA supplementation. This is further 
supported by Chapman et al. (1999) who also reported that total levels of Aβ1-40 and Aβ1-42 
was highly variable in the brain of six Tg2576 mice aged 17 to 19 months. This high 
variability in Aβ levels may therefore restrict the detection of subtle dietary effects, and 
therefore highlights the need for a larger number of mice per group when examining
treatment effects on Aβ pathology. Further investigation into the effect of DHA on Aβ 
pathology in Tg2576 mice is thereby required, ideally using large cohorts.
3.5 Experiment 3: Lipid analysis of brains
3.5.1 Introduction
The aim of this experiment was to profile the fatty acid composition of the brain in 16-month 
old Tg2576 and WT mice in order to investigate the effect of the APPswe mutation and 
dietary DHA supplementation. Firstly, lipid analysis was important to discover whether 
composition of fatty acids in the brain was altered in Tg2576 mice relative to WT mice. 
Although it is well documented that AD patients have markedly reduced levels of DHA 
[22:6ω-3] in the brain relative to aged-matched non-demented controls (e.g. Söderberg et al.,
1991), this was not reported in the frontal cortex of 20 to 22.5 month old Tg2576 mice fed a 
standard chow diet relative to WT mice (Calon et al., 2004, 2005). Similarly, levels of 
arachidonic acid (ARA [20:4ω-6]), linoleic acid (LA [18:2ω-6]), docosapentaenoic acid 
(DPA [22:5ω-6]), docosatetraenoic acid (DTA [22:4ω-6]), eicosapentaenoic acid (EPA 
[20:5ω-3]) and the ω-3/ω-6 ratio remain unaltered in the frontal cortex of aged Tg2576 mice 
(Calon et al., 2004, 2005; Lim et al., 2005). It was therefore hypothesised that Tg2576 mice 
would not have altered fatty acid composition in the brain relative to WT mice.  
Determination of any transgene-deficits was particularly important for the interpretation of 
behavioural results in this chapter. For example, numerous studies have shown a loss of DHA 
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in the brain has been associated with cognitive dysfunction in AD (e.g. Pettigrew et al.,
2001), in the ageing human population (e.g. Lauritzen et al., 2001) and in rodents (e.g. 
Gamoh et al., 1999; Greiner et al., 1999; Carrie et al., 2000; Moriguchi, Greiner & Salem,
2000; Ikemoto et al., 2001). As outlined in chapter 1, it is postulated that a loss of DHA has 
this effect because DHA plays an essential role in brain maintenance, structure and function. 
For example, DHA is the main PUFA comprising neuronal membrane phospholipids and is 
particularly concentrated in synaptic membranes, myelin sheaths, synaptic vesicles, 
astrocytes and growth cones (e.g. Horrocks & Farooqui, 2004). The brain is primarily 
composed of lipids, accounting for approximately 50 to 60% of the dry weight of the human 
brain, with DHA accounting for approximately 8% (Lauritzen et al., 2001; Muskiet et al.,
2006). Furthermore, DHA accounts for 10 to 20% of total brain fatty acids in the adult human 
brain and over 17% in the rodent brain (Hamano et al., 1996; McNamara & Carlson, 2006). 
Alterations to DHA levels in the brain can therefore have a detrimental effect.
Secondly, lipid analysis of the brain was particularly important to ensure that dietary 
supplementation of DHA was incorporated into the brain fractions. Several studies have 
shown that DHA levels are increased in the frontal cortex of Tg2576 and WT mice as a result 
of 0.6% DHA supplementation (Calon et al., 2004, 2005; Lim et al., 2005). This pattern 
however has only been reported significant relative to DHA-deficient mice (induced by 
DHA-depleted diet), not relative to mice fed a standard diet. It would therefore be interesting 
to examine whether a diet supplemented with DHA would significantly increase DHA levels 
in the cortex of Tg2576 and WT mice relative to mice fed a suitable baseline control diet. 
Furthermore, it would be interesting to examine the effect of this diet on other fatty acids in 
the brain, as several studies have shown DHA deficiency and supplementation to alter levels 
of omega-6 PUFAs ARA, LA, DPA and DTA, as well as omega-3 PUFA EPA, in the brain 
of Tg2576 and WT mice (Calon et al., 2004, 2005; Lim et al., 2005). Based on previous 
evidence that brain levels of DHA are sensitive to dietary DHA intake, it is hypothesised that 
DHA supplementation would increase DHA levels in the brain of Tg and WT mice. Since 
omega-3 PUFA DHA competes with omega-6 PUFA for incorporation into the brain, it is 
also hypothesised that DHA supplementation would reduce omega-6 PUFA levels and the ω-
6/ω-3 ratio.
Confirmation of dietary-induced alterations to fatty acid composition in the brain was 
particularly important for the interpretation of behavioural results. For example, Arendash et 
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al. (2007) argued that an omega-3 PUFA supplemented diet failed to enhance cognitive 
performance in APPswe/PS1 transgenic mice due to unaltered omega-3 and omega-6 PUFA 
levels in the brain relative to mice fed a standard diet, suggesting a lack of omega-3 PUFA 
incorporation into the brain. A lack of DHA incorporation into the brain may therefore 
explain the limited effects of DHA supplementation on behaviour and pathology in 
experiments 1 and 2.
3.5.2 Methods
Analysis of brain fatty acids were carried out on cortex samples from 16 month old Tg2576 
and WT mice fed the DHA and oil blend diets from 4 months of age. The methodology used 
to analyse lipids in the brain was the same as detailed in the lipid analysis of diet samples 
featured in chapter 2, section 2.3. In order to collect brain samples, mice were culled by 
cervical dislocation. The brain was removed immediately and maintained on ice while 
dissecting the cortex, hippocampus and cerebellum. The dissected tissue samples were snap-
frozen in liquid nitrogen and stored at -80ºC until ready to be analysed. Lipid analysis was 
carried out on 3 mice from each experimental group (Tg DHA n=3, Tg OB n=3, WT DHA 
n=3, WT OB n=3). Statistical analyses of fatty acid levels were carried out using an ANOVA 
with genotype (Tg, WT) and diet (OB, DHA) as between-subject factors. Tests of simple 
main effects followed-up significant interactions.
3.5.3 Results
Figure 3.8 presents the percentage of main fatty acid classes and the ω-3/ω-6 ratio of cortex 
samples analysed by lipid analysis from 16-month old Tg2576 and WT mice fed the DHA 
and oil blend diet. All groups revealed that saturated fatty acids composed the highest 
percentage of fatty acids in the cortex, followed closely by a relatively high level of 
polyunsaturated acids, and smaller levels of monounsaturated fatty acids. All groups also
showed a higher percentage of total omega-3 PUFAs than total omega-6 PUFAs. Statistical 
analysis using an ANOVA with between-subject factors of genotype (Tg, WT) and diet 
(DHA, OB) revealed no main effect of genotype on any of these values (smallest, 
F(1,8)=4.769, p>0.05). Analysis also revealed that the total percentage of saturated fatty acids 
and polyunsaturated fatty acids were unaffected by diet (smallest, F(1,8)=1.419, p>0.10). 
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However, DHA supplementation significantly increased the total percentage of 
monounsaturated fatty acids relative to mice fed the oil blend diet (F(1,8)=8.425, p<0.05).
As expected, total omega-3 and omega-6 PUFAs were altered as a factor of diet. Results 
revealed mice fed the DHA diet had significantly higher levels of omega-3 PUFA 
(F(1,8)=109.747, p<0.001) and significantly lower levels of omega-6 PUFA (F(1,8)=520.044, 
p<0.001) relative to mice fed the oil blend diet. This significant effect of diet was also
reflected in the ω-3/ω-6 ratio (F(1,8)=383.839, p<0.001), which ranged from 1.44:1 to 1.53:1 
in mice fed the oil blend diet and 3.88:1 to 3.31:1 in mice fed the DHA diet. Analysis of these 
ratios revealed a significant genotype by diet interaction (F(1,8)=9.691, p<0.05). Following 
up this interaction, a test of simple main effects revealed WT DHA mice differed 
significantly from Tg DHA mice (F(1,8)=14.03, p<0.01) and WT OB mice (F(1,8)=135.78, 
p<0.001), and Tg DHA mice differed significantly from Tg OB mice (F(1,8)=257.75, 
p<0.001). This pattern of results is clearly displayed in Figure 3.8.
Figure 3.8 Main fatty acids classes and ω-3/ω-6 ratio in the cortex of Tg and WT mice at 16 months 
fed the DHA or oil blend diet. Results are presented as mean percentages of total fatty acids ± S.E.M. 
Significant effect of diet, * p<0.05, *** p<0.001; significant genotype by diet interaction ♦ p<0.05.
Table 3.2 presents the percentage of main fatty acids detected in cortex samples from 16-
month old Tg2576 and WT mice fed the DHA and oil blend diet, indicating significant 
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effects of genotype and diet. No main effects of genotype were observed in fatty acid 
composition except for levels of 18:2ω-6 (F(1,8)=26.672, p<0.001), which was increased as a 
function of Tg status. Statistical analysis revealed significantly higher percentages of 20:3ω-3
(F(1,8)=439.185, p<0.001), 20:5ω-3 (F(1,8)=816, p<0.001), 22:5ω-3 (F(1,8)=180.899, 
p<0.001), 18:1ω-9 (F(1,8)=26.969, p<0.001) and 18:2ω-6 (F(1,8)=10.714, p<0.05) in mice 
fed the DHA diet than mice fed the oil blend diet. Of particular importance, DHA 
supplementation significantly increased the percentage of 22:6ω-3 DHA levels in the cortex 
(F(1,8)=67.714, p<0.001) by ~5% of total fatty acids. Analysis also revealed DHA 
supplementation significantly lowered percentages of 18:1ω-7 (F(1,8)=12.566, p<0.01), 23:0
(F(1,8)=145.690, p<0.001), 20:4ω-6 (F(1,8)=358.385, p<0.001) and 22:4ω-6
(F(1,8)=3201.066, p<0.001) in mice relative to the oil blend diet. Importantly, the observed 
reduction in arachidonic acid 20:4ω-6 (by 4.6-5.4%) and docosatetraenoic acid 22:4ω-6 (by 
1.5-1.9%) was as expected.
Table 3.2 Fatty acid composition of cortex samples from 16 month-old Tg2576 and WT mice fed the 
DHA or OB diet. Presenting the main fatty acids (values >0.1%), represented as mean percentage of 
total fatty acids  S.E.M. 
Fatty acids Tg OB WT OB Tg DHA WT DHA
Hexadecanoic acid 16:0 19.2 ± 0.7 20.0 ± 1.0 20.4 ± 0.6 19.2 ± 0.1
Hexadecenoic acid 16:1ω-7 0.3 ± tr. 0.3 ± tr. 0.4 ± tr. 0.4 ± tr.
Octadecanoic acid 18:0 23.9 ± 0.2 23.7 ± 0.3 23.6 ± 0.1 23.5 ± 0.2
Oleic acid 18:1ω-9 *** 14.7 ± 0.2 14.4 ± 0.1 15.6 ± 0.3 16.0 ± 0.3
cis-vaccenic acid 18:1ω-7 ** 3.4 ± tr. 3.3 ± 0.1 3.0 ± 0.1 3.1 ± 0.1
Linoleic acid 18:2ω-6 * † 0.6 ± tr. 0.4 ± tr. 0.6 ± tr. 0.5 ± tr.
Gamma-linolenic acid 18:3ω-6 N.D. N.D. N.D. N.D.
α-Linolenic acid 18:3ω-3 N.D. N.D. N.D. N.D.
Eicosanoic acid 20:0 0.2 ± tr. 0.1 ± tr. 0.2 ± tr. 0.2 ± tr.
Eicosenoic acid 20:1ω-9 0.9 ± tr. 0.8 ± 0.1 0.9 ± 0.1 0.9 ± tr.
Eicosadienoic acid 20:2ω-6 0.1 ± tr. 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
Eicosatrienoic acid 20:3ω-3 *** 0.3 ± tr. 0.3 ± tr. 0.9 ± tr. 0.8 ± tr.
Arachidonic acid 20:4ω-6 *** 11.2 ± 0.1 11.0 ± 0.4 5.6 ± 0.2 6.6 ± 0.2
Eicosapentaenoic acid 20:5ω-3 *** N.D. N.D. 0.4 ± tr. 0.3 ± tr.
Docosanoic acid 22:0 0.2 ± tr. 0.2 ± tr. 0.2 ± tr. 0.2 ± tr.
Docosatetraenoic acid 22:4ω-6 *** 2.7 ± tr. 2.5 ± tr. 0.8 ± tr. 1.0 ± tr.
Docosapentaenoic acid 22:5ω-3 *** 0.1 ± tr. 0.1 ± tr. 0.4 ± tr. 0.3 ± tr.
Docosahexaenoic acid 22:6ω-3 *** 20.3 ± 0.7 21.0 ± 0.8 25.5 ± 0.1 25.3 ± 0.4
Tricosanoic acid 23:0 *** 0.2 ± tr. 0.2 ± tr. N.D. N.D.
Tetracosanoic acid 24:0 0.2 ± tr. 0.1 ± tr. 0.2 ± tr. 0.2 ± tr.
Nervonic acid 24:1 0.9 ± tr. 0.9 ± 0.1 0.9 ± 0.1 1.0 ± tr.
N.D. = not detected, tr. = trace (less than 0.1). Significant effect of diet, * p<0.05, **p<0.01, 
***p<0.001. Significant effect of genotype, † p<0.001.
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3.5.4 Discussion
Fatty acid composition in the cortex did not generally alter as a factor of genotype in Tg2576
mice aged 16 months, corroborating previous reports in the frontal cortex of Tg2576 mice 
aged 20 to 22.5 months fed a standard control diet or high-DHA diet (Calon et al., 2004, 
2005; Lim et al., 2005). However, levels of omega-6 PUFA linoleic acid were significantly 
higher in Tg mice, although this did not alter the total level of omega-6 PUFA or ω-3/ω-6 
ratio in the brain. Transgene effects on fatty acid composition however have been reported 
following intake of DHA-depleted diets, whereby Tg2576 mice were more susceptible to the 
effects of DHA deficiency than WT mice (Calon et al., 2004, 2005; Lim et al., 2005). These 
results suggest that this genotype effect is limited to DHA deficiency, as a genotype effect 
was not reported under normal control conditions or DHA supplementation. These results 
would therefore suggest that in the absence of DHA deficiency, Tg mice can incorporate 
dietary omega-3 PUFA into brain fractions as well as WT mice. This was supported in the 
current study, and in fact, this study interestingly revealed Tg DHA mice had a significantly 
higher ω-3/ω-6 ratio than WT DHA mice. This unexpected increase may be a result of a 
higher intake of DHA diet in Tg mice relative to WT mice. This explanation requires further 
investigation.
The fatty acid composition of the cortex in all mice was primarily composed of SAT, 
followed by PUFA and MUFA. Total SAT and PUFA were unaffected by dietary intake, 
although total MUFA was higher in DHA-fed mice relative to mice fed the oil blend diet 
(primarily driven by higher levels of omega-9 oleic acid). This was interesting as the oil 
blend diet contained higher levels of SAT and MUFA to compensate for the supplementary 
DHA omega-3 PUFA in the DHA diet. In contrast to the results, greater levels of PUFA and 
lower levels of SAT and MUFA was anticipated in the brains of DHA-fed mice. Also 
interestingly, the main PUFA in the cortex of all mice was DHA, despite the absence of DHA 
in the oil blend diet. This therefore suggests the conversion of omega-3 PUFA ALA (present 
in the oil blend diet) to DHA. Consistently, it has previously been reported that DHA levels 
in the brain can be maintained by the sole intake of dietary ALA, through conversion in the 
liver (Rapoport, Rao & Igarashi, 2007).
As predicted, dietary DHA supplementation led to a higher ω-3/ω-6 ratio in the cortex 
relative to mice fed the oil blend diet. Total levels of omega-3 PUFAs were also higher with 
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DHA supplementation, which was primarily contributed by elevations in DHA which 
increased by 5% of total fatty acids. Higher percentages of omega-3 PUFA eicosatrienoic 
acid (ETA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) were also 
observed with DHA supplementation. Interestingly the DHA diet also led to higher levels of 
omega-6 PUFA linoleic acid (LA) and omega-9 oleic acid. As predicted, the DHA diet 
induced lower levels of total omega-6 PUFAs, suggesting that DHA supplementation 
replaced omega-6 PUFA with omega-3 PUFA incorporation into brain phospholipids. This 
pattern of results is consistent with literature demonstrating that omega-3 and omega-6 
PUFAs compete for metabolism and incorporation into brain phospholipids (Russo, 2009). 
The greatest reductions of omega-6 PUFAs were arachidonic acid (ARA) by 4.6-5.4% and 
docosatetraenoic acid (DTA) by 1.5-1.9% of total fatty acids. Lower levels of 18:1ω-7 and 
23:0 were also detected with DHA supplementation. The reduction of ARA and DTA by 
DHA supplementation is consistent with reports which show the reverse effect whereby DHA 
is replaced by ARA and DTA in the brain of mice fed omega-3 PUFA depleted diets 
(Ikemoto et al., 2001; Greiner et al., 2003). Although the increase in DPA with DHA 
supplementation may appear contrary to reports which show an increase in DPA following 
omega-3 PUFA/DHA dietary depletion (Youyou et al., 1986; Salem et al., 2001; Greiner et 
al., 2003; Cole & Frautschy, 2006), these studies report omega-6 PUFA DPA rather than 
omega-3 PUFA DPA. 
In summary, this is the first study in Tg2576 mice which has shown that DHA 
supplementation relative to a suitable baseline diet can increase total omega-3 PUFAs
(particularly DHA) and reduce total omega-6 PUFAs (particularly ARA and DTA) levels in 
the cortex of Tg and WT brains. In contrast, Calon et al. (2004, 2005) and Lim et al. (2005) 
reported that DHA supplementation relative to a control diet did not alter DHA or omega-6
PUFAs ARA, DTA and DPA levels in the frontal cortex of Tg2576 or WT mice. Since their 
control diet contained a higher ω-3/ω-6 ratio (1:5) than the DHA diet (1:7), representing 
greater levels of total omega-3 PUFA or lower levels of total omega-6 PUFA, this may have 
prevented the detection of changes as a result of DHA supplementation since DHA can be 
converted from omega-3 PUFAs ALA or EPA. Studies in Tg2576 mice have however 
reported alterations of DHA, ARA, DTA and DPA levels with dietary DHA depletion, which 
was restored with DHA supplementation (Calon et al., 2004, 2005; Lim et al., 2005; Cole & 
Frautschy, 2006). The lack of transgene effect on fatty acid composition found in this study, 
paired with previous reports of oxidative stress in Tg2576 mice (Smith et al., 1998; Pappolla 
118
et al., 1998; Praticò et al., 2001) together suggest that oxidative stress does not alter brain 
lipids in the Tg2576 model. Since DHA deficiency does alter brain lipids in Tg2576 mice 
(e.g. Calon et al., 2004), these results may suggest that dietary conditions contribute more to 
the loss of brain DHA in AD patients than oxidative conditions (contrary to Reich et al., 
2001), further highlighting the importance of diet in AD. These results also question the 
potential role of Aβ pathology in altering brain lipids, contrary to previous reports 
(Hashimoto et al., 2002, 2005b, 2006).
3.6 Chapter Discussion
The aim of this chapter was to investigate the longitudinal effect of omega-3 PUFA DHA 
dietary supplementation from an early age on spatial memory and Aβ pathology in Tg2576 
mice, relative to a suitable baseline control diet. Prior to the discussion of dietary effects, it 
was important to establish that Tg2576 mice showed a cognitive deficit and Aβ pathology. In 
agreement with the literature surrounding the Tg2576 model, results from experiment 1 
revealed Tg mice to show an age-related decline in spatial memory between 12 and 16 
months of age (Hsiao et al., 1996; Barnes, Hale & Good, 2004). This spatial memory deficit 
in the T-maze FCA task was not observed at 8 months of age, contrary to previous reports in 
this model (Chapman et al., 1999; Barnes, Hale & Good, 2004). Further to behavioural 
testing, brain analysis by ELISA detection confirmed the presence of soluble and insoluble 
forms of Aβ1-40 and Aβ1-42 proteins in the cortex of Tg mice aged 16 months of age. 
Consistent with previous reports, Aβ1-40 levels were higher than Aβ1-42 levels, and 
insoluble isoforms of Aβ were higher than soluble isoforms, which were expected at this age 
(Hsiao et al., 1996; Kawarabayashi et al., 2001). 
Regarding dietary effects on spatial memory, experiment 1 revealed that DHA 
supplementation generally failed to enhance T-maze performance in Tg2576 or WT mice. 
Analysis of data at 16 months however provided some evidence of DHA ameliorating a 
transgene-related performance deficit in Tg mice. The results therefore indicate that DHA 
may provide subtle protection against cognitive decline caused by the APPswe mutation in 
aged Tg2576 mice at 16 months old. This is the first report providing evidence that DHA 
supplementation can reduce behavioural deficits in an AD model relative to a baseline control 
diet. This effect is somewhat supported by Calon et al. (2004) who reported DHA 
supplementation to reduce Morris water maze acquisition deficits in 21-22 month old Tg2576 
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mice, although this was relative to a DHA-depleted diet. Together with the data from 
experiment 1 showing no amelioration of spatial memory deficit at 8 or 12 months as a 
function of diet, this may suggest that DHA may only be effective during advanced stages of 
Aβ pathology. It could be argued that DHA targets plaque pathology which is extensive from 
16 months of age, but scattered and modest at 12 months (e.g. Kawarabayashi et al., 2001; 
Jacobsen et al., 2006).
The results from experiment 2 revealed that dietary DHA failed to significantly alter levels of 
soluble or insoluble Aβ1-40 and Aβ1-42 detected by ELISA in cortex samples of Tg mice
aged 16 months. In contrast, Lim et al. (2005) reported 3-5 month dietary DHA 
supplementation significantly reduced total insoluble Aβ by 77% and Aβ42 levels by ~49.1% 
measured by ELISA in Tg mice aged 22.5 months old compared to mice fed a DHA-depleted 
diet. Furthermore, they reported DHA significantly reduced plaque burden by 40.3%, as well 
as soluble Aβ by 38%, although this latter effect was not significant. It is important to 
consider here however that the lack of significant effects found in experiment 2 may be 
affected by the small number of mice analysed per group, and that future studies should aim 
to examine larger cohorts of mice.
Although the ELISA results in experiment 2 provide no support for previous findings, it is 
important to consider the potential effect of the experimental diets used. For instance, Lim et 
al. (2005) reported a reduction in Aβ pathology by DHA supplementation when compared to 
a diet deficient in DHA. In contrast however, when results were compared to a control diet 
containing 0.09% DHA with a low ω-6/ω-3 ratio of 7:1 (similar to their DHA diet at 5:1), 
DHA failed to reduce total soluble or insoluble Aβ levels, and total Aβ1-40 levels, although a 
significant reduction in total Aβ1-42 levels was observed. This therefore highlights that the 
apparent positive effects of DHA supplementation on Aβ pathology previously claimed by 
Lim et al. (2005) when compared to the DHA-deficient diet was likely driven by the high 
levels of omega-6 PUFA or the excessive ω-6/ω-3 ratio (85:1) rather than the addition of 
dietary DHA per se. In contrast, when compared to the control diet which more accurately 
assessed DHA supplementation, the results show limited evidence that DHA can reduce Aβ 
pathology measures, similar to the results of experiment 2.
However, it is also important to consider the effect of total fatty acid content in the diets 
when comparing the control and high-DHA diet in Lim et al. (2005) study. Here, their control 
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diet contained 11% total fat compared to 6.1% in the DHA diet. It is therefore possible that 
the apparent positive effects of DHA supplementation may be led by the reduction in total 
fatty acids. Some support for this comes from Julien et al. (2010) who reported that a high 
35% fat diet increased Aβ pathology in Tg2576 mice compared to a 5% fat diet. In contrast to 
Lim et al. (2005) study, the DHA and control diets used in this chapter contained an equal 
level of fatty acids, thereby preventing a potential effect caused by differential levels of fatty 
acids in the diets. Under these conditions, DHA supplementation failed to alter Aβ pathology 
in Tg2576 mice.
Studies in other AD models have also shown DHA supplementation to reduce Aβ pathology, 
although it is argued here that the control diet is not suitably designed to assess the sole effect 
of DHA supplementation, but rather the effect of a diet with reduced omega-6 PUFA levels 
or ω-6/ω-3 ratio. For example, Oksman et al. (2006) reported that 3-4 month fish oil 
supplementation (0.4% DHA) reduced Aβ pathology in the APPswe/PS1 model at 10 months 
of age relative to a control diet (0% DHA). Although the study controlled for the total level of 
fatty acids in both diets, the different levels of omega-6 PUFAs (30% and 52%, respectively), 
omega-3 PUFAs (22% and 7%, respectively) and the ω-6/ω-3 ratio (1.41:1 and 8:1, 
respectively), prevented the inference that effects were a result of the omega-3 PUFA or 
DHA supplementation per se rather than the high omega-6 PUFA or ω-6/ω-3 ratio in the 
control diet. 
Similarly, Green et al. (2007) reported that 3-, 6- and 9-month 1.28% DHA supplementation 
(ω-6/ω-3 ratio of 1:1) reduced soluble Aβ levels in the 3xTg mouse model compared to a 
control diet (0% DHA, ω-6/ω-3 ratio 10:1). Since the control diet contained almost double 
the amount of 18:2ω-6, it could be argued that the lower ω-6/ω-3 ratio of the DHA diet 
(driven by the reduced levels of 18:2ω-6) could have driven the Aβ-reducing effect, rather 
than the increased DHA content. Furthermore, this study found that replacement of 
approximately half the DHA content of the DHA diet with omega-6 PUFAs ARA or DPA 
(while maintaining the ω-6/ω-3 ratio at ~1:1) resulted in a loss of Aβ-reducing efficiency 
after 3 months in the DHA-ARA diet and after 6 months in the DHA-DPA diet. This 
highlights the potential impact of increased omega-6 PUFAs, rather than simply an increase 
in DHA levels. These studies therefore highlight how important the experimental design of 
the diets used in this chapter was in order to accurately assess the effect of DHA on 
pathology and behaviour. Our results therefore show that when a diet is supplemented with 
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DHA, relative to a suitable baseline diet with an equal level of total fatty acids and similar 
omega-6 PUFA levels, Aβ pathology is not affected and its affect on behaviour is somewhat 
limited.
The same argument relating to the important influence of experimental diet design can be 
applied to explain discrepancies between the amelioration of a spatial memory deficits by 
DHA supplementation reported in some studies (e.g. Calon et al., 2004) and the less 
convincing effect found in experiment 1. As Calon and colleagues used the same 
experimental diet design as Lim et al. (2005), it could be argued that the positive effect of 
DHA supplementation was driven by the increased levels of omega-6 PUFA and high ω-6/ω-
3 ratio in the DHA deficient diet, rather than the addition of DHA in the DHA diet. 
Unfortunately, this study did not assess behaviour in Tg2576 mice fed the control diet 
containing a similar ω-6/ω-3 ratio, which prevented any potential comparisons to a diet which 
is argued to more accurately assess the effects of DHA supplementation. Similar arguments 
could be made in other AD mouse models investigating dietary DHA supplementation. For 
example, the improved cognition reported by Arsenault et al. (2011) in a 3xTg model by 
DHA supplementation relative to a DHA-depleted diet could again to attributable to the 
lower level of 18:2ω-6 rather than the addition of DHA per se.
The discrepancies between the results of previous studies investigating DHA supplementation 
and the results of experiment 1 and 2 of this chapter could also be caused by differences in 
age or experimental model. For example, this is the first study investigating effects of DHA 
supplementation from an early age during the initial stages of pathological development. 
Since previous studies have failed to examine dietary effects before 17 months of age and our 
study provides no evidence of positive effects at an early age (before 16 months), it is 
therefore possible that DHA is only effective at reducing behavioural deficits during 
advanced stages of pathology. However, since our T-maze experiment failed to detect a 
transgene deficit before 12 months in Tg2576 mice, this needs further investigation using 
more sensitive tests able to detect subtle differences in behaviour at an earlier age. This is 
important as behavioural deficits have been reported from as early as 3 months of age (e.g. 
Hsiao et al., 1996, King et al., 1999). Furthermore, it is also important to assess multiple 
forms of behaviour rather than simply memory as Oksman et al. (2006) reported DHA 
supplementation to reduce exploratory deficits in the APP/PS1 model, but failed to improve 
spatial learning the Morris water maze. Chapter 4 will address this issue, whereby Tg2576 
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mice are examined on a number of tasks from an early age to extend the behavioural profile 
of this model in order to 1) further establish the onset of behavioural deficits in Tg2576 mice, 
and 2) investigate the effect of DHA supplementation of the onset and progression of 
behavioural deficits detected.
The choice of experimental model may also have a large influence on the effect of dietary 
intervention. For example, positive effects of DHA supplementation have been shown in the 
APPswe/PS1 model on behaviour and pathology (e.g. Oksman et al., 2006; Hooijmans et al.,
2007, 2009). Since this model shows an accelerated development of Aβ pathology and 
preferential deposition of Aβ1-42 (Borchelt et al., 1997; Holcomb et al., 1998), it may be 
possible that DHA is particularly effective against reducing Aβ1-42 isoforms or during 
periods of significant pathological development. This could be supported by our results 
which show DHA to be only effective at reducing a spatial memory deficit in aged Tg2576 
mice, during advanced stages of Aβ aggregation and deposition at 16 months. Also 
supporting this theory, Lim et al. (2005) found DHA supplementation to reduce Aβ1-42 but 
not Aβ1-40 relative to both a control and DHA-depleted diet. Furthermore, the Aβ1-42 
protein is more pathogenic or neurotoxic than Aβ1-40 (Wang et al., 1999; McGowan et al.,
2005), which may explain why DHA supplementation appeared more effective in the 
APPswe/model than the Tg2576 model. Positive effects of DHA supplementation have also 
been reported in the 3xTg mouse model (e.g. Green et al., 2007; Ma et al., 2009; Arensault et 
al., 2011). Since Aβ and tau pathologies interact with each other to accelerate pathological 
development in AD, it is possible that part of the positive effect of DHA on reducing Aβ or 
cognitive deficits in this model is attributable to the effects on tau pathology reported in these 
studies. 
Finally, the results of experiment 3 confirmed that brain levels of fatty acids were reflective 
of dietary intake in Tg2576 and WT mice at 16 months, whereby DHA supplementation 
increased DHA levels in the brain with compensatory reductions in omega-6 PUFAs and the 
ω-6/ω-3 ratio. Similar results have been reported following DHA supplementation, although 
these have been limited to a DHA diet relative to a DHA-depleted diet (e.g. Calon et al.,
2004, 2005; Lim et al., 2005; Cole & Frautschy, 2006). Although experiment 3 confirmed 
incorporation of DHA in the brain at 16 months following 12-month DHA supplementation, 
it should be considered whether DHA was incorporated following 4- and 8-month dietary 
DHA supplementation during T-maze assessment at 8 and 12 months of age. It could be 
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argued that DHA was not incorporated into the brain fractions at 8 and 12 months, resulting 
in the lack of dietary effects observed, but incorporated at 16 months which was associated 
with cognitive improvement. However, this argument is unlikely as Lim et al. (2005) 
demonstrated incorporation of DHA into the Tg2576 brain following 3-5 months of 0.6% 
DHA supplementation. Furthermore, Ma et al. (2009) found fish oil supplementation (0.6% 
DHA) improved cognitive performance in the Y-maze after 2 and 3 months on the diet, but 
not after 1 month, suggesting incorporation of dietary fatty acids into the brain from early as 
2 months supplementation. 
Since DHA supplementation failed to significantly alter Aβ levels and yet some cognitive 
deficits were reduced, these results suggest that DHA may have improved cognitive or 
neuronal processes, or targeted pathological mechanisms such as neuroinflammation or 
oxidative stress. DHA supplementation may therefore have provided neuroprotection against 
Aβ-induced neurotoxicity, inflammation or oxidative damage. In support of this, in vitro
studies have shown a neuroprotective effect of DHA in neuronal cells by reducing apoptosis 
and increasing cell viability (Akbar et al., 2005; Florent et al., 2006). In particular, this may 
be caused by the release of the DHA-metabolite neuroprotectin D1, which has been shown to 
protect against oxidative stress-induced apoptosis (Mukherjee et al., 2004). Furthermore, in 
vivo studies have shown DHA supplementation to improve synaptic membrane fluidity, 
reduce neuronal apoptotic products, lower lipid peroxide and ROS levels, and increase 
glutathione levels and glutathione reductase activity (Suzuki et al., 1998; Hashimoto et al.,
2002, 2005b, 2006). Similar results have also been shown in the Tg2576 model including 
reduced postsynaptic marker loss, apoptosis, caspase activation and oxidative stress (Calon et 
al., 2004, 2005; Cole & Frautschy, 2006). However, it is important to note that these in vivo
results were relative to DHA-depletion, so these effects may not be applicable to our study.
In conclusion, the results of this chapter suggest that dietary DHA supplementation had mild 
effects in reducing a spatial memory deficit in Tg2576 mice, which was relatively consistent 
with the lack of effect observed on Aβ pathology. The contrasting results of previous studies 
were likely attributable to their choice of control diet which was generally high in omega-6
PUFAs, depleted in omega-3 PUFAs, contained unequal levels of total fatty acids, and/or 
contained an excessive ω-6/ω-3 ratio. Since our study controlled for these factors, the results 
together suggest that DHA is only effective in robustly reducing transgene-related deficits 
and pathology when compared to a particularly poor diet. The observation of some positive 
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effects in reducing spatial memory deficits at 16 months may suggest that longitudinal DHA 
supplementation is particularly effective, or that DHA supplementation is effective during 
stages of advanced pathological development or during times of great cognitive dysfunction. 
However, it is argued that use of the T-maze FCA task, which had limited sensitivity in 
detecting transgene deficits at an early age, may have prevented the detection of more subtle 
dietary effects. It remains possible that a broader assessment of learning and memory may be 
more sensitive to dietary effects during stages of early pathological development. This was 
assessed in chapter 4. Since DHA supplementation failed to alter Aβ levels, it was 
hypothesised that the changes in behaviour caused by DHA supplementation were likely 
attributable to more general effects on cognitive or neuronal function, or a reduction in other 
pathological processes in the Tg2576 model such as oxidative stress or neuroinflammation. 
Further research is required to investigate this theory using a suitable baseline control diet.
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Chapter 4
The effect of dietary omega-3 PUFA docosahexaenoic acid (DHA) 
supplementation on the behavioural phenotype of Tg2576 mice
4.1 Introduction
As a follow-up study to chapter 3, the main aim of the experiments reported in this chapter 
was to test the hypothesis that dietary DHA supplementation would improve the behavioural 
phenotype of Tg2576 mice when administered chronically from an early age. In addition, the 
selection of behavioural tests was expanded to include measures of spatial memory, anxiety 
and executive function which may be sensitive in detecting transgene-related deficits and diet 
effects.
Results from epidemiological studies highlight the importance of assessing intervention 
during early stages of disease development. For example, the results of the Rotterdam study 
reported an association between lifelong dietary omega-3 PUFA intake and reduced risk of 
early-stage (2 years after non-demented baseline) AD and dementia cases (Kalmijn et al., 
1997a). In contrast, the results from the Rotterdam study at a later follow-up revealed no 
association in later-stage AD cases, 6 and 9.6 years after baseline (Engelhart et al., 2002; 
Devore et al., 2009). Devore et al. (2009) therefore suggested that omega-3 PUFAs may be 
protective against very early stages of dementia, potentially by targeting early pathological 
mechanisms or because pathology becomes too advanced in later stages to be substantially 
attenuated by omega-3 PUFAs. Supporting this, Devore et al. (2009) analysed the results 
from the Rotterdam study and found a modest but non-significant association (26% risk 
reduction) during short-term follow up (8 years after baseline), but no association (16% risk 
reduction) during long-term follow-up (9-14 years after baseline).
Westerman et al. (2002) reported the presence of soluble Aβ from 4 to 5 months of age in 
Tg2576 mice, which became significant at 6 to 7 months of age. Furthermore, studies have 
reported a reduction in dendritic spine density, impaired LTP and a deficit in basal synaptic 
transmission from 4 months of age in Tg2576 mice (Lanz, Carter & Merchant, 2003; 
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Jacobsen et al., 2006). The early manifestation of these transgene-related deficits highlights 
the need for earlier intervention. Little is understood about these early changes and their 
significance in the development of Aβ pathology and the onset of cognitive impairment in 
Tg2576 mice. Nevertheless, interventions that may interact with these early stages of 
neuronal pathology may have more profound effects on cognition. The experiments reported 
in this chapter therefore used a dietary supplementation procedure implemented from 2 
months of age, when no behaviour or synaptic alterations have been observed in this model 
(e.g. Hsiao et al., 1996; Chapman et al., 1999; Lanz, Carter & Merchant, 2003; Jacobsen et 
al., 2006).
In order to accurately examine the effect of dietary omega-3 PUFA DHA supplementation, 
the experimental design of the DHA-rich and baseline control diet was an important 
consideration of the study. The same experimental diet design as chapter 3 was employed, 
whereby the baseline control diet was designed to have an equal level of total fat and total 
omega-6 PUFA content as the DHA-rich diet. Furthermore, the control diet was designed to 
be depleted in DHA but not omega-3 PUFAs, whereby levels of other omega-3 PUFAs were 
similar between diets. The resulting difference in the ω-6/ω-3 ratio was therefore attributable 
to the DHA content in the diets, and importantly, was not excessive. This design should 
therefore accurately examine the effect of DHA supplementation. In contrast, previous 
studies have provided evidence that DHA supplementation can ameliorate behavioural 
deficits, synaptic deficits and Aβ pathology relative to feeding a poor diet low in omega-3 
PUFAs and high in omega-6 PUFAs, with an excessive ω-6/ω-3 ratio (e.g. Calon et al., 2004, 
2005; Lim et al., 2005; Cole & Frautschy, 2006). This will be the first study to accurately 
examine the effects of DHA supplementation relative to a suitable baseline diet, and the first 
study to investigate early DHA intervention in Tg2576 mice.
In order to extend the behavioural profile of the Tg2576 model and assess the effect of 
dietary DHA supplementation, a battery of behavioural tasks were used to assess spatial 
memory, anxiety and executive function. Principally, spatial memory tasks were selected as 
this remains an important memory domain affected in mouse models of AD pathology. A 
novel ‘foraging task’ was developed to provide a more comprehensive analysis of spatial 
memory and performance. Further to this, anxiety was assessed using the elevated plus maze 
and marble burying task. These spatial memory and anxiety tests are believed to be 
amygdala- and hippocampal-dependant, and were therefore predicted to show deficits since 
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pathology is well established in these regions. Furthermore, a measure of prefrontal cortex 
(PFC) functioning was also assessed using a mouse-analogue of the biconditional 
discrimination task developed by Haddon & Killcross (2005). Importantly, this was one of 
the few experiments to directly measure PFC function in the Tg2576 model and was the first 
to assess the effect of DHA supplementation on PFC function. It was predicted that this task 
may detect a deficit since pathology is well established in the frontal cortex and PFC function 
is particularly affected in AD patients. Relative to a suitable baseline control diet, it was 
hypothesised that longitudinal dietary supplementation of DHA from an early age would slow 
the onset and reduce the progression of behavioural deficits in Tg2576 mice. 
4.2 Overview of mouse cohort and dietary intervention design used
The experiments in this chapter used one cohort of male Tg2576 transgenic (Tg) and non-
transgenic (wildtype, WT) mice. The cohort of Tg2576 and WT mice used in this chapter was 
generated and maintained as outlined in chapter 2, section 2.2. At 2 months of age, mice were 
taken off standard laboratory mouse chow and were fed experimental diets composed of 
standard mouse chow containing either a 5% DHA-rich oil (DHA; containing 1.86% DHA, 
2.05% total omega-3 PUFA, 1.60% total omega-6 PUFA, and an ω-3/ω-6 ratio of 1.28:1) or a 
5% oil blend (OB; containing 0% DHA, 0.22% total omega-3 PUFA, 2.07% total omega-6
PUFA, and an ω-3/ω-6 ratio of 0.10:1). Importantly, the difference in ω-3/ω-6 ratio was 
caused almost entirely by the DHA content, and the difference in omega-6 PUFA content was 
minimal compared with previous studies investigating DHA supplementation (e.g. Calon et 
al., 2005; Green et al., 2007). Furthermore, the absence of DHA in the control oil blend diet 
was compensated by “neutral” monounsaturated fatty acids and saturated fatty acids. Further 
details concerning these diets are outlined in chapter 2, section 2.3. The experimental and 
control diet design used in this chapter was the same as detailed in chapter 3. It was thought 
that the different diets would not alter body weight in the mice, since this was not found 
between the fish oil diet (containing DHA) and oil blend diet in chapter 5 (see chapter 5, 
section 5.2). The experimental schedule employed for chapter 4 is outlined in Figure 4.1.
Figure 4.1 Experimental schedule employed in c
4.3 Experiment 4: Anxiety measures
4.3.1 Introduction 
This experiment aimed to evaluate
supplementation. This was deemed important as 
including fear-related memory disruption,
anxiety (Hamann, Monarch & Goldstein
2006; Spoletini et al., 2008). The neurological basis of emotional disturbances in AD is 
thought to reflect pathology in the medial temporal and frontal lobes
amygdala and hippocampus (e.g. 
LeDoux, 2006; Maren, 2008; Truitt et al.
these regions, which likely contribute to a range of 
observed in anxiety tests and fear conditioning 
passive avoidance deficits involving memory of footshocks at 
not at the later age of 19 or 22 months
studies have also shown impaired fear conditioning to context and/or auditory cues in 
contextual fear conditioning paradigms in Tg2576 mice
Barnes & Good, 2005; Comery et al.
al., 2007). Although the latter findings were inconsistent across ages, the results suggest 
emotional dysfunction in Tg2576 mice similar to AD patients.
hapter 4.
anxiety in Tg2576 mice and examine the effect of DHA 
AD patients show emotional disturbances 
apathy, depression, agitation, disinhibition and 
, 2000; Lesser & Hughes, 2006; Hollingworth et al.
, particularly in t
LeDoux, 2000; Kim & Jung, 2006; Sotres-Bayon, Cain & 
, 2009). Similarly, Tg2576 mice show pathology in 
emotional-related behaviou
experiments. For example, Tg2576 mice show 
3, 9 and 14 months
(King et al., 1999; King & Arendash, 2002
from 5 months (Dineley et al.
, 2005; Dong et al., 2005; Jacobsen et al., 2006
128
,
he 
ral deficits
, although 
). Several 
, 2002;
; Quinn et 
129
Tg2576 mice also show emotional-related behavioural deficits in anxiety tests such as the 
elevated plus maze which measures abnormal responses to unconditioned aversive or 
anxiogenic stimuli (e.g. Gil-Bea et al., 2007). In this test, the rodent is presented with an 
aversive or anxiogenic element within the elevated plus maze environment (two exposed 
open arms) which induces agoraphobic and inhibitory responses in normal rodents whereby a 
preference for the two ‘safe’ closed arms is observed (Pellow et al., 1985). Abnormal 
responses to the anxiogenic stimuli, such as increased exploratory activity in the open arms, 
correspond to reduced anxiety and behavioural disinhibition. The elevated plus maze is 
therefore a well documented test used to evaluate anxiety and disinhibitory behaviour in 
rodents (Pellow et al., 1985; Ognibene et al., 2005). Behavioural disinhibition is often 
associated with reduced anxiety and is defined as the inability to withhold inappropriate 
responding (Gil-Bea et al., 2007).
Previous studies have reported a deficit at 9 and 17 months of age in Tg2576 mice in the 
elevated plus maze, whereby Tg2576 mice spent increased time in the open arms and showed 
greater open arm entries relative to WT mice (Lalonde et al., 2003; Gil-Bea et al., 2007). 
These results suggest that Tg2576 mice are less anxious than WT mice. Furthermore, 
Ognibene et al. (2005) also reported a non-significant tendency for these deficits to emerge at 
7 to 12 months of age. They also reported a number of ethological measures consistent with 
reduced anxiety, including increased head dipping (exploratory behaviour), less stretch-attend 
postures (risk-assessing behaviour) and increased self-grooming (behavioural disinhibition) 
in the elevated plus maze. However, there are no published reports of behaviour in the 
elevated plus maze at an age earlier than 7 months. This experiment therefore investigated the 
effects of the APPswe mutation on elevated plus maze behaviour at 3 and 10 months of age. 
Based on previous research it was hypothesised that Tg2576 mice would show a transgene-
related deficit in the elevated plus maze.
Supporting these predictions, similar reports of reduced anxiety in the Tg2576 model has 
been shown in the open field test. The open field test is an anxiety test whereby large open 
spaces (an anxiogenic environment for rodents) normally induce agoraphobic and inhibitory 
responses such as reduced exploratory behavior consistent with increased anxiety (Pellow et 
al., 1985). It is well documented however that Tg2576 mice show increased activity in the 
open field test from 3 months, although some reports have been inconsistent (Chapman et al.,
1999; King et al., 1999; King & Arendash, 2002; Lalonde et al., 2003; Deacon et al., 2008, 
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2009). Furthermore, Deacon et al. (2008) reported reduced rearing in the open field at 12 
months, which was supported in the holeboard task. In contrast however, rearing behaviour in 
the open field was reported normal at 3, 8.5 and 21 months and increased at 22 to 23 months 
(Deacon et al., 2008, 2009). Despite these inconsistencies, other measures in the open field at 
the 22 and 23 months were consistent with reduced anxiety, including a higher latency to 
rear, the production of less faecal boli and failure to habituate (Deacon et al., 2009). In 
contrast, Deacon et al. (2008) reported normal defecation, latency to rear, latency to head dip 
and number of head dips in the holeboard test at 12 months. These inconsistencies highlight 
the need for further investigation into the onset and progression of anxiety-related behaviour.
The marble burying task is also frequently used to assess anxiety and screen anxiogenic drugs
in rodents (Nicolas, Kolb & Prinssen, 2006; Crawley, 2008). In this test, rodents are 
presented with glass marbles in a digging medium in which they show spontaneous burying 
of these harmless novel objects (Poling et al., 1981; Archer et al., 1987). Although the normal 
response of burying the majority of marbles is often used as an index of anxiety, its validity 
remains questioned by some (as reviewed in Nicolas, Kolb & Prinssen, 2006). For example, 
some argue that marble burying behavior is dependent upon impulsive behavior or 
locomotory activity. Typically however, an abnormal response of leaving the marbles 
unburied corresponds to reduced anxiety. Since Tg2576 mice have been reported to have 
altered anxiety in tasks such as the elevated plus maze, open field and holeboard task (e.g. 
Lalonde et al., 2003; Deacon et al., 2008, 2009; Ognibene et al., 2005), we used the marble 
burying procedure in this experiment to extend the analysis of anxiety behaviour in Tg2576 
mice.
To date, a review of the literature has presented only one study reporting marble burying 
assessment in Tg2576 mice at 3, 12 and 23 months of age. Here, Deacon et al. (2008) 
reported a lack of transgene-related deficit. However, the background strain of these mice 
differed from the cohort used in these experiments, whereby the Tg2576 cohort were the 
female offspring of Tg2576 hybrid BL6/SJL male mice crossed with F1 BL6/SJL females. In 
contrast, Tg2576 mice in our experiments were maintained by crossing heterozygous Tg2576 
mice to C57BL/6j x SJL F1 mice. These background differences may therefore alter marble 
burying behaviour. Several studies have highlighted the effect of strain differences on 
behaviour, with particular reference to marble burying (Deacon et al., 2006; Thomas et al.,
2009). Furthermore, Lasselle et al. (2008) outlined the important influence of genetic 
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background on the behavioural phenotype of the APPswe transgene in Tg2576 mice in 
particular.  In light of the potential effects of background strain, together with evidence of 
anxiety-related deficits in Tg2576 mice in other tasks, gives cause to predict that Tg2576 
mice would show marble burying deficits.
The second main aim of this experiment was to investigate whether early DHA dietary 
supplementation would modify the onset of anxiety deficits in Tg2576 mice. Although no 
studies have assessed DHA supplementation relative to a suitable baseline diet, several 
studies have shown that DHA improves cognitive function in hippocampal-dependant 
memory tasks including the Morris water maze, Y-maze and the novel object recognition task 
in AD mouse models (e.g. Calon et al., 2004; Hooijmans et al., 2009; Ma et al., 2009; 
Arsenault et al., 2011). In contrast, only one study has assessed DHA supplementation on a 
task related to anxiety. Here, Hooijmans et al. (2009) reported no effect of DHA on open 
field behavior at 8- and 15-month old APPswe/PS1 mice. Marble burying and elevated plus 
maze behaviour has been shown to be dependent on hippocampal function (Deacon & 
Rawlins, 2005; Barkus et al., 2009; Xiang et al., 2011), which has been reported 
dysfunctional in Tg2576 mice (e.g. Hsiao et al., 1996). Based on previous evidence showing 
DHA to reduce hippocampal-dependant memory deficits in AD models (Calon et al., 2004; 
Hooijmans et al., 2009; Ma et al., 2009; Arsenault et al., 2011), it was hypothesised that DHA 
supplementation may reduce a marble burying and elevated plus maze deficit relative to the 
oil blend diet.
4.3.2 Methods
4.3.2.1 Design and subjects
One cohort of male Tg2576 transgenic (Tg) and non-transgenic (wildtype, WT) mice were 
evaluated in the elevated plus maze and marble burying task at two ages. Experimentally 
naïve mice were first tested at approximately 3 months of age, before the onset of plaque 
pathology and major changes in synaptic morphology and function. This cohort was tested 
again at 10 months of age when plaque pathology was developing and where synaptic deficits 
should be clearly manifest. This design therefore investigated transgene- and diet-dependant 
changes at these ages, in addition to whether these changes were age-dependant. When tested 
in the elevated plus maze at 3 months of age, 14 Tg mice received DHA diet (Tg DHA), 14 
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Tg mice received the oil blend diet (Tg OB), 18 WT mice received the DHA diet (WT DHA) 
and 16 WT mice received the oil blend diet (WT OB). Group numbers were the same for the 
marble burying assessment at 3 months, except one Tg DHA mouse was excluded for circling 
behaviour. By the second stage of experimentation at 10 months of age in the elevated plus 
maze, the loss of 12 mice resulted in group numbers of 7 Tg DHA, 12 Tg OB, 15 WT DHA 
and 16 WT OB. These group numbers were the same for the marble burying assessment at 10 
months. The running order of mice was counterbalanced so that one mouse from each 
experimental group was tested after another in the elevated plus maze as far as possible, blind 
to the experimenter. In the marble burying task, running order was counterbalanced so that 
approximately equal numbers of each experimental group was run in each batch (n=4). Mice 
were tested only once at each age.
4.3.2.2 Apparatus
Elevated plus maze
The elevated plus maze (EPM) was constructed from four arms each 40cm long and 6cm
wide in a cross arrangement with a 6cm2 central area, elevated 70cm above the floor. As 
illustrated in Figure 4.2, two arms provide a closed setting and two provide an open setting. 
The closed arms were surrounded by high-sided 15cm tall black Perspex walls, whereas the 
open arms had extremely short 1cm tall clear Perspex walls to prevent falls. The base of the 
maze arms were composed of white laminate wood which were supported by a black metal 
frame. The maze was placed inside a wooden arena (102cm2 and 43cm height) with a
sawdust-covered floor to cushion the mouse in the event of a fall. The apparatus was located 
in quiet and brightly illuminated room. A camera was attached to the ceiling directly above 
the maze, which was connected to a computer, a television monitor and video recorder 
(VCR). The camera input was used to visualise the maze activity on the television monitor 
and each session was recorded using the VCR. Noldus® Ethovision software on the computer
was utilised to collect data using the camera input by ‘manual scoring’ (see procedure).
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Figure 4.2 Elevated plus maze apparatus from two perspectives. A. Front-view, B. Ariel view.
Marble burying test
Each marble burying arena was composed from a large white polycarbonate cage base 41cm 
long, 24.5cm wide and 12.5cm tall, filled with a level compact layer of sawdust 6.5cm deep 
(Figure 4.3). Twenty mixed-colour glass marbles (1.5cm diameter) were placed on top of the 
sawdust layer equally distanced apart in a 4-column by 5-row arrangement. This 
arrangement, in comparison to a grouped-marble arrangement, forced the mice to encounter 
the marbles more frequently and prevented an alternative avoidance response rather than 
burying the aversive stimuli (see Njung’e & Handley, 1991). A transparent Perspex lid 41cm 
long, 27cm wide and 1cm thick was placed securely on top of the cage base to prevent the
mouse from escaping the arena. The lid was placed in a central position allowing for a 
1.25cm gap either side for ventilation. Four marble burying arenas were placed on a table 
elevated 121cm from the floor, allowing 4 mice to be tested during one 30-minute session. A 
camera was attached to the ceiling directly above the arena to allow viewing and recording 
for documentation using a monitor and VCR. Each marble burying arena was photographed 
for documentation using a digital camera at the end of each session.
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Figure 4.3 Marble burying arena and marble arrangement
4.3.2.3 Procedure
Elevated plus maze
Mice were transported to the test room in individual home cages and the experimenter was 
present throughout all sessions in a maintained location. Each mouse received one 5-minute 
session in the maze with free-access, without habituation. The maze was cleaned with 1:20 
dilution of Mr Muscle® Glass Cleaner between sessions to remove odours, urine and 
excrement. Each mouse was placed in the maze so that they faced the left-hand closed arm. 
Noldus© Ethovision software on the computer was used to record mouse activity measures by 
the ‘manual scoring’ method. Here, each arm was assigned a specific keyboard key which 
was pressed upon entry into and exit from each arm. An arm entry was defined as when all 
four paws of the mouse passed the entrance of the arm, and an arm exit was defined as when 
all four paws crossed outside the arm. This criteria matched that used in Lalonde et al. (2003) 
and Ognibene et al. (2005) experiments. Using this methodology, Noldus® Ethovision 
software automatically calculated the total duration spent in each arm and the total number of 
entries into each arm. The accuracy of this manual scoring method was checked for the first 3 
mice tested per session. The total frequency of entries and total duration spent in the open and 
closed arms were calculated. The latency to enter an open arm was also recorded by the 
experimenter on a notepad. Mice which did not enter the open arm at all were assigned a 
latency of 300 seconds (the total time spent in the maze).
135
Marble burying test
Mice were transported to the test room in individual home cages and the experimenter was 
present throughout all sessions out of sight. Each mouse received one 30-minute session in 
the marble burying arena with free-access, without habituation. Each mouse was placed in the 
middle of the arena at the start of the session, and carefully removed after 30 minutes using 
their home-cage cardboard tube to prevent any disturbance to the sawdust and marbles. The 
number of marbles buried/unburied was counted. Figure 4.4 shows two example photographs 
from the marble burying test. Using the criteria used in previous studies, a buried marble was 
defined as a marble covered at least two thirds by sawdust (e.g. Millan et al., 2002; Young et 
al., 2006). An unburied marble was therefore over one third visible on the surface of the 
sawdust layer. Between sessions, the sawdust in the arena was mixed to remove odours trails
and the excrement removed. A handful of old sawdust was replaced with fresh after each 
session. 
Figure 4.4 Example photographs from the marble burying test. A. Example from a WT mouse, 
showing 3 unburied marbles, 17 buried. B. Example from Tg mouse, showing 13 unburied marbles, 7 
buried.
4.3.3 Elevated plus maze results
4.3.3.1 Elevated plus maze results at 3 months of age
Frequency of entries into the open and closed arms
Figure 4.5 shows the mean frequency of entries into the open and closed arms of the EPM for 
each experimental group at 3 months of age. An ANOVA with arm (open, closed), genotype 
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and diet as factors revealed a significant main effect of genotype (F(1,58)=19.960, p<0.001), 
no significant main effect of diet (F(1,58)=0.878, p>0.05) and a significant interaction of 
genotype by diet (F(1,58)=11.547, p<0.001). Statistical analysis also showed a significant 
effect of arm (F (1,58)=58.91, p<0.05), no significant interaction of arm by genotype 
(F(1,58)=3.043, p>0.05), a significant interaction of arm by diet (F(1,58)=7.686, p<0.01), and 
no significant interaction of arm by genotype by diet (F(1,58)=1.750, p>0.05). Follow-up 
tests of simple main effects for the significant arm by diet interaction revealed that frequency 
of entries into both open arms (F(1,60)=5.72, p<0.05) and closed arms (F(1,60)=7.14, 
p<0.01) altered as a consequence of diet. Overall these results are reflected in Figure 4.5, 
whereby all mice show a preference for closed over open arms and that this natural 
preference was exaggerated with DHA supplementation. However, as inspection of Figure 
4.5 suggests, this appears to be predominately driven by the Tg OB group that showed little 
preference for the closed arms relative to open arms.
Figure 4.5 Mean frequency of entries into open and closed arms of the EPM at 3 months in Tg and 
WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M (standard error of the mean).
Duration of time spent in open and closed arms
Figure 4.6 shows the duration of time spent in the open and closed arms of the EPM for each 
experimental group at 3 months of age. The figure shows that all mice had a preference for 
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closed over open arms. Interestingly, Tg mice appear to show a heightened normal response 
by spending more time in the closed arm. Furthermore, the time spent in the open arm 
appears reduced by DHA supplementation in Tg mice compared to all groups. An ANOVA
with arm, genotype and diet as factors revealed a significant main effect of genotype 
(F(1,58)=19.960, p<0.001), no significant main effect of diet (F(1,58)=0.878, p>0.05) and a 
significant interaction of genotype by diet (F(1,58)=11.547, p<0.001).
Figure 4.6 Mean duration spent in open and closed arms of the EPM at 3 months in Tg and WT mice 
fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
Statistical analysis also showed a significant effect of arm (F (1,58)=889.273, p<0.001), a 
significant interaction of arm by genotype (F(1,58)=20.536, p<0.001), no significant 
interaction of arm by diet (F(1,58)=3.417, p>0.05), and a significant three-way interaction of 
arm by genotype by diet (F(1,58)=6.332, p<0.05). Follow-up tests of simple main effects and 
interactions revealed a significant genotype effect for both open and closed arm measures of 
duration (F(1,58)=6.332, p<0.05 and F(1,58)=6.332, p<0.001, respectively), a significant 
effect of diet for the open arm measure (F(1,58)=5.15, p<0.05), and a significant genotype by 
diet interaction for the closed arm measure (F(1,58)=10.23, p<0.05). Following up this 
interaction, tests of simple main effects revealed a significant difference between Tg OB and 
WT OB mice (F(1,58)=35.78, p<0.001) and a significant difference between Tg DHA and Tg 
OB (F(1,58)=9.99, p<0.01). Overall these results are reflected in Figure 4.6, whereby Tg 
groups appear to show a heightened normal response, supported by the main effect of 
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genotype in both open and closed arms. However, this appears to be predominately driven by 
the Tg DHA group, which is supported by the genotype by diet interaction. The results also 
reveal that the time spent in the open arm is lowered as a consequence of DHA, although this 
appears to be numerically driven by the Tg DHA group. 
Latency to enter an open arm
Figure 4.7 shows the mean latency to enter an open arm of the EPM for each experimental 
group at 3 months of age. Transgenic mice, particularly the oil blend group, appear to show 
longer latencies to enter the open arms compared to WT mice. Statistical analysis using an 
ANOVA with genotype and diet as factors revealed a significant main effect of genotype 
(F(1,58)=7.048, p<0.01), no significant main effect of diet (F(1,58)=1.220, p>0.05) and no 
significant interaction of genotype by diet (F(1,58)=0.320, p>0.05).
Figure 4.7 Mean latency to enter an open arm of the EPM at 3 months in Tg and WT mice fed the 
DHA or oil blend diet. Values are mean scores ± S.E.M.
In summary, Tg mice differ significantly from WT group at 3 months in the EPM. Although 
all mice showed a preference for the closed over open arm (both in duration spent and 
frequency of entries), as expected, some results indicate that DHA supplementation could 
exaggerate this preference.
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4.3.3.2 Elevated plus maze results at 10 months of age
Frequency of entries into the open and closed arms
Figure 4.8 shows the mean frequency of entries into the open and closed arms of the EPM for 
each experimental group at 10 months of age. The graph shows that all mice show a 
preference for the closed over open arms, although this pattern is much weaker in the Tg OB 
group. An ANOVA with arm, genotype and diet as factors revealed no significant main effect 
of genotype (F(1,46)=1.240, p>0.05), a significant main effect of diet (F(1,46)=4.787, 
p<0.05) and no significant interaction of genotype by diet (F(1,46)=3.010, p>0.05). Statistical 
analysis also showed a significant effect of arm (F (1,46)=67.379, p<0.001), no significant 
interaction of arm by genotype (F(1,46)=2.789, p>0.05), no significant interaction of arm by 
diet (F(1,46)=2.844, p>0.05), and no three-way interaction of arm by genotype by diet 
(F(1,46)=1.417, p>0.05).
Figure 4.8 Mean frequency of entries into open and closed arms of the EPM at 10 months in Tg and 
WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
Duration of time spent in open and closed arms
Figure 4.9 shows the duration of time spent in the open and closed arms of the EPM for each 
experimental group at 10 months of age. The figure shows that all mice preferred to spend 
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time in the closed arms, although Tg OB mice showed less preference, indicating that DHA 
ameliorated a deficit in Tg mice. An ANOVA with arm, genotype and diet as factors revealed 
a significant main effect of genotype (F(1,46)=5.052, p<0.05), no significant main effect of 
diet (F(1,46)=0.240, p>0.05) and no significant interaction of genotype by diet 
(F(1,46)=2.996, p>0.05). Statistical analysis also showed a significant effect of arm (F 
(1,46)=98.296, p<0.001), no significant interaction of arm by genotype (F(1,46)=0.303, 
p>0.05), a significant interaction of arm by diet (F(1,46)=4.143, p<0.05), and a significant 
three-way interaction of arm by genotype by diet (F(1,46)=6.518, p<0.05).
Follow-up tests of simple main effects and interactions revealed a significant diet effect for 
the open arm (F(1,46)=4.18, p<0.05) but a non-significant effect of diet for the closed arm
(F(1,46)=3.48, p>0.05), and a significant genotype by diet interaction for both the open and
closed arm measure (F(1,46)=5.40, p<0.05 and F(1,46)=7.11, p<0.05, respectively). 
Following up these interactions, a test of simple main effects revealed Tg OB mice spent 
significantly more time in the open arms than WT OB mice (F(1,46)=8.90, p<0.01) and Tg 
DHA mice (F1,46)=9.18, p<0.01), and Tg OB spent significantly less time in the closed arms 
than Tg DHA mice (F(1,46)=8.90, p=0.005). Figure 4.9 clearly depicts this difference 
between Tg groups and the overall preference for closed over open arms in all mice. The 
significant diet effect in the open arm appears to be driven by the Tg OB group, as is the main 
effect of genotype.
Figure 4.9 Mean duration spent in open and closed arms of the EPM at 10 months in Tg and WT mice 
fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
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Latency to enter an open arm
Figure 4.10 shows the mean latency to enter an open arm of the EPM for each experimental 
group at 10 months of age. This figure shows that mice had similar latencies, except WT 
mice fed the OB diet had longer latencies. Statistical analysis using an ANOVA with 
genotype and diet as factors revealed no significant main effect of genotype (F(1,46)=0.154, 
p>0.05), no significant main effect of diet (F(1,46)=1.241, p>0.05) and a significant 
interaction of genotype by diet (F(1,46)=4.902, p<0.05). Following-up this interaction, a test 
of simple main effects showed WT OB to have significantly longer latencies than WT DHA 
mice (F(1,46)=4.20, p<0.05).
Figure 4.10 Mean latency to enter an open arm of the EPM at 10 months in Tg and WT mice fed the 
DHA or oil blend diet. Values are mean scores ± S.E.M.
In summary, at 10 months of age, both Tg and WT mice show a preference for the closed 
over open arms (both in duration spent and frequency of entries). However, this effect was 
considerably weaker in Tg2576 mice on the oil blend diet. DHA supplementation generally 
restored performance of Tg mice to that of control WT mice. 
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4.3.4 Marble burying test results
4.3.4.1 Marble burying results at 3 months of age
Figure 4.11 shows the mean number of unburied marbles in the marble burying test for each 
experimental group at 3 months of age. This figure shows that Tg OB mice showed abnormal 
marble burying compared to WT mice, and that DHA ameliorated this deficit. Statistical 
analysis using an ANOVA with genotype and diet as factors revealed a significant main 
effect of genotype (F(1,57)=11.759, p<0.001), no significant main effect of diet 
(F(1,57)=3.361, p>0.05) and a significant interaction of genotype by diet (F(1,57)=5.940, 
p<0.05). Following-up this interaction, a test of simple main effects revealed Tg OB left 
significantly more marbles unburied than WT mice (F(1,57)=16.44, p<0.001) and Tg DHA 
mice (F(1,57)=8.75, p<0.01). This effect is clearly illustrated in Figure 4.11, whereby Tg OB 
mice left an average of approximately 13 marbles unburied in contrast to ~7 marbles in the 
Tg DHA group which were comparable to WT mice (~6 and 5 unburied marbles). This effect 
was also demonstrated in ratio values (= [mean number of unburied marbles / total number of 
marbles available], where 0 = all marbles unburied, 0.5 = equal level of buried and unburied 
marbles, and 1 = all marbles buried). Here, Tg DHA = 0.35, Tg OB = 0.63, WT DHA = 0.28 
and WT OB = 0.24, thereby showing that all groups except Tg OB have a higher buried to 
unburied marble ratio. These results indicate that the main effect of genotype was likely 
driven by the Tg OB group. 
Figure 4.11 Mean number of unburied marbles (20 marbles in total) in the marble burying test at 3
months in Tg and WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
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4.3.4.2 Marble burying results at 10 months of age
Figure 4.12 shows the mean number of unburied marbles in the marble burying test for each 
experimental group at 10 months of age. Statistical analysis using an ANOVA with genotype 
and diet as factors revealed a significant main effect of genotype (F(1,46)=5.507, p<0.05), no 
significant main effect of diet (F(1,46)=1.325, p>0.05) and no significant interaction of 
genotype by diet (F(1,46)=1.243, p>0.05). These effects are clearly displayed in Figure 4.12, 
whereby Tg groups had similar results (~11 unburied marbles) and WT groups had relatively 
similar results (~5-7 unburied marbles). The diet appeared to have no effect in the Tg mice, 
although interestingly, DHA appeared to non-significantly alter WT performance. This effect 
is clearly illustrated in ratio values (number of unburied marbles/total marbles) whereby Tg 
DHA = 0.58, Tg OB = 0.55, WT DHA = 0.46 and WT OB = 0.27, thereby showing that Tg 
groups similarly had a higher buried to unburied marble ratio, and DHA appears to alter WT 
behaviour to deviate from the normal higher unburied to buried marble ratio.
Figure 4.12 Mean number of unburied marbles (20 marbles in total) in the marble burying test at 10
months in Tg and WT mice fed the DHA or oil blend diet. Values are mean scores ± S.E.M.
4.3.5 Discussion
The results from the elevated plus maze study at 3 and 10 months of age showed that WT 
mice entered the closed arms more frequently than the open arms and spent more time in the 
closed arms during the 5-minute test (see also, Pellow et al., 1985; Lalonde et al., 2003). 
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Tg2576 mice however showed an abnormal pattern of EPM behaviour at both 3 months and 
10 months of age, whereby preference for the closed arms was reduced compared to WT 
mice. This is consistent with other evidence for reduced anxiety and disinhibitory behaviour 
in Tg2576 mice (Lalonde et al., 2003; Ognibene et al., 2005). 
Although Tg2576 mice showed behaviour associated with reduced anxiety, this was not 
consistently shown at 3 months. For example, young Tg mice entered the closed arms 
significantly less than WT mice, consistent with reduced anxiety, however, they spent 
significantly more time in the closed arms and less in the open arms. This latter result is 
consistent with a normal response of increased anxiety, which has been demonstrated in other 
AD models but not the Tg2576 model (e.g. España et al., 2010). Similarly, Tg mice had 
longer latencies to enter the open arm, consistent with a normal anxiety response. 
At 10 months of age, Tg2576 mice showed a more consistent pattern of reduced anxiety 
across measures. For example, Tg mice fed the oil blend diet showed more entries into the 
open arms and fewer entries into the closed arms, in contrast to WT mice, which displayed a 
clear preference for the closed arms. Consistent with the arm entries measure, Tg OB mice 
spent more time in the open arms and a similar amount of time in the closed arms compared 
to WT groups. Tg mice also had shorter latencies to enter the open arm than WT mice fed the 
oil blend diet. Overall therefore, Tg mice showed altered anxiety at both 3- and 10-months 
compared to WT mice, and the pattern of altered anxiety is consistent with previous reports in 
the elevated plus maze in Tg2576 mice aged 10 months (Lalonde et al., 2003; Ognibene et
al., 2005).
With regards to dietary effects, DHA supplementation appeared to enhance the natural 
preference for the closed arms at 3 months of age. More specifically, Tg mice fed the DHA 
diet showed reduced entries to the open arms and increased entries into the closed arms. A 
significant effect of diet was also found for the time spent in the open arm, which was 
reduced with DHA supplementation. This effect appeared to be particularly driven by the Tg 
DHA group, suggesting a beneficial effect of DHA supplementation. At 10 months of age, a 
main effect of diet was observed in the frequency of open and closed arm entries. 
Furthermore, Tg OB mice differed significantly from Tg DHA mice in the time spent in both 
the open and closed arms. Overall therefore, this study provides evidence that DHA 
supplementation can reduce anxiety-related deficits associated with the APPswe mutation in 
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Tg2576 mice. This effect was most apparent at 10 months of age when amyloid pathology is 
clearly evident in cortical and subcortical brain regions (see also Calon et al., 2004, 2005; 
Lim et al., 2005). Furthermore, this is the first experiment to provide evidence that DHA 
supplementation can ameliorate transgene-related anxiety deficits relative to a suitable 
baseline control diet. These findings compliment other published work showing positive 
effects of DHA supplementation on behaviour in AD mouse models (Calon et al., 2004; 
Hooijmans et al., 2009; Ma et al., 2009; Arsenault et al., 2011).
The results of the marble experiment showed a significant effect of genotype at both at 3 and 
10 months of age, whereby Tg mice left significantly more marbles unburied than WT mice. 
This study therefore provides evidence that the APPswe mutation leads to behavioural 
deficits as early as 3 months of age. Importantly, WT mice on the control diet showed a 
higher ratio of buried to unburied marbles, which is consistent with normal marble burying 
behaviour in rodents (e.g. Deacon, 2006; Nicolas, Kolb & Prinssen, 2006). Furthermore, this 
behaviour is consistent across the ages whereby the ratio values (unburied/total marbles) for 
WT mice fed the control diet were 0.24 at 3 months of age and 0.27 at 10 months. Comparing 
the ratio values of Tg mice on the control oil blend diet also showed similar values at the two 
ages, with 0.63 at 3 months, and 0.55 at 10 months of age. This transgene-dependant deficit, 
consistent with a reduction in anxiety, was therefore non-progressive and age-independent.
This study is the first experiment to report a marble burying deficit in Tg2576 mice and 
stands in contrast to a previous report by Deacon et al. (2008) who tested similar mice at 3, 
12 and 23 months of age. However, it is important to consider methodological differences 
that may explain the contrasting results. Firstly, mice at 3 and 12 months of age in Deacon 
and colleagues study were tested on a marble burying experiment using 12 marbles, in 
contrast to the 20 marbles used in our methodology. This lower number of marbles may have 
reduced their ability to detect genotypic changes. Secondly, and of particular importance, 
strain differences were reported by Deacon et al. (2008) which may have accounted for the 
differing results. The potential effect of background strain differences was demonstrated by 
directly comparing WT results in this experiment, where WT mice buried 15 marbles, to 
results from Deacon et al. (2008) at 23 months of age in the 20-marble task, where WT mice 
buried 12 marbles. The relatively low number of buried marbles reported by Deacon and 
colleagues may therefore account for the lack of genotype effect. Validation of a marble 
burying deficit in Tg2576 mice with a background strain identical to the cohort used in this 
146
experiment therefore needs further investigation, and is assessed in chapter 5. It is important 
to note however, that the reduced anxiety-related deficit observed in this experiment is 
consistent to reports of reduced anxiety in Tg2576 mice in other tasks such as the elevated 
plus maze (e.g. Gil-Bea et al., 2007).
Although no significant main effect of diet was observed in the marble-burying experiment at 
both ages, a significant genotype by diet interaction was reported at 3 months of age. Tg OB 
mice differed from all groups and thus provided evidence that DHA supplementation reduced 
the marble burying deficit in young but not aged Tg2576 mice. In an attempt to explain this, 
it could be argued that DHA targets early but not late pathological changes. However, this is 
inconsistent with reports in the elevated plus maze in this chapter. In addition, Calon et al. 
(2004) reported that DHA supplementation ameliorated hippocampal-dependant deficits 
during advanced stages of pathology in APP mice. Comparisons to Calon et al. (2004) study 
however is somewhat limited by the differential use of task, time of intervention and use of 
control diet which was high in omega-6 PUFAs with an excessive ω-6/ω-3 ratio.
An important consideration of these marble burying results is interpretation of the reported 
deficits in Tg mice. As discussed in the introduction, alterations to marble burying behaviour 
is typically associated with anxiety-states (e.g. Crawley, 2008), although this interpretation 
remains controversial (Njung’e & Handley, 1991; Nicolas, Kolb & Prinssen, 2006). For 
example, locomotor activity may affect the degree of marble burying, and reports of 
hyperactivity in Tg2576 mice could therefore be directly related to the marble burying deficit. 
Evidence has both supported and refuted its involvement (as reviewed in Millan et al., 2002 
and Nicolas, Kolb & Prinssen, 2006). Similar to locomotor activity, motor impairments 
related to a digging and a burrowing deficit reported by Deacon et al. (2006, 2009) in Tg2576 
mice aged 22 to 23 months may contribute to marble burying deficits. Interestingly, similar to 
spatial memory deficits, digging deficits have also been associated with hippocampal 
function (Deacon, Croucher & Rawlins, 2002; Deacon & Rawlins, 2005). Alternatively, 
Millan et al. (2002) argued that marble burying behaviour reflects a form of impulsive 
behaviour. Although the biological basis of marble burying behaviour remains unclear, it is 
evident that Tg2576 show clear deficits that can be altered following DHA supplementation
at an early age. The reduction of marble burying deficits by DHA may therefore reflect 
changes in anxiety, or behaviour such as impulsivity.
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4.4 Experiment 5: Foraging task
4.4.1 Introduction 
The foraging task was a novel cognitive test design based on the radial arm maze task. The 
radial arm maze measures spatial memory for previously visited locations within a maze 
composed of multiple arms radiating from a central platform (Olton, Collison & Werz, 1977). 
Rodents are motivated to perform this task by a food reward placed at the end of each arm 
(Olton & Samuelson, 1976; Olton, 1987), or selected arms depending on the version of task 
(as reviewed in Foreman & Ermakova, 1998). This task has been extensively used to assess
spatial memory in animals and is particularly sensitive to hippocampal dysfunction (e.g. 
Olton & Paras, 1979; Ward, Stoelzel & Markus, 1999; He et al., 2002; Crusio & Schwegler,
2005). To date, only one study has reported radial arm maze deficits in Tg2576 mice at 24 
months (Asuni et al., 2006). This is likely due to the slow acquisition displayed in mice on 
this task compared to other spatial memory tasks such as water maze paradigms (as reviewed 
in Foreman & Ermakova, 1998). As a result,  the water maze and radial arm water maze tasks 
have been more extensively employed to assess transgene-related deficits in Tg2576 mice 
(e.g. Hsiao et al., 1996; Westerman et al., 2002; Adriani et al., 2006; Wilcock et al., 2004, 
2006). Further to this, radial arm maze tasks results in longer testing periods due to the use of 
various delay-periods between choice trials, whereby animals are confined to the central 
platform using guillotine doors (see Foreman & Ermakova, 1998; Dudchenko, 2004).
Therefore a task based on the radial arm maze was designed which employed more rapid 
testing and potentially quicker acquisition in mice. Similar to the radial arm maze, the 
foraging task employed a food reward motivation as opposed to aversive escape motivation 
in the water maze which can induce stress and can affect performance (Harrison, Hosseini & 
McDonald, 2009). Unlike the radial arm maze however, the foraging task permitted free 
navigation as opposed to constrained search, similar to the water maze task. Such design 
features may probe different processes involved in spatial learning which are not tapped by 
the radial arm or water maze tasks individually (Hodges, 1996; Foreman & Ermakova, 1998). 
The foraging task also exploited the natural foraging tendencies of rodents. This may assess 
spatial memory more accurately than the radial arm maze as Spetch and Edwards (1986) 
reported that an open field version of the radial arm maze (particularly a version resembling 
more natural feeding behaviour) facilitated performance in pigeons compared to that of the 
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traditional radial arm apparatus. Unlike the radial arm maze, these environments allowed the 
pigeon to choose its own path between food sites. Therefore, this open-field foraging task 
version of the radial arm maze, that exploits natural foraging behaviour in mice, may probe 
spatial memory more accurately than the traditional radial arm maze. Consequently, this task 
may also be more sensitive in detecting treatment effects.
In brief, the foraging task presents rodents with 8 pots in different locations within an open
field arena. Each pot is baited with food reward at the start of the session. Each mouse 
receives 10 minutes in which to retrieve the food rewards from the pots. Mice are trained to 
collect food rewards from pots in their home cage prior to testing. Efficient performance 
requires the mouse to recall the spatial locations of the pots within the maze that it has visited 
within each session in order to collect food rewards from unvisited pots. A number of 
measures are taken, such as the time taken to complete the task (collected all 8 rewards) and 
the number of return errors (a return is defined as when the mouse visits an already depleted 
pot). As this procedure provides an opportunity for the mouse to access multiple locations 
within the environment and thus increase the demand placed upon spatial memory it was 
anticipated that this procedure would be sensitive to the APPswe mutation and provide a 
means of further characterising the foraging strategies of mutant and WT control mice. 
Mice were assessed in the foraging task at 3 and 10.5 months of age. Based on previous 
literature showing behavioural deficits from 3-4 months of age in the water maze probe trial, 
circular platform and Y-maze (e.g. Holcomb et al., 1998; King et al., 1999; King & 
Arendash, 2002), it was hypothesised that Tg2576 mice would show spatial memory 
impairments in the foraging task when assessed at both 3 and 10.5 months of age. Further 
supporting this, a rather robust spatial memory deficit has been reported from 6-9 months in 
the Morris water maze (Hsiao et al., 1996; Westerman et al., 2002) and from 8-10 months in 
the T-maze test (Chapman et al., 1999; Corcoran et al., 2002; Hale & Good, 2005; Barnes, 
Hale & Good, 2004).
Based on evidence from experiment 4, it was hypothesised that DHA supplementation would 
improve foraging task performance in Tg2576 mice at 3 and 10.5 months of age. This was 
further supported by Calon et al. (2004) which showed amelioration of Morris water maze 
acquisition (but not retention) deficits by DHA supplementation in Tg2576 mice aged 21 to 
22 months. Similarly, Hooijmans et al. (2009) reported DHA supplementation to improve 
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spatial memory in the Morris water maze probe trial (but not during acquisition) in 15-month 
old APPswe/PS1 mice. Furthermore, Ma et al. (2009) reported a reduction of Y-maze deficits 
by DHA supplementation in a 3xTg model. In contrast however, Oksman et al. (2006) 
reported no effect of DHA supplementation on water maze performance in APPswe/PS1 
mice. Supporting this, Arendash et al. (2007) reported omega-3 supplementation did not 
improve spatial memory performance in the Morris water maze, Y-maze, circular platform 
and radial arm water maze in the APPswe/PS1 model. Despite these inconsistencies in the 
APPswe/PS1 model, the prediction that DHA supplementation would reduce transgene-
related deficits in Tg2576 mice was maintained based on previous results in Tg2576 mice by 
Calon et al. (2004) and the results of experiment 4.
4.4.2 Methods
4.4.2.1 Design and subjects
One cohort of male Tg2576 transgenic (Tg) and wildtype (WT) mice were evaluated in the 
foraging task at two ages following dietary supplementation of DHA or control oil blend. 
Experimentally naïve mice were first tested at 3 months of age, before the onset of plaque 
pathology. This cohort was tested again at 10.5 months of age when plaque pathology was 
developing. When tested at 3 months of age, 11 Tg mice received DHA diet (Tg DHA), 13 
Tg mice received the oil blend diet (Tg OB), 18 WT mice received the DHA diet (WT DHA) 
and 16 WT mice received the oil blend diet (WT OB). By the second stage of 
experimentation at 10.5 months of age, the attrition of 8 mice resulted in group numbers of 7 
Tg DHA, 10 Tg OB, 15 WT DHA and 16 WT OB. The running order of mice was
counterbalanced so that approximate equal numbers of each experimental group of mice were 
run in each batch, with several batches of mice being tested once per day over 11 consecutive 
days. 
4.4.2.2 Apparatus
The foraging task was carried out in an open field wooden arena (102cm2 x 43cm tall), filled 
with a layer of sawdust 3cm deep and containing eight white ceramic pots in a 3 x 2 x 3 
arrangement (Figure 4.13). Each pot was filled with sawdust and baited with a food reward 
hidden in the middle of the sawdust. Trial testing with another mouse cohort demonstrated 
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mice responded well to the food reward which was half a grain of Kellogg’s® Cocopops. The 
arena was situated in a quiet, illuminated room surrounded by numerous distinct visual cues 
such as posters and shelving on the walls, benching and air conditioning ducts. A camera was 
attached to the ceiling directly above the arena to allow viewing and recording for 
documentation using a monitor and VCR. Experimental measures were recorded manually by 
the experimenter using a notepad.
Figure 4.13 Foraging task apparatus showing pot arrangement within the open field arena, and a 
mouse attending a foraging pot during the task.
4.4.2.3 Procedure
Mice were placed on a food restriction regime throughout this experiment in order to 
motivate them to consume the food reward. Here, mice received a restricted amount of food 
per day varying between 2 to 5g of experimental mouse diet, provided approximately 2 hours 
after the experiment. The amount of food provided was individually calculated per mouse 
depending on their body weight profile. Each mouse was checked daily for general health and 
weighed to ensure their body weight was maintained above 85 to 90% of their ad lib weight. 
The experimenter remained in the room throughout all sessions and maintained their location 
out of sight. Mice were transported to the test room in individual home cages and habituated 
to the room for 10 minutes prior to each habituation and test session.
The foraging task consisted of an 8-day habituation and training period, followed by a 3-day 
testing period. The first 3 days of habituation and training involved 3 repeated exposures to a 
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baited pot in their home-cage to encourage foraging behaviour in the pot and the association 
of a food reward. Once mice successfully foraged within the pots, they received a 10-minute 
habituation session to the foraging arena without pots on habituation day 4. On habituation 
days 5 to 8, mice received a 10-minute habituation and training session in the arena 
containing 2 baited pots to encourage foraging in the pots. If the food reward was not 
consumed within 10 minutes on each day, mice received one extra session per day to ensure 
that all mice successfully foraged from both pots within 10 minutes.  Between sessions, the 
sawdust layer in the arena was mixed and excrement removed to eliminate odour trails.
The 3-day test was conducted over consecutive days immediately following the habituation 
period. During each testing day, mice were given a maximum of 10 minutes to freely roam 
the arena containing 8 pots that were baited with half a grain of Kellogg’s® Cocopops buried 
in the middle of the sawdust to 2/3rds of the pot depth. Mice were removed from the arena 
after 10 minutes or once all 8 food rewards were successfully consumed. The experimenter 
recorded mouse activity in the arena including which pots in turn had foraging visits and 
when food rewards from each pot were consumed. A foraging visit was defined as when a 
mouse actively manoeuvred sawdust within the pot using its head or paws in order to search 
for food. The measures of behaviour included the total number of pots successfully foraged 
(i.e. the number of food rewards gained), the number of consecutive pots successfully 
foraged, the total number of return errors made (revisiting a pot after depleting the food 
reward), the number of consecutive return errors made, and the number of foraging errors 
made (visiting a baited pot without reward consumption). The time taken to complete the task 
was also recorded.
4.4.2.4 Data analysis
A separate ANOVA analysed the data at 3 and 10.5 months independently. Statistical 
analyses on the foraging task measures were carried out using an ANOVA with genotype 
(Tg, WT) and diet (DHA, OB) as between-subject factors, and day (1-3) as a within-subject 
factor. Tests of simple main effects were carried out following significant interactions. 
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4.4.3 Results
4.4.3.1 Foraging task: 3 months of age
Time taken to complete the foraging task
Figure 4.14 shows the mean time taken to complete the foraging task for both Tg and WT 
mice fed the DHA or oil blend diet at 3 months of age during days 1 to 3. The graph shows 
that Tg mice took more time to complete the task than WT mice, and the DHA diet generally 
failed to alter performance in both Tg and WT mice. An ANOVA with day, genotype and 
diet as factors revealed a significant effect of genotype (F(1,54)=38.967, p<0.001), no 
significant main effect of diet (F(1,54)=2.358, p>0.05) and no interaction between these 
factors (F(1,54)=0.532, p>0.05). Statistical analysis also showed a significant effect of day 
(F(2,108)=12.137, p<0.001), no significant interaction of day by genotype (F(2,108)=0.236, 
p>0.05), no significant interaction of day by diet (F(2,108)=1.423, p>0.05) and no significant 
three-way interaction of day by genotype by diet (F(2,108)=0.878, p>0.05). 
Figure 4.14 Mean time taken to complete the foraging task at 3 months of age (total time = 600 
seconds). Values are mean scores ± S.E.M.
Number of pots successfully foraged (number of rewards gained)
The mean number of rewards gained in the foraging task across testing for both Tg and WT 
mice fed the DHA or oil blend diet at 3 months of age is shown in Figure 4.15. The graph 
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shows that Tg mice gained fewer rewards than WT mice, which successfully foraged from all 
pots to receive all 8 rewards. DHA supplementation appeared to improve Tg performance 
slightly, with no impact in WT mice. An ANOVA with day, genotype and diet as factors 
revealed a significant effect of genotype (F(1,54)=15.406, p<0.001), no significant main 
effect of diet (F(1,54)=1.152, p>0.05) and no interaction between these factors 
(F(1,54)=0.1.152, p>0.05). Statistical analysis also showed a significant effect of day 
(F(2,108)=5.201, p<0.01), a significant interaction of day by genotype (F(2,108)=5.201, 
p<0.01), no significant interaction of day by diet (F(2,108)=2.101, p>0.05) and no significant 
three-way interaction of day by genotype by diet (F(2,108)=2.101, p>0.05). A follow-up test 
of simple main effects for the significant day by genotype interaction revealed Tg mice 
performed significantly worse than WT mice on days 1 and 2 (smallest, F(1,56)=8.64, 
p<0.01).
Figure 4.15 Mean number of rewards gained (number of pots successfully foraged) in the foraging 
task at 3 months of age (total time = 600 seconds). Values are mean scores ± S.E.M. S.E.M = 0 for 
WT groups.
Number of consecutive pots successfully foraged (number of consecutive rewards gained)
The mean number of consecutive pots successfully foraged by experimental groups during 
days 1 to 3 of the foraging task at 3 months of age is shown in Figure 4.16. The graph depicts 
that all mice made a similar number of errors across days, although 1-month DHA 
supplementation appeared to improve performance in Tg but not WT mice. An ANOVA with 
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day, genotype and diet as factors revealed no significant effect of genotype (F(1,54)=0.837, 
p>0.05), no significant effect of diet (F(1,54)=2.188, p>0.05), but a interaction between these 
factors (F(1,54)=4.238, p<0.05). Following-up this interaction, a test of simple main effects 
revealed Tg OB mice foraged from significantly less pots consecutively than WT OB mice 
(F(1,54)=4.11, p<0.05) and Tg DHA mice (F(1,54)=5.63, p<0.05). Statistical analysis also 
showed a significant effect of day (F(2,108)=12.401, p<0.001), no significant interaction of 
day by genotype (F(2,108)=0.904, p>0.05), no significant interaction of day by diet 
(F(2,108)=1.925, p>0.05) and no significant three-way interaction of day by genotype by diet 
(F(2,108)=0.595, p>0.05). 
Figure 4.16 Mean number of consecutive pots successfully foraged in the foraging task at 3 months of 
age. Values are mean scores ± S.E.M.
Total number of foraging errors made
Figure 4.17 shows the mean number of total foraging errors made by experimental groups 
across training at 3 months of age. An ANOVA with day, genotype and diet as factors 
revealed no significant effect of genotype (F(1,54)=1.199, p>0.05), diet (F(1,54)=0.115, 
p>0.05) or interaction between these factors (F(1,54)=2.714, p>0.05). As illustrated in Figure 
4.17, these results indicate that Tg and WT mice performed equally well with no significant 
beneficial effect of 1-month DHA supplementation compared to oil blend diet. Statistical 
analysis also showed no significant effect of day (F(2,108)=0.406, p>0.05), no significant 
interaction of day by genotype (F(2,108)=0.011, p>0.05), a significant interaction of day by 
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diet (F(2,108)=3.482, p<0.05) and no significant three-way interaction of day by genotype by 
diet (F(2,108)=1.486, p>0.05). A follow-up test of simple main effects for the significant day 
by diet interaction revealed no effect of diet on days 1, 2 or 3 (smallest, F(1,56)=2.79, 
p>0.05). 
Figure 4.17 Mean number of total foraging errors made in the foraging task at 3 months of age. 
Values are mean scores ± S.E.M.
Total number of return errors made
Figure 4.18 shows the mean number of total return errors made by experimental during days 
1 to 3 of the foraging task at 3 months of age. The graph shows that Tg and WT mice 
performed similarly, although Tg OB mice made more return errors than all groups. 
Furthermore, the results indicate that DHA supplementation appeared to benefit performance.
An ANOVA with day, genotype and diet as factors revealed no significant effect of genotype
(F(1,54)=3.341, p>0.05), a significant effect of diet (F(1,54)=4.214, p<0.05) and no 
significant interaction between these factors (F(1,54)=0.620, p>0.05). Statistical analysis also 
showed no significant effect of day (F(2,108)=1.059, p>0.05), no significant interaction of 
day by genotype (F(2,108)=0.602, p>0.05), no significant interaction of day by diet 
(F(2,108)=0.180, p>0.05) and no significant three-way interaction of day by genotype by diet 
(F(2,108)=0.744, p>0.05).
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Figure 4.18 Mean number of total return errors made in the foraging task at 3 months of age. Values 
are mean scores ± S.E.M.
Number of consecutive return errors (2+) made
The mean number of consecutive return errors (2+) made by experimental groups during days 
1 to 3 of the foraging task at 3 months of age is shown in Figure 4.19. The figure shows that 
Tg mice, particularly Tg OB, made more errors than WT mice. DHA supplementation also 
appeared to improve performance across days, particularly in Tg mice. An ANOVA with day, 
genotype and diet as factors revealed a significant effect of genotype (F(1,54)=7.449, 
p<0.01), a significant effect of diet (F(1,54)=4.817, p<0.05), but no significant interaction 
between these factors (F(1,54)=2.414, p>0.05). Statistical analysis also showed a significant 
effect of day (F(2,108)=3.668, p<0.05), no significant interaction of day by genotype 
(F(2,108)=0.100, p>0.05), no significant interaction of day by diet (F(2,108)=0.410, p>0.05) 
and no significant three-way interaction of day by genotype by diet (F(2,108)=0.618, 
p>0.05). The effect of day is clearly demonstrated in Figure 4.19, whereby errors decline over 
days.
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Figure 4.19 Mean number of consecutive return errors (2+) made in the foraging task at 3 months of 
age. Values are mean scores ± S.E.M.
4.4.3.2 Foraging task: 10.5 months of age
Time taken to complete the foraging task
Figure 4.20 shows the mean time taken to complete the foraging task for both Tg and WT 
mice fed the DHA or oil blend diet at 10.5 months of age during days 1 to 3. The graph 
illustrates that Tg mice took more time to complete the task than WT mice. Figure 4.20 also 
shows that DHA failed to alter performance in WT mice, but appeared to improve 
performance in Tg mice on days 2 and 3. An ANOVA with day, genotype and diet as factors 
revealed a significant effect of genotype (F(1,44)=23.319, p<0.001), no significant main 
effect of diet (F(1,44)=1.105, p>0.05) and no interaction between these factors 
(F(1,44)=0.629, p>0.05). Statistical analysis also showed a significant effect of day 
(F(2,88)=42.888, p<0.001), no significant interaction of day by genotype (F(2,88)=1.780, 
p>0.05), no significant interaction of day by diet (F(2,88)=0.611, p>0.05) and no significant 
three-way interaction of day by genotype by diet (F(2,88)=1.833, p>0.05). The difference 
between Tg groups is therefore not supported statistically.
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Figure 4.20 Mean time taken to complete the foraging task at 10.5 months of age (total time = 600 
seconds). Values are mean scores ± S.E.M.
Number of pots successfully foraged (number of rewards gained)
Figure 4.21 shows the mean number of rewards gained in the foraging task for both Tg and 
WT mice fed the DHA or oil blend diet at 10.5 months of age. Overall, all mouse groups 
successfully foraged from the majority of pots to receive most rewards. An ANOVA with 
day, genotype and diet as factors revealed no significant effect of genotype (F(1,44)=0.211, 
p>0.05), no significant main effect of diet (F(1,44)=1.042, p>0.05) and no interaction 
between these factors (F(1,44)=0.778, p>0.05). Statistical analysis also showed a significant 
effect of day (F(2,88)=4.833, p<0.01), no significant interaction of day by genotype 
(F(2,88)=2.286, p>0.05), no significant interaction of day by diet (F(2,88)=1.287, p>0.05) 
and no significant three-way interaction of day by genotype by diet (F(2,88)=1.515, p>0.05). 
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Figure 4.21 Mean number of rewards gained (number of pots successfully foraged) in the foraging 
task at 10.5 months of age (total time = 600 seconds). Values are mean scores ± S.E.M.
Number of consecutive pots successfully foraged (number of consecutive rewards gained)
Figure 4.22 depicts the mean number of consecutive pots successfully foraged by 
experimental groups across testing at 10.5 months of age. An ANOVA with day, genotype 
and diet as factors revealed a significant effect of genotype (F(1,44)=4.372, p<0.05), no 
significant effect of diet (F(1,44)=1.158, p>0.05) and no interaction between these factors 
(F(1,44)=0.491, p>0.05). As illustrated in Figure 4.22, these results show that Tg mice made 
less consecutive successful visits to pots than WT mice, and that diet failed to alter 
performance. Statistical analysis also showed a significant effect of day (F(2,88)=7.991, 
p<0.001), no significant interaction of day by genotype (F(2,88)=0.265, p>0.05), no
significant interaction of day by diet (F(2,88)=1.847, p>0.05) and no significant three-way 
interaction of day by genotype by diet (F(2,88)=2.366, p>0.05). Unfortunately, the numerical 
difference between Tg groups on day 3, where DHA supplementation appears to improve Tg 
performance, is not supported by a significant interaction.
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Figure 4.22 Mean number of consecutive pots successfully foraged in the foraging task at 10.5 months 
of age. Values are mean scores ± S.E.M.
Total number of foraging errors made
Figure 4.23 shows the mean number of total foraging errors made by experimental groups
across days of the foraging task at 10.5 months of age. Tg and WT mice appear to perform 
equally well, with no effect of DHA supplementation compared to the oil blend diet.
However, Tg mice fed the DHA diet appear to have made more errors than all other groups 
on day 1. An ANOVA with day, genotype and diet as factors revealed no significant effect of 
genotype (F(1,44)=1.064, p>0.05), diet (F(1,44)=1.897, p>0.05) or interaction between these 
factors (F(1,44)=1.919, p>0.05). Statistical analysis also showed a significant effect of day 
(F(2,88)=8.054, p<0.001), no significant interaction of day by genotype (F(2,88)=1.149, 
p>0.05), no significant interaction of day by diet (F(2,88)=1.587, p>0.05) and no significant 
three-way interaction of day by genotype by diet (F(2,88)=2.672, p>0.05). 
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Figure 4.23 Mean number of total foraging errors made in the foraging task at 10.5 months of age. 
Values are mean scores ± S.E.M.
Total number of return errors made
Figure 4.24 illustrates the mean number of total return errors made for both Tg and WT mice 
fed the DHA or oil blend diet during days 1 to 3 of the foraging task at 10.5 months of age. 
The results demonstrate that Tg mice (particularly the Tg OB group) made more return errors 
than WT mice. The DHA diet failed to alter performance in WT mice, but appeared to 
improve performance across days in Tg mice. An ANOVA with day, genotype and diet as 
factors revealed a significant effect of genotype (F(1,44)=13.817, p<0.001), no significant
main effect of diet (F(1,44)=1.139, p>0.05) and no significant interaction between these 
factors (F(1,44)=0.604, p>0.05). Statistical analysis also showed a significant effect of day 
(F(2,88)=7.747, p<0.001), no significant interaction of day by genotype (F(2,88)=2.076, 
p>0.05), and no significant interaction of day by diet (F(2,88)=1.998, p>0.05), but a 
significant three-way interaction of day by genotype by diet (F(2,88)=5.097, p<0.01). A 
follow-up test of simple interactions revealed a significant genotype by diet interaction on 
day 2 (F(1,44)=5.39, p<0.05). To follow up this interaction on day 2, a test of simple main 
effects revealed Tg OB mice made significantly more return errors than WT OB mice 
(F(1,44)=24.91, p<0.001), WT DHA mice (F(1,44)=10.91, p<0.01) and Tg DHA mice 
(F(1,44)=7.94, p<0.01). These results therefore show that DHA supplementation reduced the 
return errors deficit in Tg mice.
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Figure 4.24 Mean number of total return errors made in the foraging task at 10.5 months of age. 
Values are mean scores ± S.E.M.
Number of consecutive return errors (2+) made
Figure 4.25 shows the mean number of consecutive return errors (2+) made by experimental 
groups during days 1 to 3 of the foraging task at 10.5 months of age. The figure shows that 
Tg mice, particularly Tg OB, made more errors than WT mice across days, and that DHA 
supplementation appeared to reduce the number of errors made, particularly in Tg mice. An 
ANOVA with day, genotype and diet as factors revealed a significant effect of genotype 
(F(1,44)=15.995, p<0.001), a significant main effect of diet (F(1,44)=4.678, p<0.05) and no 
significant interaction between these factors (F(1,44)=1.931, p>0.05). Statistical analysis also 
showed a significant effect of day (F(2,88)=17.396, p<0.001), a significant interaction of day 
by genotype (F(2,88)=3.712, p<0.05), no significant interaction of day by diet 
(F(2,88)=1.667, p>0.05) and no significant three-way interaction of day by genotype by diet 
(F(2,88)=0.933, p>0.05). A test of simple main effects revealed a significant effect of 
genotype on days 1, 2 and 3 (smallest, F(1,46)=8.37, p<0.01).
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Figure 4.25 Mean number of consecutive return errors (2+) made in the foraging task at 10.5 months 
of age. Values are mean scores ± S.E.M.
4.4.4 Discussion
The results of the foraging task showed a significant effect of genotype at both at 3 and 10.5
months of age on a number of measures; whereby Tg mice took significantly longer to 
complete the task, made less consecutive successful visits to pots and made more consecutive 
return errors (2+). At 3 months of age, Tg mice also showed a transgene-related deficit by 
gaining less rewards than WT mice. In contrast, this was not shown at 10.5 months of age, 
although Tg mice made more return errors than WT mice at 10.5 months but not 3 months. 
Together, these measures suggest that Tg mice showed a spatial memory impairment, and the 
return error deficit may indicate perseverative or disinhibitory behaviour. In contrast to these 
transgene-related deficits, Tg mice made a similar number of foraging errors (whereby mice 
visited a pot without consuming the food reward) as WT mice at both 3 and 10.5 months of 
age. Importantly, this leads to the conclusion that Tg mice could forage as efficiently as WT 
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mice. This suggests that the observed deficits were not related to a general inability to forage 
successfully for food rewards.
This study therefore provides evidence that the APPswe mutation leads to a spatial memory 
deficit in Tg2576 mice as early as 3 months of age. This is consistent with previous reports of 
spatial memory deficits at 3 months of age in the Y-maze spontaneous alternation task and in 
a water maze task (Holcomb et al., 1998; King et al., 1999; King & Arendash, 2002). In 
contrast, other studies have not reported spatial memory and learning deficits around this age 
point in the Morris water maze and other water-maze paradigms (Hsiao et al., 1996; King et 
al., 1999; King & Arendash, 2002). It could be argued however that this lack of deficits may 
be specific to reference spatial memory, as opposed to the working spatial memory measured 
in this task. In contrast to this however, Tg2576 mice were not impaired at 3 months of age in 
tasks probing working spatial memory including the paddling Y-maze and Y-maze 
spontaneous alternation task (Hsiao et al., 1996; King et al., 1999; Deacon et al., 2008). 
However it could be argued that these Y-maze tasks, which have limited complexity by 
offering a choice of only two spatial locations (left and right arms), may not be sensitive 
enough to detect small but significant changes in spatial memory. Further investigation of 
working spatial memory using more putatively complex tasks is therefore required to 
understand the onset of transgene-related deficits in Tg2576 mice.
The spatial memory deficit reported in Tg mice at 10.5 months of age in the foraging task 
was consistent with a number of studies demonstrating spatial memory deficits from around 9 
months of age in this model (e.g. Hsiao et al., 1996). For example, a reference spatial 
memory deficit in the Morris water maze and paddling Y-maze has been reported in Tg2576 
mice from between 6 and 9 months of age (Hsiao et al., 1996; Westerman et al., 2002; 
Deacon et al., 2008). Similarly, progressive working spatial memory deficits have generally 
been reported in the T-maze FCA task from 8 months of age in Tg2576 mice (Chapman et 
al., 1999, Corcoran et al., 2002; Barnes, Hale & Good, 2004; Hale & Good, 2005). Together, 
the results of the foraging task at 3 and 10.5 months suggest that the spatial memory deficits 
in Tg mice is not necessarily associated with Aβ pathology as deficits were observed prior to 
Aβ pathological development. Instead, the observed deficit may be related to early synaptic 
deficits caused by the APPswe mutation (e.g. Jacobsen et al., 2006). The progressive 
worsening of the deficit by 10.5 months of age (as shown by a return errors deficit not 
observed at 3 months) may instead be associated with Aβ pathology.
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Although the transgene deficits reported in this task suggest impaired spatial memory, it is 
important to consider alternative explanations for the deficits such as sensorimotor 
impairments including visual ability (as discussed in experiment 1), hyperactivity and digging 
deficits. Measures of hyperactivity in Tg2576 mice have been supported between 3 and 23 
months in the open field task, although these results are inconsistent (Chapman et al., 1999; 
King et al., 1999; King & Arendash, 2002; Deacon et al., 2008, 2009; Lalonde et al., 2003). 
Hyperactivity could lead to an increase in pot visits, perhaps resulting in an increase in 
foraging or return errors. Conversely however, it could also be argued that hyperactivity in 
Tg mice could facilitate performance in the foraging task, such as completing the task in a 
quicker time. It is therefore thought that the deficits in the foraging task was unlikely a 
consequence of simple hyperactivity, but rather, it may exaggerate performance depending on 
spatial memory status. An additional factor that should also be considered is whether a simple 
digging impairment could account for foraging task deficits. Indeed, Deacon et al. (2006, 
2009) reported a digging and burrowing impairment in Tg2576 mice aged 22 to 23 months 
assessed in several tasks. However, it was also reported that this impairment did not affect 
their ability to find and dig up hidden food pellets. Although these results cannot lead us to 
rule out the involvement of digging impairments, the fact that the deficit appeared to reflect a 
preseverative error strategy would suggest a more selective cognitive impairment. 
Another important consideration is the potential use of olfactory cues by mice to solve the 
task. For example, mice could use olfactory trails such as urine to track its activity within the 
arena to guide responding to unvisited pots. Unfortunately this could not be controlled in this 
task, unlike tasks such as the T-maze. It is important to consider whether an olfactory 
impairment (rather than a spatial memory impairment) led to the observed transgene-deficit. 
In support of a spatial memory deficit, Deacon et al. (2009) ruled out a general olfactory 
impairment in Tg2576 mice aged 22 to 23 months, whereby Tg mice could find a hidden 
food pellet under woodchip bedding as easily as WT controls. In fact, they reported that Tg 
mice showed enhanced performance compared to controls, although this was not statistically 
significant. It was therefore concluded that an olfactory impairment was unlikely responsible 
for the foraging task deficit in Tg2576 mice. Another possibility is that Tg2576 mice failed to 
habituate to the arena as well as control mice. However, all mice reached the habituation 
criteria of successfully foraging within 2 pots in the foraging arena within a 5-minute period 
and thus this seems an unlikely factor underpinning the deficits in Tg2576 mice on this task.
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The foraging task experiment showed several significant main effects of diet or genotype by 
diet interactions in mice aged 3 and 10.5 months age, suggesting that DHA supplementation 
ameliorated some performance deficits in Tg and WT mice. Improvements were restricted to 
the number of total and consecutive return errors made, and the number of consecutive 
rewards gained. At 3 months, significant diet effects were shown for the number of total and 
consecutive return errors made, with a selective improvement in Tg performance by DHA in 
the number of consecutive rewards gained. By 10 months, the results were less convincing, 
with positive effects of DHA shown only in the number of consecutive return errors measure, 
and positive effects of DHA selectively in Tg mice for the number of total return errors 
measure. A trend showed Tg DHA mice gained more consecutive rewards than Tg OB mice, 
although this was not supported statistically at 10.5 months. In contrast to these positive 
performance effects of DHA supplementation, no effects were found in several measures 
including the time taken to complete the task, the number of rewards gained, and the number 
of foraging errors. Overall however, these results provide some evidence that DHA improved 
spatial memory in Tg and WT mice, particularly at 3 months of age, with some selective 
improvements in Tg mice only. This would suggest that DHA can improve general cognitive 
function, as well as transgene-related deficits in Tg mice. These results are the first of its kind 
to provide evidence suggesting positive effects of DHA supplementation in reducing spatial 
memory deficits in Tg2576 mice at an early age relative to a suitable baseline diet. 
These results are supported by the potent effects described by Calon et al. (2004) which 
reported DHA supplementation to reduce spatial memory and learning deficits in the Morris 
water maze in 21-22 month old Tg2576 mice, relative to a diet depleted in DHA with an 
excessive ω-6/ω-3 ratio. It is argued that the relative strength of the diet effects reported by 
Calon et al. (2004) were a likely consequence of the high levels of omega-6 PUFA and 
excessive ω-6/ω-3 ratio in their control diet, rather than the addition of DHA per se. Similar 
arguments could be made regarding positive effects of DHA supplementation in reports of 
other AD models (Hooijmans et al., 2009; Ma et al., 2009; Arsenault et al., 2011). For 
example, Hooijmans et al. (2009) failed to accurately examine DHA supplementation as the 
standard control diet was composed of almost double the amount of saturated fatty acids and 
the DHA diet contained supplementary levels of omega-3 PUFA which were not attributable 
to DHA. Similarly, the DHA diet in Arsenault et al. (2011) study contained supplementary 
EPA and half the amount of omega-6 PUFA relative to the control diet. Finally, Ma et al. 
(2009) examined the effect of fish oil supplementation containing DHA rather than the sole 
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effect of DHA, and was compared to a poor diet high in saturated fatty acids and omega-6
PUFAs. 
4.5 Experiment 6: Biconditional discrimination training, Stroop interference test and 
reversal learning
4.5.1 Introduction 
A plethora of evidence has shown the Tg2576 model to display a rather specific cognitive 
deficit in spatial, episodic and emotional memory primarily related to Aβ pathology in 
structures within the medial temporal lobe such as the hippocampus and amygdala (e.g. Hsiao 
et al., 1996; King & Arendash, 2002; Good, Hale & Staal, 2007). In contrast, cognitive 
function associated with the prefrontal cortex (PFC) is not well studied in the Tg2576 model.
Interestingly, the results of the foraging task experiment revealed that Tg2576 mice displayed 
perseverative-like behaviour, which has been related to PFC damage (Barcelo et al., 1997;
Munakata, Morton & Stedron, 2003; Carli et al., 2006). This therefore indicated that PFC-
function may be disrupted in Tg2576 mice, and warranted further investigation, perhaps 
through the examination of executive function. Executive function is a common umbrella 
term used for a number of complex cognitive processes including planning, inhibition, 
cognitive flexibility, response-control and goal-directed behaviour (Binetti et al., 1996; 
Stauss & Knight, 2002; Swanberg et al., 2004; Schillerstrom, Horton & Royall, 2005). These 
skills underlie the ability to perform attentional, discrimination and reversal learning tasks. 
Such activities are dependent upon the integrity of the frontal cortex (as reviewed in Duke & 
Kasznick, 2000), although the more basic stimulus-response learning is also controlled by 
motor areas and the striatum (Spencer & Murphy, 2000; Partridge et al., 2002; Boettiger & 
D’Esposito, 2005).
It was also deemed important to assess executive function in Tg2576 mice and the effect of 
dietary intervention, since cognitive deficits related to the frontal lobe have been widely 
reported in human AD patients. Such deficits include executive dysfunction and attentional 
impairments (Collette, Van der Linden & Salmon, 1999; Perry & Hodges, 1999; Baddeley et 
al., 2001; Foldi, Lobosco & Schaefer, 2002; Swanberg et al., 2004; Baudic et al., 2006; Waltz 
et al., 2004). For example, Swanberg et al. (2004) reported that executive dysfunction was 
present in 64% of human AD patients. Furthermore, frontal lobe dysfunction has been 
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reported at early stages of disease development (e.g. Binetti et al., 1996; Sgaramella et al.,
2001). Interestingly, cognitive function supported by cortical regions has not been 
exhaustively studied in the Tg2576 model, despite the age-related increase in Aβ pathology 
in the cortex. For example, Zhuo et al. (2008) reported that the prefrontal cortex (PFC) 
contained higher levels of Aβ42 compared to the hippocampus at both 3 and 6 months of age, 
indicating that this brain region may be highly vulnerable to the effects of amyloidosis and 
may suffer a greater functional impairment. 
Consistently, some executive dysfunction has been reported in Tg2576 mice. Zhuo et al. 
(2007, 2008) reported reversal learning deficits in an attentional set-shifting test at 6 months 
of age, which corresponded to a three-fold increase in Aβ42 in the PFC compared with 3 
months of age when no cognitive impairment was evident. In particular, Tg2576 mice were 
unable to successfully acquire a reversed stimulus-reward association which involved 
suppressing previously relevant rules and replacing them with new rules. Reversal learning is 
highly dependent upon PFC integrity, as demonstrated by lesion studies and frontal dementia 
patients (e.g. Duke & Kaszniak, 2000; Schoenbaum et al., 2002; McAlonan & Brown, 2003;
Hornak et al., 2004). Reversal learning deficits in Tg2576 mice were also reported by Pompl 
et al. (1999) in the circular platform task at 7 months. Overall, this data suggests that 
employment of sparsely used PFC-dependant behavioural tasks could be an alternative tool 
for detecting early cognitive changes caused by Aβ-related pathology and probing the 
effectiveness of therapeutic strategies, such as dietary intervention. The first aim of this 
experiment was therefore to investigate PFC-dependant executive functioning in the Tg2576 
mouse model from an early age at 5.5 to 9 months, when pathological changes have been 
reported in this region (Hsiao et al., 1996; Kawarabayashi et al., 2001; Zhuo et al., 2008). 
Secondly, this experiment aimed to investigate the effect of DHA supplementation on 
executive function in Tg and WT mice. 
In order to assess executive function in Tg2576 mice, a mouse adaptation of the biconditional 
discrimination task and Stroop test in rats developed by Haddon and Killcross (2005) was 
used which was analogous to the human Stroop test. The human Stroop test (Stroop, 1935) is 
a common test used to assess executive functioning in AD patients (MacLeod, 1992). The test 
presents participants with a list of colour-related words (e.g. red, blue) which are coloured 
congruently (the red word is a red colour) or incongruently (the red word is a green colour), 
as shown in Table 4.1. Here, the test requires participants to follow one of two instructions: 
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1) to name the word presented, or 2) to name the colour of the word. Typically, participants 
take longer to respond to the incongruent presentations which induce different responses than 
the congruent presentations which induce the same response. This is caused by an 
‘interference effect’ during incongruent presentations, whereby the over-learned response to 
read the word must be inhibited before the ink colour can be named (MacLeod, 1992).
Table 4.1 Presentations of congruent and incongruent word lists used in the Stroop test (Stroop, 
1935). Congruent presentations invoke the same response regardless of instruction (read the word or 
state the colour of the word), whereas incongruent presentations invoke differential responses and the 
interference effect results in a reduced response time to state the correct answer for both instructions.
List 1 (Congruent) List 2 (Incongruent)
Red Red
Blue Blue
Green Green
Yellow Yellow
Several studies assessing AD patients in the Stroop test have shown patients have difficulty in 
inhibiting these automatic competing responses during incongruent presentations, resulting in 
stronger Stroop interference effects than age-matched controls (Koss et al., 1984; Perry & 
Hodges, 1999; Amieva et al., 2002, 2004a,b). However, AD patients can display facilitated 
performance on congruent trials, possibly due to the lack of interference and lower level of 
executive functioning required (Spieler et al., 1996). Furthermore, AD patients show 
impairments in the reverse Stroop test, whereby patients show difficulty in shifting between 
task instructions (Perry & Hodges, 1999; Amieva et al., 2004b). It is thought that AD patients 
are impaired as they demonstrate difficulty in shifting attention to suppress previously learnt 
rules in order to learn new ones.
Haddon and Killcross (2005) developed a rodent specific PFC-dependant task that is 
analogous to the human Stroop test. In their study, rats were first subject to biconditional 
discrimination training whereby they received two auditory stimuli in one context (where 
each stimulus cued either a left or right lever-press response to gain reinforcement) and two 
visual stimuli in another context (where each stimulus cued either a left or right response to 
gain reinforcement). Following successful acquisition, rats were then subject to a Stroop 
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interference test which presented congruent and incongruent audiovisual compounds in each 
context, which cued either the same or different lever-press response learnt during training, 
respectively. To solve the response conflict during incongruent compound presentations, rats 
were required to use contextual cues to guide correct responding. Therefore, if tested in the 
context that was previously associated with auditory training, the rat should respond to the 
auditory stimulus in the compound rather than the visual stimulus. The test therefore requires 
inhibition of the previously learnt response. In relation to the human Stroop test, the 
audiovisual compounds are comparable to ink colour and words, and the contextual cues are 
comparable to the task instructions given (Haddon et al., 2008). Rats with medial PFC lesions 
were impaired in incongruent trials, but not in congruent trials or during biconditional 
discrimination training (Haddon & Killcross, 2005). Table 4.2 illustrates the basic 
experimental design used in this procedure.
Table 4.2 Basic experimental design of the Biconditional and Stroop interference test developed by 
Haddon & Killcross (2005).
Context Biconditional Stroop interference test
discrimination _____________________________________________
    training Congruent compound Incongruent compound
Context 1: A1→R1, A2→R2 A1V1, A2V2→ A/V guide A1V2, A2V1→ A guide
Context 2: V1→R1, V2→R2 A1V1, A2V2→ A/V guide A1V2, A2V1→ V guide
Key: A1 = Auditory stimulus 1; A2 = Auditory stimulus 2; V1 = Visual stimulus 1; V2 = Visual 
stimulus 2; R1 = Lever-press response 1 (Left); R2 = Lever-press response 2 (Right); A1V1, A2V2, 
A1V2, A2V1 = Audiovisual compound presentations; A/V guide = responses can be guided by either 
auditory or visual component of audiovisual compound; A guide = responses guided by auditory 
component of audiovisual compound; V guide = responses guided by visual component of 
audiovisual compound. 
To investigate PFC-related executive function in the Tg2576 model, mice were tested in a 
modified version of biconditional discrimination training and the Stroop interference test 
outlined by Haddon and Killcross (2005). Tg2576 mice were also subject to reversal 
discrimination training, whereby the stimulus-response association learnt during the initial 
discrimination training was reversed. Based on previous evidence outlined in Tg2576 mice 
and AD patients (e.g. Zhuo et al., 2007, 2008; Perry & Hodges, 1999; Amieva et al., 2004b), 
it was hypothesised that Tg2576 mice would exhibit impaired performance during 
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incongruent trials in the Stroop test and reversal discrimination training, consistent with PFC 
dysfunction. 
In contrast, it was hypothesised that Tg2576 mice would show intact performance during 
biconditional discrimination training and congruent test trials, as studies have shown intact or 
enhanced discrimination acquisition in similar tasks in AD patients (Spieler et al., 1996) and 
Tg2576 mice. For example, Zhuo et al. (2007) reported Tg2576 mice were able to learn the 
initial two-choice compound discriminations at 6 and 14 months. Similarly, Barnes, Hale and 
Good (2004) showed intact performance at 12 to 14 months in an intramaze brightness 
discrimination, a simple room discrimination, and a contextual biconditional left–right 
discrimination. These results suggest that acquisition of stimulus-reward associations may not 
be fully dependant on the PFC and instead dependent upon a region liberated from pathology 
(Zhuo et al., 2007). Indeed, the dorsomedial striatum has been shown to control executive 
function (Ragozzino, Jih & Tzavos, 2002; Ragozzino, 2003, 2007; Buckner, 2004; Palencia 
& Ragozzino, 2004), and the striatum is relatively spared from Aβ pathology in Tg2576 mice 
(as stated in Zhuo et al., 2008). Furthermore, compensatory morphological improvements in 
dorsolateral striatal spiny neurons have been reported (Middei et al., 2004). Together, this 
may explain how some executive function is intact in Tg2576 mice. Supporting this, striatal-
dependant active avoidance performance and motor-response learning in the cross maze was 
intact or enhanced in Tg2576 mice aged 3 to 19 months (King et al., 1999; King & Arendash, 
2002; Middei et al., 2004). Although one study has reported a deficit at 22 months in a cued
T-maze discrimination task (Deacon et al., 2008), this may suggest that the striatum or its 
neural connections (such as the afferent corticostriatal connection) may be pathologically-
affected during advanced stages. 
Although no research has addressed the effect of DHA supplementation on PFC-dependant 
executive function in Tg2576 mice, it was predicted that DHA would reduce performance 
deficits based on results showing reduced cognitive deficits by DHA in Tg2576 mice in 
experiments 4 to 5 and previous research (e.g. Calon et al., 2004).
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4.5.2 Methods
4.5.2.1 Design and subjects
One cohort of male Tg2576 transgenic (Tg) and wildtype (WT) mice were evaluated in this 
task from 5.5 to 9 months of age, during the development of Aβ pathology and prior to 
plaque onset. The task consisted of three sub-experiments including: Stage 1) biconditional 
discrimination task training at 5.5 to 7 months of age, Stage 2) the Stroop interference test at 
7 months of age, and Stage 3) reversal discrimination training at 7.5 to 9 months of age. This 
design therefore investigated transgene- and diet-dependant changes in these PFC-dependant 
tasks.
The cohort of mice used in these experiments consisted of 8 Tg mice which received DHA 
diet (Tg DHA), 11 Tg mice which received the oil blend diet (Tg OB), 16 WT mice which 
received the DHA diet (WT DHA) and 15 WT mice which received the oil blend diet (WT
OB). In addition to these reported mouse group numbers, 7 mice were excluded from the 
experiment; 5 died before completing the experiment (3 Tg DHA, 1 WT DHA and 1 WT OB) 
and 2 failed to respond during initial training (1 Tg OB and 1 WT OB). The running order of 
mice was counterbalanced so that approximate equal numbers of each experimental group of 
mice were run in each batch, which were tested twice per day during all experiments once in 
the morning and once in the afternoon. Mice were run blindly to the experimenter. Mice were 
maintained on water restriction throughout these experiments (as detailed in the procedure), 
and gradually reduced to 85 to 90% of their ad lib body weights over 7 days prior to the start 
of the experiment.
4.5.2.2 Apparatus
All three experiments were conducted within 16 identical Med Associates® (St. Albans, 
Vermont, USA) mouse operant chambers 12cm tall, 15cm wide and 14cm deep. Each 
chamber (Figure 4.26) was situated within a wooden sound- and light-attenuating box to 
prevent permittance of external stimuli into the chamber. Each chamber was composed of 
aluminium with two transparent polycarbonate walls and a ceiling. The front-facing 
polycarbonate wall was on hinges to function as a door. The floor consisted of 20 stainless 
steel bars 2.5mm in diameter and spaced 5mm apart, which were situated 4cm above a 
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removable aluminium box containing wood chippings designed to collect defecation. An 
additional 12.5cm2 removable transparent Perspex sheet covered the bar flooring in half of 
the 16 boxes to create different contextual cues (bar floors = context 1; smooth floors = 
context 2). The apparatus was located in a quiet room. 
Figure 4.26 Mouse operant chamber and set-up used for biconditional discrimination, Stroop task and 
reversal learning experiments. Photograph depicts Context 2 (smooth flooring) with transparent 
polycarbonate sheet used in 8 of the 16 chambers. Context 1 (bar flooring), used in the remaining 8 
chambers, was identical but without the transparent polycarbonate sheet on the floor.
As shown in Figure 4.27, each chamber contained a magazine (2.5cm2), two identical nose-
poke manipulanda (10mm diameter) and two light-emitting stimulus lights (15cm height, 
above the nose-poke manipulanda) on one wall, and a 28V 100mA house light and sound-
emitting speaker on the other wall. Nose-poke manipulanda were used as opposed to levers in 
the operant chamber as nose-poke responses are readily required by mice (Crawley, 2007). 
Each nose-poke manipulanda contained a yellow stimulus light and an infra-red photo beam
to detect nose-poke entry. The recessed magazine also contained an infra-red photo beam 
which detected head entry responses and a yellow stimulus light which cued reinforcement 
delivery from a dipper dispenser attached to the magazine. The dipper delivered 0.04ml of 
one of two liquid reinforcements (dependant on the context), sourced from a container 
located immediately outside of the chamber, as shown in Figure 4.26. Liquid reinforcement 
was either a 20% sucrose solution flavoured with cherry Kool Aid (0.05% w/v) or a 10% 
maltodextrin solution flavoured with grape Kool Aid (0.05% w/v) (Cybercandy, London).
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Pilot studies demonstrated that these liquid reinforcements could be easily discriminated and 
were well matched for motivational value under a water restriction regime.
Figure 4.27 Layout of mouse operant chamber, showing location of magazine, nose-poke 
manipulanda, stimulus lights, house light and speaker.
The house and stimulus lights were used to deliver two types of visual stimuli to cue 
responding, including flashing illumination of the two stimulus lights (V1) or steady 
illumination of the house light (V2). Similarly, the speaker was used to deliver two types of 
auditory stimuli to cue responding, including a 2Hz tone (A1) or 2Hz buzz (A2). Each 
operant chamber was connected to a computer running MED-PC® software version IV (Med 
Associates Inc., Vermont, USA) which was programmed to control all stimulus presentations,
and record nose-poke responses and magazine entries. The software automatically calculated 
the number of correct and incorrect responses.
4.5.2.3 Procedure
All mice received pretraining, biconditional discrimination training, the stroop interference 
test and reversal discrimination training. During all training and test experiments, mice 
received two sessions per day, once in the morning in one context and once in the afternoon 
in the alternative context. Sessions were separated by a 4-hour period in which mice were 
returned to their home cages. To strength the distinction of the contexts, reinforcement-
context pairings were made whereby one liquid reinforcement (R1) was always provided in 
one context (C1), and the other liquid reinforcement (R2) was provided in the other context 
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(C2). Context order and reinforcement-context pairings were kept constant for each mouse 
during experiments. The combination of context, auditory and visual stimuli, nose-poke 
responses and reinforcement solutions were counterbalanced across mice and experimental 
groups as far as possible. Operant chambers were cleaned with 70% alcohol wipes after each 
session.
Pretraining
In order to form the association between the magazine and reinforcement delivery location, 
mice received two 20-minute sessions of magazine training for one day. During sessions the 
magazine light was illuminated to cue availability of liquid reinforcement which was 
delivered into the magazine on a random interval (RI) schedule of 30 seconds.  Mice then 
received 7 consecutive days of two 36-minute reinforced nose-poke training sessions per day, 
once in the morning in one context and once in the afternoon in the alternative context. Here, 
mice were trained to nose-poke respond to the illumination of nose-poke manipulanda 
stimulus lights to gain reinforcement. During each session, mice received 12 randomized 
trials of 6 left and 6 right 120-second nose-poke manipulanda stimulus light illuminations. 
When presented with a left illumination, the correct response was to nose-poke the left 
manipulanda. When presented with a right illumination, the correct response was to nose-
poke the right manipulanda. Following a correct response, reinforcement was immediately 
available and the magazine light was illuminated to cue the delivery. Each trial was separated 
by an average 50 second inter-trial interval (ITI), with a range of 40 to 60 seconds. The house 
light was not illuminated during training. Following successful nose-poke training, mice 
received nose-poke training on an RI-5, RI-10 and RI-15 schedule, each for one day, where 
reinforcement was available after an average of 5, 10 and 15 seconds respectively.
Stage 1: Biconditional discrimination training
Mice received 44 days of biconditional discrimination training, consisting of one 24-minute 
training session in the morning in one context (C1), and one session in the afternoon in the 
alternative context (C2). Each session contained 8 trials of 120-second discriminative 
stimulus presentations of auditory cues (A1 and A2) or visual cues (V1 and V2). Auditory 
and visual cues were only ever presented in separate contexts during training. Each trial was 
separated by a 50-second ITI, ranging from 40 to 60 seconds. Presentation of A1 in C1 or V1
176
in C2 would require either a left or right nose-poke response to receive reinforcement, and 
presentation of A2 in C1 or V2 in C2 would require the alternative nose-poke response. Both 
nose-poke manipulanda stimulus lights were illuminated for the duration of stimulus 
presentation. Reinforcement was available during the entire stimulus presentation and was 
delivered on a RI-15 schedule following a correct response. Correct responses were rewarded 
with 20% cherry-flavoured sucrose in one context and 10% grape-flavoured maltodextrin in 
the alternative context. The context, cue presentations and correct response-cue pairings were 
counterbalanced across mice and experimental groups.
An example of a typical biconditional discrimination training day for a mouse is shown in 
Table 4.3. This table shows that during morning trials in context 1 (bar floors [C1]), mice
received random presentations of the auditory cues (buzz or tone [A1 or A2]) and were 
required to perform the correct nose-poke response (left or right [NP1 or NP2]) to receive 
reinforcement (e.g. cherry-flavoured sucrose [R1]). In this example, A1 cued an NP1 
response and A2 cued an NP2 response. During afternoon trials in context 2 (smooth floors 
[C2]), mice received random presentations of the visual cues (stimulus lights or house lights 
[V1 or V2]) and were required to perform the correct nose-poke response (left or right [NP1 
or NP2]) to receive reinforcement (e.g. grape maltodextrin [R2]). In this example, V1 cued an
NP1 response and V2 cued an NP2 response.
Table 4.3 Experimental design for a biconditional discrimination training day. Pairings altered 
between mice subject to counterbalancing.
Session Context Cue type Correct response-cue pairings
Morning Bar floors (C1) Auditory (A) Buzz (A1) = Left nose-poke (NP1) 
Tone (A2) = Right nose-poke (NP2)
Afternoon Smooth floors (C2) Visual (V) Stimulus light (V1) = Left nose-poke (NP1)
House light (V2) = Right nose-poke (NP2)
Stage 2: Stroop interference test
Mice received 8 consecutive days of the Stroop interference test. Each day consisted of two 
30-minute test sessions, one in each context. Each session contained 2 types of probe trial 
(congruent and incongruent) and 8 reinforced training trials, separated with an ITI of an 
average of 50s ranging from 40 to 60 seconds. The training trials were identical to the 
biconditional discrimination trials (Stage 1). Probe trials involved presentations of auditory 
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and visual training stimuli combined into audiovisual stimulus compounds. These included 
presentations of A1V1 (buzz and stimulus lights), A1V2 (buzz and house light), A2V1 (tone 
and stimulus lights) and A2V2 (tone and house light). Each compound was presented for 30 
seconds and was presented in extinction whereby no reinforcement was available. 
Presentation of these audiovisual compounds could be classified as either congruent or 
incongruent. Congruent trials contained compounds that require the same response, based on 
the previously learnt ‘rules’ of training in Stage 1. As shown in Table 4.4, presentation of an 
A1V1 compound would require a NP1 (left nose-poke) response, regardless of context, as 
both A1 and V1 cued NP1. Similarly, both stimulus elements in the A2V2 compounds would 
cue a NP2 (right nose-poke) response, regardless of context. Responses consistent with these 
previously learnt ‘rules’ were recorded as correct, whilst those that were inconsistent were 
recorded as incorrect.
Incongruent trials however contained audiovisual compounds that cued conflicting responses. 
For example, presentation of the A1V2 compound required both a NP1 response (cued by 
A1) and NP2 response (cued by V2). This response conflict was also presented with the 
A2V1 compound. During such trials, the mouse must resolve the response conflict by using 
the contextual information to guide correct responding. That is, the nose-poke response that 
was consistent with the current context. As shown in Table 4.4, presentation of the A1V2 
compound in C1 (bar floors), where they had previously learnt the auditory discriminations 
A1 and A2, would require a response previously associated with the context – so NP1 
response cued by the A1 element of the compound. However, presentation of the compound 
in C2 (smooth floors), where they had previously learnt the visual discriminations V1 and 
V2, would require a response previously associated with the context – so NP2 response cued 
by the V2 element of the compound. Responses inconsistent with the context, such as a 
response associated with the V2 element of A1V2 presentation in C1, was therefore recorded 
as incorrect.
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Table 4.4 Experimental design for the Stroop interference test. Mice received one of each audiovisual 
compound in each context, which contained two congruent and two incongruent trials. Pairings 
altered between mice subject to counterbalancing.
Context + trial type Audiovisual compound Correct response
In C1 (Bar floors):
Congruent A1V1 (Buzz + Stimulus lights) NP1 (Left) 
Congruent A2V2 (Tone + House light) NP2 (Right)
Incongruent A1V2 (Buzz + House light) Guided by A1 = NP1 (Left)
Incongruent A2V1 (Tone + Stimulus lights) Guided by A2 = NP2 (Right)
In C2 (Smooth floors):
Congruent A1V1 (buzz + Stimulus lights) NP1 (Left)
Congruent A2V2 (Tone + House light) NP2 (Right)
Incongruent A1V2 (Buzz + House light) Guided by V1 = NP1 (Left)
Incongruent A2V1 (Tone + Stimulus lights) Guided by V2 = NP2 (Right)
Stage 3: Reversal discrimination training
Mice received 56 days of reverse discrimination training, whereby the previously learnt 
stimulus-response discriminations in Stage 1 were reversed. This experiment was identical to 
the biconditional discrimination training, except mice received identical training sessions in 
the morning and afternoon in only one context and with only one discrimination (either 
auditory or visual stimulus) presentation. Allocation of the context (and therefore auditory or 
visual stimulus presentations) was counterbalanced so that approximately half of each 
experimental group received reversed auditory discriminations and half reversed visual 
discriminations. Table 4.5 shows the new rules of the reversal discriminations, whereby the 
previously learnt discrimination rules in Stage 1 were reversed. A response inconsistent with 
the new reversal rules were recorded as incorrect.
Table 4.5 The experimental design for the reverse discrimination test. Presenting the original 
discrimination rules previously learnt in Stage 1, which were reversed for reversal discrimination 
training in this experiment. Showing the correct responses required for each stimulus. Each mouse 
received either auditory or visual discrimination reversal. Pairings altered subject to counterbalancing.
Original discrimination rules       Reversed discrimination rules
A1 (Buzz) = NP1 (Left), A2 (Tone) = NP2 (Right)    A1 = NP2, A2 = NP1
V1 (Stimulus lights) = NP1 (Left), V2 (House light) = NP2 (Right) V1 = NP2, V2 = NP1
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4.5.2.4 Data analysis
Statistical analysis of data has been described throughout the results section, with further 
details in chapter 2, section 2.4. During the discrimination trainings (Stage 1 and 3), only the 
SD’ (stimulus presentation prime) responses were examined. The SD’ responses were the 
measure of performance in the variable time period prior to reinforcement on the RI-15 
schedule during the 120-second stimulus presentation (SD). Similar to Haddon and Killcross 
(2005, 2006), examination of these responses prior to reinforcement availability was a 
measure of discrimination performance uncontaminated by the presentation of reward. 
4.5.3 Results
4.5.3.1 Pretraining results
In both contexts, all mice successfully learnt to collect liquid rewards from the magazine and 
produce nose-poke responses for reward.
4.5.3.2 Stage 1: Biconditional discrimination training results
Visual inspection of the mean number of correct and incorrect responses per minute for the 
visual and auditory discriminations revealed an obvious difference in response rates between 
groups. For ease of display, this has been shown in Figure 4.28 collapsing across stimulus 
types (auditory and visual) and day (1-44). Tg mice showed much higher response rates 
compared to WT mice, and mice fed the DHA diet also showed higher response rates, 
although both results appeared to be numerically driven by the Tg DHA group. Statistical 
analysis of this data using an ANOVA with between subjects factors of genotype (Tg, WT) 
and diet (DHA, OB) on the total number of responses per minute data revealed a significant 
effect of genotype (F(1,46)=10.734, p<0.01), a significant effect of diet (F(1,46)=4.463, 
p<0.05) and no significant genotype by diet interaction (F(1,46)=2.061, p>0.05). Similarly, 
analysis of the total correct responses data revealed a significant effect of genotype 
(F(1,46)=12.756, p<0.001), a significant effect of diet (F(1,46)=5.041, p<0.05) and no 
significant genotype by diet interaction (F(1,46)=1.841, p>0.05). Analysis of the total 
incorrect responses data revealed no significant effect of genotype (F(1,46)=3.771, p>0.05), a 
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significant effect of diet (F(1,46)=1.909, p>0.05) and no significant genotype by diet 
interaction (F(1,46)=1.741, p>0.05).
Figure 4.28 Mean number total SD’ responses per minute for each experimental group, displaying 
correct and incorrect response contributions, collapsed across stimulus types (auditory and visual) and 
days (1-44). SD’ responses = performance measure uncontaminated by reward delivery. Values are 
mean scores + S.E.M (correct responses) and - S.E.M (incorrect responses).
In order to account for this large difference in response rates between groups in evaluating 
acquisition of the discriminations, a discrimination ratio was calculated. Discrimination ratios 
(DR) were calculated using the following formula: [mean number of correct SD’ responses 
per minute / mean number of total SD’ responses per minute]. A DR of 0.5 was therefore 
equivalent to equal correct and incorrect responding, and was therefore not indicative of 
learning the auditory or visual stimulus discriminations. DRs were calculated for each trial 
and the data from the 44 acquisition days were averaged into eleven 4-day blocks for ease of 
presentation and analysis. Figure 4.29 shows the discrimination ratio data for each
experimental mouse group over blocked days during acquisition of the biconditional 
discriminations. The data in this figure was collapsed across stimulus type (auditory and 
visual discriminations) to display overall group differences. Visual inspection of this figure 
shows that Tg mice, particularly those fed the DHA diet, successfully discriminated auditory 
and visual stimuli better than WT groups. 
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Statistical analysis of this data using an ANOVA with genotype (Tg, WT) and diet (DHA, 
OB) as between-subject factors, and blocked days (1-11) as a within-subject factor, revealed 
a significant main effect of genotype (F(1,46)=22.781, p<0.001), no significant main effect of 
diet (F(1,46)=3.387, p>0.05) and no significant interaction between these factors 
(F(1,46)=3.174, p>0.05). Analysis also revealed a significant effect of block 
(F(10,460)=47.485, p<0.001), a significant interaction of block by genotype 
(F(10,460)=9.498, p<0.001) and a significant interaction of block by diet (F(10,460)=3.171, 
p<0.001). A follow-up of simple main effects revealed a significant main effect of genotype 
at blocks 3 to 11 (smallest F(1,46)=5.94, p<0.05) and a main effect of diet at blocks 4, 7, 8 
and 11 (smallest F(1,46)=4.18, p<0.05). Statistical analysis therefore confirmed that Tg mice 
showed superior discrimination acquisition relative to WT mice, and that DHA 
supplementation further enhanced performance. 
Indeed, analysis also revealed a significant three-way interaction of block by genotype by diet 
(F(10,460)=2.506, p<0.01). Following up this interaction with a test of simple interactions, a 
near-significant interaction of genotype by diet was revealed at block 6 (F(1,46)=4.01, 
p=0.051), which was significant at block 11 (F(1,46)=10.54, p<0.01). Following-up this 
significant interaction at block 11, a test of simple main effects revealed Tg OB mice 
performed significantly better than WT OB mice (F(1,46)=4.36, p<0.05), and Tg DHA 
performed significantly better than WT DHA mice (F(1,46)=29.24, p<0.001) and Tg OB 
mice (F(1,46)=11.27, p<0.01). DHA supplementation therefore enhanced performance in Tg 
mice.
182
Figure 4.29 Acquisition of discriminations during the biconditional discrimination acquisition phase 
across 4-day blocks, collapsed across stimulus types. Graph showing the mean discrimination ratio 
(correct SD’ responses per minute/total SD’ responses per minute). SD’ responses = performance 
measure uncontaminated by reward delivery. DR of 0.5 = equal level of correct and incorrect 
responding. Error bars represent ± S.E.M.
Prior to proceeding to the Stroop interference test (Stage 2), it was important to ensure that all 
experimental mouse groups had acquired the biconditional discriminations. Visual inspection 
of Figures 4.30 and 4.31, showing the discrimination ratios for auditory and visual 
discriminations respectively for each group over blocked days, depicts that all groups 
performed above the 0.5 chance level. In order to test this, unpaired samples t-tests compared 
the auditory DR and visual DR to chance levels (DR 0.5) for each group separately using the 
4-day blocks of data. Statistical analysis revealed all groups significantly discriminated the 
auditory stimulus presentations at blocks 1 to 11 (smallest t(14)=18.219, p<0.01), and the 
visual stimulus presentations at blocks 1 to 11 (smallest t(14)=9.833, p<0.001). This was 
particularly shown at the final block of training (block 11) for auditory discriminations 
(smallest t(28)=15.039, p<0.001) and visual discriminations (smallest t(14)=27.346, 
p<0.001). Thus, all mice produced significantly more correct than incorrect responses on both 
the auditory and visual discriminations during training, as shown in Figures 4.30 and 4.31.
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Figure 4.30 Acquisition of auditory stimulus discriminations during the biconditional discrimination 
acquisition phase across 4-day blocks. Graph showing the mean discrimination ratio (correct SD’ 
responses per minute/total SD’ responses per minute). SD’ responses = performance measure 
uncontaminated by reward delivery. DR of 0.5 = equal level of correct and incorrect responding. Error 
bars represent ± S.E.M.
Figure 4.31 Acquisition of visual stimulus discriminations during the biconditional discrimination 
acquisition phase across 4-day blocks. Graph showing the mean discrimination ratio (correct SD’ 
responses per minute/total SD’ responses per minute). SD’ responses = performance measure 
uncontaminated by reward delivery. DR of 0.5 = equal level of correct and incorrect responding. Error 
bars represent ± S.E.M.
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4.5.3.3 Stage 2: Stroop interference test results
Similar to the results of Stage 1, the mean number of correct and incorrect responses per 
minute for the training, congruent and incongruent trials of Stage 2 revealed a significant 
difference in response rates between groups. During training trials, Tg mice (particularly Tg 
DHA) showed much higher total response rates compared to WT mice, and Tg mice fed the 
DHA diet showed higher response rates than Tg OB mice (Figure 4.32). Statistical analysis 
using an ANOVA with between-subjects factors of genotype (Tg, WT) and diet (DHA, OB) 
on the total number of responses data revealed a significant effect of genotype 
(F(1,46)=75.478, p<0.001), no significant effect of diet (F(1,46)=3.808, p>0.05) and no 
significant genotype by diet interaction (F(1,46)=1.122, p>0.05). Similar analysis of the total 
correct responses data revealed a significant effect of genotype (F(1,46)=12.048, p<0.001), a 
significant effect of diet (F(1,46)=4.396, p<0.05) and no significant genotype by diet 
interaction (F(1,46)=2.630, p>0.05). Analysis of the total incorrect responses data revealed 
no significant effect of genotype (F(1,46)=0.595, p>0.05), no significant effect of diet 
(F(1,46)=1.690, p>0.05) and no significant genotype by diet interaction (F(1,46)=0.026, 
p>0.05).
Figure 4.32 Mean number total SD’ responses per minute for each experimental group, displaying 
correct and incorrect response contributions during training trials, collapsed across days (1-8). SD’ 
responses = performance measure uncontaminated by reward delivery. Values are mean scores + 
S.E.M (correct responses) and - S.E.M (incorrect responses).
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During congruent trials, Tg DHA mice appeared to show much higher total response rates 
compared to all groups, and WT OB mice showed lower responses than WT DHA mice 
(Figure 4.33). Statistical analysis using an ANOVA with between subjects factors of 
genotype and diet on the total number of responses data revealed a significant effect of 
genotype (F(1,46)=5.842, p<0.05), a significant effect of diet (F(1,46)=4.053, p<0.05) and no 
significant genotype by diet interaction (F(1,46)=0.731, p>0.05). Similar analysis of  the total 
correct responses data revealed a significant effect of genotype (F(1,46)=8.990, p<0.01), a 
significant effect of diet (F(1,46)=4.052, p<0.05) and no significant genotype by diet 
interaction (F(1,46)=1.045, p>0.05). Analysis of the total incorrect responses data revealed a 
significant effect of genotype (F(1,46)=4.951, p<0.05), no significant effect of diet 
(F(1,46)=1.358, p>0.05) and no significant genotype by diet interaction (F(1,46)=0.299, 
p>0.05).
Figure 4.33 Mean number total SD’ responses per minute for each experimental group, displaying 
correct and incorrect response contributions during congruent trials, collapsed across days (1-8). SD’ 
responses = performance measure uncontaminated by reward delivery. Values are mean scores + 
S.E.M (correct responses) and - S.E.M (incorrect responses).
During incongruent trials, Tg mice (particularly Tg DHA) showed higher total response rates 
compared to WT mice, as shown in Figure 4.34. Furthermore, Tg DHA mice showed higher 
response rates than Tg OB mice, and WT DHA mice showed higher response rates than WT 
DHA mice. Statistical analysis using an ANOVA with between subjects factors of genotype 
and diet on the total number of responses data revealed a significant effect of genotype 
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(F(1,46)=4.232, p<0.05), no significant effect of diet (F(1,46)=2.206, p>0.05) and no 
significant genotype by diet interaction (F(1,46)=0.393, p>0.05). Similar analysis of the total 
correct responses data revealed a significant effect of genotype (F(1,46)=4.905, p<0.05), no 
significant effect of diet (F(1,46)=3.618, p>0.05) and no significant genotype by diet 
interaction (F(1,46)=0.790, p>0.05). Analysis of the total incorrect responses data revealed 
no significant effect of genotype (F(1,46)=2.291, p>0.05), no significant effect of diet 
(F(1,46)=0.225, p>0.05) and no significant genotype by diet interaction (F(1,46)=0.001, 
p>0.05).
Figure 4.34 Mean number total SD’ responses per minute for each experimental group, displaying 
correct and incorrect response contributions during incongruent trials, collapsed across days (1-8). SD’ 
responses = performance measure uncontaminated by reward delivery. Values are mean scores + 
S.E.M (correct responses) and - S.E.M (incorrect responses).
Due to these differences in response rates, performance was analysed using discrimination 
ratios. Data was collapsed across testing days (1-8). Figure 4.35 illustrates that all mice 
showed higher discrimination ratios (therefore higher proportion of correct responses) for 
congruent compound trials relative to incongruent compound trials, which is consistent with 
Stroop interference literature. Interestingly, Tg mice appear to perform better than WT mice 
during congruent trials, although all groups appear to perform better than chance (DR 0.5), 
thereby demonstrating memory for the biconditional discriminations. Furthermore, Tg DHA 
mice appear to perform better than all groups during incongruent trials, and mice fed the 
DHA diet appear to be the only groups that performed better than chance, indicating memory 
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for the biconditional discriminations and its use to guide responding during presentation of 
incongruent compounds.
Statistical analysis using an ANOVA with genotype (Tg, WT) and diet (DHA, OB) as 
between-subject factors on congruent data revealed a significant main effect of genotype 
(F(1,46)=19.929, p<0.001) and diet (F(1,46)=45.709, p<0.05), but no significant interaction 
of genotype by diet (F(1,46)=2.106, p>0.05). This therefore confirms that Tg mice performed 
better than WT mice on congruent trials, and that DHA supplementation enhanced 
performance, although the latter appears to be predominately driven by Tg mice as WT 
groups show similar performance. Interestingly, the trend showing that Tg DHA was 
predominately driving the significant genotype effect was not statistically supported by a 
significant interaction. Similar statistical analysis on the incongruent data revealed a 
significant main effect of genotype (F(1,46)=5.645, p<0.05) and diet (F(1,46)=16.433, 
p<0.001), but no significant interaction of genotype by diet (F(1,46)=1.771, p>0.05). Similar 
to the congruent data, these results confirm that Tg mice performed better than WT mice on 
incongruent trials and that DHA supplementation generally enhanced performance across all 
groups. It is interesting to note that the effect of diet appeared to be predominately driven by 
the Tg DHA group, but this was not statistically supported by a significant interaction.
In order to test whether groups successfully showed above-chance performance on congruent 
trials, DR data from each group on the last day of training was compared to chance levels 
(DR 0.5) using an unpaired samples t-test. Statistical analysis revealed all groups differed 
significantly from chance; Tg DHA (t(14)=21.723, p<0.001), Tg OB (t(18)=19.790, 
p<0.001), WT DHA (t(28)=26.614, p<0.001) and WT OB (t(30)=28.051, p<0.01). This 
confirmed that all mice demonstrated memory for the biconditional discriminations. A similar 
analysis of the incongruent trials using an unpaired samples t-test showed all groups except 
WT OB mice differed significantly from chance; Tg DHA (t(14)=15.537, p<0.01), Tg OB 
(t(18)=46.028, p<0.05), WT DHA (t(28)=27.399, p<0.05) and WT OB (t(30)=26.905, 
p>0.05). This therefore shows that all mice except the WT OB group were able to 
successfully utilise the contextual information to guide responding during incongruent trials
by the end of training. The statistical analysis reflects the pattern of results during 
incongruent trials shown in Figure 4.35, whereby Tg DHA mice performed particularly above 
chance levels, with Tg OB and WT DHA mice performing less well, and WT OB failing to 
perform significantly above chance.
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Figure 4.35 Mean discrimination ratio data for the congruent and incongruent compound probe trials, 
collapsed across testing days 1 to 8. Error bars represent + S.E.M.
Mice were given 8 reinforced training trials during the Stroop interference test to re-establish 
performance on the biconditional discriminations. Figure 4.36 depicts the average 
performance during training trials for each experimental group. Similar to Stage 1, the figure 
shows Tg mice performed better than WT mice, but with little effect of diet. Statistical 
analysis of this data using an ANOVA with between-subject factors of genotype and diet 
revealed a significant main effect of genotype (F(1,46)=16.768, p<0.001), no significant main 
effect of diet (F(1,46)=01.147, p>0.05) and a significant genotype by diet interaction 
(F(1,46)=5.778, p<0.05). To follow-up this interaction, a test of simple main effects revealed
Tg DHA mice performed significantly better than WT DHA mice (F(1,46)=18.28, p<0.001). 
To examine whether experimental groups were correctly discriminating above chance levels, 
training trial DR data from each group on the last day of training was compared to chance 
levels (DR 0.5) using an unpaired samples t-test. Statistical analysis revealed all groups 
differed significantly from chance; Tg DHA (t(14)=15.815, p<0.001), Tg OB (t(18)=12.049, 
p<0.001), WT DHA (t(28)=21.075, p<0.001) and WT OB (t(30)=11.740, p<0.001). All 
groups therefore showed successful discrimination of auditory and visual stimulus 
presentations during testing.
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Figure 4.36 Mean discrimination ratio data (correct SD’ responses per minute/total SD’ responses per 
minute) for the training trials, collapsed across testing days. SD’ responses = performance measure 
uncontaminated by reward delivery. DR of 0.5 = equal level of correct and incorrect responding. Error 
bars represent + S.E.M.
4.5.3.4 Stage 3: Reversal discrimination training results
Similar to the results from Stages 1 and 2, the mean number of correct and incorrect 
responses per minute during the reversal training revealed an obvious difference in response 
rates between groups, as shown in Figure 4.37. For ease of display, the results have been 
collapsed across stimulus types (auditory and visual) and day (1-56). Tg DHA mice showed 
much higher response rates than all other groups. In particular, this was driven by higher 
correct response rates. All other groups showed relatively similar levels of correct responses 
(although WT OB showed fewer), and all groups showed a similar level of incorrect 
responding. Statistical analysis of this data using an ANOVA with between-subjects factors 
of genotype (Tg, WT) and diet (DHA, OB) using the total number of responses per minute 
data revealed no significant effect of genotype (F(1,46)=2.313, p>0.05), no significant effect 
of diet (F(1,46)=2.474, p>0.05) and no significant genotype by diet interaction 
(F(1,46)=0.458, p>0.05). Analysis of the total correct responses data revealed no significant 
effect of genotype (F(1,46)=3.236, p>0.05), a significant effect of diet (F(1,46)=4.451, 
p<0.05) and no significant genotype by diet interaction (F(1,46)=0.966, p>0.05). Analysis of 
the total incorrect responses data revealed no significant effect of genotype (F(1,46)=0.584, 
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p>0.05), no significant effect of diet (F(1,46)=0.129, p>0.05) and no significant genotype by 
diet interaction (F(1,46)=0.001, p>0.05).
Figure 4.37 Mean number total SD’ responses per minute for each experimental group, displaying 
correct and incorrect response contributions, collapsed across stimulus types (auditory and visual) and 
days (1-56). SD’ responses = performance measure uncontaminated by reward delivery. Values are 
mean scores + S.E.M (correct responses) and - S.E.M (incorrect responses).
Due to these differences in response rates, performance was analysed using discrimination 
ratios. Data from the 56 acquisition days were averaged into fourteen 4-day blocks for ease of 
presentation and analysis. Figure 4.38 shows the discrimination ratio data for each
experimental mouse group over blocked days during acquisition of reversed discriminations.
The data in this figure was collapsed across stimulus type (auditory and visual 
discriminations) to show overall group differences. Visual inspection of this figure shows that
Tg mice, particularly those fed the DHA diet, successfully acquired reversed discriminations 
better than WT groups, indicative of enhanced reversal learning.
Statistical analysis of this data using an ANOVA with genotype (Tg, WT) and diet (DHA, 
OB) as between-subject factors, and block (1-14) as a within-subject factor, revealed a 
significant main effect of genotype (F(1,46)=5.407, p<0.05), no significant main effect of diet 
(F(1,46)=1.946, p>0.05) and no significant interaction between these factors (F(1,46)=0.312, 
p>0.05). Analysis also revealed a significant effect of block (F(13,598)=42.615, p<0.001), a 
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significant interaction of block by genotype (F(13,598)=4.147, p<0.001), no significant 
interaction of block by diet (F(13,598)=0.737, p>0.05), and no significant three-way 
interaction of block by genotype by diet (F(13,598)=0.540, p>0.05). A follow-up of simple 
main effects revealed a significant effect of genotype at blocks 6 and 8 to 14 (smallest 
F(1,46)=4.60, p<0.05). Overall, statistical analysis confirmed that Tg mice were superior at 
acquiring reverse discriminations relative to WT mice, and that diet failed to alter 
performance. However, the overall effect of genotype appeared to be numerically driven by 
the Tg DHA group. 
Figure 4.38 Acquisition of reversed discriminations during the reversal discrimination training across 
4-day blocks, collapsing across stimulus types (auditory and visual). Graph showing the mean 
discrimination ratios (correct SD’ responses per minute/total SD’ responses per minute). SD’ responses 
= performance measure uncontaminated by reward delivery. DR of 0.5 = equal level of correct and 
incorrect responding. Error bars represent ± S.E.M.
4.5.4 Discussion
Stage 1: Biconditional discrimination training
Stage 1 of experimentation investigated the effect of transgene and DHA supplementation on 
performance in the biconditional discrimination task at 5.5 to 7 months of age. Interestingly, 
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inspection of correct and incorrect SD’ responses per minute revealed group differences 
whereby Tg mice showed significantly higher response rates than WT mice, and DHA 
supplementation also increased responses rates, although both results appeared to be 
predominately driven by the Tg DHA group. These results may be suggestive of 
hyperactivity in Tg2576 mice, which has been documented in tasks including the open field, 
Y-maze, automated activity boxes and the circular open field activity chamber (King et al.,
1999; King & Arendash, 2002; Lalonde et al., 2003; Asuni et al., 2006; Deacon et al., 2008, 
2009). Interestingly, DHA supplementation increased response rates in mice (particularly Tg 
mice), perhaps suggesting that DHA also increased hyperactivity. In order to compensate for 
these group differences which may otherwise bias interpretation of results, discrimination 
ratios (DR) were calculated and analysed for all experiments.
DR results from biconditional discrimination training showed that both Tg and WT mice fed 
the DHA and oil blend diet significantly acquired the auditory and visual discriminations 
from blocks 1 to 11. This lack of transgene deficit in Tg mice was as hypothesised, and was 
consistent with previous reports by Zhuo et al. (2007, 2008) who found 6- and 14-month old 
Tg2576 mice successfully acquired simple discriminations whereby 1 odour or digging 
medium was rewarded over the other odour or digging medium. This was also consistent with 
reports by Barnes, Hale and Good (2004) who found Tg2576 mice at 12 to 14 months to 
successfully acquire a contextual biconditional left-right discrimination in the T-maze, as 
well as an intramaze brightness discrimination and simple room discrimination.
When examining group differences during acquisition of the biconditional discriminations 
(collapsing across stimulus type), the results interestingly revealed Tg mice discriminated 
significantly better than WT mice. This effect was predominately driven by the Tg DHA 
group as Tg OB mice performed significantly worse than Tg DHA mice, although Tg OB 
also performed significantly better than WT. This therefore shows that Tg mice on the control 
oil blend diet were not impaired at acquiring the biconditional discriminations relative to WT 
mice, and DHA enhanced Tg performance. This lack of transgene deficit in Tg2576 mice was 
consistent with reports by Zhuo et al. (2007, 2008). This experiment presents the first 
evidence that DHA supplementation can enhance executive function in Tg2576 mice, which 
is somewhat supported by positive effects of DHA supplementation in other cognitive tasks 
(e.g. Calon et al., 2004).
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Stage 2: Stroop interference test
Similar to Stage 1, the Stroop test results revealed a significant difference in response rates 
between groups. Tg mice had significantly higher responses during training, congruent and 
incongruent trials. DHA supplementation also resulted in significantly higher responses 
during training and congruent trials, with a non-significant trend in Tg mice during 
incongruent trials. In order to compensate for these group differences, discrimination ratios 
(DR) were calculated and analysed for all data. 
Similar to the results found during biconditional discrimination training, all groups 
discriminated significantly above chance levels during the reinforced training trials in the 
Stroop interference test at 7 months. Similarly to Stage 1, Tg mice performed significantly 
better than WT mice and this effect appeared to be driven by Tg DHA mice. Indeed, Tg DHA 
(not Tg OB) mice performed better than WT groups. This therefore indicates that Tg mice on 
the control oil blend diet were not impaired at acquiring the biconditional discriminations 
relative to WT mice during the Stroop test, and DHA enhanced Tg performance to levels 
significantly better than WT groups. Diet failed to alter WT performance. This lack of 
transgene deficit was as predicted, and is consistent with previous reports by Zhuo et al. 
(2007, 2008) who found Tg2576 mice aged 6- and 14-months to successfully acquire 
compound discriminations whereby mice had to discriminate between simple odour stimuli in 
the presence of an irrelevant dimension (digging medium). This lack of transgene deficit was 
also corroborated by Barnes, Hale & Good (2004) who reported Tg2576 mice aged 12 to 14 
months successfully acquired a contextual biconditional left-right discrimination in the T-
maze, as well as an intramaze brightness discrimination and simple room discrimination.
Analysis of congruent trials during the Stroop interference test showed that all mouse groups 
could successfully discriminate above chance levels (equivalent to equal correct and incorrect 
responding) using the previously learnt stimulus-reward associations acquired in Stage 1. 
This lack of discrimination deficit in Tg2576 mice was consistent with reports by Zhuo et al. 
(2007, 2008) and Barnes, Hale and Good (2004). These results were also consistent with 
reports of AD patients in congruent trials of the human Stroop test (Koss et al., 1984; Perry & 
Hodges, 1999; Amieva et al., 2002, 2004a, 2004b). 
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Examination of congruent trial data also revealed Tg2576 mice performed significantly better 
than WT mice. This enhanced performance in congruent trials by Tg2576 mice is consistent 
with reports by Spieler et al. (1996) who found that AD patients displayed facilitated 
performance on congruent trials in the human Stroop test. One explanation for this facilitation 
in AD patients is that a deficit in attentional or inhibitory control of responses leads to 
immediate output of the dominant word pathway which is processed faster than colour 
processing. In contrast, age-matched controls have slower responses due to consideration of 
the instructions given during compound presentation, which is guided by inhibitory or 
attentional control. As a result, AD patients display lower response times which could be a 
result of disinhibitory behaviour rather than increased cognitive performance. The same 
argument could be applied to Tg2576 mice which show enhanced performance during 
congruent trials of the Stoop interference test. However, this genotype effect appeared to be 
driven by the Tg DHA group. Although this was not supported statistically, DHA 
supplementation was shown to significantly improve performance (which appeared to be 
numerically driven by the Tg DHA group). This therefore indicates that Tg mice fed the 
control oil blend diet were not impaired on the congruent trials, and similarly did not show 
enhanced performance unless fed the DHA diet. Based on the previous argument, it is unclear 
whether DHA supplementation increased cognitive performance or increased a tendency to 
show disinhibitory responses. The similar enhanced performance in biconditional 
discrimination training would support the argument for increased cognitive performance 
rather than the latter.
Examination of the incongruent trial data relative to congruent trial data revealed that all 
groups performed significantly better at congruent trials, consistent with Stroop test literature 
whereby the response-conflict caused by incongruent compounds leads to a reduction in 
correct responses (Stroop, 1935). This ‘interference effect’ was thereby present in all mice. 
Interestingly, analysis of incongruent trial data revealed that Tg2576 mice performed better 
than WT mice during incongruent trials, and WT OB mice failed to perform significantly 
above chance (in contrast to all other groups). Again, this result appeared to be driven by the 
Tg DHA group as Tg OB mice had similar responses to WT groups. Although no significant 
interaction was found to support this, DHA supplementation was shown to significantly 
improve performance. Overall therefore, Tg mice were not impaired in incongruent trials, and 
DHA supplementation enhanced executive function (particularly in Tg mice). These results 
suggest that Tg2576 mice had no difficulty in inhibiting automatic responses during 
195
incongruent presentations and were able to successfully utilise the contextual information to 
guide responding during incongruent trials. This was contrary to predictions, since previous 
research has shown the PFC to be pathologically affected at 6 months, which was anticipated 
to affect executive function (Zhuo et al., 2008). The results were also inconsistent with 
human literature whereby AD patients show stronger interference effects than age-matched 
controls (Koss et al., 1984; Perry & Hodges, 1999; Amieva et al., 2002, 2004a, 2004b). 
The result showing that all groups except the WT OB group could perform significantly 
above chance during incongruent trials is interesting and suggests that WT mice are unable to 
successfully utilise the contextual information to guide responding during incongruent trials.
Similarly, Zhuo et al. (2008) reported poor performance in WT control mice during a reversal 
learning task at 14 months of age, but interestingly, not at 6 months of age. Importantly the 
results also suggest that DHA supplementation can improve WT performance and enable 
successful performance during incongruent trials. DHA supplementation therefore appears to 
enhance performance in both Tg and WT mice in this task.
Stage 3: Reversed discrimination training
Reversal training was carried out at 7.5 to 9 months of age. Similar to Stages 1 and 2, the 
reversal training results revealed a significant difference in response rates between groups. 
Statistical analysis revealed that DHA supplementation significantly produced higher correct 
responses. This appeared to be numerically driven by the Tg DHA group, similar to results in 
Stages 1 and 2, although this was not supported statistically. Unlike Stages 1 and 2, Tg mice 
did not show significantly higher response rates, although Tg DHA were numerically higher 
than all groups. In order to compensate for this difference, discrimination ratios (DR) were 
calculated and analysed for all data, consistent with previous data analysis.
DR results revealed that Tg mice acquired the reverse discriminations more effectively than 
WT mice. This enhanced learning was particularly shown on blocked days 6 and 8 to 14. 
Although no significant effect of diet or interaction was shown, the effect of genotype 
appeared to be predominately driven by Tg DHA mice, indicative of enhanced performance 
by DHA supplementation. 
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These results were inconsistent with previous reports of impaired reversal discrimination 
learning in Tg2576 mice at 6 months of age in versions of an attentional set-shifting test (see 
Zhuo et al., 2007, 2008). These results were also inconsistent with reports by Pompl et al. 
(1999) who found that Tg2576 mice aged 7 months showed a robust reversal learning 
impairment in an adapted circular platform task. Moreover, results were in contrast to 
reversal learning impairments reported in AD patients tested in the Stroop test (Perry & 
Hodges, 1999; Amieva et al., 2004b). In contrast to these studies however, the results were 
consistent with reports of intact reversal learning in Tg2576 mice at a later age. For example, 
Dong et al. (2005) reported intact reversal learning in a water-based T-maze task at 11 
months. Similarly, Zhuo et al. (2007) reported no deficits at 14 months in reversed compound 
discriminations and during reversed intra-dimensional shifts (although it was argued that this 
was a result of poor WT performance). In an attempt to explain these differences, it could be 
argued that reversal learning deficits in Tg2576 mice may be associated with early stages of 
pathological development such as the increase in soluble Aβ, which is then lost during later 
stages when soluble Aβ is reduced and insoluble Aβ increases. Since soluble Aβ species are 
converted to insoluble forms during the time of experimentation at 7.5 to 9 months of age 
(Kawarabayashi et al., 2001), this may explain the transgene effect observed whereby Tg 
mice did acquire reverse discriminations. Further research is therefore required to examine 
the progression of PFC-related deficits and their underlying pathological cause.
Together the results from these experiments show that Tg2576 mice can successfully acquire 
biconditional discriminations and use information acquired during this initial training to 
guide responding in congruent trials of the Stroop test. Tg2576 mice could also successfully 
utilise the contextual information to guide responding during incongruent trials (in contrast to 
WT OB mice). Furthermore, Tg2576 mice showed intact acquisition of reversed 
discriminations at 7.5 to 9 months of age. Overall therefore, these results suggest that PFC-
dependant executive function is generally intact. Further research to probe PFC-function 
longitudinally in Tg2576 mice at different ages is required to examine if and when deficits 
emerge. Further to this, these experiments also provide evidence that DHA supplementation 
can improve executive function, primarily in Tg2576 mice.
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4.6 Chapter discussion
The aim of this chapter was to examine the behavioural phenotype of the Tg2576 model from 
an early age using a large battery of anxiety and cognitive tasks and to assess the effect of 
DHA supplementation on performance. Tg2576 and WT mice were examined in the elevated 
plus maze, marble burying task, foraging task, the biconditional discrimination task, the 
Stroop test and a reverse discrimination task. The tasks probed a wide-range of behaviours 
dependant on hippocampal, amygdala and prefrontal-cortex function. 
Previous studies have reported early emerging deficits from 3 months of age in the Tg2576 
model including impaired spontaneous alternation in the Y-maze, water maze retention in the 
water maze probe test, circular platform performance, memory retention of a footshock in the 
passive avoidance test, and hyperactivity in the open field and Y-maze (Hsiao et al., 1996; 
King et al., 1999). The absence of Aβ pathology reported before 4 to 5 months of age 
(Westerman et al., 2002) would suggest the involvement of other pathological processes. 
Supporting this, progressive synaptic deficits have been reported from 4 months of age, 
including a reduction in dendritic spine density, LTP impairment and basal synaptic 
transmission deficit in DG and CA1 hippocampal regions (Lanz, Carter & Merchant, 2003; 
Jacobsen et al., 2006). Moreover, a non-significant 8% reduction in dendritic spine density 
was also reported from 2 months of age (Jacobsen et al., 2006), with a significant 6% loss 
occurring between 2 and 4.5 months (Lanz, Carter & Merchant, 2003). The progressive 
worsening of such deficits until 18-20 months of age would suggest the involvement of Aβ-
related pathology. Corroborating these early changes, Klingner et al. (2003) reported 
cholinergic and noradrenaline neurotransmitter receptor alterations at 5 months. Although the 
underlying mechanisms of these early changes remain unclear, it is evident that pathological 
processes begin from an early age which is related to early-emerging behavioural deficits.
Consistent with reports of early-emerging behavioural changes, experiment 4 revealed 
transgene-related deficits in the elevated plus maze and marble burying task at 3 months of 
age. Furthermore, experiment 5 revealed impaired performance in the foraging task at 3 
months of age. These deficits were reported again between 10 and 10.5 months of age, 
suggesting a robust impairment in these tasks. Together these results suggest impaired 
hippocampal- and amygdala-function from an early age, before and during Aβ deposition. 
These changes therefore support the need for investigation of early-stage therapeutic 
198
strategies. The transgene-deficit in the foraging task at 10.5 months was consistent with 
previous reports of spatial memory impairments around this age in several tasks such as the 
Morris water maze, T-maze, paddling Y-maze and appetitive Y-maze (Hsiao et al., 1996; 
Barnes, Hale & Good, 2004; Deacon et al., 2008; Adriani et al., 2006). The results of these 
experiments therefore highlight the potential use of 2 pre-existing tasks and 1 novel task in 
detecting transgene-related deficits from an early age in the Tg2576 model.
Experiment 6 was one of the few assessments of PFC-dependant function in Tg2576 mice, 
and used three tasks never before assessed in this model. Firstly, the results interestingly 
revealed increased response rates in Tg2576 mice, suggestive of hyperactivity which was 
consistent with previous reports in other tasks (e.g. King & Arendash, 2002). Analysis of 
discrimination ratio data from these experiments overall showed that PFC-dependant 
executive function is intact in Tg2576 mice at 5.5 to 9 months of age. The biconditional 
discrimination results were supported by previous studies, whereby Tg2576 mice showed 
intact acquisition of a simple discrimination, compound discrimination, contextual 
biconditional left-right discrimination, intramaze brightness discrimination and a simple room 
discrimination at 6 and 12-14 months (Zhuo et al., 2007, 2008; Barnes, Hale & Good, 2004). 
In contrast, intact Tg2576 performance during incongruent trials of the Stroop test was 
contrary to predictions. Intact reversal learning was also contrary to predictions and 
inconsistent with some literature of reversal learning impairments at 6 and 7 months of age 
(Zhuo et al., 2007, 2008; Pompl et al., 1999). In contrast however, some studies supported 
our results by showing no reversal learning deficits in other tasks at 11 and 14 months of age 
(Dong et al., 2005; Zhuo et al., 2007). Together, it was suggested that reversal learning 
deficits may be associated with early, not late, stages of pathology. This questions to what 
extent Aβ pathology affects executive function in Tg2576 mice. Overall, this highlights the 
need for further examination of PFC-function in Tg2576 mice. 
With regards to DHA supplementation, further investigation was required in the Tg2576 
model as previous studies failed to assess the effect of early-stage intervention or assess DHA 
supplementation per se relative to a suitable baseline control diet. The detection of synaptic 
changes and behavioural impairments from as early as 3 months of age in the Tg2576 model 
highlighted the need for early intervention strategies. This was supported by the experiments 
in this chapter. The second aim of this chapter was therefore to examine the effect of DHA 
supplementation by comparing it to a suitable baseline control diet which had very similar 
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levels of omega-6 PUFAs and total fatty acids, with compensatory increases in ‘neutral’ fatty 
acids to substitute the DHA content in the DHA diet. The primary difference between the 
diets was therefore the addition of DHA and an increase in the ω-3/ω-6 ratio caused by the 
DHA supplementation.
Experiments 4 and 5 revealed some evidence that DHA supplementation reduced transgene-
related deficits in Tg2576 mice at 3 months of age in the elevated plus maze, marble burying 
task and the foraging task. These results therefore suggest that dietary DHA may target very 
early pathological processes emerging prior to Aβ development. Secondly, the results suggest 
that DHA may ameliorate dysfunction specific to hippocampal and amygdala regions, which 
are thought to control such behaviour (e.g. Hsiao et al., 1996; LeDoux, 2000; Deacon & 
Rawlins, 2005). Positive effects of DHA supplementation on PFC-dependant executive 
function were also found in mice aged 5.5 to 9 months in experiment 6. Although this effect 
was primarily generic to both Tg and WT mice, some results suggested that this was specific 
to Tg mice. In contrast to previous experiments, DHA supplementation interestingly 
enhanced Tg2576 performance when a transgene-deficit was not present. Moreover, DHA 
supplementation enhanced performance in Tg mice above WT levels. At the later age of 10 
months, the positive effect of DHA supplementation in experiments 4 and 5 were less 
prominent. Although the elevated plus maze task provided strong evidence that DHA 
supplementation reduced deficits in Tg mice and enhanced WT performance, no diet effects 
were evident in the marble burying task. Some positive effects of DHA supplementation in 
reducing a transgene-deficit was also observed in the foraging task, although these were 
limited to a reduction in the number of total and consecutive return errors. Although no 
significant effects of DHA were found on the other measures, a non-significant reduction in 
Tg deficits was observed.
Together, these results suggest that DHA supplementation can provide some protection 
against transgene-induced deficits and improve normal cognitive performance at an early age 
in Tg2576 mice, but its efficiency reduced over time in 10-10.5 month old mice. Although 
these results may suggest that short-term dietary intervention is more effective than long-term 
intervention, the results from the T-maze experiment in chapter 3 conversely support the 
latter. Similarly, it could be argued that this chapter provides evidence that DHA targets 
early-stage pathological processes rather than later-stage pathology, although the results from 
experiment 1 again support the latter. Alternatively, the results from chapters 3 and 4 together 
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may suggest that intermediate stages of pathology (at around 10-12 months of age) are less 
altered by DHA supplementation. For example, DHA may effectively reduce soluble 
monomeric Aβ and amyloid plaques better than soluble oligomeric forms. However, DHA 
has been shown to effectively reduce oligomeric Aβ25-35 species in vitro, although 
oligomeric Aβ40 and Aβ42 have not been assessed (Hashimoto et al., 2009b). Further 
research into the effects of DHA on oligomeric Aβ40/Aβ42 would therefore be insightful.
In conclusion, the results from chapter 3 together with chapter 4 show some potential in using 
DHA supplementation as a therapeutic strategy for AD. However, these results have not been 
as robust as previous reports and it remains unresolved whether early-stage longitudinal 
intervention is an optimal strategy. Although a number of studies have provided strong 
evidence that DHA supplementation can ameliorate behavioural deficits and pathology in AD 
models, this has often been relative to a particularly poor control diet or a control diet which 
is not designed appropriately to assess the effect of DHA supplementation per se. Together, 
this may suggest that DHA supplementation may be particularly beneficial in replacement of 
a poor diet.
Since epidemiological evidence suggests that omega-3 PUFA or fish oil intake can reduce the 
risk of AD (e.g. Kalmijn et al., 1997a; Albanese et al., 2009), it is worth considering whether 
other aspects of these dietary sources are more important than DHA supplementation alone. 
For instance, fish oils contain a rich source of both omega-3 PUFAs EPA and DHA which 
may both be attributable to the positive effects observed in epidemiological studies. 
Furthermore, fish oil supplementation may be more important than algal sources of omega-3 
PUFAs. Supporting this, several studies have reported positive effects of fish oil or EPA 
supplementation on behaviour and pathology in normal rodents or AD models (Suzuki et al.,
1998; Song & Horrobin, 2004; Oksman et al., 2006; Hashimoto et al., 2009a; Ma et al., 2009;
Arsenault et al., 2011). These aspects of omega-3 PUFA supplementation were therefore 
examined in chapter 5 to investigate whether this would be a more optimal strategy in 
targeting Aβ-induced behavioural deficits and pathology.
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Chapter 5
The effect of fish oil and curcumin supplementation on the behaviour and 
pathology of Tg2576 mice
5.1 Introduction
The aim of the experiments reported in this chapter was to examine the effect of dietary 
supplementation with either fish oil (containing omega-3 PUFAs), curcumin, or their co-
supplementation on the behavioural phenotype and pathology of Tg2576 mice. A number of 
epidemiological studies show dietary intake of fish to reduce the risk and incidence of AD 
(Kalmijn et al., 1997a; Barberger-Gateau et al., 2002, 2007; Morris et al., 2003; Larrieu et al.,
2004; Huang et al., 2005; Schaefer et al., 2006; Albanese et al., 2009). Huang et al. (2005) 
provided evidence that oily but not lean fish were associated with risk, providing evidence 
that fish oils likely accounted for these positive effects. In support of this, several studies 
have shown fish oil to improve cognitive function in healthy rodents (Jensen, Skarsfeldt & 
Høy, 1996; Suzuki et al., 1998), reduce cognitive dysfunction and tau pathology in 3xTg AD 
models (Ma et al., 2009), and reduce Aβ pathology in the APPswe/PS1 model (Oksman et al., 
2006). Fish oil supplementation can therefore target general cognitive processes and 
pathological mechanisms involved in AD.
A major nutritional feature of fish oils is the high levels of omega-3 PUFAs EPA and DHA.
The findings in chapters 3 and 4 failed to provide compelling evidence of robust therapeutic 
benefit from DHA supplementation alone compared to an appropriate control condition. 
However, epidemiological findings implicate EPA content as important. Dietary 
supplementation of DHA and EPA was found to reduce synaptic deficits in an AD rat model 
(Kitajka et al., 2002) and reduce tau pathology, synaptic alterations and cognitive dysfunction 
in the 3xTg AD model (Arsenault et al., 2011). Moreover, Hashimoto et al. (2009a) 
demonstrated the importance of EPA alone in reducing Aβ-induced oxidative stress, 
cognitive dysfunction, synaptic alterations and neurotoxicity in an AD rat model. The EPA 
and DHA combination in fish oils therefore likely contribute to the positive effects observed 
in epidemiological and animal studies. Since fish oil supplementation has not been examined 
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in the Tg2576 mouse model, the experiments in this chapter investigated its effect on Aβ-
pathology and its associated behavioural deficits in Tg2576 mice. Furthermore, since 
epidemiological studies are generally reflective of long-term intake, this chapter investigated 
longitudinal supplementation from an early age. In order to initiate treatment prior to 
pathological alternations, mice were given dietary supplementation from 2 months of age 
since no pathological, synaptic or behavioural deficits have been reported at that age in 
Tg2576 mice (Hsiao et al., 1996; Chapman et al., 1999; Lanz, Carter & Merchant, 2003; 
Jacobsen et al., 2006).
This chapter also aimed to investigate the effect of longitudinal curcumin supplementation 
from an early age in the Tg2576 model. Previous reports have shown 4 to 6 month dietary 
curcumin to reduce inflammation, oxidative stress, Aβ levels and plaque pathology in aged 
Tg2576 mice (Lim et al., 2001; Yang et al., 2005; Begum et al., 2008). In rat models of AD, 
1-2 month dietary curcumin reduced plaque pathology, synaptic deficits, oxidative stress and 
cognitive dysfunction (Frautschy et al., 2001; Ishrat et al., 2009). Furthermore, Garcia-Alloza 
et al. (2007) reported 7-day i.v. injected curcumin was effective at reducing plaque pathology
and dendritic abnormalities in aged APPswe/PS1 mice. Finally, Ma et al. (2009) found 4-
month dietary curcumin reduced poor-diet induced (a high-fat diet rich in saturated fat and 
omega-6 PUFA) deficits including cognitive dysfunction, tau phosphorylation and abnormal 
insulin signalling in the 3xTg AD model. It is therefore evident that curcumin can target a 
number of pathological processes related to AD and their associated deficits. However, no 
study has examined the effect of curcumin supplementation prior to pathological 
development in transgenic models. For example, curcumin treatment was initiated in Tg2576 
mice aged 10, 14.5 and 17 months when pathology is already manifest. The positive effects 
of curcumin raise the possibility that early intervention may prevent or delay the onset of 
cognitive and pathological changes induced by Aβ. This chapter will therefore present 
experimental evidence testing the hypothesis that early longitudinal treatment of curcumin in 
Tg2576 mice from 2 to 12 months of age will influence the cognitive and pathological 
phenotype in this APP model. This will be the first report of chronic curcumin treatment for 
greater than 6-months in any animal model of AD.
Since both fish oil and curcumin administration can reduce pathological processes of AD and 
associated deficits, it could be hypothesised that their co-supplementation may have 
synergistic beneficial effects. For example, these compounds may target differential 
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mechanisms which overall have more impact than individual supplementation. For instance, 
evidence showing curcumin to directly bind to aggregated Aβ may suggest that curcumin 
would be better at reducing plaque pathology than DHA (Yang et al., 2005; Garcia-Alloza et 
al., 2007). Alternatively these compounds may target similar mechanisms which may result 
in an exaggerated effect. Supporting this, synergistic effects in reducing AD-related 
pathology and deficits by combining supplements have been demonstrated with vitamin C 
and E combinations (Morris et al., 1998; Kontush et al., 2001; Zandi et al., 2004), herb 
combinations such as ‘Zhokemei-to’ (Williamson, 2001; Tohda et al., 2004), combined fish 
oil and the green tea extract EGCG (Giunta et al., 2010), and a DHA and catechin 
combination (Shirai & Suzuki, 2004).
Further to their potent pleiotropic effects individually, the author asserts that a combination of 
curcumin and fish oil may have synergistic effects by simply increasing their bioavailability. 
Humans and mouse studies have reported that lipid-curcumin formulations can provide 
higher plasma and brain levels of curcumin than unformulated curcumin, in addition to 
greater pharmacological effects in reducing oxidative stress and inflammation (Begum et al.,
2008; Gota et al., 2010). Frautschy and Cole (2010) also developed a solid lipid-curcumin 
formulation which reportedly resolved bioavailability issues of curcumin (see Kelloff et al.,
1996; Lao et al., 2006). The lipids present in the fish oil may therefore increase curcumin 
bioavailability and efficiency. Conversely, evidence also supports the idea that curcumin may 
increase bioavailability of omega-3 PUFA in the fish oils by providing antioxidant protection
(Asai, Nakagawa & Miyazawa, 1999; Frautschy, Ma & Cole, 2009). Curcumin may not only 
maintain the level of omega-3 PUFA in vivo and prior to administration in the diets, but it 
may also limit the production of neurotoxic lipid oxidation products which can exacerbate 
pathology (Horrocks & Farooqui et al., 2004). Antioxidant protection may therefore be 
critical when administering lipids to pathological oxidative environments. Supporting this, 
Shinto et al. (2009) reported more effective stabilisation of cognitive decline in AD patients 
when fish oil supplementation was combined with the antioxidant alpha-lipoate in a pilot 
clinical trial. Curcumin and fish oil co-supplementation may therefore overcome factors that 
may otherwise limit their clinical efficiency.
This chapter therefore aimed to investigate the effect of a combination of dietary curcumin 
and fish oil on behaviour and pathology in the Tg2576 model. Supporting the potential 
advantages of this approach, Ma et al. (2009) reported this combination to have synergistic 
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effects in suppressing poor diet-induced activation of tau pathology, JNK, IRS-1 and 
cognitive deficits in 3xTg AD model mice. JNK and IRS-1 (insulin-resistant substrate 1) are 
involved in synaptic activity, insulin signalling, tau phosphorylation and Aβ-toxicity (as 
reviewed in Ma et al., 2009). Importantly, this effect was greater than reported in mice fed 
curcumin or fish oil alone, and the cognitive improvement in the Y-maze was reported after 1 
month in contrast to 2 and 3 months in single compound treatments. Continuing their ongoing 
studies, Frautschy and Cole (2010) reported that this dietary combination can limit cognitive 
deficits and tau pathology in the Htau mouse model from 14 months of age when tau 
pathology and cognitive deficits are well developed (unpublished results). In vitro studies 
have also supported the synergistic effects of curcumin with omega-3 PUFAs DHA and EPA
in reducing markers of inflammation and oxidative stress (Saw, Huang & Kong, 2010). This 
chapter provides the first report of curcumin and fish oil co-supplementation in the Tg2576 
mouse model. Again, supplementation was initiated from an early age and was provided 
longitudinally throughout the course of pathological development until 12 months of age.
In order to investigate the effects of dietary supplementation from 2 months of age on 
behaviour and pathology in Tg2576 mice, behaviour was assessed using the marble burying 
and T-maze test. These measures were selected since chapters 3 and 4, as well as previous 
studies (e.g. Hsiao et al., 1996) have shown a rather selective hippocampal-related 
behavioural deficit in Tg2576 mice from an early age. Behaviour was first assessed from 8-9 
months of age when Aβ pathology is developed and impairments are present in order to 
examine whether dietary treatment delayed the onset of deficits. Furthermore, both Tg2576 
and WT mice were assessed to examine the potential treatment effects on general cognitive 
processes and pathological processes.
Ideally, more extensive behavioural testing would be carried out (similar to chapter 4) but the 
need for large cohorts of mice limited the number of behavioural tasks carried out. It was 
deemed particularly important to examine a large cohort (~20 mice per experimental group) 
since Tg2576 mice appear particularly susceptible to attrition and large numbers were 
required for multiple brain analysis (including immunohistochemistry, ELISA and lipid 
analysis). Moreover, it is argued that the small number of subjects in experimental groups 
used in previous studies reduced the validity of their findings (e.g. n=4-6 mice in Yang et al., 
2005). This may have also contributed to the lack of DHA effect on Aβ measures in chapter 3 
due to high variability; and so a large cohort of mice was examined in this chapter to prevent 
205
such issues. Mice were culled at 12 months of age (following 10-month supplementation) for 
examination of Aβ pathology in the brain using both ELISA and immunohistochemical 
techniques. The 12-month time-point was selected in order to examine the effect on plaque-
like ‘amyloid body’ pathology, since appreciable numbers of diffuse plaques were not shown 
histologically until 12 months of age (Kawarabayashi et al., 2001). Furthermore, this early 
period of amyloid deposition and beginning of plaque development between 6-12 months is 
thought to parallel early changes in the human AD brain (Funato et al., 1998). 
It was hypothesised based on the evidence outlined above that supplementation of curcumin, 
fish oil and their combination would reduce behavioural deficits and Aβ pathology in Tg2576 
mice. It was also predicted that co-supplementation of curcumin and fish oil would have a 
synergistic effect relative to their individual supplementation. Lipid analysis was carried out 
on brains at 12 months of age in order to examine dietary effects and ensure that omega-3 
PUFAs were incorporated into brain fractions. This was important to determine as a lack of 
incorporation may explain a lack of diet effect on behavioural or pathology measures. Such 
an argument was suggested to explain the failure of omega-3 PUFA supplementation to 
reduce behaviour deficits in APPswe/PS1 mice (Arendash et al., 2007). Similar to chapter 3, 
it was hypothesised that fish oil supplementation would increase omega-3 PUFA levels in the 
brain.
5.2 Overview of the mouse cohort and the dietary intervention design used
The experiments in this chapter used one cohort of male Tg2576 transgenic (Tg) and non-
transgenic (wildtype, WT) mice. The cohort of Tg2576 and WT mice used in this chapter 
were generated and maintained as outlined in chapter 2, section 2.2. At 2 months of age, mice 
were taken off standard laboratory mouse chow and were fed experimental diets containing 
either 2.5% oil blend (OB; containing 0% DHA and EPA, 0.19% total omega-3 PUFA, 
1.65% total omega-6 PUFA, and an ω-3/ω-6 ratio of 0.10:1), 2.5% oil blend + 500ppm 
curcumin (OB+C; containing 0% DHA and EPA, 0.17% total omega-3 PUFA, 1.51% total 
omega-6 PUFA, and an ω-3/ω-6 ratio of 0.10:1), 2.5% fish oil (FO; containing 0.34% DHA, 
0.53% EPA, 1.69% total omega-3 PUFA, 1.36% total omega-6 PUFA, and an ω-3/ω-6 ratio 
of 1.21:1), or 2.5% fish oil + 500ppm curcumin (FO+C; containing 0.34% DHA, 0.53% EPA, 
1.67% total omega-3 PUFA, 1.36% total omega-6 PUFA, and an ω-3/ω-6 ratio of 1.19:1). 
Importantly, the diets containing fish oil supplementation (FO and FO+C) were similar in 
lipid content, and the diets containing oil blend supplementation (OB and OB+C) were 
similar in lipid content. Furthermore, the difference in 
caused almost entirely by the additional 
although there was a slight difference in 
and fish oil containing diets, this was minimal compared with previous studies investigating 
fish oil supplementation whereby the
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can be observed, transgenic mice consistently had lower body weights compared to wildtype 
mice across their lifespan; a pattern that becomes more apparent with increasing age. 
Furthermore, dietary supplementation appears to not affect body weight. This apparent 
genotype effect is consistent with previous reports in the Tg2576 model (e.g. Toda et al.,
2011) and in AD patients, which show weight loss compared to a non-demented population 
(Poehlman & Dvorak, 2000). This data suggests that pathological changes, particularly Aβ, 
lead to a weight loss phenotype. This may perhaps be caused by metabolic alterations or 
associated with low dietary intake. However, Toda et al. (2011) reported no differences in 
food intake or metabolic parameters (mean time course of oxygen consumption rates and 
respiratory quotients) in Tg2576 mice compared to controls at 6 to 7 months fed a standard 
diet. Further research into this phenotype is therefore required, and it is suggested that future 
studies examining dietary supplementation should monitor food consumption levels. A lack 
of obvious change detected in body weights between mice fed different experimental diets 
importantly suggested no difference in metabolic factors between diets and also suggest no 
particular aversion to specific diets.
Figure 5.2 Body weight profile of Tg and WT mice from 1 month of age. Mice were fed standard 
chow from birth to 2 months of age, and then experimental diets from 2 months of age. Values are 
mean weight (grams) ± S.E.M.
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Similar to the previous experimental chapters, a between-subjects ANOVA with factors of 
genotype (Tg, WT) and diet (OB, OB+C, FO, FO+C) was used to analyse the data. Further 
details and justification for this analysis is outlined in chapter 2, section 2.4. It is important to 
note however that the exclusion of the WT FO+C group in this analysis would likely alter the
error term (the value of the F statistic; since this is fixed by the degrees of freedom) and 
therefore potentially result in a Type I or II statistical error (Kinnear & Gray, 2009). In order 
to validate the accuracy of the between-subjects ANOVA results, a one-way ANOVA with 
factor of group (Tg OB, Tg OB+C, Tg FO, Tg FO+C, WT OB, WT OB+C, WT FO) and 
post-hoc Tukey test was used to confirm the statistical results, since this statistical test would 
have an accurate error term. No discrepancies were found in the results of experiments 7 to 9 
and so the between-subjects ANOVA results were reported. In contrast, the between-subjects 
ANOVA results for experiment 10 appeared inaccurate and differed from the one-way 
ANOVA analysis. The one-way ANOVA results were therefore reported in experiment 10 
since these reflected the pattern of results more accurately and prevented error term problems.
5.3 Experiment 7: Marble burying assessment
5.3.1 Introduction
In order to assess the effects of early dietary intervention on the behavioural phenotype of 
Tg2576 mice, Tg and WT mice fed the experimental diets were assessed in the marble 
burying test at 8 to 9 months of age when pathology is present. Since experiment 4 (chapter 
4) reported genotype and DHA-diet effects in this task, it was therefore argued that the 
marble burying test would be a suitable task to probe anxiety-related emotional deficits and 
should be sensitive to detect diet-induced changes. Based on the marble burying results in 
experiment 4 and reports of reduced anxiety in the elevated plus maze, open field and 
holeboard task (e.g. Lalonde et al., 2003; Deacon et al., 2008, 2009; Ognibene et al., 2005), it 
was hypothesized that Tg2576 mice would show deficits in the marble burying test at 8 to 9 
months of age.
Although no study has examined the effect of fish oil supplementation in Tg2576 mice, Ma et 
al. (2009) reported fish oil to reduce a hippocampal-dependant spatial memory deficit in the 
Y-maze in the 3xTg AD model. Since the marble burying test is hippocampal-dependant, it 
was hypothesized that fish oil supplementation would reduce a marble burying deficit in 
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Tg2576 mice. Further support for this was provided by the positive effects of omega-3 PUFA
DHA and EPA supplementation in reducing pathologically-induced behavioural deficits (e.g. 
Calon et al., 2004; Oksman et al., 2006; Arsensault et al., 2011). It was also hypothesized that 
curcumin supplementation would reduce marble burying deficits in Tg2576 mice since 
curcumin supplementation has been shown to reduce cognitive deficits in other animal 
models of AD (e.g. Frautschy et al., 2001; Ishrat et al., 2009; Ma et al., 2009). Similarly, it is 
hypothesized that fish oil and curcumin co-supplementation would reduce marble burying
deficits in Tg2576 mice since studies have reported this combination to reduce cognitive 
deficits in the triple transgenic and Htau model of AD (Ma et al., 2009; Frautschy & Cole,
2010).  Importantly, this is the first study to directly assess these supplements on behaviour 
(and specifically marble burying) in the Tg2576 model.
5.3.2 Methods
One cohort of male Tg2576 transgenic (Tg) and wildtype (WT) mice were evaluated in the 
marble burying task at 8 to 9 months, when plaque pathology was first developing. This 
design therefore investigated transgene- and diet-dependant changes. A minimum of 14 mice 
from each experimental group were tested (Tg OB n=14, Tg FO n=16, Tg OB+C n=14, Tg 
FO+C n=16, WT OB n=19, WT FO n=20, WT OB+C n=21). In addition to these numbers, 6 
mice were excluded from the experiment due to circling behaviour which prevented reliable 
involvement in the task (WT OB n=1, Tg OB n=2, Tg OB+C n=1, Tg FO+C n=2). The 
running order of mice was counterbalanced so that one mouse from each experimental group
of mice was tested after another as far as possible, which was run blindly to the experimenter. 
Mice were tested only once, with all testing occurring over 4 consecutive days. The apparatus 
and procedure used in this experiment was as described under the marble burying headings in 
chapter 4 sections 4.3.2. 
5.3.3 Results
Figure 5.3 shows the mean number of unburied marbles in the marble burying test for each 
experimental group at 8 to 9 months of age. Statistical analysis using an ANOVA with 
genotype (Tg or WT) and diet (OB, OB+C, FO, FO+C) as factors revealed a significant main 
effect of genotype (F(1,113)=41.162, p<0.001), no significant main effect of diet 
(F(3,113)=0.035, p>0.05) and no significant interaction of genotype by diet (F(2,113)=0.825, 
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p>0.05). This genotype effect is clearly illustrated in Figure 5.3, whereby Tg groups left an 
average of approximately 14 marbles unburied in contrast to ~6 marbles in the WT groups.
The experimental diets appeared to have no effect in Tg or WT mice.
Figure 5.3 Mean number of unburied marbles (20 marbles in total) in the marble burying test at 8 to 9 
months in Tg and WT mice fed the oil blend (OB), oil blend + curcumin (OB+C), fish oil (FO) and 
fish oil + curcumin (FO+C) diets. Values are mean scores ± S.E.M.
5.3.4 Discussion
The results of the marble burying experiment showed Tg2576 mice left significantly more 
marbles unburied than WT mice at 8 to 9 months of age. This study therefore corroborates 
previous results in experiment 4 providing evidence that the APPswe mutation leads to 
marble burying deficits in Tg2576 mice. This reduction in marble burying was also consistent 
with previous reports of reduced anxiety in Tg2576 mice in other anxiety-related tasks such 
as the elevated plus maze (e.g. Gil-Bea et al., 2007). Importantly, WT mice buried a higher 
number of marbles, which is consistent with normal marble burying behaviour in rodents 
(e.g. Deacon, 2006; Nicolas, Kolb & Prinssen, 2006).
Interestingly, this experiment provided no evidence that fish oil, curcumin or a combination 
of fish oil and curcumin affected marble burying behaviour in either Tg or WT mice. This 
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was in contrast to the prediction that that these supplements would reduce the marble burying 
deficit in Tg2576 mice. As outlined in the introduction of this experiment, multiple studies 
provide evidence that these supplements can reduce cognitive impairments in animal models 
of AD. However, these cognitive impairments were found in tasks assessing spatial memory, 
not anxiety-related behaviour (e.g. Frautschy et al., 2001; Ishrat et al., 2009; Hashimoto et al.,
2009a; Ma et al., 2009; Frautschy & Cole, 2010).
It could also be argued that the lack of dietary effect in this experiment at 8 to 9 months is 
age-specific. For example, it is possible that the dietary supplements may have been more 
potent at earlier stages of pathological development. This argument may be supported for the 
fish oil supplement in particular as results from experiment 4 found that 1.86% DHA 
supplementation effectively reduced anxiety deficits at 3 months, with less convincing results 
at 10 months of age. It is possible that the reduced levels of omega-3 PUFA or DHA in the 
fish oil diet compared to the DHA diet in chapters 3 and 4 contributed to this lack of effect. 
Alternatively, it could be argued that the dietary supplements may be more effective at 
reducing behavioural deficits during advanced stages of pathology when there are greater 
levels of Aβ. Indeed, this could be supported by the majority of studies investigating omega-3 
PUFA and curcumin supplementation in animal models of AD including Tg2576 mice, which 
have shown a robust reduction in Aβ pathology during advanced stages of disease (e.g. 
Frautschy et al., 2001; Lim et al., 2001; Calon et al., 2004; Lim et al., 2005; Yang et al.,
2005; Cole & Frautschy, 2006; Begum et al., 2008; Garcia-Alloza et al., 2007).
Unfortunately, the affect of age cannot be determined in this study as longitudinal 
behavioural assessment was not carried out. Longitudinal investigation of these supplements 
from early to advanced stages of disease in the Tg2576 model should therefore be carried out 
in future experiments. 
5.4 Experiment 8: T-maze assessment
5.4.1 Introduction 
This experiment aimed to assess the effect of supplementary fish oil, curcumin, and their 
combination from an early age of 2 months on spatial learning and memory in Tg2576 and 
WT mice aged 9.5 to 12 months. As detailed in experiment 1 (chapter 3), the assessment of 
spatial memory and learning was important as this is particularly affected in Tg2576 mice 
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and other models of AD. The T-maze forced choice alternation (FCA) task was selected as 
experiment 1 and previous studies have revealed Tg2576 mice to show deficits after 8 months 
of age, at 12 and 16 months (Chapman et al., 1999; Corcoran et al., 2002; Barnes, Hale & 
Good, 2004). Furthermore, experiment 1 found the T-maze task was sensitive in detecting 
dietary effects, albeit at 16 months. This robust task, sensitive to both the APPswe mutation 
and dietary effects, was therefore selected to examine the effect of the dietary supplements in 
Tg2576 and WT mice.
Firstly, it was hypothesised that Tg2576 mice would be impaired in the T-maze FCA task at 
9.5 to 12 months of age based on results from experiment 1 and previous literature. Secondly, 
it was hypothesized that dietary supplementation of fish oil, curcumin, and a combination of 
fish oil and curcumin would reduce these spatial memory deficits in the T-maze. This 
hypothesis was based on evidence showing fish oil supplementation to ameliorate a spatial 
memory deficit in the Y-maze in the 3xTg AD model (Ma et al., 2009). This is further 
supported by studies of DHA and EPA supplementation showing reduced spatial memory 
deficits in rodent AD models (e.g. Calon et al., 2004; Hashimoto et al., 2009a; Hooijmans et 
al., 2009). The hypothesis was also based on studies reporting fish oil and curcumin co-
supplementation reduced cognitive deficits in the triple transgenic and Htau model of AD 
(Ma et al., 2009; Frautschy & Cole, 2010). Furthermore, evidence has shown curcumin to 
reduce cognitive deficits in animal models of AD (e.g. Frautschy et al., 2001; Ishrat et al.,
2009; Ma et al., 2009). This is the first experiment to assess these dietary supplements on 
spatial learning and memory in the Tg2576 mouse model.
5.4.2 Methods
One cohort of naïve male Tg2576 transgenic (Tg) and wildtype (WT) mice were evaluated in 
the T-maze forced-choice alteration (FCA) task at 9.5 to 12 months of age when plaque 
development is observed. Mice were placed on experimental diets from 2 months of age. This 
design therefore investigated transgene- and diet-dependant changes. The cohort of mice used 
in this experiment consisted a minimum of 16 mice per experimental mouse group (Tg OB 
n=16, Tg OB+C n=15, Tg FO n=16, Tg FO+C n=18, WT OB n=18, WT OB+C n=20, WT 
FO n=20). The running order of mice was counterbalanced so that approximate equal 
numbers of each experimental group of mice were run in each batch (n=8), run blind to the 
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experimenters, with several batches of mice being tested once per day over 8 consecutive 
days. Mice were maintained on water restriction throughout this experiment. 
The apparatus and procedure was the same as described in chapter 3 section 3.3.2, except 
mice were tested for a period of 8 consecutive days rather than 10 days as performance 
stabilised by day 8. The experiment was carried out by the author with help from a research 
assistant (John Anderson), with all analysis carried out by the author. T-maze FCA 
performance was calculated as a percentage of correct trials (successful alternations) of the 
six sessions conducted per day. 
5.4.3 Results
Figure 5.4 shows the percentage of correct trials for both Tg and WT mice fed the
experimental diets during acquisition of the T-maze FCA task at 9.5 to 12 months of age. An 
ANOVA with genotype (Tg or WT) and diet (FO, OB, OB+C, FO+C) as between-subject 
factors and day (1-8) as a within-subject factor revealed a significant effect of genotype 
(F(1,116)=68.273, p<0.001), no significant effect of diet (F(3,116)=0.567, p>0.05) and no 
significant interaction between genotype and diet (F(2,116)=0.165, p>0.05). Statistical 
analysis also showed a significant effect of day (F(7,812)=17.389, p<0.001), a significant 
interaction of day by genotype (F(7,812)=3.433, p<0.001), no significant interaction of day 
by diet (F(21,812)=0.917, p>0.05) or day by genotype by diet (F(14,812)=0.649, p>0.05). A 
follow-up test of simple main effects for the significant day by genotype interaction revealed 
that WT mice performed significantly better than Tg mice on days 2 to 8 (smallest, 
F(1,121)=17.98, p<0.001). As illustrated in Figure 5.4, these results indicate that Tg mice 
perform significantly worse than WT mice, and that the dietary supplements failed to alter 
performance.
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Figure 5.4 T-maze forced choice alternation task performance at 9.5 to 12 months of age. Mean 
percentage of correct trials over 8 days acquisition in Tg and WT mice fed the oil blend (OB), oil 
blend + curcumin (OB+C), fish oil (FO) and fish oil + curcumin (FO+C) diets. Values are mean 
scores ± S.E.M.
5.4.4 Discussion
The T-maze FCA task revealed Tg mice to be significantly impaired relative to WT control 
mice at 9.5 to 12 months of age, which supports previous findings (e.g. Chapman et al., 1999; 
Corcoran et al., 2002; Hale & Good, 2005; Barnes, Hale & Good, 2004; Zhuo et al., 2007).
This experiment did not reveal any main effects of diet or interactions, thereby illustrating 
that the dietary supplementation of fish oil, curcumin or a combination of fish oil and 
curcumin failed to alter performance in Tg or WT mice. This experiment therefore did not 
provide any evidence that these supplements improved spatial working memory or learning. 
These results were not expected as previous studies have shown fish oil, curcumin and their 
combination to improve spatial memory in animal models of AD (e.g. Frautschy et al., 2001; 
Ishrat et al., 2009; Hashimoto et al., 2009a; Ma et al., 2009; Frautschy & Cole, 2010). A 
number of differences between these studies may have accounted for the discrepancies in 
results, such as the animal model and its underlying pathology, the experimental diets (e.g. 
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the amount of supplementation, the control diet) and the stage of experimentation. These 
factors will be considered in more detail in the chapter discussion.
Interestingly, this lack of diet effect was consistent with experiment 7 which showed that 
these dietary supplements failed to ameliorate marble burying deficits in Tg2576 mice at 8 to 
9 months of age. Furthermore, the failure of the fish oil supplement in ameliorating the 
spatial memory deficit in Tg2576 mice was similar to the results in experiment 1 which 
showed that DHA supplementation failed to ameliorate T-maze deficits in Tg2576 mice aged 
12 months (but showed some success at 16 months of age). It is therefore possible that these 
supplements may only be effective at reducing deficits during more advanced stages of 
pathology. This argument is supported by previous studies showing cognitive benefit of 
omega-3 PUFA/fish oil, curcumin, and its combination in animal models of AD during more 
advanced stages of pathology (e.g. Calon et al., 2004; Ma et al., 2009; Frautschy & Cole,
2010). Alternatively, it could be argued that the lack of diet effect in this experiment could be 
a result of the T-maze failing to sufficiently detect more subtle changes in spatial memory. 
Other spatial memory tasks, such as the radial arm maze which contains more arm choices, 
could therefore be employed in future research to probe perhaps more subtle effects caused 
by dietary supplementation.
5.5 Experiment 9: Pathological assessment 
5.5.1 Introduction
This experiment aimed to investigate the effect of longitudinal dietary supplementation of 
curcumin, fish oil and their combination from an early age on Aβ pathology in Tg2576 mice
aged 12 months. This study will provide the first evidence investigating the effect of early 
curcumin supplementation on Aβ pathology in Tg2576 mice. Previous studies have shown 
dietary curcumin (160ppm and 500ppm) to reduce amyloid plaque burden or deposits, as well 
as reduce soluble and/or insoluble Aβ levels in Tg2576 mice aged 16-22 months (Lim et al., 
2001; Yang et al., 2005; Begum et al., 2008). Curcumin supplementation has also been 
shown to reduce amyloid plaque burden in the aged APPswe/PS1 mice and an Aβ-infused rat 
model (Frautschy et al., 2001; Garcia-Alloza et al., 2007). Interestingly however, Garcia-
Alloza et al. (2007) found curcumin did not alter soluble and insoluble Aβ40 and Aβ42 levels 
in APPswe/PS1 model, but reduced plaque size and number. Supporting the Aβ-reducing 
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effect, in vitro studies have shown curcumin to inhibit Aβ40 and Aβ42 fibril formation and 
aggregation, Aβ extension and disaggregate pre-aggregated Aβ (Ono et al., 2004; Yang et al., 
2005; Begum et al., 2008). 
This study will provide the first evidence investigating the effect of fish oil supplementation, 
and fish oil plus curcumin co-supplementation on Aβ pathology in Tg2576 mice. Only two 
studies have examined the effect of fish oil in AD models, with Ma et al. (2009) failing to 
report effects of fish oil on Aβ pathology in the 3xTg model and Oksman et al. (2006) 
reported fish oil to reduce Aβ42 but not plaques in the APPswe/PS1 model relative to a poor 
diet. Similarly, only one study has reported the effects of fish oil and curcumin co-
supplementation, but Ma et al. (2009) failed to report effects of fish oil on Aβ pathology in 
the 3xTg model. It is therefore evident that further investigation is required into the effects of 
these supplements on Aβ pathology.
In order to investigate whether supplementation of these diets reduced Aβ pathology in 
Tg2576 mice, brain samples of mice aged 12 months were analysed by 
immunohistochemistry and ELISA methods. In brief, immunohistochemistry is a biochemical 
method commonly used to visualise proteins in tissue sections. Indirect 
immunohistochemistry was used which process involves incubation of tissue sections in a 
primary rabbit antibody which binds to the target antigen (Aβ1-40 or Aβ1-42), which is 
followed by incubation with a biotinylated secondary anti-rabbit antibody which binds to the 
primary antibody. The secondary antibody is anti-rabbit so it is against the immunoglobulin 
(IgG) of the species in which the primary antibody was raised. Subsequent incubation in an 
avidin-biotinylated enzyme complex (ABC complex) and 3’3’-diaminobenzidine (DAB) is 
used to stain the secondary antibody, which therefore corresponds to staining of the antigen 
(Aβ1-40 or Aβ1-42) to allow visualisation in tissue sections.
ELISA analysis allows precise quantification of soluble and insoluble Aβ40 and Aβ42 levels
in the hippocampus, whereas immunohistochemistry allows visualisation of Aβ40 and Aβ42 
aggregate deposits throughout multiple brain regions. Both assessments would therefore
ensure a comprehensive assessment of Aβ pathology. Furthermore, it was deemed important 
to assess plaque-like amyloid body deposits in addition to Aβ levels measured by ELISA as 
one biochemical method does not necessarily predict the results of another. For example, 
Garcia-Alloza et al. (2007) reported curcumin supplementation reduced plaque burden but 
217
not soluble and insoluble Aβ40 and Aβ42 levels in the APPswe/PS1 model. Similarly, 
Oksman et al. (2006) reported fish oil supplementation reduced total Aβ42 levels, but had no 
effect on plaque load.
Levels of Aβ were measured in the hippocampus as this was one of the most pathologically 
affected brain regions in Tg2576 mice and correlates best with the behavioural assessments in 
this chapter which were hippocampal-dependant measures. It was deemed important to 
measure both Aβ40 and Aβ42 isoforms, as well as soluble and insoluble extracts as a 
reduction in one does not necessarily predict the other, and can shed light on the potential 
mechanisms of the intervention. For example, Lim et al. (2005) reported DHA to reduce total 
insoluble Aβ (both Aβ40 and Aβ42) and plaque burden, but not soluble Aβ, perhaps 
suggesting that DHA supplementation facilitates plaque clearance. Pathology was assessed in 
Tg2576 mice aged 12 months in order to assess Aβ pathology at a relatively early time point, 
but during a time when both soluble and insoluble species would be present, in addition to 
plaques. Although plaque pathology would not be substantial at 12 months, Kawarabayashi et 
al. (2001) reported that histological detection of diffuse plaques should be evident at this age, 
and so dietary effects may be observed. Furthermore, this period of early amyloid deposition 
and plaque development between 6 and 12 months was thought to parallel early changes in 
the human AD brain (Funato et al., 1998, as stated in Kawarabayashi et al., 2001). Important 
to the fish oil supplement in particular, this age is likely to mimic the time-point in 
epidemiological studies when positive effects of omega-3 supplementation has been reported 
in MCI and early AD patients.
Although this chapter has provided no evidence that the dietary supplements can ameliorate 
behavioural deficits in Tg2576 mice, it was important to evaluate the effect of the dietary 
supplements on underlying amyloid pathology as one does not consistently predict the other.  
For example, Oksman et al. (2006) reported DHA supplementation to reduce Aβ levels but 
not ameliorate spatial memory deficits. In contrast, Calon et al. (2004) and Arsenault et al. 
(2011) reported that DHA altered cognitive measures but not Aβ pathology. Although it may 
be hypothesised, based on the behavioural results, that the dietary supplements would fail to 
alter Aβ levels, it is possible that the dietary supplements may affect Aβ pathology without 
translation to the behavioural phenotype. 
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Based on the previous results surrounding curcumin supplementation on Aβ pathology in AD 
models, it was hypothesised that curcumin supplementation would reduce Aβ pathology in 
Tg2576 brains. Since only one study has reported fish oil supplementation to reduce Aβ42 
but not plaque pathology in the APPswe/PS1 model (Oksman et al., 2006), it could be 
hypothesised that the same effect could be observed in Tg2576 mice. However, since fish oils 
contain omega-3 PUFAs, and omega-3 PUFA/DHA supplementation has been shown to 
reduce Aβ pathology in Tg2576 mice and other AD models (Lim et al., 2005; Oksman et al., 
2006; Green et al., 2007; Hooijmans et al., 2007, 2009), it was hypothesised that fish oil 
supplementation would reduce Aβ pathology. Further supporting this, a reduction of Aβ40 
and Aβ42 levels, as well as oligomeric species and mature fibrils by DHA has also been 
shown in vitro (Lukiw et al., 2005; Oksman et al., 2006; Hashimoto et al., 2009b). Finally, no 
study has directly assessed the effect of a combination of fish oil and curcumin on Aβ 
pathology in any AD model. Based on evidence from curcumin and fish oil/omega-3
PUFA/DHA supplementation studies individually, it was hypothesised that the combined 
supplement would reduce Aβ pathology in Tg2576 mice. Supporting this, Ma et al. (2009) 
provided evidence that fish oil and curcumin co-supplementation may target Aβ pathology by 
inhibition of JNK.
5.5.2 Methods
5.5.2.1 Design and subjects
Soluble and insoluble human Aβ1-40 and Aβ1-42, expressed from the APPswe transgene, 
were quantified by ELISA using left-hemisphere hippocampal samples of Tg2576 mice aged 
12 months fed the oil blend, oil blend +curcumin, fish oil, and fish oil + curcumin diets. A 
minimum of 11 Tg mice were analysed from each diet group (Tg OB n=11, Tg FO n=12, Tg 
OB+C n=12, Tg FO+C n=14) following the T-maze FCA alternation task. The remaining 
mice from experimental groups were assigned for lipid analysis and immunohistochemistry 
analysis of brain samples. Immunohistochemistry was carried out on left-hemisphere brain 
samples from a minimum of 3 Tg mice and 1 WT mouse from each experimental group (Tg 
OB n=3, Tg FO n=4, Tg OB+C n=3, Tg FO+C n=4, WT OB n=1, WT FO n=1, WT OB+C 
n=1). Since WT mice do not possess the human APPswe transgene and therefore do not 
develop Aβ pathology, brain sections were used as negative controls for 
immunohistochemistry. WT mice were not systematically assessed using the ELISA protocol 
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due to their lack of pathology, although one WT mouse from each diet group was analysed to 
confirm this.
5.5.2.2 ELISA procedure
Mice were culled by cervical dislocation. The brain was immediately removed and 
maintained on ice while dissecting the cortex, hippocampus and cerebellum from the left and 
right hemispheres. The dissected tissue samples were immediately weighed and snap-frozen 
in liquid nitrogen. These samples were then stored at -80ºC until ready to be analysed. The 
hippocampus from the left hemisphere was analysed for Aβ pathology by ELISA, while the 
cortex from the left hemisphere was used for lipid analysis (experiment 10). The left-
hemisphere sample was selected for ELISA analysis to match the left hemisphere selected for 
immunohistochemistry analysis. Samples from the right hemisphere were reserved for 
additional future research.
The samples were analysed as described in chapter 3 section 3.4.2, including protein 
extraction, protein assay and ELISA techniques. All aspects of data collection were carried 
out by the author with assistance from a research associate (Dr. Cécile Bascoul-Colombo).
5.5.2.3. Immunohistochemistry procedure
Tissue collection and preparation
In order to collect the brain samples for immunohistochemistry, mice received a lethal i.p. 
injection of 0.2ml sodium pentobarbitone (Euthatal®) and exsanguinated by intra-cardiac 
perfusion of 80ml 0.01M PBS pH7.4. Perfusion was carried out through cannula insertion 
into the left cardiac ventricle and incision to the right cardiac atrium, followed by perfusion 
with PBS using a perfusion pump for approximately 2 minutes until exsanguinated. The brain 
was immediately removed and maintained on ice to dissect the left and right hemispheres. 
The right hemisphere was dissected further to collect hippocampal, cortex and cerebellum 
samples for lipid analysis (experiment 10), then snap-frozen in liquid nitrogen and stored at -
80ºC until use. The left hemisphere, used for immunohistochemical analysis, was fixed by 
transferring into cold 4% (w/v) paraformaldehyde in 0.01M PBS for 24 hours at 4ºC. 
Following this, the left hemisphere was transferred to 25% (w/v) reagent grade sucrose in 
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dH2O for 48 hours at 4°C until the tissue sank. Tissue was then mounted on a freezing 
microtome at -25ºC and cut into 40µm coronal sections, which were stored in cryoprotectant 
(300g analytical reagent grade sucrose, 10g molecular biology grade polyvinylpyrrolidone 
and 300ml ethylene glycol in 500ml 1M PBS pH 7.4) at -20ºC until required for 
immunohistochemistry analysis.
Immunohistochemical staining and slide preparation
Immunohistochemical staining for Aβ1-40 and Aβ1-42 species was carried out identically 
using the procedure below but with different primary antibodies for Aβ1-40 and Aβ1-42 (as 
specified in the procedure). This process was carried out by the author with assistance from a 
research associate (Dr. Cécile Bascoul-Colombo). 
Tissue sections were first washed 4 x 5 minutes to remove cryoprotectant using 0.1M TBS 
(1.2% [w/v] trizma base and 0.9% [w/v] sodium chloride in dH2O, pH7.4). Antigen retrieval 
was then performed to reduce the effect of the PFA fixative by incubating the tissue in 85% 
(v/v) formic acid in dH2O at 25ºC for 10 minutes. Following a wash in 0.1M TBS, tissue was 
incubated in quench (10% methanol and 10% hydrogen peroxide in dH2O) for 5 minutes to 
reduce background staining caused by endogenous peroxidise activity. Following 3 x 10 
minute washes in 0.1M TBS, non-specific binding of the primary antibody was blocked by 
incubating sections in 3% (v/v) normal goat serum (NGS) in TXTBS (0.1% Triton X-100 in 
0.1M TBS, pH7.4) for 1 hour. This was then removed and sections were incubated in 0.1% 
(v/v) rabbit primary antibody with 1% (v/v) NGS in TXTBS overnight at room temperature 
on a stirrer. The primary antibody used to stain Aβ1-40 was rabbit anti β-amyloid 1-40 
(Millipore, Cat.# AB5074P), and Aβ1-42 was stained using rabbit anti β-amyloid 1-42 
(Millipore, Cat.# AB5078P).
Following this, sections were washed 3 x 10 minutes in 0.1M TBS, and incubated in 0.05% 
(v/v) goat anti-rabbit biotinylated IgG secondary antibody (provided in Vectastain® Elite 
ABC Kit) in TBS with 1% NGS for 2 hours at room temperature on a stirrer. After three 10 
minute washes in 0.1M TBS, sections were incubated in an ABC complex (Vectastain® Elite 
ABC kit, Vector Laboratories, Cat.# PK-6101) for 2 hours at room temperature on a stirrer. 
This avidin-biotinylated enzyme complex (ABC) consisted of 0.25% (v/v) solution A (Avidin 
DH) and 0.25% (v/v) solution B (biotinylated peroxidise) into TBS with 1% (v/v) NGS. 
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Sections were washed 3 x 10 minutes in 0.1M TBS and further washed 2 x 5 minutes in 
0.05M TNS (0.6% [w/v] trizma base in dH2O, pH7.4) to remove free-floating biotin in the 
ABC complex and sodium chloride in the TBS which may interfere with 3,3’-
diaminobenzidine (DAB) reactions. Sections were then incubated in fresh DAB solution 
(DAB Peroxidase Substrate Kit, Vector Laboratories, Cat.# SK-4100) for 1 to 3 minutes until 
stained a purple-brown colour. Importantly, DAB incubation was kept constant between 
samples for each Aβ-40 and Aβ-42 staining. The DAB solution consisted of 5ml dH2O, 1 
drop of buffer stock reagent, 2 drops of DAB stock reagent, 1 drop of hydrogen peroxide and 
1 drop of nickel, added in respective order and mixed between reagents. The reaction was 
stopped by washing in cold PBS and stored in TBS at 4ºC overnight for mounting the next 
day.
Stained sections were then mounted on gelatine-coated slides, air-dried for 2 days and 
dehydrated in an ascending series of alcohol solutions and xylene (50% ethanol → 70% → 
90% → 100% → 100% → xylene → xylene) each for 2 minutes. Sections were coverslipped 
using DPX (Di-n-butyl Phthalate in Xylene) mounting medium and air-dried in the dark 
ready for viewing under a light microscope.
Immunohistochemistry examination
Stained brain sections showing Aβ1-40 and Aβ1-42 deposition were observed using a Leica 
DMRB microscope and photographed using an Olympus DP70 camera. A lack of staining 
was confirmed in sections from WT samples, as expected. Representative sections of staining 
in each Tg experimental group were collated and shown in the results section.
5.5.3 ELISA Results
Figure 5.5 shows the levels of soluble and insoluble Aβ1-40 and Aβ1-42 measured by ELISA 
in the hippocampus of Tg mice fed the experimental diets at 12 months of age. Individual 
values are shown in addition to the mean value (indicated by the black bar). The figures show 
that all Tg groups appear to have similar levels of soluble Aβ1-40, insoluble Aβ1-40, soluble 
Aβ1-42 and insoluble Aβ1-42. In order to test whether diet altered Aβ levels in the 
hippocampus of Tg mice, an ANOVA with diet (OB, OB+C, FO, FO+C) as a between-
subject factor, and brain extract (soluble, insoluble) and Aβ isoform (Aβ1-40, Aβ1-42) as 
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within-subject factors was carried out. Statistical analysis revealed no significant effect of 
diet (F(3,45)=0.597, p>0.05), no significant interaction of isoform by diet (F(3,45)=1.026, 
p>0.05), no significant interaction of extract by diet (F(3,45)=111.884, p>0.05) and no three-
way interaction of isoform by extract by diet (F(1,45)=1.791, p>0.05). Diet therefore failed to 
alter Aβ levels, as illustrated in Figure 5.5.
Figure 5.5 Levels of Aβ in the hippocampus (left-hemisphere) of 12 month old male Tg2576 mice fed 
the oil blend (Tg OB), oil blend + curcumin (Tg OB+C), fish oil (Tg FO), and fish oil + curcumin (Tg 
FO+C) diet. Four species of Aβ were analysed by ELISA: A. Soluble Aβ1-40, B. Insoluble Aβ1-40, 
C. Soluble Aβ1-42, and D. Soluble Aβ1-42. Individual values are represented, in addition to the mean 
value by a black bar.
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Statistical analysis also revealed 
caused by higher levels of Aβ1
(F(1,45)=105.784, p<0.001) caused by higher levels of insoluble Aβ than soluble Aβ, and a 
significant interaction of isoform by extract (F(1,45)=58.208, p<0.001)
effects revealed this interaction to be caused by higher levels of insoluble than soluble Aβ for 
both the Aβ1-40 isoform (F(1,48
p<0.001), and higher levels of Aβ1
p<0.001) and insoluble extracts (F(1,
5.5.4 Immunohistochemistry results
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hippocampus and the cerebellum (latter not shown). 
Figure 5.6 Representative example of 40µm brain sections from WT mice following staining for Aβ1
42 and Aβ1-40; A. Frontal cortex, B. 
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Figure 5.7 presents representative examples of Aβ1-40 immunohistochemical staining of 
brain sections from 12-month old Tg2576 mice fed the experimental diets. Overall Aβ1-40 
load was highly variable between individual mice, with no apparent differences in the pattern 
of amyloid deposition or density as a result of dietary supplementation. Staining was 
observed in multiple brain regions including cortical and medial temporal lobe structures. In 
contrast, staining in the cerebellum was limited, with most brain sections devoid of staining 
(data not shown). Aβ1-40 deposition in the frontal lobe was particularly extensive relative to 
other brain regions, where staining revealed relatively large amyloid bodies scattered 
throughout the frontal cortex. Aβ1-40 was predominately deposited within the prelimbic, 
orbital and motor cortices, in addition to the piriform cortex in some cases. Scattered
deposition was also present throughout the cerebral cortex and hippocampus, with some 
particularly large aggregates observed. Within the hippocampus, the majority of sections 
revealed a concentration of staining along the hippocampus fissure and the outer molecular 
layer of the dentate gyrus, extending to the CA1 and radiatum layer in some cases. Aβ1-40 
deposition was also observed in the piriform, entorhinal, perirhinal, parietal and retrospenial 
dysgranular cortices, as well as the amygdala.
Figure 5.7 Immunohistochemical staining of Aβ1
hippocampus of 12 month Tg2576 mice fed the oil blend (Tg OB; A,B,C,D), the oil blend + curcumin 
diet (Tg OB+C; E,F,G,H), the fish oil diet (Tg FO; I,J,K,L), and the fish oil 
FO+C; M,N,O,P). Four representative sections shown for each Tg group. 40µm sections were 
immunostained for human Aβ1-40. Scale bar, 1000µm.
-40 in the frontal lobe, cerebral cortex and 
+ curcumin diet (Tg 
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Figure 5.8 Immunohistochemical staining of Aβ1
hippocampus of 12 month Tg2576 mice fed the oil blend (Tg OB; A,B,C,D), the oil blend + curcumin 
diet (Tg OB+C; E,F,G,H), the fish oil diet (Tg FO; I,J,K,L), and the fish oil
FO+C; M,N,O,P). Four representative sections shown for each Tg group. 40µm sections were 
immunostained for human Aβ1-42. Scale bar, 1000µm.
Figure 5.8 presents representative examples of Aβ1
brain sections from 12-month old Tg2576 mice fed the experimental diets
-42 in the frontal  lobe, cerebral cortex and 
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. In contrast to 
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Aβ1-40 staining, Aβ1-42 load was relatively uniform between individual mice and deposition 
was not as extensive. Similarly to Aβ1-40 staining, analysis revealed no overt differences in 
Aβ1-42 deposition between Tg groups, indicating no effect of dietary supplementation. Aβ1-
42 deposits were observed as small and diffuse amyloid bodies throughout the frontal, 
cortical and hippocampal regions. Staining was observed around the cingulate, motor, 
piriform, entorhinal and perirhinal cortices. Within the hippocampus, Aβ1-42 was
concentrated along the hippocampal fissure. Little to no staining was observed in the 
cerebellum.
In summary, no systematic differences in amyloid staining was observed throughout brain 
regions in 12-month old Tg2576 mice fed the different experimental diets.
5.5.5 Discussion
Analysis of Aβ pathology by ELISA confirmed the presence of soluble and insoluble Aβ in 
brains of Tg2576 mice aged 12 months, consistent with previous reports (Hsiao et al., 1996; 
Kawarabayashi et al., 2001; Westerman et al., 2002). This experiment also corroborated 
evidence by Kawarabayashi et al. (2001) reporting higher levels of insoluble Aβ1-40 and 
Aβ1-42 relative to their soluble forms at this age. Greater levels of Aβ1-40 than Aβ1-42 
levels were also found at 12 months of age, consistent with reports from Hsiao et al. (1996) in 
Tg2576 mice aged 11 to 13 months. Immunohistochemical analysis confirmed the absence of 
Aβ1-40 and Aβ1-42 deposits in WT mice and their presence in Tg2576 mice aged 12 months. 
Amyloid bodies were deposited throughout the frontal lobe, cortical and hippocampal regions 
for both isoform staining. Importantly, the observation of amyloid pathology within the 
hippocampus was consistent with reports of hippocampal-dependant behavioural deficits in 
Tg2576 mice in this chapter. Furthermore, Aβ1-40 staining was much more extensive than 
Aβ1-42 staining, which corroborated the ELISA results. Together, these results were 
consistent with previous immunohistochemical reports in the Tg2576 model (Hsiao et al., 
1996; Frautschy et al., 1998; Kawarabayashi et al., 2001).
Interestingly, analysis of Aβ by ELISA revealed no significant effect of diet or significant 
interactions of isoform and/or extract with diet. Visual inspection of immunohistochemistry 
analysis confirmed this finding. These results consistently show that 10-month dietary 
supplementation of curcumin, fish oil, and a combination of fish oil and curcumin did not 
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reduce Aβ accumulation in the hippocampus of Tg2576 mice aged 12 months. Although 
these results did not support the hypotheses, they were consistent with results of experiments 
from this chapter which provided evidence that these dietary supplements failed to ameliorate 
behavioural deficits. Overall therefore, it could be concluded that relative to an oil blend diet, 
these supplements failed to alter the behavioural phenotype and Aβ levels measured by 
ELISA in Tg2576 mice. 
This experiment provided the first evidence that fish oil, curcumin and a combination of fish 
oil and curcumin supplementation does not reduce Aβ pathology in Tg2576 mice. This was 
consistent with reports by Oksman et al. (2006) who reported fish oil supplementation failed 
to reduce plaque burden in APPswe/PS1 mice. The results of this experiment however were 
in contrast to numerous reports that supplementary diets containing omega-3 PUFA can 
reduce amyloid pathology in AD models (e.g. Lim et al., 2005; Hooijmans et al., 2007, 
2009). Furthermore, the results of this experiment were also contradictory to previous reports 
that dietary supplementation of curcumin can reduce amyloid pathology in rodent models of 
AD including the Tg2576 model (e.g. Frautschy et al., 2001; Lim et al., 2001; Yang et al.,
2005; Garcia-Alloza et al., 2007; Begum et al., 2008). It is important to note however that 
several factors may account for these discrepancies, such as the design of experimental diets, 
the time of intervention, and choice of AD model or age of subjects (corresponding to the 
stage of pathological development). For example, previous studies (e.g. Lim et al., 2001) of 
curcumin supplementation in the Tg2576 model was carried out after pathology had 
developed, at 10 months of age and over (in contrast to 2 months in our experiment), which 
could suggest that curcumin supplementation was only effective during advanced stages of 
disease when Aβ burden is particularly high. A more detailed outline of such discrepancies is 
reserved for the chapter discussion.
5.6 Experiment 10: Lipid analysis of brains
5.6.1 Introduction
The aim of this experiment was to profile the fatty acid composition in the brain of 12-month 
old Tg2576 and WT mice in order to investigate the effect of the APPswe mutation and 
dietary supplementation. Similar to chapter 3, it was important to examine whether 
composition of fatty acids in the brain was altered in Tg2576 mice relative to WT mice aged 
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12 months. No difference in several fatty acids has been reported in the frontal cortex of 
Tg2576 mice aged 20 to 22.5 months fed a standard chow, including omega-3 PUFAs DHA 
and EPA, omega-6 PUFAs ARA, DTA and LA, as well as the ω-3/ω-6 ratio (Calon et al., 
2004, 2005; Lim et al., 2005). Similar findings were reported in chapter 3 in cortex samples 
of Tg2576 mice aged 16 months. It was therefore hypothesised that Tg2576 mice would not 
have altered fatty acid composition in the brain relative to WT mice. As outlined in chapter 3, 
determination of any transgene-deficits was particularly important for the interpretation of 
behavioural results as brain omega-3 and omega-6 PUFA levels are associated with cognitive 
function in humans and rodents, including AD patients and models (e.g. Gamoh et al., 1999; 
Greiner et al., 1999; Carrie et al., 2000; Ikemoto et al., 2001; Lauritzen et al., 2001; 
Moriguchi, Greiner & Salem, 2000; Pettegrew et al., 2001). An increase in brain omega-6 
PUFA and reduction in omega-3 PUFA levels may therefore be related to impaired cognitive 
function.
Analysis of fatty acid composition in the brain was also important to ensure that dietary 
supplementation of fish oil altered levels of omega-3 and omega-6 PUFAs in the brain due to 
the high omega-3 PUFA content. Increased omega-3 PUFA content in the diet has been 
shown to be incorporated into brain fractions in healthy rodents and AD models (e.g. Jensen, 
Skarsfeldt & Høy, 1996; Calon et al., 2004, 2005; Lim et al., 2005; Oksman et al., 2006). 
chapter 3 also confirmed this with DHA supplementation relative to a suitable baseline 
control diet. Based on evidence that brain fatty acid levels are sensitive to dietary omega-3
PUFA intake (including fish oil sources; e.g. Jensen, Skarsfeldt & Høy, 1996; Suzuki et al., 
1998), it is hypothesised that fish oil supplementation would increase omega-3 PUFA levels 
in the brain of Tg and WT mice. Since omega-3 PUFAs compete with omega-6 PUFAs for 
incorporation into the brain, it was therefore also hypothesised that fish oil supplementation 
would reduce omega-6 PUFA levels and the ω-6/ω-3 ratio. Confirmation of dietary-induced 
alterations to fatty acid composition in the brain was particularly important for the 
interpretation of behavioural results. For example, Arendash et al. (2007) argued that an 
omega-3 PUFA supplemented diet failed to enhance cognitive performance in APPswe/PS1 
transgenic mice due to unaltered omega-3 and omega-6 PUFA levels in the brain relative to 
mice fed a standard diet, suggesting a lack of omega-3 PUFA incorporation into the brain. A 
lack of omega-3 PUFA incorporation into the brain may therefore explain the lack of fish oil 
effect observed in this chapter.
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The analysis of brain fatty acids was also interesting in order to examine any effects of 
curcumin supplementation and co-supplementation with fish oil. Since curcumin has potent 
antioxidant properties, it could be hypothesised that curcumin may increase the levels of 
omega-3 PUFA in the brain by providing antioxidant protection against lipid peroxidation 
caused by oxidative stress in the Tg2576 model (Pappolla et al., 1998; Smith et al., 1998; 
Praticò et al., 2001; Frautschy, Ma & Cole, 2009). Although it may be argued that curcumin 
could similarly increase omega-6 PUFA levels, it is likely that curcumin would offer more 
protection to omega-3 PUFA levels since DHA is highly vulnerable to lipid peroxidation due 
to its six double bonds and high content in the brain (Yavin, Brand & Green, 2002; Montine 
et al., 2004; Frautschy, Ma & Cole, 2009). In contrast, omega-6 PUFA contain fewer double 
bonds and its peroxidisability is five times less than DHA, as mirrored in F2-isoprostane 
levels (Cosgrove, Church & Pryor, 1987; Nourooz-Zadeh et al., 1999; Reich et al., 2001). 
Furthermore, co-supplementation of curcumin with fish oil may also protect omega-3 PUFA
content in the fish oil supplemented diet resulting in greater levels of omega-3 PUFAs in the 
brain.
5.6.2 Methods
Analysis of brain fatty acids were carried out on cortex samples from 12 month old Tg2576 
and WT mice fed the experimental diets from 2 months of age. The materials and procedure 
used for lipid analysis of brain samples was the same as detailed in the lipid analysis of diet 
samples (see chapter 3, section 3.5.2). Lipid analysis was performed by a research associate 
(Dr. Cécile Bascoul-Colombo). Lipid analysis was carried out on cortex samples from the 
right-hemisphere from a minimum of 3 mice from each experimental group (Tg OB n=3, Tg 
FO n=4, Tg OB+C n=3, Tg FO+C n=4, WT OB n=4, WT FO n=4, WT OB+C n=4). Samples 
were collected differently from experiment 3 in chapter 3 as the tissue was being utilised for 
both lipid analysis and immunohistochemistry by dissecting the two hemispheres of the brain. 
In order to collect the tissue appropriately for both analyses, mice were injected with 0.2ml of 
sodium pentobarbitone (Euthatal®) and exsanguination was performed by perfusion with 
0.1M PBS pH7.4, as detailed in experiment 9 (see section 5.5.2 for perfusion method). The 
brain was removed immediately and maintained on ice while dissecting the cortex,
hippocampus and cerebellum from the right hemisphere. The dissected samples from the 
right-hemisphere were immediately snap-frozen in liquid nitrogen and stored at -80ºC until 
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ready to be used for lipid analysis. The left-hemisphere was prepared for immunohistological 
analysis (experiment 9). 
5.6.3 Results
Figure 5.9 presents the percentage of main fatty acid classes and the ω-3/ω-6 ratio of cortex 
samples analysed by lipid analysis from 12-month old Tg2576 and WT mice fed the 
experimental diets. All groups revealed that saturated fatty acids composed the highest 
percentage of fatty acids in the cortex, followed closely by a relatively high level of 
polyunsaturated acids, and smaller levels of monounsaturated fatty acids. All groups also 
showed a higher percentage of total omega-3 PUFAs than total omega-6 PUFAs. Statistical 
analysis using one-way ANOVA with factor of group revealed no significant group 
differences in the percentage of total saturated fatty acids (F(6,25)=1.667, p>0.05), total 
polyunsaturated fatty acids (F(6,25)=1.284, p>0.05) and total monounsaturated fatty acids 
(F(6,25)=1.362, p>0.05). 
As expected, significant group differences were found in the percentage of total omega-3 
PUFAs (F(6,25)=47.883, p<0.001), total omega-6 PUFAs (F(6,25)=87.566, p<0.001), and 
the ω-3/ω-6 ratio (F(6,25)=136.560, p<0.001). A post-hoc Tukey test revealed that omega-3
PUFA, omega-6 PUFA and the and ω-3/ω-6 ratio altered as a factor of diet, whereby mice 
fed the oil blend and oil blend + curcumin diets differed significantly from mice fed the fish 
oil and fish oil + curcumin diets. Here, cortex samples contained higher levels of omega-3 
PUFAs (p<0.001), lower levels of omega-6 PUFAs (p<0.001) and a higher ω-3/ω-6 ratio 
(p<0.001) in mice fed diets containing fish oil relative to the oil blend. The ω-3/ω-6 ratio 
ranged from 1.42 to 1.48 in the oil blend containing diets and 2.18 to 2.41 in the fish oil 
containing diets. Interestingly, Tg mice fed the fish oil containing diets had a higher ω-3/ω-6 
ratio than WT mice fed the fish oil diet, although this did not reach significance. Therefore, 
these fatty acids did not alter as a factor of genotype or as a result of curcumin content.
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Figure 5.9 Main fatty acids classes and ω-3/ω-6 ratio in the cortex of Tg and WT mice at 12 months 
fed the oil blend, oil blend + curcumin, fish oil, or fish oil + curcumin diet. Results are presented as 
mean percentages of total fatty acids ± S.E.M. Significant effect of group, ♦♦♦ p<0.001.
Table 5.1 presents the percentage of main fatty acids detected in cortex samples from 12-
month old Tg2576 and WT mice fed the oil blend, oil blend + curcumin, fish oil, and fish oil 
+ curcumin diets, indicating significant effects of group. Statistical analysis revealed 
significant differences between groups for saturated fatty acids 18:0 (F(6,25)=3.892, p<0.05) 
and 23:0 (F(6,25)=11.001, p<0.001). Furthermore, polyunsaturated fatty acids  LA 18:2ω-6 
(F(6,25)=4.097, p<0.05), 20:3ω-3 (F(6,25)=36.733, p<0.001), ARA 20:4ω-6 
(F(6,25)=68.471, p<0.001), EPA 20:5ω-3 (F(6,25)=408.835, p<0.001), 22:4ω-6 
(F(6,25)=82.636, p<0.001), DPA 22:5ω-3 (F(6,25)=728.377, p<0.001) and DHA 22:6ω-3 
(F(6,25)=28.129, p<0.001) altered as a factor of group. 
A post-hoc Tukey test revealed mice fed oil blend-containing diets significantly differed to 
mice fed the fish oil-containing diets by having lower levels of 20:3ω-3 (smallest, p<0.05), 
20:5ω-3 (smallest, p<0.05), 22:5ω-3 (smallest, p<0.001) and 22:6ω-3 (smallest, p=0.006), 
and higher levels 20:4ω-6 (smallest, p<0.001) and 22:4ω-6 (smallest, p<0.001). Interestingly, 
post-hoc analysis also revealed WT FO mice to have lower levels of 20:5ω-3 and 22:5ω-3 
than Tg FO (smallest, p<0.001) and Tg FO+C mice (smallest, p<0.001), and lower levels of 
20:3ω-3 than Tg FO mice (p<0.05). The results therefore suggest a genotype effect whereby 
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Tg mice incorporated these fatty acids at higher levels. Inspection of Table 5.1 suggests that 
mice fed curcumin-containing diets had lower levels of 23:0, which was supported 
statistically (smallest, p<0.05) with the exceptions of WT FO were not different to WT 
OB+C, WT OB were not different to WT FO+C, and Tg OB were not different to Tg FO+C. 
In addition, a number of other differences were found including higher levels of 18:0 in Tg 
OB relative to WT FO (p<0.05) and WT OB+C (p<0.05) mice, and lower levels of 18:2ω-6 
in WT OB+C relative to Tg OB (p<0.05) and Tg FO+C (p<0.05) mice, and WT OB relative 
to Tg FO+C (p<0.05). Overall therefore, analysis confirmed that fish oil supplementation 
increased all omega-3 PUFAs except ALA and reduced omega-6 PUFAs ARA and DTA.
Table 5.1 Fatty acid composition of cortex samples from 12 month-old Tg and WT mice fed the oil 
blend, oil blend + curcumin, fish oil, or fish oil + curcumin diet. Presenting the main fatty acids 
(values >0.1), represented as mean percentage of total fatty acids  S.E.M.
Fatty acids Tg OB Tg OB+C Tg FO Tg FO+C WT OB WT OB+C WT FO
14:0 16.6 ± 0.6 18.2 ± 0.7 17.1 ± 0.6 17.2 ± 0.5 17.0 ± 0.5 18.9 ± 1.0 18.4 ± 0.6
16:0 17.5 ± 0.1 17.3 ± 0.3 17.6 ± 0.1 17.4 ± 0.2 17.7 ± tr. 17.0 ± 0.3 17.6 ± 0.2
16:1ω-7 0.40 ± tr. 0.50 ± tr. 0.50 ± tr. 0.50 ± tr. 0.50 ± tr. 0.50 ± tr. 0.50 ± tr.
18:0 ♦ 18.5 ± 0.2 17.9 ± 0.2 18.2 ± 0.2 18.2 ± 0.2 18.1 ± 0.1 17.4 ± 0.3 17.4 ± 0.2
18:1ω-9 12.1 ± 0.2 11.7 ± 0.1 12.5 ± 0.1 12.6 ± 0.1 12.2 ± 0.2 11.7 ± 0.3 12.5 ± 0.2
18:1ω-7 3.0 ± 0.1 2.9 ± 0.1 2.8 ± tr. 2.8 ± 0.1 3.0 ± tr. 3.0 ± 0.1 2.8 ± 0.1
18:2ω-6 ♦♦ 0.5 ± tr. 0.5 ± tr. 0.5 ± tr. 0.5 ± tr. 0.4 ± tr. 0.4 ± tr. 0.4 ± tr.
18:3ω-6 N.D. N.D. N.D. N.D. N.D. N.D. N.D.
18:3ω-3 0.1 ± tr. 0.1 ± tr. 0.1 ± tr. 0.1 ± tr. 0.1 ± tr. N.D. N.D.
20:0 0.2 ± tr. 0.2 ± tr. 0.2 ± tr. 0.2 ± tr. 0.2 ± tr. 0.2 ± tr. 0.2 ± tr.
20:1ω-9 1.0 ± 0.1 1.0 ± tr. 0.9 ± tr. 0.9 ± 0.1 0.9 ± tr. 0.9 ± tr. 0.9 ± tr.
20:2ω-6 0.1 ± tr. 0.1 ± tr. 0.1 ± tr. N.D. 0.1 ± tr. N.D. N.D.
20:3ω-3 ♦♦♦ 0.4 ± tr. 0.4 ± tr. 0.6 ± tr. 0.6 ± tr. 0.2 ± tr. 0.3 ± tr. 0.5 ± tr.
20:4ω-6 ♦♦♦ 8.7 ± 0.1 8.5 ± tr. 6.7 ± 0.2 6.7 ± 0.1 8.9 ± 0.1 8.5 ± 0.2 6.9 ± 0.1
20:5ω-3 ♦♦♦ N.D. N.D. 0.3 ± tr. 0.3 ± tr. N.D. N.D. 0.2 ± tr.
22:0 0.2 ± tr. 0.4 ± 0.2 0.2 ± tr. 0.2 ± tr. 0.3 ± tr. 0.4 ± 0.2 0.3 ± tr.
22:4ω-6 ♦♦♦ 2.6 ± tr. 2.6 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 1.5 ± tr.
22:5ω-3 ♦♦♦ 0.1 ± tr. 0.1 ± tr. 0.5 ± tr. 0.5 ± tr. 0.1 ± tr. 0.1 ± tr. 0.4 ± tr.
22:6ω-3 ♦♦♦ 15.6 ± 0.2 15.2 ± 0.2 17.8 ± 0.2 17.5 ± 0.3 15.1 ± 0.2 15.1 ± 0.3 17.0 ± 0.1
23:0 ♦♦♦ 0.5 ±0.1 0.4 ± tr. 0.3 ± tr. 0.3 ± tr. 0.6 ± 0.1 0.4 ± tr. 0.2 ± tr.
24:0 0.6 ± 0.1 0.9 ± 0.1 0.7 ± 0.1 1.0 ± 0.2 0.8 ± 0.1 1.0 ± 0.3 0.8 ± 0.1
24:1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.3 ± tr. 1.0 ± 0.1 1.2 ± tr.
N.D. = not detected, tr. = trace (less than 0.1%). Significant effect of group, ♦ p<0.05, ♦♦ p<0.01, ♦♦♦ 
p<0.001.
5.6.4 Discussion
The results of this experiment revealed that fatty acid composition in the cortex did not 
generally alter as a factor of genotype in Tg2576 mice aged 12 months, corroborating 
evidence in chapter 3 in mice aged 16 months and previous reports (Calon et al., 2004, 2005; 
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Lim et al., 2005). However, results showed Tg mice fed the fish oil diets incorporated higher 
levels of 20:5ω-3, 22:5ω-3 and 20:3ω-3 (Tg FO only in latter) than WT FO mice, suggesting 
an effect of genotype. Despite this effect, total levels of omega-3 PUFAs were unaffected by 
genotype. Previous reports of a genotype effect whereby Tg2576 mice show reduced omega-
3 PUFA incorporation following intake of DHA-depleted diets high in omega-6 PUFAs, 
therefore suggests that this transgene-effect is limited to an intake of a particularly poor diet 
high in omega-6 PUFAs (Calon et al., 2004, 2005; Lim et al., 2005).
The fatty acid composition of the cortex in all mice was primarily composed of SAT, 
followed by PUFA and MUFA, which were all unaffected by genotype and diet.
Interestingly, the increased SAT and MUFA content in the oil blend-containing diets did not 
significantly alter brain levels of SAT and MUFA. Similarly to results in chapter 3, the main 
PUFA in the cortex of all mice was DHA, despite the absence of DHA in the oil blend diet. 
This therefore suggests the conversion of omega-3 PUFA ALA (present in the oil blend diet) 
to DHA in vivo. This is consistent with reports that DHA levels in the brain can be 
maintained by the sole intake of dietary ALA through its conversion in the liver (Rapoport, 
Rao & Igarashi, 2007).
As predicted, fish oil supplementation (FO and FO+C) led to significantly higher ω-3/ω-6 
ratios in the cortex relative to mice fed the oil blend-containing (OB and OB+C) diets. This is 
consistent with literature demonstrating that omega-3 and omega-6 PUFAs compete for 
metabolism and incorporation into brain phospholipids (Russo, 2009) and so supplementation 
of diets containing omega-3 PUFA leads to greater incorporation of omega-3 PUFAs in 
replacement of omega-6 PUFAs. In accordance, total levels of omega-3 PUFA were 
significantly higher with fish oil supplementation, which was primarily contributed by 
significant elevations in DHA which increased by 2.1-2.7% of total fatty acids. Higher 
percentages of omega-3 PUFAs eicosatrienoic acid (ETA, 20:3ω-3), eicosapentaenoic acid
(EPA, 20:5ω-3) and docosapentaenoic acid (DPA, 22:5ω-3) were also observed with fish oil
supplementation. The higher level of DHA relative to EPA in the brain following fish oil 
supplementation (where EPA content was higher than DHA) would suggest the conversion of 
EPA to DHA in vivo. Also accordingly, fish oil supplementation lowered total levels of 
omega-6 PUFAs, caused by a reduction in arachidonic acid (ARA, 20:4ω-6) by 1.8-2.2% and 
docosatetraenoic acid (DTA, 22:4ω-6) by 1.2-1.3%. The reported effects on brain omega-3 
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and omega-6 PUFA content following fish oil supplementation was therefore consistent with 
previous reports (e.g. Jensen, Skarsfeldt & Høy, 1996; Suzuki et al., 1998).
With regards to curcumin supplementation and co-supplementation with fish oil, the results 
revealed no robust effects on fatty acid composition in Tg or WT mice. Some evidence 
suggested that curcumin altered levels of 23:0, although this was not fully supported. Aside 
from curcumin effects, a number of other differences were reported in levels of 18:0 and 
18:2ω-6 which suggested interactions between genotype and dietary intake, although no 
consistent patterns would be ascertained. Overall therefore, fish oil supplementation but not 
curcumin supplementation appeared to alter fatty acid composition of brains. The lack of 
curcumin effect was contrary to predictions since curcumin was hypothesised to protect 
omega-3 PUFAs from peroxidation in the brain caused by increased oxidative stress in 
Tg2576 mice. However, the lack of effect could be explained by the fact that although 
oxidative stress is present in the Tg2576 model, this does not alter brain composition of fatty 
acids relative to WT mice when fed control diets (Calon et al., 2004, 2005; Lim et al., 2005; 
experiment 3). 
In summary, this is the first study in Tg2576 mice which has shown that fish oil 
supplementation can alter fatty acid composition in the cortex of Tg and WT mice. The 
results also show that fish oil supplementation has a similar pattern of increasing total omega-
3 PUFA (particularly DHA) and reducing total omega-6 PUFA (particularly ARA and DTA)
as DHA supplementation, and can have this effect relative to a suitable baseline diet. In 
contrast, Calon et al. (2004, 2005) and Lim et al. (2005) reported that DHA supplementation 
relative to a control diet did not alter omega-3 and omega-6 PUFA levels in Tg2576 or WT 
mice, although the higher ω-3/ω-6 ratio in the control diet may have accounted for this effect. 
Overall, the altered brain lipid composition reported in this study would have anticipated 
complementary effects on behaviour (based on evidence outlined in the experiment 
introduction). This will be discussed in the chapter discussion.
5.7 Chapter Discussion
This chapter examined the effect of early-intervention longitudinal dietary supplementation 
of fish oil, curcumin and their combination on behavioural deficits and Aβ pathology in 
Tg2576 mice. Firstly, it is important to note that transgene-related deficits were observed in 
236
Tg2576 mice in the marble burying test at 8 to 9 months of age and the T-maze FCA task at 
9.5 to 12 months. These results therefore support studies showing impairments in Tg2576 
mice related to tasks of hippocampal function and spatial memory (e.g. Hsiao et al., 1996; 
Westerman et al., 2002; Adriani et al., 2006). These results were also consistent with T-maze 
findings in chapter 3, and marble burying findings in chapter 4. 
Despite predictions, results from these experiments consistently failed to show any effect of 
fish oil, curcumin or fish oil and curcumin supplementation on behaviour or pathology in 
Tg2576 mice. This was found in 2 behavioural measures sensitive to the APPswe mutation 
and 2 assessments of Aβ pathology including measures of Aβ40 and Aβ42 isoforms in 
soluble, insoluble and amyloid-body deposited forms. These consistent results therefore 
provide some evidence that these supplements are not suitable for treating Aβ-related 
pathological changes and its associated behavioural deficits, or for general cognitive 
improvement in healthy individuals. In contrast, studies have shown positive effects of all 
three supplements in animal models of AD. Firstly, Ma et al. (2009) reported positive effects 
of 2.4% dietary fish oil supplementation in the 3xTg AD model, which reduced cognitive 
deficits and tau pathology, as well as inhibited JNK activation and improved insulin 
signalling. A number of factors may explain this discrepancy, such as the differential use of 
control diets whereby fish oil reduced deficits induced by a poor diet high in omega-6 PUFAs 
and saturated fatty acids. This therefore does not provide evidence that fish oil per se can 
protect against deficits relative to a suitable baseline control diet, but may be instead be 
limited to conditions induced by a poor diet. In addition to this, the positive effects of fish oil 
reported by Ma et al. (2009) may be a result of targeting pathological processes which are 
absent in the Tg2576 model such as tau pathology. 
In another study, Oksman et al. (2006) reported 2.2% fish oil reduced Aβ42 levels but not 
plaque pathology in the APPswe/PS1 model. Again, this discrepancy could be explained by 
the control diets which were high in omega-6 PUFAs, and so effects may be limited to a poor 
diet which can exacerbate pathology. The discrepancy could also be explained by the 
different animal model, as although both models express amyloid pathology, the 
APPswe/PS1 model shows an exaggerate state of pathology with greater levels of Aβ42. 
These results may therefore suggest that fish oil effects are limited to such conditions. It may 
therefore be likely that fish oil supplementation would reduce Aβ pathology and its 
associated deficits in advanced stages of pathological development in Tg2576 mice when 
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amyloid load is high. Indeed, such predictions are consistent with positive effects of omega-3 
PUFA DHA supplementation in aged Tg2576 mice (e.g. Calon et al., 2004, 2005 Lim et al., 
2005). If indeed fish oil targets large pathological loads, this may explain the lack of 
effectiveness of early-stage longitudinal intervention in this study. It is therefore evident that 
further investigation is required into fish oil supplementation, primarily concerned with its 
affects on late-stage pathology in Tg2576 mice. Since brain fatty acids were altered as a 
consequence of fish oil, this would suggest that sole increases in brain omega-3 PUFA and 
reductions in brain omega-6 PUFA were not effective in ameliorating deficits related to the 
APPswe mutation.
The results of this experiment were also inconsistent with a plethora of evidence showing 
positive effects of curcumin treatment in AD models, including Tg2576 mice. Discrepancies 
from reports in the APPswe/PS1 model (Garcia-Alloza et al., 2007) or the 3xTg AD model 
(Ma et al., 2009) may be attributable or limited to effects on different pathological processes 
such as tau pathology or accelerated amyloid deposition. Similar to the issues described 
above with fish oil supplementation, the effects of curcumin reported in Ma et al. (2009) was 
also relative to a poor diet and so may be limited to such conditions. Furthermore, curcumin 
effects reported in Garcia-Alloza et al. (2007) study may be attributable to differences in 
administration, whereby curcumin was injected rather than supplemented in the diet. For 
instance, injected curcumin has been shown to label Aβ plaques greater than dietary 
administration, suggesting greater bioavailability (Yang et al., 2005). Frautschy et al. (2001) 
also showed positive effects of dietary curcumin in an Aβ-infused rat model of AD, although 
the effects may be limited to injections of Aβ rather than natural forms and processes of Aβ 
accumulation in the brain. 
Regarding curcumin supplementation specifically in the Tg2576 model, inconsistencies with
Lim et al. (2001) reports may be attributable to dosage differences whereby 160ppm and 
5000ppm curcumin was used. In contrast, Yang et al. (2005) and Begum et al. (2008) 
reported positive effects of curcumin while using the same 500ppm dose, although 
discrepancies may be due to the presence of an oil blend supplement in our experiment or the 
age of intervention. Since the oil blend contained neutral oils, it is thought unlikely that this 
would reduce the impact of curcumin. In fact, studies have shown increased bioavailability of 
curcumin in lipidated formulations, which may have been expected to increase potential 
effects of curcumin. It is therefore more likely that the different age of intervention may 
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account for the discrepancies, whereby late-stage intervention starting from 14.5 months 
(Begum et al., 2008) or 17 months (Yang et al., 2005) is more effective. Similar to fish oil 
supplementation, it may therefore be argued that curcumin supplementation primarily targets 
late-stage pathological processes. For example, curcumin may be most effective during 
periods of great amyloid burden, oxidative stress or inflammation; which would be consistent 
with its potent anti-plaque, antioxidant and anti-inflammatory properties. Overall, it is 
therefore evident that early-intervention longitudinal supplementation of curcumin is 
ineffective at reducing pathology and behavioural deficits in middle-age Tg2576 mice, while 
other evidence shows its effectiveness during advanced-stages. Further investigation into 
whether longitudinal early-stage intervention is more effective than late-intervention in 
reducing deficits during advanced stages of disease development is therefore required.
Alternatively to this hypothesis, it should be considered whether sufficient levels of curcumin 
were present in the brain of mice in this study following dietary intake in order to exert an 
effect. It is well documented that curcumin has bioavailability issues, particularly following 
oral dosing (e.g. Kelloff et al., 1996; Lao et al., 2006). This has been attributed to poor 
absorption into the bloodstream, difficulty crossing the blood-brain barrier, rapid metabolism 
and rapid systematic elimination through the faeces (Pan, Huang & Lin, 1999; Aggarwal & 
Harikumar, 2009). Despite this however, 500ppm dietary doses of curcumin have been 
reported effective in reducing deficits in animal models of AD, suggesting sufficient uptake 
in this study. Supporting this, Yang et al. (2008) reported 500ppm doses of curcumin to label 
plaques in the Tg2576 brain. Furthermore, metabolites of curcumin such as 
tetrahydrocurcumin have also been shown to have potent effects on pathology in Tg2576 
mice (Begum et al., 2008). It was therefore assumed that curcumin bioavailability should not 
be an issue in this study explaining the lack of diet effect. Ideally it would have been 
advantageous to demonstrate this by measuring curcumin in the brain however tissue samples 
were unavailable for analysis. 
Since curcumin bioavailability could be an issue following oral dosing, it could be argued 
that other administration methods may be more suitable for treatment. However, since 
curcumin is instable in solution which results in losses of 50% after 8 hours incubation in 
human blood (Wang et al., 1997), it is argued that ad lib dietary consumption is the best 
method to ensure maintained levels of curcumin longitudinally, which could not be 
practically achieved with injections. Supporting this need for frequent administration, Cheng 
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et al. (2001) reported serum concentration of curcumin peaks 1 to 2 hours after intake and
declines gradually within 12 hours.
One of the most unexpected findings of this chapter was the results showing no beneficial 
effects of curcumin and fish oil co-supplementation. Although research into this supplement 
is in its infancy in AD models, positive findings were anticipated based on evidence that the 
supplements individually were effective in AD models and evidence indicated that their co-
supplementation would likely increase their bioavailability. For example, Ma et al. (2009) 
reported that this combination supplement was more effective than fish oil or curcumin 
supplementation alone at reducing reported deficits in the 3xTg AD model. Together with 
Frautschy and Cole (2010) claiming that this combination supplement can reduce cognitive 
deficits and tau pathology in the Htau model (unpublished results), these are the only in vivo
studies reporting effects of fish oil and curcumin co-supplementation in AD models. The 
experiments in this chapter are the first reports in the Tg2576 model and the first report on 
Aβ pathology in vivo. The discrepancies between the studies could therefore be explained by 
the animal model and underlying pathology, whereby the effectiveness of the supplement 
may be dependent upon targeting tau pathology. Alternatively, the differential results could
be explained by the control diet used, whereby Ma et al. (2009) used a chow high in omega-6
PUFAs and saturated fat, perhaps indicating that the effectiveness of the combination diet is 
limited to such conditions. 
Overall, it is therefore evident that early-stage longitudinal fish oil and curcumin co-
supplementation does not reduce behavioural deficits or pathology in the Tg2576 model. 
Further investigation is required at more advanced stages of pathology, since conclusions 
from fish oil and curcumin individual supplementation suggests that these compounds may be 
more effective during periods of great pathological load. However, it is important to note that 
curcumin may not enhance the effectiveness of fish oil since lipid analysis revealed no 
alterations to brain fatty acids following co-supplementation relative to fish oil 
supplementation alone. The results of the chapter would also suggest that fish oil failed to 
increase the effectiveness of curcumin, although alterations to curcumin bioavailability by
fish oil co-supplementation needs to be confirmed as this was not measured in this study. In 
conclusion, this chapter presents evidence that longitudinal early-stage supplementary fish 
oil, curcumin and their combination does not ameliorate behavioural deficits or pathology in 
the Tg2576 model. Further examination at more advanced stages of pathology is required 
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before we conclude that these supplements are not generally suitable for treating Aβ-related 
pathology and deficits. We can conclude however that treatment of these supplements from 
an early age does not slow the progression of Aβ pathology or behavioural deficits caused by 
expression of the APPswe mutation in middle-age Tg2576 mice.
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Chapter 6
General discussion
Alzheimer’s disease is the most common form of dementia with a growing incidence and a 
huge socioeconomic impact. Due to the complex aetiology of the disease there is no cure and 
current treatments have only limited symptomatic benefit. Investigations into new therapeutic 
strategies which target underlying pathological processes are therefore imperative. 
Furthermore, the discovery of treatments suitable for long-term use is also required in order 
to sustain its benefits throughout the aging process. Technological advances in diagnosis are 
leading to the possibility for earlier intervention, which may be a significant factor in 
delaying the progression and even preventing the onset of disease. Support for this comes 
from epidemiological studies which show long-term features such as genetic and 
environmental factors can reduce the risk and incidence of AD. In particular, there is growing 
support for the role of diet in modifying disease development and its potential for therapeutic 
use. There is a large body of evidence suggesting that fish oils and omega-3 PUFAs, such as 
DHA, can reduce the risk of AD, and in vivo and in vitro studies have demonstrated their 
capability to target pathological mechanisms. Similar evidence has been provided for the 
polyphenolic compound curcumin. The aim of this thesis therefore was to test the hypothesis 
that dietary DHA, fish oil and curcumin can reduce behavioural and pathological changes in a 
mouse model of AD-related amyloid pathology.
It has been argued in this thesis that although DHA supplementation has been examined in 
animal models of AD, none had accurately assessed the effect of DHA per se compared to a 
suitable baseline control diet - whereby the primary difference is DHA supplementation. The 
majority of previous studies used a control diet high in omega-6 PUFAs, saturated fatty acids 
and/or depleted in omega-3 PUFA. Therefore, the resulting conclusion that could be made 
from these studies was that DHA supplementation was beneficial relative to a poor diet that 
exacerbated pathological processes. A similar conclusion could be drawn from the two 
studies that have examined fish oil supplementation in transgenic AD models. These studies
also used a poor diet high in omega-6 PUFAs and saturated fatty acids. Furthermore, only 
one of these studies reported effects on β-amyloid pathology and only one study assessed 
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effects on behaviour (Oksman et al., 2006; Ma et al., 2009). This highlights the need for 
further investigation of these supplements using a suitable baseline control diet that provide a 
more rigorous test of the hypothesis that these dietary supplements can ameliorate amyloid 
pathology and its impact on cognition. Moreover, these studies had only examined the effect 
of these supplements after pathology had developed, which may have limited the 
effectiveness of treatments and failed to examine whether these supplements would delay the 
onset of pathological development. The examination of early intervention would therefore be 
insightful. This issue was also a feature that needed addressing in curcumin supplementation 
studies, which showed positive effects in only aged AD model mice including the Tg2576 
model. Finally, the co-supplementation of fish oil and curcumin may offer positive 
synergistic treatment effects, although its examination is in its infancy. Only one published 
study has reported positive effects, but this was relative to a poor control diet and failed to 
report effects of the diet on β-amyloid pathology.
A number of experiments were therefore carried out to test the putatively beneficial effects of 
dietary DHA, fish oil and curcumin supplementation, as well as fish oil and curcumin co-
supplementation in the Tg2576 mouse model of AD. Particular emphasis was placed on using 
a suitable baseline control diet in order to accurately examine the effect of DHA and fish oils, 
in addition to examining longitudinal supplementation from an early age prior to pathological 
development. Importantly, both transgenic and wildtype mice were examined in order to 
determine transgene-dependant effects of diet. 
Chapter 3 examined the effect of a DHA-rich diet containing 1.86% DHA supplemented from 
4 months of age, when Aβ pathology is reported to first emerge. Results revealed spatial 
memory deficits in the T-maze at 12 and 16 months of age in transgenic mice, consistent with 
previous reports (e.g. Hsiao et al., 1996; Chapman et al., 1999; Barnes, Hale & Good, 2004). 
Results also revealed a mild amelioration of spatial memory deficits with DHA 
supplementation at 16 months of age, which was not found at 8 or 12 months. However, 
DHA failed to reduce Aβ accumulation in brains of Tg mice aged 16 months. The mild 
alleviation of spatial memory deficit by DHA was therefore likely related to a reduction of 
other pathological processes present in the Tg mouse related to Aβ pathology such as 
inflammation or oxidative stress. Since DHA supplementation altered levels of brain fatty 
acids at 16 months, whereby omega-3 PUFAs were increased and omega-6 PUFAs were
reduced, this may have improved neuronal function in Tg mice, explaining the positive effect. 
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The presence of elevated DHA in the brain following DHA supplementation indicated that 
the lack of robust positive effect was not due to a lack of omega-3 PUFA incorporation, as 
shown with Arendash et al. (2007). However, it is unclear whether brain fatty acids were 
altered before 16 months, which may have explained the lack of dietary effect on behaviour 
at 8 and 12 months. Incorporation of DHA into brain fractions following 4-5 month 
supplementation in previous studies would suggest that this was not an issue (e.g. Calon et 
al., 2004).
In a second study, chapter 4 examined the effect of the same DHA-rich diet relative to the 
same baseline control diet, but was supplemented before the onset of any known pathological 
changes at 2 months of age. A large range of behavioural tests were used which aimed to be 
sensitive in potentially detecting smaller transgene and diet effects, which may have been an 
issue in the first study. Results revealed the presence of behavioural deficits from as early as 
3 months of age, corroborating previous reports (e.g. King et al., 1999). Importantly, this 
suggested that deficits are present prior to pathological Aβ development; further highlighting 
the need for earlier intervention. The results also provided some evidence that DHA 
supplementation reduced a number of deficits including spatial memory and anxiety-related 
behaviour, as well as enhanced executive functioning; although similar to chapter 3, the 
reported effects were relatively mild. Interestingly, the effects were more robust at a younger 
age. Firstly, this demonstrated the importance of employing a battery of behavioural tasks 
when examining treatment effects since early-stage treatment effects were not reported in 
chapter 3 (likely due to the T-maze’s lack of complexity and therefore sensitivity in detecting 
changes). Secondly, the results provide support that DHA does not simply target Aβ 
pathology, since deficits were reduced at 3 months before Aβ pathology emerged. In order to 
examine the effect of early DHA supplementation on Aβ pathology, future studies should aim 
to measure Aβ throughout the course of treatment. This would be difficult without large 
cohorts of mice, and so Aβ levels could perhaps be measured in the plasma. Although the 
pattern of plasma Aβ levels does not reflect brain Aβ levels, it is well documented that a 
decrease in plasma Aβ coincides with marked deposition in the brain (Kawarabayashi et al., 
2001) and so an increase in plasma Aβ may suggest a reduction in the brain.
Chapter 4 results may suggest that DHA is more effective during early stages of pathology, 
which are similar to clinical trial results, showing omega-3 PUFA supplementation was only 
effective in people with very mild AD or MCI (e.g. Chiu et al., 2008; Freund-Levi et al., 
244
2006; Kotani et al., 2006). Alternatively however, since benefits were also observed during 
periods of significant Aβ load in Tg2576 mice, it is possible that DHA delayed the 
accumulation of Aβ during early stages, but lost efficiency over time. Similarly, Otsuka 
(2000) reported positive effects of EPA in a clinical trial of AD patients to cease after 6 
months. If efficiency is lost over time, this would suggest that DHA treatment should be 
reserved for more advanced stages of pathology when more symptomatic benefit can be 
achieved. This requires further investigation. Overall therefore, the results of chapters 3 and 4 
showed that DHA offers some protection from transgene-related deficits in the Tg2576 model 
relative to a baseline control diet, in contrast to its potent beneficial effects relative to a poor 
diet with omega-3 PUFA depletion, high omega-6 PUFA and/or an excessive ω-6/ω-3 ratio 
(e.g. Gamoh et al., 2001; Ikemoto et al., 2001; Calon et al., 2004, 2005; Lim et al. 2005; 
Hashimoto et al., 2005b). Although comparing DHA supplementation to DHA-depletion may 
reflect conditions in a number of AD cases which show depleted levels of DHA in the brain 
(e.g. Söderberg et al., 1991), these conditions are not reflective of all AD cases since not all 
show reduced DHA in the brain (Skinner et al., 1993). A reasonable conclusion from these 
studies therefore is that DHA deficiency and intake of high omega-6 PUFA should at least be 
avoided in AD, and that DHA may provide some protection under such conditions.
Chapter 5 examined the effect of 2.5% fish oil supplementation relative to a baseline control 
diet identical to the first two studies although it contained 2.5% rather than 5% oil blend. 
Diets were again provided before pathological changes at 2 months of age. Results revealed 
no beneficial effect of fish oil supplementation in two behavioural measures previously 
shown to be sensitive to the APPswe transgene and dietary DHA. Consistently, no effects 
were found on Aβ pathology at 12 months. The behavioural results were in contrast to Ma et 
al. (2009) in the 3xTg model, although this may suggest that fish oil targets pathological 
processes present in this model, such as tau (which was shown to be reduced with fish oil) 
rather than Aβ (which was not assessed by Ma et al., 2009). Furthermore, these results were 
in contrast to epidemiological studies showing fish intake to reduce the risk and incidence of 
AD. However, it is important to consider that epidemiological studies do not show a cause 
and effect relationship and a number of other extraneous factors may be involved. For 
example, this may suggest that other nutritional components of fish intake may be important 
or that healthier lifestyle choices are adopted by fish eaters that may account for the effect. 
These issues highlight the importance of highly controlled animal studies. 
245
Since the same oil blend control diet was used in the DHA and fish oil experiments, it is 
possible to draw some conclusions between these studies. The results showed that the DHA-
rich diet can provide some protective benefit whereas fish oil does not relative to the control 
diet. This may suggest that the higher levels of total omega-3 PUFAs or DHA in the DHA-
rich diet were attributable for this effect, and that relatively lower levels of total omega-3 
PUFAs or DHA in the fish oil diet had limited benefits. Although similar levels of omega-3
PUFAs or DHA in the fish oil diet have been reported beneficial in other studies, those 
results were in contrast to a poor diet (e.g. Calon et al., 2004). Furthermore, these results 
suggest that the amount of omega-3 PUFA is likely more important than the ω-3/ω-6 ratio 
alone since the DHA and fish oil diets had similar ratios. Alternatively, the comparison of 
DHA to fish oil results may suggest that a higher level of total fatty acids in the DHA-rich 
diet (5% oil compared to 2.5% oil in the fish oil study) provided more protection. However, 
this is unlikely since studies have shown that increased fat in the diet can exacerbate 
pathology in AD mouse models (e.g. Julien et al., 2010; Schroeder, Richardson & Virley, 
2010), so it is more likely that the higher level of DHA is accountable.
With this in mind, it is interesting that the higher-fat DHA-rich diet had positive effects in 
contrast to the fish oil diet since it is well documented that the addition of dietary lipids, 
including omega-3 PUFA and DHA, can increase the production of oxidative products in vivo
(Alexander-North et al., 1994; Allard et al., 1997; Kubo et al., 1997; Jenkinson et al., 1999; 
Song & Miyazawa, 2001; Grundt et al., 2003; Montine & Morrow, 2005; Corsinovi et al., 
2011). It is possible that the composition of lipids in the DHA-rich diet (i.e. the high level of 
DHA) may therefore be accountable for the positive effects, despite its higher level of fat. For 
example, the fish oil diet was particularly rich in EPA (13.6% total fatty acids, 0.53% of diet 
weight) which was absent in the DHA-rich diet, and relatively low in DHA (8.62% total fatty 
acids, 0.34% of diet weight) compared to the DHA diet (27.5% total fatty acids, 1.86% of 
diet weight). Since Chen et al. (2009) revealed more extensive oxidation of EPA than DHA 
in mice, and DHA has been well documented as an antioxidant and can decrease lipid 
peroxidation (e.g. Hossain et al., 1998; Kubo et al., 1998; Maekawa, 1998; Green et al., 2001; 
Yavin, Brand & Green, 2002; Lim et al., 2005), the resulting production of lipid peroxides 
and state of oxidative stress may therefore be lower in the DHA diet relative to the fish oil 
diet. Therefore, despite the increased level of fatty acids in the DHA diet relative to fish oil 
diet, the potential increase in lipid-induced oxidative products may be lower than the fish oil 
diet and this production may also be outweighed by the antioxidant effects of DHA.
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It would therefore be of interest to measure levels of various lipid peroxidation products in 
mice supplemented such diets in future studies. For example, an important measure of lipid 
peroxidation could include various isoprostanes, specifically F2-isoprostanes (an omega-6 
PUFA ARA peroxidation product), F3-isoprostanes (an EPA peroxidation product) and F4-
isoprostanes (a DHA peroxidation product). Another measure of lipid peroxidation could 
include the membrane lipid peroxidation product, 4-hydroxynonenal (HNE), which is 
increased in metabolic syndromes, cardiovascular and neurodegenerative diseases including 
AD (Mattson, 2009). Specifically, HNE can cause neuronal dysfunction by impairing 
membrane-associated glucose and glutamate transporter function and ATPases involved in 
cellular ion homeostatis, impairing ApoE antioxidant function, increasing inflammatory 
processes, altering cholinergic system function, and influencing β- and γ-secretase enzymes 
involved in Aβ production (as reviewed in Mattson, 2009). A profile of changes to these lipid 
peroxidation products may therefore shed light on the potential antioxidant roles of omega-3 
PUFA and fish oil supplements in AD pathogenesis.
Providing further support for the argument that DHA may provide more antioxidant 
protection than fish oils, DHA depletion has been shown to increase oxidative stress (e.g. 
Lim et al., 2005) which highlights the important antioxidant role of DHA. Furthermore, fish 
oil intake has been shown to increase lipid peroxidation (e.g. Meydani, Natiello & Natiello, 
1991). Although Higdon et al. (2000) reported fish oils rich in EPA not to increase lipid 
peroxidation, this measure was restricted to F2-isoprostanes not F3- or F4-isoprostanes. 
Future studies should therefore examine DHA and fish oil supplementation comparatively, 
with emphasis on measuring the level of various lipid oxidation products. These results 
question the potential role of EPA in AD treatment. Although beneficial effects of EPA has 
been reported in an Aβ-injected rat model (e.g. Hashimoto et al., 2009a), the majority of 
research into the beneficial effects of omega-3 PUFAs are primarily focused on DHA 
supplementation. It could be argued that the studies reporting some positive effects of EPA 
supplementation may be due to its conversion into DHA. Further examination of EPA 
relative to DHA supplementation is also therefore required since results from human studies 
have been inconsistent with regards to the beneficial effects of EPA monotherapy (e.g. 
Otsuka, 2000; Morris et al., 2003; Boston et al., 2004). The results of this thesis suggest that 
DHA monotherapy is more advisable than combined EPA and DHA therapy.
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Chapter 5 examined the effect of curcumin and fish oil co-supplementation. Contrary to 
expectations, this supplement failed to ameliorate behavioural deficits or Aβ pathology in the 
Tg2576 model. This may suggest that fish oil supplementation increased the production of 
lipid peroxides which counteracted any beneficial effects of fish oil supplementation, and that 
curcumin failed to offer antioxidant protection. Similarly, the addition of the antioxidant 
vitamin E to omega-3 PUFA supplementation failed to reduce increased lipid peroxide 
products (e.g. Allard et al., 1997; Kubo et al., 1997). This is somewhat unlikely as curcumin 
is a potent antioxidant which has been shown to inhibit the oxidation of lipids (Asia, 
Nakagawa & Miyazawa, 1999; Ramírez-Tortosa et al., 1999). Instead, it could be argued that
curcumin did provide antioxidant protection to the fish oil supplement, but this prevented the 
positive effects of lipid oxidation. For instance, oxidation of DHA is necessary for the 
generation of neuroprotective docosanoids such as neuroprotectin D1 (Bazan, 2005). Not 
only is NPD1 important for reducing oxidative stress, but it can also have an Aβ-lowering 
effect (Lukiw et al., 2005; Zhang & Bazan, 2010). Our efforts to limit lipid peroxidation with 
curcumin may therefore have limited the positive effects of one of the likely beneficial 
candidates in fish oil – the DHA. The measure of lipid peroxidation products (both 
neurotoxic and neuroprotective forms) following curcumin co-supplementation with fish oil, 
relative to fish oil alone, may therefore be informative in future studies.
This argument may also explain the lack of effect observed with curcumin supplementation 
in chapter 5. However, previous studies have documented positive effects of the same 
curcumin dose in aged Tg2576 mice (Yang et al., 2005; Begum et al., 2008). The lack of 
positive effect may therefore be related to the young age at which curcumin intervention was 
employed; i.e., curcumin may only be effective during more advanced stages of pathology. In 
support of this position, curcumin is well documented to target plaque pathology (e.g. Yang 
et al., 2005; Garcia-Alloza et al., 2007; Begum et al., 2008), which is most predominant 
during advanced stages. These results would therefore suggest that early intervention of 
curcumin does not alleviate behavioural deficits and Aβ pathology during mid-stage 
pathological development in the Tg2576 model, but together with previous reports, this 
would suggest that curcumin treatment is limited to late-stages. This however does not 
support the notion that early-stage intervention of curcumin is less effective than later-stage 
intervention at reducing pathology and deficits during advanced stages. Research into this 
would therefore be insightful. Another issue that may need further examination is whether the 
oil blend supplement added to the curcumin contributed to the lack of dietary effect observed. 
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This may be unlikely, since the control diet contained the same level of oil blend supplement. 
However, we cannot account for potential interactions between the oil blend and curcumin 
supplement, and therefore future examinations could compare this supplement to a curcumin 
alone treatment.
Another important issue that was not addressed in this study was the level of cholesterol in 
the diets. It has been well documented that cholesterol is associated with AD risk and can 
acerbate pathological processes (Notkola, 1998; Refolo, 2000; Morris et al., 2003; Puglielli, 
Tanzi & Kovacs, 2003). Since cholesterol was not measured in the diets, it cannot be 
ascertained whether differential levels of cholesterol in the diets may have contributed to the 
results. However, SDS reported that the supplementary oil blend, DHA-rich oil and curcumin 
formulation contained no cholesterol, although it was likely that the fish oil supplement 
contained small levels of cholesterol. It is therefore possible that the lack of positive effects 
of fish oil supplementation may have been caused by additional levels of cholesterol 
compared to the oil blend control diet. In contrast, positive effects of DHA supplementation 
(containing no cholesterol, according to SDS) were found when compared to the same oil 
blend control diet, suggesting that cholesterol in the fish oil diet could be a contributory 
factor. Future research examining the effect of such diets should therefore measure 
cholesterol, which is routinely done by some research groups (e.g. Calon et al., 2004, 2005; 
Lim et al., 2005; Cole & Frautschy, 2006).
Another question that may need further examination is whether the level of omega-6 PUFAs 
in the diets limited the efficiency of the DHA or fish oil supplementation, since Green et al. 
(2007) found high levels of omega-6 PUFAs DPA and ARA supplemented with DHA lost 
efficiency in reducing Aβ and tau pathology after 6 and 9 months, respectively. It may 
therefore be worth examining the effect of DHA or fish oil supplementation while containing 
the lowest level of omega-6 PUFA essentially required in contrast to the typical level of 
omega-6 PUFA intake. Another issue that needs addressing in future research is the 
limitations inflicted by a small sample size. Although this was addressed in chapter 5 with 
use of a large cohort, this was particularly a problem for the assessment of Aβ pathology in 
the DHA study in chapter 3. As a result, this may have prevented the detection of diet effects; 
which may have otherwise led to a considerably different conclusion regarding the potential 
mechanisms of DHA effect in Tg2576 mice. Future studies should therefore adopt a similar 
approach to sample size as used in chapter 4, which led to a reasonably confident conclusion.
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Overall therefore, the results of this thesis suggest that DHA supplementation from an early 
age had some positive effects in reducing behavioural deficits in Tg2576 mice, particularly at 
a young age. Since DHA failed to alter Aβ pathology, this would suggest that DHA targeted 
other pathological processes such as inflammation or oxidative stress. Further research 
however is required to test such hypotheses, and to re-examine the effect on Aβ pathology 
using a large sample size. This thesis also presents robust evidence that fish oil, curcumin and 
their co-supplementation from an early age consistently failed to reduce behavioural deficits 
or Aβ pathology in Tg2576 mice. Future research should aim to examine whether other 
nutritional features of fish oil may be beneficial in AD models, and whether an omega-3 
PUFAs DHA and EPA combination approach is as effective as DHA monotherapy. Further 
investigation is also required into whether co-supplementation of other antioxidants may 
enhance or limit the positive actions of fish oil or DHA, and perhaps whether low level doses 
of antioxidants with these oils may present an optimal approach. Furthermore, this study 
examined the effects of sardine fish oil and so further research could examine whether 
different types of fish oil (such as salmon, pollock and mackerel) have differential effects.
The differential use of fish oil sources are rarely reported in published studies.
These results therefore provide some support for the positive effects of DHA in human 
studies of AD, but fail to corroborate the positive effects of fish oil reported in 
epidemiological studies. While comparing the results to human studies it is important to 
consider that the Tg2576 model is simply a model of amyloid pathology, which does not 
represent the complex aetiology and nature of disease pathogenesis present in AD cases. For 
example, the early emergence of cognitive deficits before Aβ aggregation in the Tg2576 
model is not the case in AD patients where pathology often develops over many years prior to 
an identifiable impairment (Smith, 2002). Furthermore, Tg2576 mice do not express tau 
NFTs or significant neuronal loss. With this differing pathology, one should therefore not 
expect the same results with intervention strategies as achieved in an animal model. So 
although the results of this thesis suggest limited effectiveness of DHA, fish oil and curcumin 
dietary treatment on Aβ-related pathology, it does not shed light on whether such 
manipulations could be protective in models displaying a more comprehensive pattern of AD-
like pathologies.
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